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Abstract  
Cardiovascular disease (CVD) is the leading cause of death amongst people with 
severe mental illness (SMI) and drives substantial portion of the 15-20 year deficit in 
life expectancy experienced by this group relative to the general population.  Statins 
form a core part of CVD prevention in the general population, but the evidence-base 
for people with SMI is unclear. Evidence on the effectiveness of statins for primary 
prevention of CVD was systematically searched but did not identify any studies 
investigating CVD events or associated mortality in people with SMI; therefore 
highlighting the need for studies on the long term impacts of statin prescribing. Two 
analytical studies were undertaken using longitudinal data from The Health 
Improvement Network (THIN) primary care database to investigate: 1) CVD 
screening and statin prescribing in people with and without SMI and 2) to explore 
the effectiveness of statins for CVD prevention in individuals with SMI. Collectively 
the work has established that CVD screening and statin prescribing is increasingly 
accessed by individuals with SMI at levels that are comparable to people without 
similar mental health conditions. The results from this study provide the first 
evidence that statin prescribing to people with SMI is associated with statistically 
significant reductions in total cholesterol (of 1.2mmol/L for up to 2 years, p<0.001). 
There were small non-significant reductions in the rate of combined MI and stroke 
(0.89; 95% CI; 0.68-1.15) and all-cause mortality 0.89 (95% CI; 0.78, 1.02). This 
study provides evidence that statin prescribing to people with SMI may have a 
magnitude of effectiveness that is broadly similar to the general population. 
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Chapter 1 : Background 
1 Chapter Content 
Cardiovascular disease (CVD) is the leading cause of death amongst people with 
severe mental illness (SMI) and contributes to the high burden of mortality and 
morbidity experienced by this group. Statins form a core part of CVD primary 
prevention in the general population, but the evidence-base for statin use amongst 
people with SMI is unclear. The research outlined in this thesis therefore aims to 
explore the effectiveness of statins for primary prevention of CVD amongst people 
with SMI. This chapter introduces the concepts that are central to statin prescribing 
for prevention of CVD amongst individuals with SMI. I define SMI and CVD and 
describe the causes, epidemiology and management of these conditions in the 
context of the United Kingdom (UK). I introduce the complex network of factors 
(graphically represented in Figure 5-1) that drives the higher risk of CVD amongst 
people with SMI and outline the role of statins for primary prevention of CVD. I 
introduce the research aim of this thesis and outline the objectives addressed within 
each chapter. 
2 Introduction 
SMI has been used in psychiatric literature to describe a collection of non-organic 
psychoses including schizophrenia, schizoaffective disorder and bipolar disorder 
that have both a long duration - often requiring life-long treatment - and devastating 
personal implications (Ruggeri et al., 2000). SMI is usually first diagnosed in young 
adulthood, and although many individuals recover, relapses can occur at any age 
thus impacting upon long-term quality of life. The financial and societal costs of SMI 
are high: figures for the UK suggest annual costs are currently £11.8 billion for 
schizophrenia (Andrew et al., 2012) and £6.2 billion for bipolar disorder (McCrone et 
al., 2008). 
SMI is associated with substantially higher levels of physical comorbidity and 
premature mortality than the general population. CVD, including myocardial 
infarction (MI) and stroke, is the leading cause of death amongst people with SMI 
and accounts for approximately one third (Brown et al., 2010) of the 13-30 year 
deficit in life expectancy experienced by this group (Lahti et al., 2012;Tiihonen et al., 
2009;Hennekens et al., 2005;Colton and Manderscheid, 2006). The scale and cost 
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of CVD amongst people with SMI highlights the need to find cost-effective strategies 
for the primary prevention and management of CVD in this group of people. 
3 Epidemiology of SMI 
Introductory texts on schizophrenia and bipolar disorder often state that, on average, 
1 in 100 people will develop SMI during their lifetime (Lawrie and Johnstone, 2014). 
Although broadly correct, this statistic does not reflect the diverse and complex 
epidemiology of the spectrum of conditions defined as SMI. SMI encompasses 
clusters of non-organic psychoses (those with a psychiatric cause) that usually 
present with features common to specific subgroups such as schizophrenia or 
bipolar disorder. The incidence of SMI is associated with a wide range of factors 
including genetics, age, gender, ethnicity, urbanicity, deprivation and living alone 
(Kirkbride et al., 2012;Markham, 2012;Velakoulis et al., 2006). The most recent 
meta-review estimated the incidence of non-organic psychosis to 31.7 per 100,000 
person years amongst people aged 16-64 years in England between 1950 and 2009 
(Kirkbride et al., 2012). However, the certainty with which these incidence rates can 
be interpreted is limited by heterogeneity between studies (pooled results from eight 
studies, I2 statistic = 0.97) and wide 95% confidence interval (CI) (24.6-40.9 per 
100,000 person years) around the point estimate. A subset of these studies was 
further analysed to estimate the incidence of specific psychoses, which was 15.2 per 
100,000 person years (95% CI; 11.9-19.5) for schizophrenia and 5.3 per 100,000 
person years for bipolar disorder (95% CI; 3.7-7.6) (Kirkbride et al., 2012).  
3.1 Schizophrenia, schizo-affective disorder and associated 
psychoses 
3.1.1 Definition 
Schizophrenia is a cluster of related disorders characterised by positive symptoms 
of psychosis including delusion, hallucination or thought disorder. In addition, 
negative symptoms such as social withdrawal, loss of motivation and flattening of 
mood are usually present in individuals with schizophrenia (Semple and Smyth, 
2011). There are two major classification systems for schizophrenia; the Diagnostic 
and Statistical Manual of Mental Disorders fifth edition (DSM-V) and the 
International Classification for Diseases version 10 (ICD-10). DSM-V and ICD-10 
criteria for schizophrenia are not identical: however, both outline requirements for 
the presence of positive and negative symptoms for a minimum of one month. 
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3.1.2 Burden of disease and life-course 
The first acute episode of schizophrenia most commonly presents in late 
adolescence and often results in admission to secondary care, where a formal 
diagnosis is made. The prognosis for schizophrenia is variable and related to factors 
such as prompt diagnosis and intervention (Picchioni and Murray, 2007): over 80% 
of individuals who experience a first episode of psychosis recover, but less than 
20% will have no further episodes (Robinson et al., 1999). The age at which 
schizophrenia first occurs varies, and is associated with gender, socioeconomic 
status, ethnicity and environmental factors (Kirkbride et al., 2012;Markham, 
2012;Velakoulis et al., 2006). Gender appears to be a particularly important 
predictor of age at onset, with incidence generally declining with increasing age in 
both sexes. Peak incidence of schizophrenia occurs in males aged 15-24 and 
females aged 20-29 years, with some evidence of increased incidence in women 
(but not men) after the age of 45 years (Hardoon et al., 2013;Markham, 
2012;Kirkbride et al., 2012;Munk-Jorgensen, 1987;Hafner et al., 1991).  
Late and very late onset schizophrenia are characterised by similar symptoms to 
schizophrenia but have onset in older age. The minimum age for the first psychotic 
episode of late or very late onset schizophrenia has been inconsistently defined in 
the literature but generally centres on an age range of 40 to 60 years (Howard et al., 
2000). The symptoms associated with late onset schizophrenia are subtly different 
to schizophrenia in younger patients and it is unclear if the two conditions are similar 
in terms of their underlying aetiology. Symptoms of late onset schizophrenia and 
dementia can be the same and it may take several years to obtain a firm diagnosis 
for either condition (Howard et al., 2000). 
3.1.3 Aetiology 
The causes of schizophrenia are multifactorial and, at present, family history is the 
strongest risk factor; suggesting a causal role for genetic and environmental factors 
in tandem (Kendler et al., 1993;Cardno et al., 1999). A large number of genetic 
regions (also termed loci) are over-represented amongst people with schizophrenia 
compared to those without mental illness, but no single region is strongly associated 
with schizophrenia (Doherty et al., 2012;Craddock and Sklar, 2013;Sullivan et al., 
2012).  
Environmental factors appear to play an important role, with stressful life events 
often preceding the first signs of schizophrenia. Developing research has also 
highlighted a myriad of other potential associations with schizophrenia. These 
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include winter or spring season of birth, perinatal infection, birth and pregnancy 
complications and prenatal starvation, which may subtly impair early brain 
development (Morgan et al., 2011;Picchioni and Murray, 2007). It is also possible 
that poorer childhood development - such as speech problems and lower 
educational test scores – may be predictive of the development of schizophrenia in 
adulthood (Jones et al., 1994).  
The interaction between psychosocial, environmental and genetic factors are 
important with a higher incidence of schizophrenia reported amongst some ethnic 
groups, second generation migrants and living in an urban environment (McDonald 
and Murray, 2000). Further factors, including cannabis use, social isolation, greater 
deprivation and unemployment may reflect both the causes and consequences of 
schizophrenia (Morgan et al., 2011;Picchioni and Murray, 2007). To date, 
understanding of the aetiology of schizophrenia remains incomplete and no single 
factor has been established as a universal cause (Walker et al., 2004;Picchioni and 
Murray, 2007). 
Further discussion of the potential confounders of the association between 
schizophrenia and CVD is outlined later in section 5. 
3.1.4 Management 
UK guidelines for the management of schizophrenia have been developed by the 
National Institute for Health and Clinical Excellence. These guidelines outline the 
use of oral antipsychotics for treatment of the first psychotic episode and provision 
of cognitive behavioural therapy or family therapy (National Institute for Health and 
Clinical Excellence, 2009). Antipsychotic agents are most effective in reducing 
positive symptoms of schizophrenia such as psychosis, but may also be used for 
other medical conditions such as brain damage or toxic delirium (Joint Formulary 
Committee, 2012). Antipsychotics often need to be taken for prolonged periods of 
time, both for the purposes of maintenance and prevention of relapse in individuals 
at risk of episodes of psychosis. Classification of antipsychotic agents is into first or 
second generation groups: first generation antipsychotics (such as haloperidol, 
flupentixol, zuclopenthixol and chlorpromazine (Joint Formulary Committee, 2012)) 
were first formulated in the 1950s. The predominant mode of action for first 
generation antipsychotics is binding dopamine (D2) receptors in the brain, although 
interaction with other receptors may also occur, which can induce unintended side 
effects that present as movement disorders (termed extra pyramidal side-effects).  
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Second generation antipsychotics (such as amisulpride, clozapine, olanzapine, 
quetiapine, risperidone and aripiprazole) have a different binding profile to first 
generation agents (including blocking serotonin neurotransmitters such as 5-HT2A) 
and are associated with fewer extra pyramidal side-effects. However, second 
generation antipsychotics are associated with a range of other unintentional 
changes to lipid and glucose metabolism, and large increases in weight gain have 
been attributed to these drugs (Citrome et al., 2011). In addition, some second 
generation antipsychotics are implicated in cardiovascular side-effects including 
malignant ventricular arrhythmia: national guidelines therefore recommend that an 
electrocardiogram (ECG) is taken prior to initiating second generation antipsychotics 
in patients who are considered at high risk of CVD (National Institute for Health and 
Clinical Excellence, 2014c). The cardiovascular effects of antipsychotics, in 
particular the impact on lipids, are described in further detail in section 5.3. 
For patients who experience treatment failure with two or more different 
antipsychotic agents, national guidelines recommend that psychological or 
psychosocial interventions should be provided in combination with the antipsychotic 
agent clozapine (National Institute for Health and Clinical Excellence, 2009).  
3.2 Bipolar disorder and associated conditions 
3.2.1 Definition 
Bipolar disorder is a spectrum of conditions that is characterised by transition 
between extreme elation (mania/hypomania) and depressed mood: these mood 
episodes may also be accompanied by symptoms of psychosis such as 
hallucination or delusion. Bipolar disorder is a severe and long-term mental illness 
that can lead to substantial decline in social functioning and quality of life. As with 
schizophrenia, DSM-V and the ICD-10 are the major classification systems for 
bipolar disorder. ICD-10 criteria distinguish between episodes with mild/moderate or 
severe depression in individuals with bipolar disorder, and the presence or absence 
of mania and/or psychosis. Similarly, criteria for DSM-V outline at least two 
categories of bipolar disorder (termed bipolar disorder I and II), as well as 
cyclothymia, which is characterised by lower grade mood cycling than bipolar 
disorder I and II. Bipolar disorder I and II differ in terms of the frequency and 
magnitude of manic (predominant in bipolar I) versus major depressive 
(predominant in bipolar II) episodes.  
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3.2.2 Burden of disease and life-course 
The lifetime risk of bipolar disorder is approximately 2%, although there is 
substantial variation in estimated rates (Merikangas et al., 2007;Merikangas et al., 
2011). The age at which the symptoms of bipolar disorder most commonly begin is 
between 15 and 24 years and typically before the age of 30 years (Hardoon et al., 
2013); although obtaining a firm diagnosis may take several years. According to a 
national survey undertaken in the United States of America (USA) it takes an 
average of 5 years to obtain a correct diagnosis of bipolar disorder from the first 
onset of symptoms (Hirschfeld et al., 2003). There are conflicting views regarding 
the relative prevalence of bipolar disorder by gender: either that bipolar disorder is 
predominantly experienced by women or that there is no gender difference (Diflorio 
and Jones, 2010). The prognosis for individuals with a diagnosis of bipolar disorder 
is varied; intervals between episodes of illness may become shorter over time and – 
amongst individuals who have been hospitalised for bipolar disorder – episodes may 
account for an average of 20% of their lifetime thereafter (Angst and Sellaro, 2000). 
3.2.3 Aetiology 
The underlying biological mechanisms of bipolar disorder are poorly understood, 
and a complex array of genetic and environmental factors appears to play a role in 
the development and progression of bipolar disorder. There is now sufficient 
evidence from genetic studies to conclude that some groups of related genes are 
over-represented in people with bipolar disorder, but that bipolar disorder is not 
caused by a single gene or gene cluster (Craddock and Sklar, 2013).  
Negative life events and chronic stress appear to be triggers for the initial and 
subsequent depressive episodes in bipolar disorder (Hillegers et al., 2004;Kim et al., 
2007). One possible mechanism through which these factors may act is via 
disruption of sleep and circadian rhythm (Miklowitz and Johnson, 2009). 
Additionally, individuals with bipolar disorder may be more sensitive to goal 
attainment than people without bipolar disorder, and this response could potentially 
contribute to the development of mania. In laboratory-based behavioural studies 
goal pursuit was more strongly associated with excitement, and failed pursuit more 
highly predictive of irritability and rage, amongst individuals with bipolar disorder 
than controls (Miklowitz and Johnson, 2009).  
Epidemiological studies provide mixed evidence on the association – or lack thereof 
– between bipolar disorder and gender, urbanicity and/or season of birth (Kroon et 
al., 2013;Lloyd et al., 2005). However, there is substantial evidence of an increased 
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burden of bipolar disorder amongst individuals with non-white ethnicity, greater 
deprivation, poor diet, greater numbers of sexual partners and individuals who are 
physically inactive, smoke and use drugs or alcohol (Kroon et al., 2013;Lloyd et al., 
2005;Scott and Happell, 2011). These associations are likely to reflect both risk 
factors for the development of bipolar disorder, and consequences of the condition.  
Further discussion of the potential confounders of the association between bipolar 
disorder and CVD is outlined later in Section 5. 
3.2.4 Management 
Recommendations for the management of bipolar disorder focus on the stabilisation 
of acute mood episodes using separate treatment for mania and depression. 
Treatment often also draws upon a selection of additional therapies including family 
interventions and cognitive behavioural therapy to supplement pharmacological 
treatment of bipolar disorder (National Institute for Health and Clinical Excellence, 
2014a). In the UK, mania in patients with bipolar disorder may be managed 
(treatment and/or prophylaxis) using; benzodiazapines (e.g. lorazepam), 
antipsychotics (e.g. olanzapine, quetiapine and risperidone; as described in section 
3.1.4 above), which can be given in combination with mood stabilisers (lithium, 
valproic acid, carbamazepine or lamotrigine) if response to treatment is poor (Joint 
Formulary Committee, 2012).  
Management of depressive episodes may require the use of antidepressants such 
as selective serotonin re-uptake inhibitors (SSRIs) (including fluoxetine) or tricyclic 
and related antidepressants such as trazodone hydrochloride (Joint Formulary 
Committee, 2012). However, the evidence-base underpinning the use of 
antidepressants for treatment of bipolar-related depression is relatively weak 
(Geddes and Miklowitz, 2013) and is further complicated by the potential for 
inducing antidepressant-induced switches to mania (Sidor and MacQueen, 2012). 
Even in patients who are given appropriate pharmacological interventions for bipolar 
disorder, the effectiveness of current medication regimens is limited with one third of 
patients responding to treatment in naturalistic studies (Judd et al., 2002;Judd et al., 
2005;Perlis et al., 2006;Geddes and Miklowitz, 2013). 
At present, the biological mechanism underpinning bipolar disorder and the action of 
pharmacological agents used in its treatment are poorly understood. Hypothyroidism 
(associated with symptoms of tiredness and weight gain) is a possible side-effect of 
lithium therapy and is particularly common in women with bipolar disorder, although 
rates are raised in both sexes relative to the general population (Baldassano et al., 
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2005;Kupka et al., 2003;Johnston and Eagles, 1999). Lithium is also associated with 
reduced kidney function (McKnight et al., 2012): for this reason renal monitoring is 
an important aspect of safe clinical use and lithium therapy is avoided in individuals 
with chronic kidney disease (CKD) (Kripalani et al., 2009). The association between 
drugs used for treatment of bipolar disorder and cardiovascular risk is discussed 
further in Section 5.3.  
4 Epidemiology of CVD 
4.1 Definition and background 
CVD is the most common cause of adult death and morbidity across the globe and 
is associated with a huge burden of preventable disease and vast financial costs 
(WHO, 2007;Lozano et al., 2012). In the USA alone, CVD costs amounted to $172 
billion in 2010 and are forecast to increase to $276 billion (a 61% increase) by 2030 
(Heidenreich et al., 2011).  
Atherosclerosis is a major cause of CVD including myocardial infarction (MI) and 
stroke. Atherosclerosis occurs through the deposition of cellular and lipid-based 
substances on arterial walls, which accumulate to form plaques that gradually 
become hardened over time, but may not cause any noticeable symptoms for 
decades. Chronic inflammation and restriction or blockage of arteries are common 
consequences of atherosclerosis and can result in CVD events (Hansson and 
Hermansson, 2011). The stability of the plaque strongly influences the likelihood of a 
CVD event occurring: greater stability is characterised by increased calcification, 
increased smooth muscle cell density, less inflammation and a small lipid core. 
Rupture of a plaque releases the lipid core into the bloodstream and initiates a 
clotting cascade that may block or restrict blood flow. Blockage of arteries serving 
the heart presents as unstable angina when blood flow is partially restricted or MI if 
blockage is complete (Toth and Maki, 2008). Restriction of blood flow to the brain 
can occur due to blockage of blood vessels in the heart or of arteries supplying the 
brain (ischaemic stroke) or due to rupture of blood vessels within the brain 
(haemorrhagic stroke). Symptoms of stroke include muscle weakness or paralysis, 
slurred speech and confusion: symptoms that subside within 24 hours are classed 
as transient ischaemic attack (TIA) (McArthur et al., 2011).  
Low and very low density lipoprotein cholesterol particles (LDL-C and VLDL-C, 
respectively) facilitate the development of atherosclerosis. Lipoproteins are made up 
of a cholesterol core that is solubilised in blood by apolipoprotein B and a 
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phospholipid membrane. Retention of LDL-C and VLDL-C particles in arterial walls 
results in their oxidation, which triggers a complex immune response that promotes 
plaque generation. High density lipoprotein-cholesterol particles (HDL-C) (for which 
apolipoprotein AI is the major protein constituent) reduce the generation of plaque 
by relocating cholesterol from cells in the arterial wall to the liver for excretion. The 
quantity of HDL-C and LDL-C is correlated with apolipoprotein AI and B levels 
(respectively): cholesterol fraction is therefore used as an indicator of apolipoprotein 
concentration and the risk of atherosclerosis (Toth and Maki, 2008). 
4.2 Epidemiology 
The mechanisms driving CVD in the general population have been well studied, with 
smoking (Mons et al., 2015), physical inactivity (Bassuk and Manson, 2005), poor 
diet (de Souza et al., 2015;Strazzullo et al., 2009;Malik et al., 2010), obesity (Klein 
et al., 2004) and high alcohol consumption (Ronksley et al., 2011) (Reynolds et al., 
2003) identified as the major modifiable risk factors that can be targeted to prevent 
CVD events. Meta-analysis of data from large prospective studies of CVD and 
mortality have established that dyslipidaemia is a key modifiable risk factor, with 
1mmol/L reductions in total cholesterol associated with a halving of mortality in 
people aged 40-49 years and reductions of 17-33% amongst 50-89 year olds 
(Lewington et al., 2007).  
The INTERHEART case-control study provides a further indication of the magnitude 
of association between modifiable risk factors and MI in thirty-thousand participants 
recruited across 52 countries between 1999 and 2003. The results from this study 
identified lipids as having the greatest population-attributable risk for MI, with 
elevated ratios of LDL-C to HDL-C accounting for half (49%) of global population-
attributable risk for MI. Similarly, smoking, psychosocial factors, abdominal obesity 
and hypertension were found to be major causes of MI, accounting for 18-38% of 
global population-attributable risk (Yusuf et al., 2004).  
The presence of the metabolic syndrome is also strongly correlated with the 
likelihood of having a CVD event. The metabolic syndrome may be defined as 
having three or more of i) central obesity (a waist circumference including or 
exceeding 88cm in women and 102cm in men), ii) triglyceride levels of 1.69mmol/L 
or higher, iii) HDL-C of less than 1.03 or 1.29mmol/L (for men and women, 
respectively), iv) blood pressure exceeding 130/85mmhg, v) fasting glucose levels of 
≥5.56mmol/L or higher, or treatment for vi) dyslipidaemia, vii) hyperglycaemia or viii) 
hypertension (Grundy et al., 2004). Some definitions may use body mass index 
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(BMI) as a proxy for waist circumference (Mottillo et al., 2010). The risk of CVD is 
over twice as high in people with the metabolic syndrome, compared to those 
without: pooled results from 16 studies combining subtly different definitions for the 
metabolic syndrome yielded a relative risk (RR) of 2.35 (95% CI: 2.02-2.73) (Mottillo 
et al., 2010). 
Risk factors for CVD are widely acknowledged to cluster and to act multiplicatively 
on CVD risk (Jackson et al., 2005;Dawber et al., 1951). This knowledge has 
promoted the use of multivariable risk prediction algorithms to estimate an 
individual’s absolute risk of future CVD events within a given timeframe. Such 
algorithms are primarily derived from large scale cohort studies that collect data over 
many decades to assess the contribution made by different types of factors to the 
risk of having a CVD event (Conroy et al., 2003;de la Iglesia et al., 2011;Hippisley-
Cox et al., 2010;D'Agostino et al., 2008). One classic example is the Framingham 
study, which was initiated in 1948 and continues to operate having enrolled in 
excess of 10,000 participants across several cohorts. Data on a subset of 8,491 
participants from the original Framingham cohort were used to develop algorithms 
for estimating 10 year CVD risk using information on each participant’s age and sex, 
blood pressure, smoking and diabetes status and either BMI or and cholesterol 
concentration (D'Agostino et al., 2008): detailed information on the estimation of 
CVD risk scores is outlined in Chapter 3, section 3.2.6. UK national guidance on 
CVD prevention recommends that General Practitioners (GPs) use risk scores 
similar to Framingham (including QRisk2, which is outlined in further detail in section 
4.4) to identify individuals at high risk of CVD and to implement appropriate 
measures to prevent the development of CVD (National Institute for Health and 
Clinical Excellence, 2014b). 
4.3 Burden of disease and life-course: 
In the UK in 2006, the prevalence of CVD exceeded 2.2 million people including 
over 1.2 million cases of MI, at least 978,000 cases of stroke and 1.7 million people 
were living with angina (Townsend et al., 2012). The incidence of MI amongst British 
men declined by 62% over a 25 year period (Hardoon et al., 2008) and mortality 
from CVD has decreased by 50% (Townsend et al., 2012). Despite the substantial 
decline in incidence, CVD is still a leading cause of death and accounted for 28% of 
all deaths in England and Wales in 2013 (Office for National Statistics, 2014). CVD 
is causally associated with a range of risk factors, for which age is the most 
important: CVD events are rare in people under the age of 30 years (Anderson et 
al., 1991;O'Flaherty et al., 2008). 
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4.4 Prevention and management 
Guidance for the UK recommends annual physical health checks for all people aged 
40-74 years, which may include calculating a 10 year CVD risk score for the 
individual and using this estimate to guide action to reduce CVD risk (Department of 
Health, 2008). Initial action to manage CVD risk should aim to improve health 
through measures such as increased physical activity, dietary control of sugar, salt 
intake, lipid levels and smoking cessation. However, a pharmacological intervention 
may be prescribed for individuals who are at greater risk of CVD, or for those who 
have been unsuccessful in modifying their CVD risk through lifestyle changes alone 
(National Institute for Health and Clinical Excellence, 2011;National Institute for 
Health and Clinical Excellence, 2014b).  
In the UK there are three major groups of pharmacological interventions for reducing 
CVD risk. Statins, antihypertensives and nicotine replacement therapy are used for 
lipid modification, lowering blood pressure and quitting smoking (respectively): 
statins are the most commonly prescribed intervention for the prevention of CVD. 
Statins lower blood cholesterol concentration by inhibiting the cholesterol 
synthesising enzyme 3-hydroxy-3-methyl-glutaryl-coenzyme-A reductase (HMG-
CoA reductase) and promoting expression of LDL-C receptors, which bind and 
thereby remove these lipoproteins from blood. In the general population, statins are 
most frequently taken as a single daily dose and treatment is usually required for the 
duration of a patient’s lifetime.  
Statins have a generally good safety profile and there is a low frequency of adverse 
events associated with their use. However, the side-effects most commonly 
attributed to statins include gastro-intestinal symptoms, rash, headache and 
generally feeling unwell (e.g. aches and fatigue): these effects are usually relatively 
mild and transient but may be unpleasant enough to deter continued medication. 
Further quantification of non-adherence to statin medication is outlined in Chapter 3 
section 5.2.2. Less common but important side-effects of statins include increases in 
liver transaminases (occurring in up to 1% of individuals) and myopathy (muscle 
weakness; occurring in 0.2% of statin trial participants) (Bellosta et al., 2004). In 
addition, statin use has been associated with increased risk of developing type II 
diabetes, although the magnitude of risk is likely to be modest (Rajpathak et al., 
2009;Parker et al., 2015). 
Randomised controlled trials (RCTs) have shown long term statin use to be a 
clinically efficacious and cost-effective means of preventing CVD events in high risk 
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people (Taylor et al., 2013). Until July 2014, the recommended threshold for 
pharmacological intervention with statins - first line treatment with simvastatin - for 
the general population (excluding individuals with familial hypercholesterolaemia) 
was set at a risk score of 20% or higher. However, current guidelines have lowered 
the risk threshold to 10% (National Institute for Health and Clinical Excellence, 
2008b;National Institute for Health and Clinical Excellence, 2014b). In addition, 
guidance now specifies that risk scores should be calculated using the QRisk2 
algorithm (Hippisley-Cox et al., 2010;Hippisley-Cox et al., 2008) and suggests that 
atorvastatin should be initiated in preference to other types of statins (National 
Institute for Health and Clinical Excellence, 2014b). Additional detail on health policy 
of relevance to statin prescribing for primary prevention in the UK is outlined at the 
start of Chapter 5. Separate guidance is issued for adults with familial 
hypercholesterolaemia, for which statin therapy may be initiated on the basis of lipid 
or genetic testing (National Institute for Health and Clinical Excellence, 2008a). 
5 CVD risk in people with SMI 
In the UK the risk of developing CVD is at least twofold higher in people with SMI 
than the general population (Osborn et al., 2007a). CVD risk is both greater 
amongst people with SMI and occurs at an earlier age than for the general 
population, with the largest RR of CVD seen in adults aged less than 30 years of 
age (Osborn et al., 2007a). Furthermore, people with SMI experience poorer CVD 
outcomes, with associated mortality being approximately three times higher than the 
general population (Lahti et al., 2012). The risk of CVD in people with SMI is driven 
by a complex network of factors (Figure 5-1) that ultimately reflect the causes and 
consequences that SMI has on social disadvantage, including social gradient, 
stress, social exclusion and unemployment (World Health Organization, 2003). 
These social and economic factors are adversely associated with maintaining a 
healthy lifestyle and accessing healthcare, and influence markers of CVD risk that 
are incorporated into the Framingham Risk score including lipid profile, BMI, blood 
pressure and diabetes (De Hert et al., 2011b;De Hert et al., 2011a). Further detail 
on the hypothesised directionality of effect for the main analysis undertaken in this 
thesis is outlined in Chapter 3 (Figure 3-2). 
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Figure 5-1: Graphical representation of the factors associated with CVD and its management in people with SMI  
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5.1 Lipid profile 
Of particular importance to this thesis is lipid profile as a marker of atherosclerosis and 
CVD risk, and because LDL-C is the primary target for statin therapy. 
Dyslipidaemia, defined as an abnormal level of lipids in the bloodstream, may be driven 
by a range of factors such as genetics, diet, lack of exercise and obesity. In addition, 
some second generation antipsychotics have been implicated in dyslipidaemia, 
potentially resulting from interaction with the sterol regulatory binding elements that 
control lipid synthesis (Ferno et al., 2005;Raeder et al., 2006;Nasrallah, 2008). These 
determinants of dyslipidaemia and CVD risk are discussed in further detail for the 
remainder of this chapter. 
The clinical thresholds for dyslipidaemia (reflecting raised lipid levels) are often defined 
as ≥5mmol/L for total cholesterol and ≥3mmol/L for LDL-C (2005), although these 
criteria are not universal. Dyslipidaemia is estimated to occur in approximately 63% of 
the general population in the UK (Townsend et al., 2012), and is at comparable levels 
amongst people with SMI: standardised mean difference of -0.10 (95% CI: -0.55, 
0.36)(Osborn et al., 2008). However, individuals with SMI may have relatively lower 
concentrations of HDL-C but higher concentrations of LDL-C fractions and this is 
associated with an elevated risk of CVD (Meyer et al., 2008). 
5.2 Other components of the Framingham score for CVD risk 
5.2.1 BMI 
Poorer diet, lower levels of physical activity in combination with the side-effects of 
some types of psychotropic medication are associated with an increased risk of obesity 
and weight gain in people with SMI. Antipsychotics are implicated in weight gain 
through a range of mechanisms that can alter appetite (Baptista, 1999;Casey, 2005). 
Second generation antipsychotics are most strongly associated with weight gain, with 
differential increases by antipsychotic type: clozapine and olanzapine are generally 
considered to lead to the greatest increases in weight, which may amount to a 6kg gain 
over a 10 week period (Citrome et al., 2011). 
Individuals with schizophrenia have been reported as having a 2.8 to 3.5 fold increased 
risk of obesity (BMI ≥30mg/m3) relative to people without SMI (Scott et al., 2008) and 
appear to have an increased propensity for abdominal obesity that is irrespective of 
treatment with antipsychotic agents (Ryan et al., 2004). By contrast, individuals with 
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mood disorders have a 1.2-1.5 increased likelihood of obesity (Scott et al., 2008;Simon 
et al., 2006;Petry et al., 2008). Weight gain is an important risk factor for CVD as it may 
contribute to the development of abdominal obesity, which is a defining feature of the 
metabolic syndrome and increases the likelihood of developing insulin resistance and 
type II diabetes.  
5.2.2 Diabetes mellitus 
The prevalence of type II diabetes and insulin resistance is 1.7 (pooled RR 95% CI: 
1.2-2.4) times higher amongst people with SMI than the general population (Osborn et 
al., 2008), with a magnitude of risk that is associated with type of mental illness, 
antipsychotic use and antipsychotic type (Lean and Pajonk, 2003;Wirshing et al., 
2002;Koro et al., 2002). Second generation antipsychotics are associated with a 20-
30% increased risk of diabetes relative to first generation drugs, and diabetes 
outcomes are worst for people prescribed olanzapine or clozapine (Holt and Peveler, 
2006;Smith et al., 2008;Treuer et al., 2009;Koller and Doraiswamy, 2002). However, 
there is insufficient evidence to determine whether or not this relationship is truly causal 
as antipsychotic use is associated with established risk factors for diabetes (Holt and 
Peveler, 2006). 
5.2.3 Smoking 
Smoking is a well-established driver of premature mortality and physical morbidity 
including MI and stroke. Meta-analysis of international studies identified that the odds 
ratio (OR) for smoking were over 3 times higher in women (OR 3.3 95% CI: 3.0-3.6) 
and 7 times higher in men (OR 7.2 95% CI: 6.1-8.3) with schizophrenia, compared to 
people without SMI (de Leon and Diaz, 2005). A large study estimated that mortality 
was twice as high amongst people with schizophrenia who were smokers, compared to 
those who did not smoke (Brown et al., 2010). In the same study, 70% of the excess 
mortality from natural causes was attributed to smoking-related diseases amongst 
people with schizophrenia: however, this may reflect a disproportionately high 
prevalence of smoking (73%) within the cohort. Other studies examining the 
prevalence of smoking have consistently reported rates that are higher amongst people 
with SMI (ranging from 53% to 73%) than the general population, which is 
approximately 24% across all ages (Townsend et al., 2012;Tran et al., 2009;Brown et 
al., 2010). The proportion of individuals with SMI who smoke heavily (20-30 cigarettes 
per day) is also greater than for the general population (Williams and Foulds, 
2007;Williams and Ziedonis, 2004;Dixon et al., 2007). There is therefore a greater 
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burden of smoking amongst individuals with SMI both in terms of the relative 
abundance of smokers and the quantity consumed within a given timeframe. 
There is evidence to suggest that smoking cessation with nicotine replacement 
therapy, bupropion and group or individual therapy is effective in people with SMI 
(Banham and Gilbody, 2010). However, smoking cessation rates amongst people with 
SMI are approximately half that of the general population and it is unclear if this is due 
to a lack of effective smoking cessation strategies, access to services or other barriers 
(Williams and Foulds, 2007). At present, the cost-effectiveness of such strategies is 
unknown and evaluation is ongoing (Peckham et al., 2015). 
5.2.4 Systolic blood pressure 
Hypertension is a risk factor for stroke and coronary heart disease (CHD) as well as 
other conditions such as kidney failure. It has been estimated that every 10mmHg 
decrease in systolic blood pressure is associated with a 25% decrease in CHD events 
and a 30% reduction in stroke (Law et al., 2009). At present, estimates of the 
proportion of people with schizophrenia who are hypertensive are imprecise, with some 
studies suggesting high levels of untreated hypertension (34-50%) (Smith et al., 
2007;Daumit et al., 2008), but with little evidence of raised risk of hypertension relative 
to the general population (pooled RR; 1.11, 95% CI: 0.91-1.35) (Osborn et al., 2008).  
5.3 Psychiatric medication 
Some types of antipsychotic drugs – particularly second generation agents – have 
been implicated in weight gain, dyslipidaemia, the development of type II diabetes and 
are thereby associated with conventional risk factors for CVD (De Hert M. et al., 2012). 
However, the causal link between antipsychotic agents and CVD events is less clear 
cut. Some studies have identified evidence of increases in the risk of MI (Brauer et al., 
2011;Brauer et al., 2015), amongst individuals prescribed antipsychotic medication; 
particularly in the month after first initiation. Similarly, the risk of stroke appears to be 
higher amongst individuals taking antipsychotic medication; especially in those with a 
dementia diagnosis (Douglas and Smeeth, 2008). However, it is unclear whether this 
increased CVD risk may be explained by changes in behaviour (such as smoking, illicit 
drug use, sleep deprivation or unhealthy eating) that are attributed to acute episodes of 
mental illness requiring pharmacological treatment, rather than a direct consequence of 
the antipsychotic drug itself (Swain et al., 2015). 
At present, there is no evidence to suggest a causal mechanism for CVD events and 
antipsychotic agents that is independent of other known CVD risk factors (including 
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dyslipidaemia, obesity and type II diabetes). However, some types of antipsychotic 
agents – particularly sertindole; which was withdrawn from the market in 1999 - have 
been implicated in cardiotoxic effects that may result in higher incidence of 
cardiomyopathy or myocarditis than the general population (Bagnall et al., 2003). There 
is also some evidence that some types of antipsychotic drugs are associated with 
higher rates of orthostatic (postural) hypotension especially in older individuals and 
those on blood pressure medication (Muench and Hamer, 2010). Mood-stabilisers and 
antidepressants are also known to be correlated with conventional CVD risk factors 
such as weight gain, although there is no consistent evidence of a direct association 
with CVD events (Correll et al., 2015;Douglas et al., 2011;McKnight et al., 2012). 
5.4 Lifestyle factors 
Amongst people with SMI, diet has been shown to be generally poorer than the general 
population, although there is conflicting evidence to support whether this is driven by 
income constraints or other factors such as a lack of knowledge about diet (Osborn et 
al., 2007b;Roick et al., 2007;Samele et al., 2007;Fagiolini and Goracci, 2009). People 
with SMI are more likely to have diets with significantly less fruit and fibre (Stokes and 
Peet, 2004;Brown et al., 1999) but more saturated fat (Dipasquale et al., 2013) than 
people without SMI and these dietary habits are associated with being overweight or 
obese. Levels of physical activity are also lower amongst individuals with schizophrenia 
than people without SMI (Roick et al., 2007;Daumit et al., 2005), with over one third of 
individuals in one study reporting no physical activity in the past month (Daumit et al., 
2005).  
5.5 Economic and social factors 
Social and economic factors associated with both CVD and mental illness include 
social support, income, employment and ethnicity (encompassing social factors such 
as cultural identity, lifestyle and behavioural factors; as well as genetic factors (National 
Research Council (US) Panel on Race Ethnicity and Health in Later Life, 2004)). The 
primary mechanism through which these factors are likely to be associated with CVD is 
through impacting upon health behaviours, such as smoking, diet, physical activity or 
healthcare utilization (Hemingway and Marmot, 1999a;Hemingway and Marmot, 
1999b). Given the breadth of social and economic factors and their wide-reaching 
implications for CVD health it is perhaps not surprising that the relative contribution of 
these factors has not been quantified for people with SMI. However, studies have 
shown that some - but not all - of the disparity in CVD risk between people with and 
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without SMI can be explained by specific socio-economic factors such as 
unemployment (Osborn et al., 2006).  
5.6 Comorbidity 
People with SMI are also more likely to have other psychiatric comorbidities: with half 
of individuals with schizophrenia receiving a lifetime diagnosis of substance abuse, 
depression or anxiety disorders (Buckley et al., 2009). Similarly, depressive episodes 
often form part of the diagnosis of bipolar disorder and may be indicative of a greater 
risk of future relapses of acute illness (Perlis et al., 2006). Anxiety and substance 
abuse are also associated with bipolar disorder (Krabbendam et al., 2004) and 
individuals with either comorbidity experience poorer outcomes (Coryell et al., 
2012;Coryell et al., 2009). Schizophrenia and bipolar disorder are associated with 
comorbid alcohol use: up to half of men and one third of women with a SMI may 
develop an alcohol disorder (Frye et al., 2003;Hendrick et al., 2000;Drake and Mueser, 
2002). 
Individuals with SMI are at increased risk of a range of comorbid physical health 
conditions including diabetes, arthritis, digestive disease and liver disease (Perron et 
al., 2009;Dixon et al., 1999). One study used the Charlson Comorbidity Score 
(Charlson et al., 1987) to summarise the level of physical morbidity amongst individuals 
with schizophrenia or bipolar disorder - relative to individuals without psychiatric 
healthcare contact - and found that comorbidity scores were approximately doubled 
amongst people with SMI (Laursen et al., 2011). Much of the increased burden of 
physical comorbidity is likely to stem from lifestyle, health behaviours and treatment 
factors amongst individuals with SMI. For example, elevated levels of liver disease may 
be attributable to viral hepatitis B or C infection, or alcohol induced liver damage, which 
reflect higher levels of injecting drug and alcohol use amongst people with psychosis 
(Frye et al., 2003;Hendrick et al., 2000;Grant et al., 2009).  
5.7 Genetic factors 
Genetic factors influencing comorbid physical health conditions and SMI are not well 
characterised, however, there is a growing body of evidence that people with SMI may 
be more susceptible to molecular changes associated with somatic comorbidity and 
premature mortality. Examples include reduced telomere length, which is associated 
with physical conditions such as diabetes and hypertension that may ultimately 
contribute to premature death (Fernandez-Egea et al., 2009). Furthermore, at least ten 
genetic regions are implicated in both CVD and schizophrenia; indicating that these 
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genes may play a causal role in both conditions (Andreassen et al., 2013;Hansen et al., 
2011). 
5.8 Healthcare Factors 
Provision of health services for people with SMI may also contribute to poorer 
management of CVD (De Hert et al., 2011a). Care pathways for people with SMI are 
complex and necessitate access to both physical and mental healthcare services, 
which are often geographically and organisationally separated (Reilly et al., 
2012;Prince et al., 2007). Furthermore, physical health needs of patients at risk of CVD 
may be overlooked or delayed for a range of reasons including prioritisation of mental 
health treatment, lack of awareness about physical health in people with SMI and a 
paucity of services providing physical healthcare (Smith et al., 2013;Buhagiar et al., 
2011;Shuel et al., 2010). This phenomenon – termed diagnostic overshadowing – 
describes the process through which people with mental illness receive sub-optimal 
care because their physical symptoms are misattributed to their mental illness, or the 
physician focuses their time with them on management of their mental illness and 
misses opportunities for preventative physical health care (Jones et al., 2008). 
Although little is known about the provision of healthcare for primary prevention of 
CVD, there is evidence that medications for physical illness are at less frequently 
prescribed to people with SMI (pooled OR 0.74 (95% CI; 0.63-0.86)): this disparity is 
largely accounted for by CVD drugs, including statins (OR of 0.61 (95% CI; 0.39-0.94)) 
(Mitchell et al., 2012). 
6 Management of CVD in people with SMI 
The National Institute for Health and Clinical Excellence has recognised the need for 
improved management of CVD in people with SMI and recommends that CVD and 
metabolic indicators should be routinely monitored (National Institute for Health and 
Clinical Excellence, 2014c;National Institute for Health and Clinical Excellence, 2014a). 
These indicators should be used in conjunction with guidance for the general 
population on managing CVD risk and lipid modification, although it is acknowledged 
that CVD risk is underestimated by standard risk scores for people with SMI (National 
Institute for Health and Clinical Excellence, 2014b). Statin therapy for primary 
prevention of CVD is recommended for people with SMI on the same basis as the 
general population: however, the evidence-base for this patient group is weak (an 
evaluation of the evidence-base is outlined in Chapter 2). 
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7 Context 
The work described in this thesis forms part of PRIMROSE (Prediction and 
Management of CVD Risk for People with SMI), a five year National Institute for Health 
Research funded programme to improve CVD risk management in people with SMI in 
primary care. PRIMROSE is establishing the evidence-base needed to design, 
implement and assess the clinical- and cost-effectiveness of a new package of care to 
prevent CVD in people with SMI. This package of care aims to promote behaviour 
change to support both pharmacological and lifestyle modification to manage CVD risk 
and therefore comprises a raft of interventions related to medication adherence, 
physical activity, smoking cessation and diet.  
8 Summary and scope of this thesis 
In the general population, CVD risk is associated with economic and social factors that 
reflect high levels of inactivity, poor diet, smoking, excessive drinking and diabetes. 
These risk factors are particularly prevalent amongst people with SMI and appear to 
explain much of the additional burden of CVD in this population. Furthermore, 
prolonged exposure to antipsychotic drugs is implicated in weight gain and changes in 
lipid and glucose metabolism, which may contribute to the development of type II 
diabetes. There is some evidence that people with SMI may have reduced access to 
CVD prevention services. Mortality and morbidity rates following CVD are also much 
higher amongst people with SMI, thus highlighting the importance of understanding the 
extent to which provision of measures to prevent primary CVD meets the needs of this 
patient group.  
Statins are the most common pharmacological intervention for managing CVD risk and 
are cost-effective for preventing CVD in high risk people in the general population. 
However, the evidence-base for statin use in people with SMI is unclear.  
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9 Research aims and objectives 
This thesis aims to explore the effectiveness of statins for primary prevention of CVD in 
people with SMI by addressing the following objectives: 
1. Evaluate the evidence-base for statin prescribing for prevention of CVD in 
people with SMI (Chapter 2) 
 
2. Describe the strengths and limitations of using UK primary care data to 
investigate the impact of statin prescribing on CVD in people with SMI 
(Chapter 3) 
 
3. Explore methods to reduce confounding and handle missing data to support 
estimates of effectiveness derived from primary care data (Chapter 4) 
 
4. Investigate the uptake of CVD screening and statin prescribing in UK 
primary care amongst people with and without SMI (Chapter 5) 
 
5. Estimate the effectiveness of statin prescribing in UK primary care for 
prevention of CVD in people with SMI (Chapter 6) 
 
6. Discuss the collective interpretation of the findings from these objectives 
and their significance in terms of policy, practice and research (Chapter 7) 
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Chapter 2 : Systematic review of the effectiveness of 
statins for the primary prevention of CVD in 
individuals with SMI 
1 Chapter Content 
Evidence from randomised controlled trials (RCTs) has shown prevention of 
cardiovascular disease (CVD) with statins to be cost-effective for high risk individuals in 
the general population. However, the risk of CVD is two-to-threefold higher amongst 
individuals with SMI and patterns of statin medication adherence and exposure to 
antipsychotic drugs may differ amongst people with SMI relative to trial participants: the 
effectiveness of statin therapy is therefore unclear for this group. This chapter initially 
describes the rationale for investigating the effectiveness of statin therapy in people 
with SMI with respect to effectiveness for primary prevention of CVD in the general 
population. The chapter then identifies evidence on the effectiveness of statins at 
primary prevention of CVD in people with SMI by systematically searching literature 
and trials databases for studies evaluating the impact of statins on CVD events, 
estimated CVD risk or changes in lipid levels. I describe the methods used for 
undertaking the search, evaluate the quality of the studies identified and summarise the 
results. The strengths and limitations of the search strategy are considered and the 
implications of the results for the objectives of the subsequent planned work, regarding 
statins in people with SMI are outlined. 
This work was peer-reviewed and subsequently accepted for a short oral presentation 
at the UK Society of Academic Primary Care (SAPC) annual conference (July 2014 - 
Edinburgh). The associated abstract is outlined in the appendix; section 18. 
2 Rationale for investigating the effectiveness of statins for 
primary prevention of CVD in people with SMI 
A recent systematic review evaluating the effectiveness of interventions for primary 
prevention of CVD risk in people with SMI highlighted the lack of evidence for lipid 
modification for this group (Gierisch et al., 2014). Statin therapy potentially offers an 
effective means of managing CVD risk in people with SMI and is particularly important 
given the absence of evidence on viable alternatives to manage dyslipidaemia. 
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2.1 Evidence-base for statin prescribing for primary prevention of CVD in 
the general population 
RCTs have shown statins to be effective for primary prevention of CVD (Taylor et al., 
2013). Meta-analysis of data on 56,934 participants identified from 18 RCTs produced 
a rate ratio of 0.75 and 95% confidence interval (CI) of 0.70-0.81, suggesting a 25% 
reduction in the frequency of combined fatal and non-fatal CVD events in individuals 
who were randomised to receive a statin. From the same study, the rate ratios for 
combined fatal and non-fatal coronary heart disease (CHD) were 0.73 (0.67-0.80) and 
0.86 (0.79-0.94) for all-cause mortality, all suggesting a protective effect of statin 
therapy (Taylor et al., 2013).  
Observational studies (outlined in greater detail in Chapter 4) have also investigated 
the impact of statin prescribing for primary prevention of CVD and have identified effect 
estimates that are compatible with RCTs of statins (Heart Protection Study 
Collaborative Group, 2002). Fully adjusted hazard ratios (HRs) for first myocardial 
infarction (MI) were 0.87 (0.77-0.98), first stroke; 0.86 (0.77-0.96) and all-cause 
mortality; 0.79 (0.75-0.83) amongst a cohort of individuals with a diagnosis of 
atherosclerosis (Smeeth et al., 2009) and thus confirm the effectiveness of statins in 
clinical practice. 
2.2 To what extent does the evidence-base for statin use in randomised 
trials reflect the effectiveness in people with SMI? 
Although there is strong evidence from randomised studies that statins are effective for 
primary prevention of CVD events within trial populations, statins may have a different 
level of effectiveness when prescribed to people with SMI because this population is 
likely to differ in terms of CVD risk profile, medication adherence and antipsychotic 
exposure.  
Studies that contributed half of the total study population (50%; n=28,390) for the most 
recent meta-analysis of statins for primary prevention of CVD (Taylor et al., 2013) 
explicitly excluded participants with psychological conditions (Ridker, 2003;Heart 
Protection Study Collaborative Group, 2002;Shepherd et al., 1995). In addition, a 
further 20% (n=10,797) of the total meta-analysis study population was obtained from 
studies that excluded individuals who were perceived as less likely to be compliant with 
treatment (Beishuizen et al., 2005;Nakamura et al., 2006;Knopp et al., 
2006;Baldassarre et al., 2000). Together these studies account for the majority (69%) 
of observations included in the meta-analysis, meaning that the effect estimates 
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derived from the meta-analysis may not accurately reflect the effectiveness of statins 
administered to people with SMI.  
Direct comparison of the characteristics of individuals with SMI and people enrolled into 
statins trials has not been undertaken: however, the relative risk (RR) of CVD events is 
two-to-threefold higher amongst people with SMI than those without SMI (Osborn et al., 
2007a). Furthermore, medication adherence may be different for individuals with SMI: 
estimates specific to statin medication or people with psychosis are not known, 
however, mental illness is more generally associated with poorer medication 
adherence (Osterberg and Blaschke, 2005;Maningat et al., 2013;Ruokoniemi et al., 
2014).  
In addition, in vitro studies indicate that some antipsychotic agents interact with 
transcription factors for sterol regulatory element-binding proteins (SREBP) (Ferno et 
al., 2005). SREBP proteins are responsible for activating several genes that encode 
enzymes for cholesterol and fatty acid synthesis (including HMG-CoA reductase, which 
is the primary binding site for statins) (Horton et al., 2002). Antipsychotic and SREBP 
interaction appears to result in increased cholesterol concentration and could therefore 
counteract the cholesterol-lowering action of statins. The degree of interaction between 
the antipsychotic and SREBP transcription factors varies by the type of drug and 
appears to be more strongly correlated with agents such as clozapine, which are 
associated with weight gain (Raeder et al., 2006;Nasrallah, 2008). 
3 Aims 
This review aims to identify evidence on the effectiveness of statins at preventing CVD 
in people with SMI. I seek to evaluate the impact on CVD risk reduction that is 
attributable to the administration of statins in a statin-naïve population (i.e. individuals 
for whom statin therapy is being newly administered) with SMI by measuring CVD 
events, estimated CVD risk or changes in lipid levels. The Cochrane Handbook (The 
Cochrane Collaboration, 2011) was used for methodological guidance, and the 
research question is considered within the standard framework of target population, 
intervention, comparison and outcome measures (PICO). The protocol for this review is 
registered on PROSPERO (ID: CRD42014009589). 
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4 Methods 
4.1 Population, Intervention, Comparison and Outcome (PICO) criteria 
- Population: people with SMI (primarily schizophrenia or bipolar 
disorder), who do not have a diagnosis of CVD and who are statin-naïve 
- Intervention: being prescribed statin medication  
- Comparison: statin-naïve individuals with SMI who are not prescribed a 
statin and do not have a CVD diagnosis 
- Outcome: incidence of CVD events, CVD risk (derived using standard 
calculations) / or lipid levels (i.e. total cholesterol, high density 
lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol 
(LDL-C) or triglycerides) 
In addition, I applied the following eligibility criteria to assist with screening citations 
identified through the search. 
Inclusion criteria 
I. People with a SMI diagnosis (in any care setting): defined as 
schizophrenia, bipolar disorder and non-organic psychosis 
II. Studies evaluating statin treatment (i.e. any drug classed as a statin, 
taken orally at any dose and treatment duration) 
III. Any of the following outcomes; mortality, CVD events (fatal or non-fatal), 
lipid concentration or estimated CVD risk 
Exclusion criteria 
IV. People with a diagnosis of non-psychotic mental illness (only), such as 
severe depression 
V. People with a prior diagnosis of CVD, or who have current or very 
recent exposure to statins 
4.2 Overarching search strategy and methodology 
I carried out an independent systematic search of the literature and trials registries and 
used work developed as part of the PRIMROSE programme to inform the selection of 
search terms and evaluate my search strategy. The process of developing the literature 
and trials search strategy is outlined in Figure 4-1. My search strategy adapted the 
PRIMROSE search for CVD risk interventions in people with SMI to focus on statins 
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(Atkins et al., 2013). This strategy was further developed through discussion with an 
Information Scientist at the Royal Free Hospital Medical Library, and I additionally 
searched NHS Evidence as well as MedLine, PsycInfo, EMBASE and CINAHL, to 
ensure coverage of a broad selection of scientific and health disciplines. I also 
searched for registered trials across a range of registry databases.  
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Figure 4-1: Development process for searching for literature and trials on the effectiveness of statins for primary prevention of CVD in 
people with SMI 
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4.3 Searching for literature 
Three key search domains were derived from the research question: 1) CVD risk; 2) 
statins; and 3) SMI. Synonyms and related words were established for each domain, 
and these were mapped to appropriate medical subject headings for searching via the 
Ovid (MedLine, PsycInfo and EMBASE) or CINAHL interfaces. The search tailored 
terms for each of the databases are outlined in the appendix; section 17.  
Table 4-1: Research question domains and terms used for searching the 
literature 
Domain 
Synonyms/related 
terms 
Subject heading term 
(exploded) 
Free-text 
Effectiveness  
(on risk of CVD) 
CVD “cardiovascular diseases” cardio* 
Cholesterol Cholesterol cholesterol* 
Lipids Lipids lipid* 
Dyslipidaemia Dyslipidemias 
metabolic* Hyperlipidaemia Hyperlipidemias 
Metabolic syndrome “Metabolic Syndrome X” 
Statins 
Statin / *statin 
“Hydroxymethylglutaryl-
CoA Reductase Inhibitors” 
statin* OR 
Hydroxymethylglutaryl
-CoA Reductase 
Inhibitor* 
Hydroxymethylglutaryl- 
cardio*CoA Reductase 
Inhibitors 
SMI 
Bipolar disorder “Bipolar Disorder” Bipolar OR mani* OR 
manic* Or hypomani* 
OR psychotic OR 
postpsychotic OR 
“post psychotic” OR 
“rapid cycling” OR 
schizoaffective OR 
psychosis OR 
psychoses 
Schizophrenia  Schizophrenia 
Psychotic disorders “Psychotic Disorders” 
Antipsychotic agents “Antipsychotic Agents” 
 
The Ovid or CINAHL interfaces allow users to identify subject headings and build up 
complex searches that can also include free-text. By contrast, NHS Evidence is 
searched using only free-text (similar to search engines such as Google) and the 
number of hits therefore tends to be larger. 
4.3.1 Developing the initial search strategy 
The search strategy mapped each of the three search domains to key search 
headings. The resulting subject headings were then combined into a single domain 
using the Boolean operator ‘OR’. Searches were undertaken i) separately for each 
domain, ii) in combination with each other domain (using ‘AND’), and lastly iii) in 
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combination with all other domains (using ‘AND’). The original systematic review 
search undertaken for PRIMROSE did not identify any RCTs of statins that recruited 
people with SMI: however, the search did find four non-randomised studies (Ojala et 
al., 2008;Landry et al., 2008;Hanssens et al., 2007;De Hert M. et al., 2006) that were 
relevant in terms of subject area. These four studies helped validate how well my 
search strategy was performing and to further develop the search. 
4.3.1.1 “Exploding” search terms 
Comparison of the subject heading terms for the four non-randomised studies and my 
initial search strategy confirmed that my selection of subject headings was 
comprehensive in terms of subject matter, but also highlighted a need to capture 
articles that were indexed to lower level subheadings without being linked to the root 
subject heading. This problem was overcome by ‘exploding’ each subject heading 
term: for example one paper (Landry et al., 2008) was indexed to the term ‘pravastatin’, 
but not ‘Hydroxymethylglutaryl-CoA Reductase Inhibitors’.  Exploding the overarching 
subject heading term ‘Hydroxymethylglutaryl-CoA Reductase Inhibitors’ therefore 
enabled the search to capture articles indexed only to named statins. 
4.3.1.2 Adding free text and wildcard terms 
Although subject headings should ultimately be assigned to all papers in MedLine, 
PsycInfo, EMBASE and CINAHL, there is often a delay between the paper entering the 
database and being indexed. I therefore modified the strategy to include free-text 
search terms with the aim of capturing newer articles that had not yet been indexed. 
Wildcards - single or multiple letter variations or truncations (for example, “mani*” will 
retrieve all terms that start with “mani”; including mania and manic) - were included as 
free-text terms to further reduce the likelihood of missing relevant publications. 
4.4 Searching for registered clinical trials 
I searched the following trials registries for relevant articles: 
- Cochrane Central Register of Controlled Trials (CENTRAL) 
- International Standard RCT Number Register  
- ClinicalTrials.gov (US National Institutes of Health service)  
- UK National Institute for Health Research Register (NRR archive) 
- UK Clinical Research Network study portfolio database (UKCRN) 
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These registries were searched using the terms: 1) schizophrenia AND statin; 2) 
bipolar AND statin; 3) “SMI” AND statin. 
4.5 Updating the review 
I updated the results sections of this review in September 2014 to capture information 
that had not been published at the time of the original literature search (in April 2013). 
Publications identified as a result of this update are outlined in section 6. 
5 Screening literature and registered trials identified from the 
systematic review search 
5.1 Literature search 
The number of articles yielded by each stage of the searches in MedLine, PsychInfo, 
EMBASE, CINAHL and NHS Evidence is outlined in Table 5-1. The final searches 
conducted in MedLine, PsycInfo, CINAHL and EMBASE retrieved 41, 15 and 72 and 
1779 hits, respectively. 
The number of articles retrieved by NHS Evidence was large (820) and included a 
substantial volume of material that was not primary research (including clinical 
guidelines and reviews): I therefore decided (after seeking further guidance from the 
Information Scientist) to filter on information type to include only ‘primary research’. 
This decision is justified by the research question, which aims to identify evidence from 
RCTs or other study designs. After excluding articles that were not primary research, 
the search conducted in NHS Evidence yielded 56 articles. 
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Table 5-1: Numbers of articles retrieved by searching MedLine, PsychInfo, 
EMBASE, CINAHL and NHS Evidence 
Domain/s 
No. of articles retrieved (to 10th April 2013) 
MedLine PsycInfo Embase CINAHL NHS 
Evidence 
1) 3,160,683 77,844 4,221,556 414,566 53,663 
2) 33,736 3,638 96,215 10,076 9,166 
3) 252,098 151,892 399,620 34,258 11,373 
1+2) 26,696 569 78,629 9,419 6,065 
1+3) 24,099 4,933 2,918 2,923 5,043 
2+3) 97 116 62,830 79 1,105 
1+2+3) 
41 15 1,799 72 
820 
FINAL 56* 
No. unique 
references 
1,965 
* 1 + 2 + 3 + information type =‘primary research’ 
All references were imported into Reference Manager (version 12) and I identified 
duplicates (articles with the same title, authors and journal citation) by manual review of 
the database as the in-built duplicate search function was overly sensitive to minor 
differences in spelling and punctuation. A total of 1965 unique references were 
identified by searching MedLine, PsychInfo, EMBASE, CINAHL and NHS Evidence. 
Two separate copies of the Reference Manager databases were used to independently 
screen and identify articles meeting the PICO criteria. The screening process was 
undertaken independently by myself and another researcher (George Salaminios 
Research Assistant, UCL Division of Psychiatry), and our selection of ‘relevant’ articles 
was compared to identify studies for inclusion in the review. We planned in advance to 
resolve any discrepancy in our selection of relevant trials through further review and 
discussion: in the event of non-resolution, a third reviewer would cast the deciding vote. 
There were no RCTs evaluating the effectiveness of statins in people with SMI and 
only the four key papers (De Hert M. et al., 2006;Hanssens et al., 2007;Ojala et al., 
2008;Landry et al., 2008) were identified as relevant. The screening process for the 
literature searches is shown in Figure 5-1: comparison of the independently assessed 
literature showed that there was total concordance between the reviewers.  
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Figure 5-1: PRISMA diagram of the results for the literature search citations 
 
MedLine: 
41 citations 
PsychInfo: 
15 citations 
EMBASE: 
1799 citations 
CINAHL: 
72 citations 
NHS Evidence: 
56 citations 
1965 citations 
screened 
Statin exposure on 
CVD outcomes 
1961 citations 
excluded 
4 articles 
included 
 
5.1.1.1 Cross-referencing the search results against the four key papers 
As an additional check that the adapted search strategy was correctly specified, I 
crossed-referenced the results of each of the searches undertaken in the five 
databases with the four studies that had previously been identified (Table 5-2): all four 
studies were retrieved from MedLine and EMBASE when the three components of the 
research question were included as search terms. The search undertaken in PsycInfo 
yielded three of the four key references: the fourth reference (Landry et al.) was not 
captured because the keywords for this paper did not include ‘statin’ (or a synonym). 
Instead, this paper was indexed to the search term ‘drug therapy’, which presumably 
reflects the range of lipid-lowering medications investigated by the study. None of the 
key references were held in either CINAHL or NHS Evidence, and therefore could not 
be captured by these searches. 
Table 5-2: The number of key references that were retrieved using each of the 
databases 
Database Number of key references retrieved 
MedLine 4 
PsycInfo 3* 
Embase 4 
CINAHL N/A (key references were not available via CINAHL) 
NHS Evidence N/A (key references were not available via NHS evidence) 
*Landry et al. was not retrieved because the keywords for this paper did not include 
statin (or a synonym)  
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5.2 Registered trials 
A total of 29 unique trials were identified: the number of trials captured by each of the 
trial registries is outlined in Table 5-3. The searches conducted were simplistic and, as 
the number of results retrieved was small, it was not necessary to apply additional 
filters or search terms.  
Table 5-3: Numbers of trials retrieved by searching CENTRAL, Controlled trials, 
Clinical trials and NRR archive Trial Registries 
Search terms CENTRAL 
Controlled 
trials 
Clinical 
trials 
NRR 
archive 
UKCRN 
schizophrenia AND 
statin 
1 12 11 0 1 
bipolar AND statin 0 9 2 0 1 
“SMI” AND statin 0 5 0 5 1 
Number of unique 
trials 
1 20 11 2 1 
Total unique trials 29 
Details of registered clinical trials were compiled into a spreadsheet and vetted against 
the PICO criteria for eligibility. The Principal Investigator (or other named primary 
contact) was contacted for all trials where the description appeared to be relevant or 
where the relevance was unclear. Investigators were asked for details of any 
publications or results, and also if they were aware of any other statins trials in people 
with SMI. The screening process for the trials registry searches is shown in Figure 5-2.  
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Figure 5-2: PRISMA diagram of the results for the trials registry citations 
 
CENTRAL: 
1 trial 
Controlled 
trials: 20 
Clinical Trials: 
11 trials 
NRR archive: 
2 trials 
UKCRN:           
1 trial 
29 trials 
Statin exposure on 
CVD outcomes 
25 trials 
excluded 
4 trials 
included 
 
6 Results 
6.1 Literature 
The literature search identified four key references. Two of these papers (Hanssens et 
al., 2007;De Hert M. et al., 2006) were developed by the same team and some patients 
were included in the study population for both papers. A summary of the studies, 
results and an appraisal of their quality is outlined in Table 6-1 and Table 6-2, 
respectively, and discussed in greater depth in the following text. Key results from 
these studies are outlined in Table 6-3. 
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Table 6-1: Summary of published literature investigating the effectiveness of statins in people with SMI 
Author Study 
design and 
time period 
Methods Participants Intervention/Exposure Comparison Outcomes Follow 
up 
Risk of bias 
Landry 
(2008) 
Single-arm 
retrospective 
cohort 
 
(time period 
not outlined) 
Review of routinely 
collected clinical data 
including lipid levels. 
Changes in the lipid 
parameters recorded in 
individuals who had 
dyslipidaemia recorded 
after clozapine 
treatment: differences 
were assessed using a 
paired t-test. 
9 adult outpatients 
and inpatients with 
hospital pharmacy 
records indicating 
concomitant use of 
clozapine (for 
schizophrenia) and 
lipid-lowering drugs. 
Lipid lowering drugs 
were initiated after 
clozapine use. 
Lipid lowering 
medication (pravastatin, 
atorvastatin, fenofibrate, 
gemfibrozil or lovastatin) 
None Total 
cholesterol, 
LDL-C, HDL-
C, triglyceride 
concentration 
Variable: 
mean = 
4.4 (±3.6) 
years 
No 
comparison 
arm. Small 
sample size. 
Individuals 
with pre-
existing CVD 
or a prior 
statin 
prescription 
were not 
excluded. 
Landry 
(2008) 
Single-arm 
retrospective 
cohort 
 
(time period 
not outlined) 
Review of routinely 
collected clinical data 
including lipid levels. 
Changes in the lipid 
parameters recorded in 
individuals who had 
dyslipidaemia recorded 
before clozapine 
treatment: differences 
were assessed using a 
paired t-test. 
9 adult outpatients 
and inpatients with 
hospital pharmacy 
records indicating 
concomitant use of 
clozapine (for 
schizophrenia) and 
lipid-lowering drugs. 
Lipid lowering drugs 
were initiated before 
clozapine use. 
Lipid lowering 
medication (pravastatin, 
atorvastatin, fenofibrate, 
gemfibrozil or lovastatin) 
None Total 
cholesterol, 
LDL-C, HDL-
C, triglyceride 
concentration 
Variable: 
mean = 
4.4 (±3.6) 
years 
No 
comparison 
arm. Small 
sample size. 
Individuals 
with pre-
existing CVD 
or a prior 
statin 
prescription 
were not 
excluded. 
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Author Study 
design and 
time period 
Methods Participants Intervention/Exposure Comparison Outcomes Follow 
up 
Risk of bias 
Ojala 
(2008) 
Single-arm 
retrospective 
cohort 
 
(1
st
 January 
2002 – 31
st
 
May 2004) 
Review of hospital 
inpatient case notes 
including laboratory 
data from routine 
annual health screens. 
Differences in the lipid 
parameters recorded 
before and after statin 
treatment were 
assessed using a 
paired t-test. 
28 adult inpatients 
at a Finnish state 
mental hospital who 
had continuous 
second generation 
antipsychotic use, 
used statins as sole 
lipid modifiers, and 
had available data 
on lipid profiles at 
baseline and follow 
up. Most patients 
(26 of 28) had a 
diagnosis of 
schizophrenia. 
100% of participants 
were male. 
Statin treatment 
(primarily atorvastatin) 
None Total 
cholesterol, 
LDL-C, HDL-
C, triglyceride 
concentration 
Variable: 
mean = 
31 days 
(±10), 
range = 
14-56 
days 
No 
comparison 
arm. Small 
sample size. 
Individuals 
with pre-
existing CVD 
or a prior 
statin 
prescription 
were not 
explicitly 
excluded. 
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Author Study 
design and 
time period 
Methods Participants Intervention/Exposure Comparison Outcomes Follow 
up 
Risk of bias 
Hanssens 
(2007) 
Prospective 
cohort study 
(with no 
comparison 
group) 
 
(from 
November 
2003) 
All participants had a 
full fasting laboratory 
screen, clinical 
assessment, 
electrocardiogram and 
oral glucose tolerance 
test at three months 
before baseline, 
baseline (when statin 
therapy was initiated) 
and at three months. 
The study was 
naturalistic and did not 
randomise individuals. 
ANOVA was used to 
investigate changes in 
lipid concentration. 
46 adult outpatients 
and inpatients at a 
Belgian hospital who 
had a schizophrenia 
or schizoaffective 
disorder diagnosis 
and were either 
stable on medication 
for >9 months or 
newly started on an 
antipsychotic. To be 
eligible, patients had 
to have a diagnosis 
of severe 
dyslipidaemia 
(according to 
SCORE criteria for 
low risk countries). 
80% of participants 
were male. 
Statin treatment (10mg 
rosuvastatin, atorvastatin 
and pravastatin) plus 
dietary advice at 
baseline 
None Total 
cholesterol, 
LDL-C, HDL-
C, triglyceride 
concentration 
3 months No 
comparison 
arm. Small 
sample size. 
Individuals 
with pre-
existing CVD 
or a prior 
statin 
prescription 
were not 
explicitly 
excluded. 
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Author Study 
design and 
time period 
Methods Participants Intervention/Exposure Comparison Outcomes Follow 
up 
Risk of bias 
De Hert 
(2006) 
Prospective 
cohort study 
 
(November 
2003 – 
December 
2005) 
All participants had a 
full fasting laboratory 
screen, clinical 
assessment, 
electrocardiogram and 
oral glucose tolerance 
test at baseline and at 
three months. The 
study was naturalistic 
and did not randomise 
individuals. ANOVA 
was used to investigate 
changes in lipid 
concentration. 
100 adult 
outpatients and 
inpatients at a 
Belgian hospital with 
a diagnosis of 
schizophrenia or 
schizoaffective 
disorder and were 
prescribed 
antipsychotics. To 
be eligible, patients 
had to have a 
diagnosis of severe 
dyslipidaemia 
(according to 
SCORE
1
 criteria for 
low risk countries) 
and had to continue 
the same 
antipsychotic 
treatment. 78% of 
participants were 
male. 
Rosuvastatin treatment 
plus dietary advice at 
baseline 
No statin 
therapy plus 
dietary 
advice at 
baseline 
Total 
cholesterol, 
LDL-C, HDL-
C, triglyceride 
concentration 
3 months The 
mechanism 
for statin 
assignment 
prescribing is 
not reported. 
Relatively 
small sample 
size. 
Individuals 
with pre-
existing CVD 
or a prior 
statin 
prescription 
were not 
explicitly 
excluded. 
                                                 
1
(Perk et al., 2012) 
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Table 6-2: Quality Assessment of literature retrieved through the search, using 
the CASP (Critical Appraisal Skills Programme) checklist for cohort studies 
CASP question: Landry Ojala Hanssens De Hert 
Did the study address a 
clearly focused issue? 
Yes Yes Yes Yes 
Was the cohort 
recruited in an 
acceptable way? 
? Yes Yes Yes 
Was the exposure 
accurately measured to 
minimise bias? 
? Yes ? Yes 
Was the outcome 
accurately measured to 
minimise bias? 
Yes Yes Yes Yes 
Have the authors a) 
identified and b) 
accounted for all 
important confounding 
factors? 
No (e.g. weight) No (e.g. no 
adjustment for 
statin dose) 
No (e.g. no 
multivariable 
adjustment) 
No (e.g. no 
multivariable 
adjustment) 
Was the follow-up of 
subjects complete and 
long enough? 
? No No No 
What are the results of 
this study? 
Reductions in 
average 
triglyceride and 
total cholesterol 
concentrations in 
both study 
groups 
49% Reduction 
in LDL-C and 
39% reduction in 
total cholesterol 
in individuals 
taking statins 
46% Reduction 
in LDL-C and 
37% reduction in 
total cholesterol 
in individuals 
taking statins 
46% Reduction 
in LDL-C and 
38% reduction in 
total cholesterol 
in individuals 
taking statins 
How precise are the 
results? 
95% CIs outlined 
in Table 6-3 
95% CIs outlined 
in Table 6-3 
95% CIs outlined 
in Table 6-3 
95% CIs outlined 
in Table 6-3 
Do you believe the 
results? 
Direction of 
results is 
plausible, but 
confounders and 
small sample 
size may 
introduce bias 
Confidence in the 
results is 
reduced by the 
lack of statin-free 
comparison  
Confidence in the 
results is 
reduced by the 
lack of statin-free 
comparison  
Direction of 
results is 
plausible, but 
confounders and 
small sample 
size may 
introduce bias 
Can the results be 
applied to the local 
population? 
No - hospital 
patients only 
No – male prison 
population 
No - rosuvastatin 
use only 
No - rosuvastatin 
use only 
Do the results fit with 
other available 
evidence? 
Yes Yes Yes Yes 
What are the 
implications of this 
study for practice? 
Lipid-lowering 
medication may 
be effective in 
individuals with 
prior 
antipsychotic use 
Statins may be 
effective in 
individuals with 
SMI 
Lipid-lowering 
medication may 
be effective in 
individuals with 
prior 
antipsychotic use 
Lipid-lowering 
medication may 
be effective in 
individuals with 
SMI 
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Table 6-3: Summary of publications investigating the effectiveness of statins in people with SMI 
First Author Exposure Parameter 
Exposed (mmol/L ± 95% CI) Diff 
(%) 
Unexposed (mmol/L ± 95% CI) Diff 
(%) 
Total diff 
P value 
N Baseline End P N Baseline End p mmol/L % 
Landry 
Lipid low ering medication 
exposure after clozapine 
treatment 
TG 9 4.30 ± 1.17 2.00 ± 1.04 0.001 -53 
-- -- 
TC 9 6.60 ± 0.55 4.48 ± 0.65 0.001 -32 
LDL-C 9 3.76 ± 0.84 3.05 ± 1.04 0.2 -19 
HDL-C 9 0.78 ± 0.26 0.85 ± 0.21 0.5 9 
Landry 
Lipid low ering medication 
exposure before clozapine 
treatment 
TG 9 3.33 ± 1.20 2.18 ± 1.20 0.03 -35 
-- -- 
TC 9 6.43 ± 1.13 4.77 ± 1.66 0.018 -25 
LDL-C 9 4.21 ± 0.31 2.01 ± 0.24 0.002 -52 
HDL-C 9 1.08 ± 0.46 1.25 ± 0.73 0.34 16 
Ojala 
Statin (exposed) plus 
continuous second generation 
antipsychotic use 
TG 28 3.4 2.6 <0.001 -23 
-- -- 
TC 28 6.2 4 <0.001 -35 
LDL-C 19 4.3 2.2 <0.001 -49 
HDL-C 28 0.8 0.8 0.575 0 
De Hert 
10 mg daily rosuvastatin 
(exposed) or no statin 
(unexposed) 
TG 52 3.09 ± 1.60a 1.85 ± 0.79a 0.011 -40 48 2.56 ± 0.55a 3.15 ± 0.69a <0.001 23 -1.83a -56 <0.001 
TC 52 6.82 ± 0.84a 4.22 ± 0.54a <0.001 -38 48 6.19 ± 0.47a 6.52 ± 0.51a 0.001 9 -2.93a -35 <0.001 
LDL-C 52 4.25 ± 0.51a 2.30 ± 0.35a <0.001 -46 48 3.82 ± 0.56a 3.90 ± 0.52a -- 3 -2.03a -49 <0.001 
HDL-C 52 1.13 ± 0.18a 1.18 ± 0.20a "NS" 4 48 1.25 ± 0.02a 1.17 ± 0.18a -- -6 0.13a 10 0.02 
Hanssens 10 mg daily Rosuvastatin 
TG 46 3.18 ± 3.07a 1.87 ± 1.55a 0.005 -41 
-- -- 
TC 46 6.81 ± 1.62a 4.27 ± 1.03a <0.001 -37 
LDL-C 46 4.19 ± 0.99a 2.25 ± 0.65a <0.001 -46 
HDL-C 46 1.15 ± 0.35a 1.20 ± 0.40a 0.182 4 
Vincenzi * 
40 mg daily pravastatin 
(exposed) versus placebo 
(unexposed) 
TG 30 1.97 ± 0.64a 1.52 ± 0.37a -- -23 30 1.64 ± 0.42a 1.53 ± 0.33a -- -7 -0.34a -16 0.3 
TC 30 4.65 ± 0.31a 4.17 ± 0.32a -- -10 30 4.62 ± 0.27a 4.63 ± 0.26a -- 0.2 -0.49a -11 0.001 
LDL-C 30 2.75 ± 0.26a 2.21 ± 0.24a -- -20 30 2.70 ± 0.21a 2.70 ± 0.18a -- 0.2 -0.55a -20 <0.001 
HDL-C 30 1.25 ± 0.12a 1.24 ± 0.11a -- -0.4 30 1.18 ± 0.09a 1.23 ± 0.10a -- 4 -0.06a -5 0.91 
aUnits converted from mg/dL to mmol/L (assuming conversion factors of 38.6 and 88.5 for cholesterol and triglycerides, respectively) 
TG; triglyerides, TC; total cholesterol, LDL-C; low  density lipoprotein-cholesterol, HDL-C; high density lipoprotein cholesterol 
Diff; percentage difference between baseline and study end. Total diff; percentage difference between exposed and unexposed participants. 
* Publication identif ied through an update to this review  in September 2014. 
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6.1.1 Landry et al. (2008)  
This study was a retrospective cohort that aimed to document the clinical efficacy of 
lipid-lowering medications on hyperlipidaemia in Canadian hospital inpatients and 
outpatients concomitantly treated with clozapine. The study examined the impact of 
lipid-lowering medication in people who developed dyslipidaemia either before or after 
clozapine use, making prior clozapine use the exposure of interest. The study 
outcomes were cholesterol (total, LDL-C and HDL-C fractions) and triglyceride 
concentrations, which were measured over time. The authors sourced the study 
population retrospectively from pharmacy records for patients with clozapine and lipid-
lowering medication use. These records included data on a range of relevant factors 
such as age, gender, type and duration of psychiatric and medical diagnoses, and 
laboratory results over the course of several years. It is unclear from the publication (a 
letter rather than a full research paper) whether the population included all eligible 
patients or whether any other exclusion criteria were applied. In addition, some 
important information on factors such as weight, was not readily available and was not 
included the analysis.  
The study examined 18 patients with concomitant use of clozapine and a lipid-lowering 
medication; changes in lipid levels were evaluated in two equally sized patient groups: 
those with prior exposure to clozapine and those initiating clozapine prior to lipid-
lowering medication. In the first of these groups, a patient’s lipid levels were compared 
at two time points: before the introduction of clozapine and at the last available time-
point where both lipid-lowering medication and clozapine were prescribed (average 
duration of follow-up of 4.4 years (±3.6 years)). By contrast, the second group, who 
were existing users of clozapine, compared lipid measurements taken before the 
introduction of the lipid-lowering medication with the last available time-point where 
both lipid-lowering medication and clozapine were prescribed (average follow-up time 
was not outlined in the publication). The prescribed lipid-lowering medications were: 
pravastatin (5 patients), atorvastatin (4 patients), fenofibrate (3 patients), gemfibrozil (3 
patients) and lovastatin (3 patients). A total of two patients stopped taking lipid-lowering 
medication during the study period. 
The key results were statistically significant reductions in average triglyceride and total 
cholesterol concentrations of 4.3 ±1.17 to 2.0 ±1.04mmol/L (p=0.001) and 6.60 ±0.55 to 
4.48 ±0.65mmol/L (p=0.001), respectively for the group initiating lipid-lowering 
medication after clozapine. A similar trend was also observed in the patient group 
initiating lipid-lowering medication prior to clozapine treatment; triglycerides and total 
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cholesterol were reduced from 3.33 ±1.2 to 2.18 ±1.2mmol/L (p=0.03) and 6.43 ±1.13 
to 4.77 ±1.66mmol/L (p=0.018), respectively. The level of variation between patients 
was large and ranged from reductions of 4-81% for triglycerides and 1-48% for total 
cholesterol. The two study groups differed slightly in terms of the reduction in LDL-C, 
which was statistically significant for patients without prior exposure to clozapine 
(4.21±0.31 to 2.01±0.24mmol/L, p=0.002), but not for group with prior exposure 
(3.76±0.84 to 3.05±1.04mmol/L, p=0.2). HDL-C levels were slightly increased in both 
groups, but not to significantly different levels (p>0.3 in both cases). 
This study aimed to answer a different research question to mine, with the author’s 
choice of research question implying that statin treatment is assumed to be effective in 
people with SMI. Consequently, the study does not include a comparison group that is 
unexposed to statins, thus making it difficult to comment on the effectiveness of statins. 
However, the average triglyceride and total cholesterol concentrations of patients in 
both clozapine groups (naïve or prior exposure) were lowered during the course of the 
study, which is compatible with the hypothesis that statins are effective in reducing 
CVD risk in people with SMI. It would be incorrect to draw any stronger conclusions 
from this study because of the lack of a control group, the small number of subjects 
and because the follow-up period was relatively long providing the opportunity for other 
factors (such as dietary interventions) to affect lipid levels. 
6.1.2 Ojala et al. (2008)  
This retrospective cohort study aimed to evaluate the effect of statins on dyslipidaemia 
amongst psychiatric inpatients taking second generation antipsychotics in a Finnish 
state mental hospital between January 2002 and May 2004. The authors sampled all 
consecutive patients receiving continuous second generation antipsychotic treatment 
who also had a statin as their sole lipid-lowering medication and who had obtainable 
lipid profiles at baseline and follow-up. Cholesterol (total, LDL-C and HDL-C fractions) 
and triglyceride concentrations were the outcomes of interest, which were measured 
during statin treatment (at 14-59 days after the study start). 
The population selected for this study was specialised: all patients were hospitalised 
with a court ruling of insanity following criminal activity; all study subjects were male. 
The authors report reductions of 49% (2.1 ±0.6mmol/L, 95%CI 1.8-2.4) for LDL-C 
cholesterol and 36% (2.2 ±0.8mmol/L; 95%CI 1.9-2.5) for total cholesterol, which they 
state is in-line with results obtained through clinical trials in the general population. 
However, no attempts were made to statistically adjust for the possible impact of a 
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range of important confounders or factors such as the statin type and dosage, although 
this information was measured and made available in the text of the publication. 
The major limitation of this study, with respect to my research question, was the lack of 
a comparison arm without statin treatment; it is therefore difficult to conclude that the 
reduction in lipid levels results from statin medication alone. However, all 28 patients 
included in the study had reductions in total and LDL-C, which could be compatible with 
statins being effective in people with SMI. In addition, the nature of the high security 
setting of the study is likely to impact upon the demographics (e.g. women were not 
represented in this group), lifestyle factors and medication adherence of the study 
population and the results may therefore not be generalizable to other settings. 
6.1.3 Hanssens et al. (2007)  
This study was a prospective cohort (without a non-statin comparison group) that 
aimed to evaluate the effects of treatment of severe hyperlipidaemia with statins in 
inpatients and outpatients with schizophrenia at a Belgian hospital. All consecutive 
patients with schizophrenia or schizoaffective disorder were enrolled prospectively into 
the study from November 2003 to develop two cohorts, which differed in terms of 
previous antipsychotic exposure. The first cohort included patients who had been 
stable on antipsychotic medication for 9 months or more, and the second cohort 
included patients who were recently started antipsychotic medication. Patients within 
these two cohorts were eligible for inclusion in the study if they had severe 
dyslipidaemia that met European guidelines (SCORE) for low risk countries (Conroy et 
al., 2003). All patients with dyslipidaemia were given dietary advice at the start of 
follow-up. All patients were initiated with lipid-lowering medication at baseline with 41 
(89%) prescribed 10mg rosuvastatin, four patients atorvastatin or pravastatin, and one 
patient fenofibrate. 
The study recorded full metabolic screening including oral glucose tolerance testing at 
three months before baseline, baseline (when statins were initiated) and three months 
after baseline. Analysis of variance with repeated measures was used to assess the 
association between statin therapy and lipid levels. 
Of the 200 patients stable on antipsychotic treatment, more than one quarter (27%) 
had severe dyslipidaemia, compared to 15% of the 65 patients that had recently started 
antipsychotic medication. It was not possible to undertake metabolic re-evaluation at 3 
months for 17 patients, leaving a total of 46 study participants. These individuals were 
predominantly male (80%) and virtually all (98%) were white Belgians. The average 
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age of participants was 39.5 years (standard deviation 9.8 years) with duration of 
illness being 13.4 years (standard deviation 7.8 years). A total of 78% of patients had a 
diagnosis of schizophrenia, with the remaining 22% schizoaffective disorder. Over one 
fifth of patients (21.7%) were treated with an antipsychotic for less than 3 months, with 
the majority (86.9%) being second generation drugs (olanzapine and clozapine 
accounted for over half of all antipsychotic usage). Polypharmacy was common with 
almost 60% of patients taking antidepressants and 46% taking somatic medication 
such as antihypertensives. There were significant decreases in total cholesterol (37% 
decrease), triglyceride (41% decrease) and LDL-C (46% decrease) levels after 3 
months of statin therapy. Non-significant increases in HDL-C were also observed 
during the study period (p=0.18). Statin treatment was stopped in one patient who 
developed abnormally high levels of creatine kinase after five months of statin therapy. 
No other negative impacts of statins were reported, and there was no evidence of 
changes in weight, waist circumference or fasting glucose measurements. 
Although this study has several strengths, the results are of limited value in terms of 
estimating the effectiveness of statins in people with SMI because there was no 
comparison arm. However, it is reassuring that this larger study mirrors results 
published by Ojala and Landry, which outline significant reductions in triglycerides, total 
and LDL-C. Whilst this study does not provide robust evidence to demonstrate the 
effectiveness of statins in people with SMI, the results are compatible with the 
hypothesis that statins are effective in lowering total cholesterol, LDL-C cholesterol and 
triglycerides. 
6.1.4 De Hert et al. (2006)  
This study was a prospective cohort that aimed to evaluate the effectiveness of 
rosuvastatin in lowering lipid concentrations in individuals with schizophrenia and 
schizoaffective disorder. The study population outlined in this paper overlaps with the 
previous paper led by Hanssens: however, the extent of overlap is not reported. All 
consecutive hospital inpatients and outpatients with a diagnosis of schizophrenia or 
schizoaffective disorder were prospectively invited to participate in extensive screening 
and follow-up of their metabolic parameters; the study started in November 2003 and 
available data extending to the period December 2005 were included in the paper. The 
study sample comprised 100 patients receiving antipsychotic treatment who had 
severe dyslipidaemia (meeting SCORE criteria (Conroy et al., 2003)). Treatment with 
rosuvastatin was initiated in 52 patients, who were compared with 48 patients who did 
not receive a statin. Although the method of treatment allocation is not detailed in the 
paper, further communication with the authors has confirmed that patients were 
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enrolled into the comparison group if they had laboratory parameters that could have 
warranted use of a statin, but did not receive one during the study period (De Hert, M. 
Personal Communication 2/8/2013). Both patient groups received dietary advice at the 
start of the study. A full metabolic screen was undertaken three months before baseline 
(and the start of statin treatment in the intervention arm), and then three months after 
baseline. The authors used analysis of variance with repeated measures to assess the 
association between statin therapy and lipid levels. 
A total of 100 patients participated in the study; 78% were male and 98% were white 
Belgians. The average age was 38.5 (standard deviation 10.1) years and the mean 
duration of illness was 13.1 (standard deviation 9.6) years. A total of 80% of patients 
had a diagnosis of schizophrenia with the remaining being diagnosed with 
schizoaffective disorder. The two study arms were balanced at baseline in terms of 
demographic variables, treatment regimen or the proportion of patients with abnormal 
lipid parameters. All participants received antipsychotic treatment during the study but 
the duration of continuous treatment with the same agent was less than three months 
for over one quarter (28%) of patients. The majority of patients (92%) used second 
generation antipsychotics with 16% of patients taking more than one type of 
antipsychotic at baseline. Olanzapine (30%), risperidone (26%) and clozapine (24%) 
were the most frequently prescribed antipsychotics, and concomitant use of 
antidepressant and somatic medications was common (41% and 48% of patients, 
respectively). 
During the three month period between the study start date and baseline, the authors 
reported a worsening of the lipid profiles of participants in both arms of the study. 
These changes were statistically significant for total cholesterol, LDL-C and triglyceride 
levels (p≤0.04 in all instances). At the end of the study period the proportion of patients 
with abnormal lipid profiles had decreased in the statin group and increased in the 
control group, and there differences between the two groups was found to be strongly 
statistically significant (p≤0.0001 in all instances) for all parameters except HDL-C. In 
the statin arm of the study, the changes from baseline were greatest for LDL-C (45.9% 
reductions), triglycerides (41.1% reductions) and total cholesterol (38.1%). There were 
no statistically significant effects of statin therapy on other parameters measured by the 
study team, although a non-significant (the authors do not report a p-value) increase in 
weight and waist circumference was observed in both groups. Statin treatment was 
stopped in one patient who developed abnormally high levels of creatine kinase. 
This paper suggests that clinically relevant reductions in lipid levels are feasible with 
rosuvastatin over a 12 week duration for people with a diagnosis of SMI. However, 
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rosuvastatin would be expected to achieve greater reductions in lipids than statins such 
as simvastatin or atorvastatin (Law et al., 2003), which are more widely used for first 
line treatment in the UK (National Institute for Health and Clinical Excellence, 2014b). A 
major limitation of this study is that measured and unmeasured confounding factors 
may not be equally distributed across both arms of the study because patients were not 
randomised to each arm. The other limitations of this study are that the number of 
patients enrolled is moderately small (n=100) and conducted at only one site. 
Furthermore, the analysis was not adjusted for potential confounders, although the 
authors did not find any evidence of a difference between the groups in terms of the 
distribution of measured demographic and clinical characteristics at baseline. 
6.2 Registered trials 
A total of four relevant studies were identified through trials registries and a summary of 
these studies is outlined in Table 6-4. The studies identified were: 
1. Add-on simvastatin in schizophrenia trial, Gross (2008) 
2. Cardio risk of acute schizophrenia olanzapine Duke (CRASOD), 
McEvoy (2008) 
3. Effects of Pravastatin on cholesterol, inflammation and cognition in 
schizophrenia, Henderson (2010) 
4. Improving symptoms of schizophrenia and schizoaffective disorder by 
supplementing medications with pravastatin, Brar (2005) 
Two trials (Gross (2008) and McEvoy (2008)) were terminated early due to recruitment 
problems (with no available results). A third trial (Brar (2005)) was completed but the 
Principal Investigator has reported a decision not to publish because the results were 
negative (Brar, J., personal communication, 23/4/2012) and was not able to provide me 
with data for the study. 
The remaining trial (Henderson (2010)) has been completed and the results are 
incorporated into this review Table 6-3 (previously) and Table 6-5 (Vincenzi et al., 
2014). However, the publication was not identified in the initial literature search 
because it was undertaken before the manuscript was published. A quality appraisal of 
the trial is outlined in Table 6-6. The study examined the impact of randomly assigning 
a 12 week course of 40mg pravastatin daily or placebo to 60 adult outpatients with a 
diagnosis of schizophrenia or schizoaffective disorder from a single centre in the United 
States of America. The authors reported statistically significant decreases in LDL-C 
and total cholesterol (but not HDL-C or triglycerides) at 6 and 12 weeks after baseline. 
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At 6 weeks after baseline total cholesterol and LDL-C were each lowered by an 
additional 0.8mmol/L in statin users (reductions of 18% and 28%, respectively) 
(Vincenzi et al., 2014). Between baseline and 12 weeks total cholesterol was reduced 
by 0.5mmol/L and LDL-C lowered by 0.6mmol/L in the statin user arm relative to the 
placebo group. Although these absolute differences are modest, the relative decreases 
of 11% and 20% are substantial and reflect relatively low baseline lipid concentrations. 
The mechanism for randomisation and details of any measures to ensure blinding were 
not reported, however, the randomised design and placebo-control group means that 
the internal validity of this study is likely to be high. Conversely, the modest sample 
size and recruitment from a single site may limit the generalizability of the results. 
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Table 6-4: Summary of registered trials investigating the effectiveness of statins in people with SMI 
Title of trial Objective Population Intervention Comparison Relevant 
Outcome 
Target 
Sample 
size 
Status Sponsors 
Add-on 
Simvastatin in 
Schizophrenia 
Trial 
To determine 
whether 
simvastatin is 
effective in the 
treatment of 
symptoms of 
schizophrenia  
Individuals with 
schizophrenia 
aged 18-70 
years 
Simvastatin Treatment as 
usual 
Cholesterol 
concentration 
at 12 weeks 
Not 
known 
Terminated 
due to slow 
recruitment 
(no results 
available) 
New York State 
Psychiatric 
Institute, Stanley 
Medical 
Research 
Institute, 
Sheba Medical 
Centre, 
Merck Sharp & 
Dohme Corp. 
Cardio Risk of 
Acute 
Schizophrenia 
Olanzapine Duke 
(CRASOD) 
Four arm trial to 
determine whether 
metformin and 
simvastatin (either 
separately or in 
combination) are 
effective in 
reducing CVD risk 
during olanzapine 
treatment  
Individuals with 
schizophrenia 
aged 18-60 
years 
Metformin 
and/or 
simvastatin 
Treatment as 
usual 
Non-HDL-C at 
28 days 
120 
patients 
Study 
withdrawn 
due to lack of 
funding 
Duke University, 
North Carolina 
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Title of trial Objective Population Intervention Comparison Relevant 
Outcome 
Target 
Sample 
size 
Status Sponsors 
Effects of 
Pravastatin on 
Cholesterol, 
Inflammation and 
Cognition in 
Schizophrenia 
To determine 
whether 
pravastatin can 
lower cholesterol, 
decrease 
inflammation and 
improve cognition 
in patients with 
schizophrenia 
Individuals with 
schizophrenia or 
schizoaffective 
disorder aged 
18-68 years 
Pravastatin Placebo LDL-C at 6 and 
12 weeks 
60 
patients 
Published 
(Vincenzi, 
2014) 
Massachusetts 
General Hospital, 
Stanley Medical 
Research 
Institute,  
North Suffolk 
Mental Health 
Association 
 
Improving 
Symptoms of 
Schizophrenia 
and 
Schizoaffective 
Disorder by 
Supplementing 
Medications With 
Pravastatin 
To determine 
whether the 
addition of 
pravastatin to 
usual care 
improves 
symptoms of 
schizophrenia 
Individuals with 
schizophrenia or 
schizoaffective 
disorder aged 
18-65 years 
Pravastatin Treatment as 
usual 
Lipid enzyme 
levels 
Not 
known 
Study lead 
reported that 
the results 
were 
negative and 
that they will 
not be 
published 
University of 
Pittsburgh, 
Stanley Medical 
Research 
Institute 
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Table 6-5: Summary of trials (with results) investigating the effectiveness of statins in people with SMI 
Author Study 
design and 
time period 
Methods Participants Intervention/Exposure Comparison Outcomes Follow 
up 
Risk of bias 
Vincenzi 
(2014) 
Randomised 
placebo-
controlled 
pilot study 
 
(time period 
not outlined) 
Individuals were 
randomised to 
receive either a 12-
week supply of 
pravastatin 
(40mg/day) or 
placebo. Physical 
and mental health 
indicators (weight, 
waist measurement, 
lipids, glucose, C-
reactive protein, 
psychopathology 
and cognition) were 
measured at 
baseline, 6 and 12 
weeks. 
60 adult outpatients 
with a diagnosis of 
schizophrenia or 
schizoaffective 
disorder recruited 
from the Freedom 
Trail Clinic at the 
Erich Lindemann 
Mental Health Centre 
(Massachusetts, 
USA). Subjects were 
not eligible to 
participate if they did 
not comply with their 
psychiatric drug 
regimen, could not 
provide informed 
consent or had health 
conditions including 
severe CVD, current 
alcohol or substance 
abuse, diabetes 
requiring insulin 
treatment or were 
using anti-
inflammatory drugs. 
40mg pravastatin 
treatment daily for 12 
weeks 
Placebo LDL-C, HDL-C, 
triglycerides, total 
cholesterol, 
weight, BMI, waist 
circumference, 
markers of glucose 
metabolism, 
inflammation, 
cognition and 
psychopathology 
6 and 
12 
weeks 
Randomisation 
process not 
described. 
Possible 
selection bias 
and loss to 
follow up. 
Moderate 
sample size.  
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Table 6-6: Quality Assessment of literature retrieved through the systematic 
search, using the CASP (Critical Appraisal Skills Programme) checklist for RCTs 
CASP question: Vincenzi 
Did the trial address a clearly focused issue? Yes 
Was the assignment of patients to treatments 
randomised? 
Yes, although the randomisation 
process is not described 
Were patients, health workers and study personnel 
blinded? 
Not known 
Were the groups similar at the start of the trial? Yes 
Aside from the experimental intervention, were the 
groups treated equally? 
Yes 
Were all of the patients who entered the trial 
properly accounted for at its conclusion? 
Yes 
How large was the treatment effect? 20% reduction in LDL-C and 18% 
reduction in total cholesterol in 
individuals taking statins over a 12 
week period 
How precise was the estimate of the treatment 
effect? 
Precise 
Can the results be applied in your context? Yes 
Were all the clinically important outcomes 
considered? 
Yes 
Are the benefits worth the harms and costs? Not known 
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7 Discussion 
7.1 Key findings 
This systematic review identified a single small RCT seeking to evaluate the 
effectiveness of statins in people with SMI, which found that a 12 week course of 
pravastatin significantly lowered total cholesterol and LDL-C compared to placebo. The 
search also identified a number of trials that were terminated due to recruitment 
problems, which suggests that operating a statins trial in patients with SMI can be 
challenging. At least one study was not published due to negative findings, which might 
result in publication bias. I assessed evidence from non-randomised studies and 
identified four relevant studies. However, only one study compared patients who 
received statin therapy to patients who did not: this study provided some evidence that 
statins are effective in people with SMI, but was limited by non-random allocation into 
study groups and lack of adjustment for confounders, the choice of statin 
(rosuvastatin), small sample size, the single site recruitment, and a relatively short 
duration of follow-up. 
The study authored by Vincenzi is the first randomised and placebo-controlled study 
examining statin prescribing in individuals with SMI and the results are therefore 
important. However, this study is a pilot, has a modest sample size, no evidence of 
blinding, and a relatively short duration of follow up. At six weeks the study identified a 
decrease in LDL-C of 28%, which is on a par with national guidance that attributes 
decreases of 29% to 40mg pravastatin (Joint Formulary Committee, 2012). However, 
the results from Vincenzi’s study suggest that by 12 weeks the decrease in LDL-C was 
reduced to 20%, which raises concerns about the long-term effectiveness of statin 
therapy on lipid modification. Such findings could be compatible with declining statin 
medication adherence between 6 and 12 weeks after baseline; although estimates of 
adherence were not reported by the authors. By contrast, the study by De Hert 
indicated that rosuvastatin may result in larger absolute and relative reductions in lipid 
concentrations in people with SMI. However, although covariates measured at baseline 
did not differ between comparison arms within the study, the mechanism determining 
statin prescribing was not made explicit and the study arms could therefore differ with 
respect to unmeasured confounding. Individuals with SMI who received 10mg 
rosuvastatin had a 49% decrease in LDL-C relative to untreated individuals, which is 
similar to the 43% decrease in LDL-C observed in RCTs examining individuals without 
mental illness (De Hert M. et al., 2006;Law et al., 2003).  
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Of the four non-randomised studies that were identified through the search, all were 
limited by relatively small sample sizes, and three included no statin unexposed 
comparison arm. Despite these limitations, the level of concordance between study 
estimates is striking: total cholesterol was reduced in all groups that were prescribed a 
statin by 25-38%, LDL-C by 46-52% (except in the clozapine naïve arm of the Landry 
study, which was reduced by 19%), triglycerides by 35-53% and levels of HDL-C were 
increased by 4.3-16%. However, these estimates must be treated with caution as there 
is potential for residual confounding and the sample size was generally small, which 
leaves these studies vulnerable to chance findings. Furthermore, it was not possible to 
calculate 95% CIs for all of these estimates because the standard error of the 
difference in lipid concentration between baseline and the study end were not reported. 
The effect estimates from these studies have not been combined because each study 
selected different patient groups, which may not respond in the same way to statin 
therapy. In addition, the overlap between the studies authored by De Hert and 
Hanssens, makes combining these estimates as independent observations 
inappropriate. 
The key finding of this review is the lack of evidence on the long-term effectiveness of 
statins in people SMI. Although there is some evidence of lipid modification with 
pravastatin and rosuvastatin therapy there is a lack of information on statins (such as 
atorvastatin) which are most commonly prescribed for primary prevention of CVD in the 
UK. Furthermore, it is unclear how reductions in lipid concentrations over a three month 
period may translate into long term prevention of CVD events in people with SMI, and 
some suggestion that benefits seen may reduce over time, perhaps due to problems 
with adherence. Thus there is a gap in the evidence-base for assessing the 
effectiveness of statins in people with SMI, which has important implications for clinical 
and cost-effective CVD prevention in this patient group.  
7.2 Evaluation of search methodology 
I aimed to identify studies that investigated the effectiveness of statins on CVD risk in 
people with SMI. My search strategy incorporated a comprehensive set of subject 
headings and free text terms that were grounded in the domains of a clear and 
focussed research question. The resulting strategy was executed in a broad and 
complementary set of scientific, clinical and trials data sources with each of the search 
terms tailored to fit the indexing system of each database.  
I developed the search strategy by cross-referencing subject headings derived from the 
research question against terms indexed to four studies that were previously identified 
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as relevant, which helped to gauge whether the search strategies were working 
correctly. Further quality checks were undertaken by investigating which of the four 
studies were captured in each search and establishing (where relevant) why a 
particular reference was not included.  
The combined results from the search included all four of the non-randomised studies, 
suggesting that the criteria were appropriate. However, not all of the individual 
database searches included all four of the key studies. For example the Landry study 
was not captured in the search executed in PsycInfo, and further investigation 
established that the paper was indexed to a term for “Drug Therapy” rather than “statin” 
(or a synonym). In light of this, I evaluated four possible options; 1) include ‘drug 
therapy’ as a key word in the statins domain of the research question, 2) merging the 
domains 1 and 2 (CVD risk and statins) into a single domain, 3) including “lipid-
lowering medications”, which was the only statin equivalent term in the title of the paper 
as a free text term or 4) leaving the strategy in its current form. I tested the impact on 
the results of applying options 1 or 2 and established that with either search conducted 
in PsychInfo, approximately 2000 additional results would be obtained, which was not 
pragmatic given the available resources. Option 3 was successful in finding the Landry 
study in the search, however, the free text term was extremely specific and inclusion of 
this term in the search seemed illogical, particularly given that it did not result in any of 
the other key articles being retrieved by the search. I therefore opted to leave the 
search in its current form. This decision may have resulted in missing some studies  of 
relevance: however, it is unlikely that any randomised studies would have been missed 
because trials registries were also searched separately. 
7.3 Implications for this thesis regarding the effectiveness of statins for 
prevention of CVD in people with SMI 
This systematic review examined the effectiveness of statins for primary prevention of 
CVD amongst people with SMI and did not identify any information on CVD events, 
mortality or long term statin use in people with SMI. However, two small studies provide 
some limited evidence that statin therapy may be associated with significant reductions 
in total cholesterol (relative decreases of 11% and 35% for pravastatin and 
rosuvastatin, respectively) and LDL-C (relative decreases of 20% and 49% for 
pravastatin and rosuvastatin, respectively) over 12 weeks in 60-100 individuals with 
SMI. In addition, several RCTs have failed to run to completion due to recruitment 
problems. These findings suggest that a large scale study to evaluate the long term 
impact of statin prescribing, particularly on CVD outcomes, is needed.  
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Chapter 3 : Exploring the Effectiveness of Statins in 
Primary Care: Description of THIN Data and Quality 
1 Chapter content  
The previous chapter evaluated the evidence-base for statin prescribing for primary 
prevention of cardiovascular disease (CVD) in people with severe mental illness (SMI) 
and highlighted the need for research on long term statin use and estimates of the 
impact on CVD events and mortality. This chapter provides the justification for using 
data from The Health Improvement Network (THIN) to explore the real-world 
effectiveness of statins in people with SMI. The first part of this chapter outlines the 
requisite features of a data source for examining this research question and the 
rationale for selecting an observational study design over experimental options. The 
subsequent parts of the chapter focus on the data source and outline the mode of data 
capture as well as case definitions for the research question. The final part of the 
chapter considers data quality, including both the ascertainment and accuracy with 
which the population, intervention, comparison group and outcome for this research 
question can be identified. 
2 Requisite features of a data source to investigate the 
effectiveness of statins on CVD events in people with SMI 
Investigating the effectiveness of statins on CVD events in people with SMI requires a 
dataset which meets a variety of standards including: providing accurate information on 
a sufficient number and rate of CVD events, and availability of minimum set of 
variables including mental health diagnoses, the presence and timing of statin 
exposure and CVD events. To provide an indication of the necessary scale, the most 
recent Cochrane systematic review of statins for the primary prevention of CVD meta-
analysed data on 56,934 individuals from 19 randomised controlled trials (RCTs) with a 
minimum duration of 18 months (Taylor et al., 2013). In addition, any study must have 
a high level of internal and external validity in order to obtain unbiased estimates that 
are representative of people with SMI diagnoses who would be eligible for treatment 
with a statin. 
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2.1 Advantages and disadvantages of observational data relative to data 
from experimental study designs for investigating effectiveness 
“At its best a trial shows what can be accomplished with a medicine under careful observation 
and certain restricted conditions. The same results will not invariably or necessarily be observed 
when the medicine passes into general use.” 
Austin Bradford Hill, 1984 (Horton, 2000) 
A randomised study design is usually considered the gold standard of evidence for 
evaluating the optimal impact - and thereby reflecting efficacy (The Cochrane 
Collaboration, 2015) - of one treatment over another; including no treatment. This is 
because randomisation ensures that treatment allocation is not associated with 
baseline characteristics. However, large and long-running randomised studies are 
extremely expensive, can be vulnerable to selection bias and may apply eligibility 
criteria that result in a study population that does not reflect the clinical population of 
interest (Gilbody et al., 2002). In the case of statins RCTs, many studies have excluded 
people who were perceived as being less likely to comply with treatment: but in reality 
these individuals may form part of the target patient group (Beishuizen et al., 
2005;Nakamura et al., 2006;Knopp et al., 2006;Baldassarre et al., 2000). This issue is 
demonstrated by the exclusion of those with mental illness from many of the major 
statin trials, as described in Chapter 2 section 2.2 earlier. 
Non-participation in psychiatric (and non-psychiatric) trials also can result in selecting a 
study population that is not representative of the target group: non-participation is 
associated with poorer physical and mental health (Haapea et al., 2007) and 
differences in attitudes to health (Woodall et al., 2011). The PRIMROSE (Chapter 1, 
section 7) trial is an ongoing cluster-randomised trial of usual care versus a tailored 
intervention package that aims to increase physical medication adherence and promote 
lifestyle modification amongst people with SMI. A number of randomised studies 
outlined in the previous chapter (Chapter 2 section 6.2) were terminated due to 
recruitment issues; thereby demonstrating the difficulties of recruitment. Despite 
employing a range of service-user led initiatives to increase patient engagement, 
recruitment has also been a challenge for PRIMROSE and, on average, more than 12 
individuals were approached for every participant who was enrolled during the early 
waves of recruitment (Burton A., Personal Communication, 21/5/2015). There were two 
main drivers at work: a high rate of non-participation and - amongst individuals who 
were willing to participate - the proportion who met the eligibility requirements 
(cholesterol >5mmol/L plus one of: diabetes, body mass index (BMI) >30kg/m2, current 
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smoker or hypertension) was lower than anticipated. One possible explanation for 
these factors is that people who were willing to participate in the study may have had 
both a better relationship with their General Practitioner (GP) and had better 
management of CVD risk relative to non-participants. 
Observational data sources using routinely collected data (such as GP records) may be 
less prone to selection bias than trials because such systems often work on an opt-out 
basis and do not require formal consent. However, the comparability of treatment 
groups in observational studies may be compromised when the exposure is not 
randomly assigned, which will bias the results if confounding is not adequately 
controlled. There are methods that can help to reduce bias in observational studies of 
effectiveness: a detailed discussion of these factors is outlined in the next chapter with 
reference to studies investigating statins (Smeeth et al., 2009;Danaei et al., 
2013;Hippisley-Cox and Coupland, 2010). Given the potential for RCTs to produce 
estimates of effectiveness (but not efficacy) that are skewed by selection bias, the vast 
time and cost implications of such studies and the difficulties in recruitment seen in 
several studies in my systematic review of registered trials (Chapter 2 section 6.2), 
there is a strong argument for using observational data for producing the first estimates 
of the effectiveness of statins for primary prevention of CVD in people with SMI. 
2.2 Primary care databases in the UK 
This section of the chapter justifies the use of primary care data for investigating statin 
prescribing to individuals with SMI in terms of size, availability and data content and 
describes the scope of available data sources for the United Kingdom (UK). 
The provision of physical healthcare to individuals with SMI has been flagged as an 
area of priority within UK primary care (National Institute for Health and Clinical 
Excellence, 2012). Each GP surgery maintains a register of all individuals with SMI and 
is financially incentivised to offer these individuals an annual physical health screen to 
guide appropriate intervention (lifestyle modification, preventative medication and/or 
continued monitoring) (National Institute for Health and Clinical Excellence, 2012).  
Several  large UK primary care data sources are available including the Clinical 
Practice Research Datalink (CPRD),  THIN and QResearch (Gnani and Majeed, 2006).  
CPRD and THIN are the modern-day descendants of the Value Added Information 
Medical Products (VAMP) database, which was first set up in 1987. The original 
business model for the VAMP was to install computer systems and practice 
management software in GP offices across the UK with the intention of supporting both 
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administration and research: the offer of free software (at an estimated value of 
£25,000) incentivised practices to share anonymised data with the company (Garcia 
Rodriguez and Perez, 1998).  
Since inception, the ownership and name for the VAMP have changed, but the 
mechanism for data capture continues through the roll-out of Vision software, which is 
used by both the CPRD and THIN. There remains an overlap of about 60% of the GP 
surgeries contributing data to both the CPRD and THIN (Cai et al., 2012;Carbonari et 
al., 2015), whereas QResearch obtains data from practices using different software 
(EMIS) (Ogdie et al., 2012). Several studies assessing the development and 
performance of clinical risk scores across the three databases have reported a high 
level of similarity; suggesting that the research implications of selecting one database 
over another may be modest (Collins and Altman, 2009;Collins and Altman, 
2010;Collins and Altman, 2012;Reeves et al., 2014;Lewis et al., 2007).  
THIN will be the data source for this research. A full licence is available via the 
Research Department of Primary Care and Population Health, UCL and a range of 
existing work on SMI (Petersen et al., 2014;McCrea et al., 2015;Osborn et al., 
2011;Hayes et al., 2011;Hardoon et al., 2013;Osborn et al., 2013) and/or CVD risk 
(Garcia Rodriguez et al., 2000;Ogdie et al., 2015;Walters et al., 2014;de la Iglesia et 
al., 2011;Gunathilake et al., 2010) has used this data source.   
3 THIN database 
The next section of the chapter provides background information on THIN, which is 
used as the data source for my work investigating statin prescribing to individuals with 
SMI (outlined in Chapters 5 and 6). 
3.1 Data Capture 
Data held in THIN database are generated through information that is entered by the 
GP for the purposes of clinical management. Data capture is efficient, unobtrusive and 
enables longitudinal follow up. Data for the most recent year (2013) captures 
information from 587 practices covering 5.7% of the UK population (i.e. 12,374,853 
patients contributing 85,803,247 person years of data) (IMS Health, 2015). Previous 
work with THIN data has identified a cohort of approximately 13,000 individuals with a 
diagnosis of schizophrenia and 10,000 with bipolar disorder (Hardoon et al., 
2013;Osborn et al., 2011;Osborn et al., 2015). 
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The file structure and data content of THIN are outlined in Figure 3-1. Data are 
primarily recorded as medical codes, free text comments, drug codes for prescribed 
medications (based on the British National Formulary (BNF)(Joint Formulary 
Committee, 2012)), referrals and additional health information such as laboratory test 
results and biometrics. In addition, information from letters – such as hospital discharge 
letters – can be captured as scanned attachments or entered either as medical codes 
or free text comments. Medical codes are recorded using the Read clinical 
classification, which is a hierarchical system that was first developed in the 1980s for 
the purpose of providing a comprehensive and dynamic system for coding disease, 
clinical history, symptoms, examinations, findings and diagnostic procedures 
(Chisholm, 1990;Dave and Petersen, 2009). Read codes have been mapped to other 
coding systems including the international classification of diseases, injuries and 
causes of death (ICD9) and OPCS-4 surgical operations and procedure codes 
(Chisholm, 1990;Stuart-Buttle et al., 1996). 
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Figure 3-1: File structure for THIN redrawn from THIN Data Guide for Researchers (CSD Medical Research UK, 2011) 
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Standardised annual rates of all-cause mortality for practices reporting to THIN were 
evaluated against expected counts estimated using national deaths data in 
combination with the age and sex structure of the practice. The comparison of these 
estimates was used to establish the earliest date of acceptable mortality reporting 
(AMR) (Maguire et al., 2009). After the date of AMR there is much greater assurance of 
data quality; particularly when combined with other measures of reporting quality such 
as acceptable computer usage (ACU)(Horsfall et al., 2012).  The ACU date marks the 
earliest time point at which a practice entered an average of two or more therapy 
records, one medical record and one data item into the additional health record per 
patient per year (Horsfall et al., 2012).  
THIN data document the care initiated by, or relayed to, the GP and thus reflect real 
world treatment decisions and health outcomes as reported by the GP. Because almost 
all (98.5%, which excludes members of the armed forces, prisoners and illegal 
immigrants) of the usually resident population are eligible to register with a GP, primary 
care patients are roughly representative of the whole UK population.  Conversely, 
certain groups - such as homeless people – who are more likely to have mental health 
conditions are less likely to be registered and may therefore be under-represented in 
studies of primary care.  
I used an extract of data from THIN to form the dataset for the studies in this thesis, as 
described in Section 3.2 below, and in Chapters 5 and 6 following. 
3.2 Case definitions 
This section describes the definitions for terms applied to Chapter 5 (investigating 
patterns of CVD screening and statin prescribing in people with and without SMI - 
Thesis Objective 4) and Chapter 6 (investigating the impact of statin prescribing on 
CVD events - Thesis Objective 5). Read code and drug code lists were compiled using 
standard methods (Dave and Petersen, 2009). Where possible pre-existing code lists 
developed by The THIN Team at the Research Department of Primary Care and 
Population Health were used as the starting point for developing each code list.  
Full code lists for all case definitions are included in the appendix; section 20. 
3.2.1 GP surgery inclusion criteria 
GP surgeries were included in the studies outlined in Chapters 5 and 6 if they had at 
least three years of data recorded and a list size of at least 2000 patients. Practices 
were excluded if less than 80% of their patients had a record of Townsend score for 
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deprivation in order to restrict the data to practices that are likely to report higher quality 
data. Townsend score for the quintile of deprivation is the most completely recorded 
socio-economic metric available in THIN; this measure is based on the deprivation 
score assigned to the enumeration district (areas of approximately 150 households) for 
a patient’s address, according to census data for 2001. The Townsend score is 
expressed as national quintiles of deprivation reflecting unemployment, overcrowding, 
home and car ownership (Townsend et al., 1986). 
3.2.2 SMI diagnoses 
The code list used to identify individuals with SMI included 209 individual Read codes, 
which have been applied to other studies undertaken in THIN (Osborn et al., 
2015;Osborn et al., 2011;Hayes et al., 2011). Individuals were classified as having a 
diagnosis of SMI if they had a Read code recorded in their medical records indicating 
schizophrenia, schizoaffective disorder or bipolar disorder recorded at any time during 
or prior to the study period. Search words (and truncated synonyms such as schizo*) 
were used to compile the Read code list. In addition, Read codes that started with E1 
and Eu (mental disorders) were reviewed for relevant terms that were missed by the 
initial word search.  Code lists were reviewed by a clinician for irrelevant codes (e.g. 
depression without psychosis), which were excluded.  Terms for SMI included: 
Schizophrenia: schizophrenia, schizoaffective, paranoid schizophrenia 
Bipolar disorder: bipolar affective, psychotic depression, hypomanic psychoses, 
manic depressive, manic disorder, manic psychoses 
Individuals with other types of psychosis, or who only had a record indicating that they 
were on the SMI register, were not included in the study. This was because the clinical 
presentation of individuals with other types of psychosis is less well characterised than 
bipolar disorder or schizophrenia and could be too diverse to form a meaningful group. 
For example, the distribution of the age at diagnosis for other psychoses was more 
skewed towards older individuals than the age at which schizophrenia and bipolar 
disorder is typically diagnosed. This group may therefore differ both in terms of mental 
health and risk factors (such as older age) for CVD. Search words (and truncated 
synonyms such as psychos*) were used to compile the Read code list that was used to 
identify people with other psychoses or who were listed on the SMI register, but did not 
have a specific SMI diagnosis included the following terms: 
Other SMI: non-organic psychoses, oneirophrenia, affective psychoses, depressive 
psychoses, paranoid states, reactive psychosis 
 
 
76 
 
SMI register: severe mental illness register, national service framework mental health 
3.2.3 CVD events 
CVD events were identified from Read codes held in the medical records: CVD events 
were classified according to whether the Read code described a new (incident) or pre-
existing (prevalent) condition as well as the type of condition (myocardial infarction 
(MI), unstable angina, angina, haemorrhagic stroke, ischaemic and unspecified stroke, 
transient ischaemic attack (TIA), surgery, unspecified coronary heart disease (CHD) or 
unspecified CVD). Records of death that were associated with a CVD diagnosis were 
identified from Read codes held in the cause of death field (1016500000) in the 
additional health records. In addition, Read codes for CVD that were recorded after the 
date of death were assumed to reflect fatal CVD events. 
The code list used to identify individuals with CVD included 408 Read codes, which 
have been applied to other studies examining CVD risk in THIN (Osborn et al., 
2015;Osborn et al., 2011). Search words (and truncated synonyms such as 
atheroscler*) were used to compile the Read code list. In addition Read codes that 
started with G3, G6, Gy (circulatory system diseases) and 7 (operations, procedures 
and sites) were reviewed for relevant terms that were missed by the initial word search. 
Code lists were reviewed by a clinician for irrelevant codes, which were excluded. 
Terms for identifying CVD included: 
MI: myocardial infarct, MI, myocardial infarction, myocardial ischaemia, acute Q-wave 
infarct, acute non-Q wave infarct, anteroseptal infection, anterolateral infection, 
anteropical infraction, acute papillary muscle infarction, acute atrial infarction, 
subendocardial infarction, Dressler’s syndrome, ECG AND infarction, acute ischaemic 
heart disease, heart attack, post infarction pericarditis, thrombosis – coronary, coronary 
thrombosis, mural thrombosis 
Unstable angina and acute coronary syndrome: coronary thrombosis not resulting 
in myocardial infarction, ACS, stenocardia, unstable angina, crescendo angina, 
subendocardial ischaemia, coronary artery spasm, preinfarction syndrome, impending 
infarction, refractory angina, worsening angina, acute coronary syndrome, acute 
coronary insufficiency, acute and subacute ischaemic heart disease, microinfarction of 
heart, angina at rest, transient myocardial infarction 
Angina: stable angina, angina pectoric, angina on effort, Prinzmetal’s angina, angina 
control, syncope angina, chronic ischaemic heart disease, nocturnal angina, angina 
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decubitus, status anginosus, new onset angina, angina, chronic coronary insufficiency, 
chronic myocardial ischaemia, post infarct angina 
Haemorrhagic stroke: bulbar haemorrhage, intracerebral haemorrhage, capsule 
haemorrhage, cerebellar haemorrhage, cortical haemorrhage, non-traumatic 
intracranial haemorrhage, pontine haemorrhage, basal nucleus haemorrhage 
Ischaemic and unspecified stroke:  unspecified occlusion or stenosis of cerebral 
arteries, cerebral infarction, lateral medullary syndrome, stroke, basilar artery 
occlusion, brainstem infarction, Wallenberg syndrome, carotid artery occlusion, carotid 
artery syndrome, precerebral artery occlusion, vertebral artery occlusion, cerebral 
embolism, cerebral artery syndrome, infarction of basal ganglia, pure sensory lacunar 
syndrome, right sided CVD, left sided CVD amaurosis fugax, subclavian steal 
syndrome 
TIA: transient cerebral ischaemia, transient ischaemic attack, TIA, intermittent cerebral 
ischamia 
Surgery: angioplasty, operations on coronary artery, replacement AND coronary 
artery, bypass AND coronary artery, connection AND coronary artery, exploration of 
coronary artery, repair of coronary artery, stent AND coronary, anastomosis AND 
coronary, Endarterectomy AND coronary, percut transluminal coronary thrombolysis, 
Unspecified CHD: ischaemic, coronary vessel disease, coronary artery disease, 
atherosclerotic heart disease, atherosclerotic cardiovascular disease, CHD 
Unspecified CVD: cerebrovascular disease, cerebral artery syndrome, cardiovascular 
disease, stenosis of precerebral arteries, vertebrobasilar insufficiency, basilar artery 
syndrome, CVD, cerebral atherosclerosis, cerebral ischaemia 
3.2.4 Statin prescriptions 
Statin prescriptions were identified from therapy records corresponding to drug codes 
for statins outlined in Chapter 2.12 (lipid-modification) of the BNF (Joint Formulary 
Committee, 2012) and by searching for generic drug names including the term “statin”. 
Code lists were reviewed by a clinician for irrelevant codes (e.g. mycostatin), which 
were excluded. 
Terms for identifying statin medication included: 
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Statin: *statin, fluvastatin, simvastatin, rosuvastatin, cerivstatin, atorvastatin, 
pravastatin, lipitor, lescol, lipostat, crestor, zocor 
Individuals were classified as statin users if they had one or more records indicating 
that a statin was prescribed. The date of the first prescription was used to estimate the 
start of statin treatment. The last date of prescribed statin medication was calculated as 
the date of the last statin prescription plus the estimated duration of the last 
prescription.  The estimated duration of prescriptions was derived as follows:  
It was assumed that plausible values for the duration of each statin prescription should 
lie within the range 7-112 days, with the most common duration (obtained from the 
BNF) anticipated as 28 days (Joint Formulary Committee, 2012).  Information on the 
duration of prescription is held in several fields in THIN.  The number of days for which 
the prescription was issued was the preferred data source because this directly 
captured the intended duration of treatment. However, approximately 95% of statin 
records for the cohort held null values and therefore additional information from pack 
size description and prescription quantity was used to estimate treatment duration 
where the number of days of medication was not recorded.  Prescription quantity was 
highly completed (<0.05% null values) but contained an unmarked mixture of the 
number of packs and tablets.  By contrast, pack size was poorly completed but 
sometimes included an unambiguous description of the medication quantity (e.g. “28 
tablets once daily”).   
Where the number of days of medication was not reported (or was outside the range 7-
112 days) values for the duration of treatment were derived as follows.  Plausible 
information on the pack size description was used in combination with the prescription 
quantity: for plausible values of pack size (7-112 days) and prescription quantity (1-6 
packs) the pack size was multiplied by the prescription quantity.  Where information 
from other fields was not available plausible values (7-112 days) of prescription 
quantity were used to estimate the duration of treatment.  Finally, remaining records 
with an estimated duration of less than 7 days or more than 112 days (<0.5%) were 
replaced with a duration of 28 days, which was the median derived from the observed 
data. 
3.2.5 Conventional CVD risk factors 
Data on conventional CVD risk factors (smoking status, height, weight, BMI, diabetes, 
systolic and diastolic blood pressure, treatment for hypertension, total cholesterol and 
high density-lipoprotein cholesterol (HDL-C)) in combination with age and gender are 
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likely to be the greatest predictors of both statin prescribing and future CVD events. 
This is because this information is used by clinicians to estimate a CVD risk score for 
an individual patient (D'Agostino et al., 2008). CVD risk scores that are calculated by 
the GP are not routinely captured in THIN data, meaning that it is necessary to 
estimate the risk score using available information on CVD covariates. 
Data on CVD risk factors were identified in line with other studies undertaken in THIN 
(Osborn et al., 2015;Marston et al., 2014;Freemantle et al., 2013;Osborn et al., 
2011;Walters et al., 2014): 
Age in years: calculated as (date of interest minus the date of birth (held in adult 
patient records as year of birth)) divided by 365.25 
Gender: held in the patient records (sex) 
Smoking status: Read codes held in either the additional health records 
(1003040000) or the medical records were used as follows to classify an individual’s 
smoking status for a given record:  
Current smokers: 1372.00, 1373.00, 1374.00, 1375.00, 1376.00, 137..11, 
8CAg.00, 8CAL.00, E251.00, E251000, E251100, E251z00, 137H.00, 137J.00, 
137P.00, 137P.11, 137Q.00, 137R.00, 137V.00, 1372.11, 137b.00, 137C.00, 
137c.00, 137d.00, 137f.00, 137g.00, 137G.00, 137h.00, 137M.00, 8H7i.00, 
8HTK.00, 9N2k.00, 9N4M.00, 67A3.00, ZG23300, ZV4K000, 8I2I.00, 8I39.00, 
ZRBm200, ZRBm211, 137Y.00, 6791.00 
Ex-smokers: 1377.00, 1378.00, 1379.00, 137A.00, 137B.00, 137F.00, 
137K.00, 137N.00, 137O.00, 137S.00, 137T.00, 13p4.00 
Never smokers: 1371.00, 1371.11 
Smoking cessation: Prescriptions recorded in the therapy records were used 
to indicate smokers attempting to quit (i.e. transition from current to ex-smoker 
status) and included the following generic drug names: nicotine, varenicline, 
menthyl valerate and quinine, buproprion. 
Weight: Records of weight (and the associated unit of measurement, e.g. kilograms) 
were identified from the additional health records (1005010200) 
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Height: Records of height (and the associated unit of measurement, e.g. centimetres) 
were identified from the additional health records (1005010100) and retained for 
measurements taken at or after the age of 21 years 
BMI: BMI was estimated as weight in kilograms divided by height in metres squared 
Diabetes: Records indicating diabetes were identified using additional health records 
(1009100000, 1020000004, 1001400327, 1001400140 and 1009120000), which 
indicate checks in people with a diagnosis of diabetes (e.g. for diabetic retinopathy) or 
diabetes medication.  Read codes held in the medical records indicating the following 
conditions were also used to identify people with diabetes. 
Diabetes: diabetic, diabetes, insulin, referral to diabetologist, diabetology, IDDM, 
NIDDM,   
In addition Read codes that started with C1 (endocrine, nutrition, metabolic and 
immunity disorders) were reviewed for relevant terms that were missed by the initial 
word search.  Code lists were reviewed by a clinician for irrelevant codes, which were 
excluded. 
Systolic and diastolic blood pressure: Records of blood pressure (and the 
associated unit of measurement; mmHg) were identified from the additional health 
records (1005010500). 
Antihypertensive medication: Records indicating treatment with antihypertensive 
medication was identified as drugs listed in Chapter 2.2.1 (thiazides and related 
diuretics), 2.5.5.1 (angiotensin-converting enzyme inhibitors), 2.5.5.1 (angiotensin-II 
receptor agonists), 2.6.2 (calcium-channel blockers) and 2.4 (beta-adrenoceptor 
blocking drugs) of the BNF (Joint Formulary Committee, 2012). 
Total cholesterol concentration and HDL-C: Records of cholesterol concentration 
(and the associated unit of measurement) were identified from the additional health 
records (total cholesterol; 1001400017 and HDL-C; 1001400031). 
3.2.6 Estimating CVD risk 
CVD risk scores were estimated in THIN using published Cox proportional hazards 
regression coefficients for men and women participating in the Framingham Heart 
Study (D'Agostino et al., 2008) in combination with the formula:  
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Where S0(t) is 10 year baseline survival, βi is the estimated regression coefficient 
outlined in the appendix (Table 19-1 and Table 19-2), Xi is the log of the value of the i th 
risk factor for continuous variables, i is the associated mean value and p is the 
number of risk factors. Further detail including mean values for the Framingham cohort 
and worked examples for calculating CVD risk are outlined in the original paper 
(D'Agostino et al., 2008). 
3.2.7 Psychiatric medication 
Individuals who were prescribed antipsychotics, antidepressants or mood stabilizers 
were identified using code lists for the following generic drug names: 
Antipsychotics 
First generation: benperidol, chlorpromazine, chlorprothixene, droperidol, 
flupentixol, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, 
pericyazine, perphenazine, pimozide, pipotiazine, promazine, thiopropazate, 
thioproperazine, thioridazine, trifluoperazine, trifluperidol, zuclopenthixol 
Second generation: amisulpride, aripiprazole, asenapine, clozapine, 
olanzapine, oxypertine, paliperidone, quetiapine, remoxipride, risperidone, 
sertindole, sulpiride, zotepine 
Mood-stabilisers 
carbmazapine, lamotrigine, lithium, sodium valproate 
Antidepressants 
Monoamine-oxidase inhibitor: iproniazid, isocarboxazid, moclobemide, 
phenelzine, tranylcypromine, trifluoperazine 
Selective serotonin re-uptake inhibitor (SSRI): citalopram, escitalopram, 
fluoxetine, fluvoxamine, paroxetine, sertraline 
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Tricyclic: amitriptyline, amoxapine, bolvidon, butriptyline, clomipramine, 
desipramine, dosulepin, dothiepin, doxepin, imipramine, iprindole, lofepramine, 
maprotiline, merital, mianserin, nomifensine, nortriptyline, perphenazine, 
protriptyline, sinequan, tofranil, trazodone, trimipramine, viloxazine, zimelidine 
Other: agomelatine, duloxetine, flupentixol, l-tryptophan, mirtazapine, 
nefazodonem, reboxetine, tryptophan, venlafaxine 
Defining predominant antipsychotic type 
In the main study (Chapter 6) the predominant type of psychiatric medication was 
investigated during baseline. Individuals who were prescribed multiple types of 
antipsychotic during baseline were classified by the drug with the greatest number of 
prescriptions. Manual review of data for 20 individuals suggested that the method of 
classification described above was an appropriate measure of the predominant drug 
type.  A possible exception was for antipsychotic drugs delivered by depot injection 
(which facilitates slow-release of the medication), where some misclassification may 
have occurred for individuals who received a mixture of tablets and depot injections 
and where both the type and treatment duration of prescription differed. However, this 
scenario is likely to be relatively uncommon and is most likely to reflect periods of 
transition from treatment with orally administered second generation drugs to depot 
injection of first generation drugs (or vice versa).  In addition, psychiatric medication 
issued outside primary care settings (particularly hospital outpatient clinics issuing and 
monitoring clozapine) may be under recorded in primary care prescribing data (The 
NHS Information Centre, 2011). 
3.2.8 Healthcare Factors 
Annual face-to-face consultation rate in primary care was used as a measure of 
healthcare utilisation, types of consultation included consultations both within surgery 
opening hours and out of hours. Face to face consultations were identified from the 
following consultation codes: nursing home visits were not included. 
Face to face consultations: walk-in centre (consultation code 034), night visit, 
practice (006), emergency consultation (018), clinic (001), community clinic (100), 
surgery consultation (009), acute visit (011), out of hours, non-practice (008), home 
visit (027),  out of hours, practice (007), night visit (110), co-op surgery consultation 
(036), co-op home visit (037), follow-up/routine visit (003) 
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3.2.9 Comorbidity 
Having one or more comorbid conditions is likely to result in more frequent GP 
consultations and thereby increases the opportunities available for GPs to prescribe a 
statin. Statin prescribing is also likely to be more common amongst patients who have 
a condition that is associated with increased risk of CVD. Comorbid diagnoses and 
conditions that were identified from the literature as of potential relevance included 
familial hypercholesterolaemia, hypothyroidism, cancer (by diagnosis type), heavy 
drinking, diabetes, chronic obstructive pulmonary disease (COPD), asthma, chronic 
kidney disease (CKD) and atrial fibrillation. In addition, individuals who were prescribed 
drugs that are used for lipid modification but are not statins (e.g. fibrates) during 
baseline were identified using a drug code list derived from Chapter 2.12 (lipid-
modification) of the BNF. 
Read codes held in the medical records were also used to identify people with the 
following conditions: 
Hypothyroidism: hypothyroidism, cretinism, Pendred’s syndrome, Goitrous cretin, 
myxoedema, thyroid deficiency, thyroid insufficiency, acquired atrophy of thyroid 
Cancer (broad description of diagnosis type – see appendix (section 20.17) for 
detailed break-down): neoplasm (not otherwise specified), dermatological, gastro-
intestinal, metastasis, haematological, chest, respiratory, bone, central nervous system 
COPD: COPD, chronic obstructive pulmonary disease, chronic obstructive airways 
disease, chronic bronchitis, bronchiolitis obliterans, emphysema, Sawyer-Jones 
syndrome 
Asthma: asthma, hyper-reactive airways disease, status asthmaticus, allergic 
bronchitis 
CKD: chronic kidney disease (stages 3-5), CKD (stages 3-5), chronic renal disease, 
chronic renal impairment 
Atrial fibrillation: atrial fibrillation 
Heavy drinking: review of additional health records (1003050000) and the associated 
units for drinking habits indicating consumption of ≥28 (women) and 35 (men) units per 
week. In addition, the following Read codes were used to identify heavy drinkers. 
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Heavy drinkers: alcohol intake above recommended sensible limits, binge 
drinker, moderate drinker, non-dependent alcohol abuse, alcoholic hepatitis, 
chronic hepatitis, hepatic failure, liver failure, alcohol amnestic syndrome, 
alcohol dependence, alcohol problem drinking, alcohol withdrawal, alcohol-
induced chronic pancreatitis, alcoholic dementia, alcohol sclerosis of liver, 
alcoholics anonymous, alcoholic psychoses, portal cirrhosis, chronic alcoholic 
syndrome,  harmful alcohol use, heavy drinker, hepatic failure, Laennec’s 
cirrhosis, recurrent hepatitis, toxic hepatitis, toxic liver, Wernicke’s,  
Read codes indicating “history of alcoholism” or “ex-alcoholic” were not included. 
Familial hypercholesterolaemia: Read codes indicating familial 
hypercholesterolaemia and/or a record of total cholesterol concentration >7.5mmol/L 
was used to identify people with possible familial hypercholesterolaemia (National 
Institute for Health and Clinical Excellence, 2008a).  Further evaluation of the strengths 
and limitations of this definition are outlined in the discussion (Chapter 7, section 9.6). 
Non-statin lipid modification: review of therapy records for all drugs outlined in 
Chapter 2.12 of the BNF (Joint Formulary Committee, 2012) excluding all drugs 
previously identified as statins (see Section 3.2.4) 
3.2.10 Economic and Social Factors 
Townsend score (held in patient records within THIN) has been shown to be correlated 
with an individual’s health status (Adams et al., 2005).  Other potentially relevant 
economic and social factors – such as household income and employment - are not 
recorded in THIN.  Information on ethnicity is captured in primary care data, but is 
infrequently and inconsistently recorded for patients registered prior to 2006 (Mathur et 
al., 2014). However, recording increased dramatically following the introduction of the 
Quality and Outcomes Framework (QOF) in 2004 (National Institute for Health and 
Clinical Excellence, 2012). 
3.2.11 Summary of the availability of data in THIN 
Chapter 1 introduced key factors identified from the literature that are associated with 
both statin prescribing and CVD events in people with SMI. Many, but not all, of the 
factors identified in Chapter 1 are recorded in THIN: Figure 3-2 outlines key data on the 
relationship between statin prescribing and CVD in primary care, and the likely 
direction of causal associations given information from the literature. Relative to the 
causal network outlined in Figure 5-1 of Chapter 1, information on several factors 
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(severity of mental illness, genetics, ethnic group and some lifestyle factors for such as 
diet and physical activity) is not systematically recorded in THIN, meaning that it is not 
possible to fully account for differences in the distribution of these characteristics in 
individuals prescribed a statin relative to non-statin users. However, because these 
factors are associated with other measured variables – for example psychiatric 
medication is likely to be correlated with severity of mental illness – residual 
confounding should be somewhat reduced. In addition, some information – such as 
economic and social factors – is imperfectly reflected in the information that is available 
in THIN, meaning that it will not be possible to fully adjust for these confounders. A 
discussion of the strengths and limitations of the information captured in THIN and the 
likely impact on the study results is outlined in Chapter 7. 
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Figure 3-2: Causal diagram for the relationship between statin prescribing in primary care and CVD events in people with SMI 
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4 Time period for the studies outlined in this thesis 
Preliminary investigations showed that the rate of statin prescribing for primary 
prevention was very low prior to 2002 (Figure 4-1 – vertical grey line indicates the 
calendar year 2002) with the total number of new prescriptions being issued annually to 
approximately 10,000 individuals with SMI being less than 100 prior to 2002.  Chapters 
5 and 6 therefore use data on statin prescribing for the time period 1st January 2002 to 
31st December 2012.  
Figure 4-1: Rates of statin prescribing (per 1000 person years) for primary 
prevention of CVD in people with and without SMI between 1995 and 2012 
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5 Data Quality 
“if you put into the machine wrong figures, will the right answers come out?"  
Charles Babbage, Passages from the Life of a Philosopher (Babbage, 1864) 
The next section of this chapter considers the quality of data captured in primary care 
databases including THIN. Primary care databases offer significant opportunities for 
analyses that can inform public health policy and practice. However, the results of such 
analyses can only be as good as the underlying data. Validity and completeness are 
two key aspects of data quality, which are often quantified using estimates of 
sensitivity, specificity, negative and positive predictive values (Goldberg et al., 1980). 
These measures do not provide information about data quality per se, but rather on the 
performance of a test either in isolation (sensitivity and specificity) or within a given 
population (negative and positive predictive values). Analyses of primary care data rely 
upon methodological tests applied by researchers to identify specific conditions using 
drug and medical codes, free text searching or other more complex algorithms. These 
tests are not perfect and are subject to measurement error arising at the level of the 
test, GP recording and the original observation (including medical diagnostics). For 
example, if individuals with SMI are identified through using a list of Read codes to find 
cases, some individuals with SMI may be missed if the code list used by the researcher 
omits the Read code for a given condition or, alternatively, if the diagnosis was entered 
as free text only.  
Validation studies aim to estimate the degree of measurement error for key study 
components such as the outcome and exposure by comparison with a “gold standard”. 
For primary healthcare data, the gold standard often includes patient notes held at the 
GP practice, additional questionnaires or other linked datasets. Validation of the 
outcome and exposure under investigation is particularly important because 
inaccuracies in these measurements has the potential to introduce substantial 
uncertainty and may bias the results.  
5.1 How valid are data from UK primary care databases? 
This section of the chapter describes the validity of primary care databases - including 
THIN – and evaluates published evidence on the validity of case definitions applied to 
the studies outlined in Chapters 5 and 6. Further discussion of the implications of these 
aspects of data quality is outlined in Chapter 7; section 9. 
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A systematic review of CPRD validation studies identified 212 publications that 
investigated 357 separate validations of 183 diagnoses (Herrett et al., 2010). The 
majority of these studies (>80%) measured validity against external data sources 
predominantly using a mixture of GP questionnaires, requests for copies of the medical 
records or comparison of disease rates. Across the breadth of conditions covered, 89% 
of cases with a diagnosis recorded in the database were confirmed by an internal or 
external data source. The range of confirmed diagnoses differed by disease category 
and method of validation (24-100%), but was at least 80% for all categories except 
diseases of blood and blood forming organs. The high level of confirmation of 
diagnoses provides evidence of a generally high positive predictive value, but the 
review found few studies that examined sensitivity, specificity or negative predictive 
values, which are important aspects of data quality. The lack of studies examining 
these aspects may be explained by the cost (estimated in 2009 as £70 per patient) of 
manually reviewing patient notes to confirm that non-cases are correctly classified. 
Furthermore, as only a subset of the GP surgeries that regularly contribute data to 
CPRD participate in additional research activities, the findings of existing validation 
studies may not be generalizable to all data providers (Herrett et al., 2010).  
5.2 Data quality for the case definitions for the population (individuals 
with SMI), intervention (statin prescriptions) and outcomes (CVD and 
mortality) of this study 
Systematic reviews of validation studies are relatively uncommon and I was unable to 
identify one specific to THIN. However, individual validation studies have been 
published for THIN and its precursor VAMP, for conditions that are the focus of this 
research question. 
5.2.1 Population: people with SMI 
Nazareth and colleagues assessed the accuracy of diagnoses of schizophrenia and 
non-affective psychosis in London practices that reported to VAMP in 1990. The study 
compared computerised diagnoses entered by GPs to written records to confirm two 
tiers of criteria (strict and broad) for a lifetime diagnosis. In addition, case note review 
was undertaken for all patients who did not have a diagnosis of schizophrenia, but who 
were prescribed antipsychotics. Finally, a further 8000 case notes for adults without a 
diagnosis or associated prescribing were reviewed for evidence of psychosis that was 
not captured in electronic records. The sensitivity of diagnoses recorded in VAMP for 
schizophrenia, non-affective psychosis and non-organic psychosis was 88-93% (strict 
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criteria) and 71-91% (broad criteria) with positive predictive values ranging from 71-
91% (strict criteria) and 81-100% (broad criteria) (Nazareth et al., 1993). 
More recently, Hardoon and colleagues estimated the incidence of SMI using THIN 
data. The incidence was 46.4 per 100,000 person years for combined diagnoses of 
SMI, and 9.2 and 15.0 per 100,000 person years for schizophrenia and bipolar 
disorder, respectively (Hardoon et al., 2013). These figures are similar to - but 
somewhat higher than - a recent meta-analysis which was outlined in Chapter 1 section 
3 (Kirkbride et al., 2012). This difference may reflect lower ascertainment of hospital 
cases (the basis for many of the published estimates included in the meta-analysis) 
than primary care, as not all individuals require hospital care and people with SMI may 
be more likely to be registered with a GP than the general population. 
These studies suggest a high degree of validity for diagnoses of SMI recorded in THIN; 
particularly schizophrenia and non-organic psychosis, for which estimates of sensitivity 
and specificity are known.  
5.2.2 Exposure: receiving a statin prescription 
I was unable to identify any published validation studies of statin prescribing in UK 
primary care databases, however, the process of prescribing should be well recorded 
because electronic data capture is an automated feature of issuing a prescription in a 
GP surgery. By contrast, it is less clear how prescribing translates into therapeutic 
exposure because individuals may not fill the prescription and/or take the medication.   
Studies investigating all prescriptions issued by a sample of practices reporting to THIN 
suggest good correlation between prescribing and redemption of the prescription; 98% 
of CVD medications were dispensed as prescribed (The NHS Information Centre, 
2011). However, some prescriptions – particularly those issued in hospital or during 
home visits – may not be fully captured.  Estimates from the literature suggest non-
adherence is relatively high for statins: one in six individuals do not fill their first statin 
prescription and long term estimates of statin medication compliance for primary 
prevention in the general population are approximately 50% (Naderi et al., 
2012;Poluzzi et al., 2008;Cheetham et al., 2013;Halava et al., 2014). 
In addition, it is possible to buy low dosage simvastatin over the counter without a 
prescription, meaning that these individuals may be misclassified as not being a statin 
user. However, because equivalent prescribed medication is much cheaper, 
misclassification arising due to over-the-counter statin use is unlikely to substantially 
impact upon the results. In addition, people with SMI are more likely than the general 
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population to be entitled to free or subsidised prescription costs making over the 
counter purchase of statins (at full price) an unfavourable choice.  
5.2.3 Outcomes: CVD events and mortality 
A systematic review of 55 validation studies of circulatory system conditions carried out 
using data confirmed that a median of 85.3% of diagnoses recorded in the CPRD could 
be verified by GP record request, algorithm or manual review. Information was not 
presented on specific CVD diagnoses such as MI or stroke (Herrett et al., 2010).  To 
date, no systematic reviews of validation studies are available specifically for THIN 
data, however positive predictive values for individual CVD diagnoses (outlined below) 
appear comparable to CPRD and well established biological associations have been 
replicated for key CVD diagnoses in both databases (Lewis et al., 2007). 
5.2.3.1 Fatal and non-fatal MI 
Garcia-Rodriguez et al. undertook a two stage validation process of Read codes for 
fatal and non-fatal MI using THIN data. Fatal MI was defined as “post-mortem evidence 
of fresh MI or a recent coronary artery occlusion or ante-mortem evidence of CHD in 
the absence of another cause of death or recorded CHD as the underlying cause of 
death”. Stage one of the validation process reviewed the computerised patient profile to 
exclude patients who were not admitted to hospital or those who were hospitalised in 
the previous month for a non-cardiac condition. Stage two obtained GP confirmation of 
the diagnosis in a random sample of 500 cases. The study team were able to confirm 
85% and >95% of diagnoses at stage one and two, respectively. Non-cases of MI were 
not reviewed (Garcia Rodriguez et al., 2004;Garcia Rodriguez et al., 2008). 
5.2.3.2 Ischemic cerebrovascular diagnoses 
Ruigomez and colleagues undertook a three step validation process to confirm 
diagnoses of ischemic cerebrovascular diagnoses. Stage one was a manual review of 
computerised medical records (excluding free text) for cerebrovascular diagnoses and 
hospitalisation within two weeks. Stage two extended the manual review of 
computerised medical records to include free text of a random sample of 300 possible 
cases and 100 non-cases. Stage three reviewed full medical records and a GP 
questionnaire for randomly sampled potential cases and non-cases. Of 15397 
individuals with a first cerebrovascular event in the study period, 4239 (28%) had a 
record that indicated hospitalisation within two weeks. During the first validation step 
81% of 4239 possible cases were confirmed and 792 were excluded (including 336 
where the event was haemorrhagic rather than ischaemic). Step 2 validated a sample 
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of possible cases and non-cases and suggested that 245/300 (82%) of cases were 
positive and that 88/100 (88%) non-cases were negative. The third validation step 
resulted in 138/161 (86%) confirmed cases and 50/61 (82%) confirmed non-cases. 
Positive predictive values varied by diagnosis type and were markedly lower for TIA 
than other diagnoses (Stage One: 60% for TIA versus 83% for stroke and 88% for 
unspecified cerebrovascular events. Stage Two: 74% for TIA versus 90% for stroke 
and 92% for unspecified cerebrovascular events) (Ruigomez et al., 2010). 
5.2.3.3 Haemorrhagic stroke 
Gaist et al. investigated the validity of primary diagnoses of non-traumatic 
haemorrhagic stroke, comprising intracerebral haemorrhage or subarachnoid 
haemorrhage. The study team reviewed electronic health records from THIN including 
free text comments to confirm that events were not: ischaemic, prevalent or induced by 
trauma. In addition, cases were excluded if the patient had a diagnosis of cancer, was 
hospitalised at the time of the event or subdural haemorrhage preceded the event. 
Further validation of 400 computer-detected cases was confirmed by GP questionnaire 
and review of anonymised medical records including use of computed tomography, 
magnetic resonance imaging, x-ray angiography or lumbar puncture (subarachnoid 
haemorrhage only).  The review of computerised records resulted in the exclusion of 
697 cases leaving 3633 potential cases (84%). The majority of exclusions reflected 
ischaemic diagnoses (35%), trauma (25%) or a diagnosis that could not be confirmed 
(16%). A further consequence of the review was that the date at which the event 
occurred was revised for 589 cases (19%): on average the true date of the event was 
believed to have occurred 13 days earlier than the date assigned to the initial Read 
code. Of the 400 computer detected computer cases that were validated by 
questionnaire and full medical record review, responses were available for 369: 
251/306 (82%) were confirmed as cases and 56/63 probable non-cases (89%) were 
discarded (Gaist et al., 2013). 
5.2.3.4 Combined fatal and non-fatal CVD events 
I was unable to find any validation studies for combined fatal and non-fatal CVD 
events, including diagnoses of angina or unspecified CHD. This is of concern because 
these diagnoses may refer to less severe events or non-specific conditions that may be 
of lower diagnostic validity than outcomes such as MI. In particular, it may be difficult to 
determine whether the record refers to a pre-existing condition, or if the individual was 
truly free of the condition prior to the date at which the Read code was recorded. 
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5.2.4 All-cause mortality 
A study investigating recording of all-cause mortality in THIN was able to confirm 99% 
of recorded deaths through additional contact with the GP surgery. The study 
examined deaths occurring within a one year period within in a subset of individuals 
who had a weight measurement taken between January 2002 and December 2008: the 
cohort comprised 142,082 individuals from 118 practices for which a total of 1,621 
deaths were identified  The study did not investigate the number of deaths that were 
not captured in THIN (Hall, 2009). 
5.2.5 Cause of death 
The study by Hall (Hall, 2009) also investigated recording of the cause of death and 
established that ascertainment of this information was much lower than for all-cause 
mortality. A cause of death was recorded in the form of Read codes for 47% of 
reported deaths and in free text for a further 17% (Hall, 2009). 
5.2.6 Interpretation of validations studies for CVD events and mortality 
These validation studies provide evidence that some types of CVD events recorded in 
THIN have a high positive predictive value and are therefore likely to provide a true 
indication of the presence (but not absence) of disease. In particular, diagnoses of MI 
were particularly well correlated with hospital admission and GP verification (positive 
predictive value >95%). The certainty with which diagnoses of stroke were recorded 
was more complex. Ischaemic stroke was poorly correlated with hospital admission: 
however, this may reflect long rehabilitation periods following stroke, which may make 
temporal linkage of the hospital admission to the CVD event more challenging. It is 
therefore possible that some unconfirmed diagnoses of ischaemic stroke may reflect 
more complex or severe CVD events. Records of haemorrhagic stroke were more 
highly correlated with admission to hospital. Furthermore, the majority of unconfirmed 
cases of haemorrhagic stroke reflected other types of (ischaemic) CVD events, which 
should not introduce bias if ischaemic and haemorrhagic events are examined in 
tandem. 
Although the positive predictive values for records indicating MI or hospitalised stroke 
in THIN were generally high, estimates of sensitivity have not been estimated. 
Incomplete ascertainment of CVD outcome data may introduce bias into estimates of 
the effectiveness of statins if the sensitivity of recording differs between statin users 
and non-users (e.g. higher ascertainment of events amongst statin users is likely to 
under-estimate effectiveness). 
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External validation of all-cause mortality data from THIN suggests both a high 
sensitivity and specificity of recording. In addition, the application of measures – such 
as restricting data to time periods after the date of AMR or ACU – provides further 
assurance that data quality is high. By contrast, information on the cause of death is 
substantially incomplete, and the sensitivity of recording for specific causes of death 
(e.g. those relating to CVD diagnoses) is therefore likely to be low. 
6 Summary and implications for this thesis 
Data from THIN provide an efficient way of capturing information on a large number of 
individuals, who have been followed up over time, and are representative of the UK 
population. These data have the advantage of being passively collected through 
routine clinical practice and the study population may therefore be less vulnerable to 
selection bias than clinical trials. Conversely, because data are collected for the 
purposes of clinical management, data on important factors such as lipid profile or 
weight may not be recorded for all time points of interest. 
Validation studies of THIN data suggest positive predictive values that are high 
(typically 80-90%), however, these values do not provide a full picture of data quality. 
With the exception of diagnoses of SMI – for which electronic data quality has been 
found to be high – few studies have investigated sensitivity or negative predicative 
values, which are indicators of ascertainment.  Validity of the full range of CVD 
diagnoses is currently unknown. Although the positive predictive values of studies 
investigating specific subsets of CVD diagnoses are high (e.g. MI), some were 
achieved by applying rigid classification criteria (e.g. hospitalised ischaemic stroke), 
which are likely to compromise the (currently unknown) sensitivity with which cases can 
be identified. 
All epidemiological studies need to balance a trade-off in sensitivity and specificity 
against the objectives and feasibility of the study. Because my main study investigates 
a relatively rare event in a population of limited size it is pragmatic to maximise 
detection of the outcome even though this is likely to result in a higher rate of false 
positives than more exhaustive criteria such as specifying an associated hospital 
admission. For this reason the CVD outcomes of interest will focus on combined MI 
and stroke, and (separately) all-cause mortality.  The feasibility of investigating other 
types of CVD outcome which have not been validated (e.g. CHD) will also be 
investigated, although it is possible that such outcomes may be a source of bias. The 
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implications of the strengths and limitations of using data from THIN for the research 
questions investigated in this thesis are discussed in greater detail in Chapter 7. 
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Chapter 4 : Choice of study design to assess 
effectiveness of statins using routine primary care 
data 
1 Chapter content 
This chapter explores the strengths and limitations of different study designs used 
within observational data to explain the choice of study design selected for the main 
analysis (Chapter 6). I provide a brief introduction to the theory underpinning causal 
inference with observational data. Then I focus on the methodological theory that is 
central to both my research aim (estimating the effectiveness of statins for primary 
prevention of cardiovascular disease (CVD) in people with severe mental illness (SMI)) 
and the practical considerations that must be factored into selecting a viable study 
design. The main emphasis of the methodological theory tackles problems of 
confounding - particularly confounding by indication; where treatment allocation is 
related to the prognosis of future health outcomes - that are common to all 
observational studies investigating causal effect. I also focus on practical issues 
specific to routinely collected datasets, such as The Health Improvement Network 
(THIN), including handling missing covariate data. To aid discussion of these 
methodological and practical considerations, I describe and appraise the study designs 
of three published studies, which were central to the choice and development of the 
design for my main analysis. Finally, I describe the core features of the proposed study 
design for the main analysis of my thesis with reference to other possible methods. 
2 Causal inference using observational data 
Causal inference can be conceptualised using the Potential Outcomes Framework, 
which considers the possible outcomes experienced by the same individual – at the 
same time point – both in the absence and presence of the treatment (Rubin, 2005). 
For example, whether or not the choice to prescribe a statin or not to a specific patient 
on a given date results in a CVD event. In reality, experimental evidence can allow us 
to see only one potential outcome for an individual, where the other outcome/s 
experienced if a different treatment (or no treatment) had been administered remain 
unobserved (counterfactual). For this reason causal inference using data derived from 
real-life settings cannot examine the effects of a given treatment on a single individual 
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and must instead focus on estimating the average effect across equivalent individuals 
who receive different treatments. 
Random assignment of treatment is the primary feature of randomised controlled trials 
(RCTs) and this process produces treatment groups that are similar at the point of 
randomisation. In the context of the Potential Outcomes Framework, randomisation 
ensures that treatment assignment is not associated with the counterfactual outcome 
and that the participants are therefore equivalent; this is formally termed 
exchangeability2. Exchangeability is important because under ideal conditions (e.g. no 
loss to follow-up) the differences in the outcomes observed between each trial arm are 
the same as the average difference in potential outcomes. In addition, the causal effect 
(of intervention versus control) is the same regardless of which group actually receives 
the intervention. Randomisation therefore forms the link between theory that examines 
potential outcomes for the same individual and experimental studies that compare 
average outcomes across equivalent groups of individuals. 
Classical RCTs usually randomly assign individuals to one of two different treatment 
options (e.g. statin or placebo); such that 50% receive treatment and 50% receive 
placebo. This type of randomisation is described as marginal, because all individuals 
have an equal probability of receiving either treatment option. However, RCTs are not 
always marginally (unconditionally) randomised; instead, randomisation may be 
conditioned on one or more variables, which define the likelihood of receiving one 
treatment option over another. For example, an RCT examining the effect of statin 
therapy versus placebo on CVD events could choose to prioritise statin therapy for 
individuals with high CVD risk scores (defined as >20% over a ten year period) by 
randomly assigning 75% of high risk and 25% of low risk individuals to receive a statin. 
In this scenario, the statin arm will include three times more high risk individuals than 
the placebo arm and the groups therefore differ with respect to CVD risk both at the 
point of randomisation and their subsequent probability of future events. However – 
crucially - within strata of the conditioning variable (high/low CVD risk score) the groups 
are equivalent, which is termed conditional exchangeability3. 
The conditionally randomised trial provides a helpful framework with which to consider 
how data from observational studies may be best analysed. However, obtaining 
                                                 
2
 Exchangeability can be written mathematically as Pr[Y
a
=1|A=1] = Pr[Y
a
=1|A=0] where Y is a binary 
outcome, Y
a
 is the counterfactual outcome given the other treatment option, A denotes the administered 
treatment option. 
3
 Conditional exchangeability can be written mathematically as Pr[Y
a
=1|A=1,L=1] = Pr[Y
a
=1|A=0,L=1] 
where Y is a binary outcome, Y
a
 is the counterfactual outcome given the other treatment option, A denotes 
the administered treatment option and L denotes the conditioning variable. 
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accurate estimates of effectiveness using observational datasets remains a challenge, 
primarily because treatment allocation (such as statin prescribing) is clinically indicated 
and not random. This chapter aims to explore the study designs employed by existing 
observational studies that have estimated the effectiveness of statin therapy (versus no 
treatment) on CVD events and to evaluate the best study design to investigate primary 
CVD in people with SMI. The selection of comparable exposed and unexposed 
individuals is a key issue when using observational data to estimate effect and is 
important because failure to do so results in biased estimates. In order to choose 
comparable groups the selection process must go beyond considering who is treated to 
also account for the timing of treatment and follow-up. I outline the major features that 
epidemiological studies can use to improve the validity of the results (Gagne et al., 
2012) and I have selected three studies (Hippisley-Cox and Coupland, 2010;Smeeth et 
al., 2009;Danaei et al., 2013) to help discuss the relative merits and shortfalls of 
different design features.  
3 Confounding by indication 
Confounding by indication describes the imbalance in characteristics between exposed 
and unexposed individuals, which results when treatment allocation (such as a statin 
prescribing) is clinically determined, associated with the prognosis and, therefore, not 
random. Treatment is therefore related to the risk of future health outcomes, such that 
direct comparison of the outcomes between exposure groups yields a biased result 
(Signorello et al., 2002). The challenges of confounding by indication are illustrated by 
a study using data from THIN to estimate the effectiveness of adding spironolactone to 
standard treatment with high dose loop diuretics on mortality in people with severe 
heart failure (Freemantle et al., 2013). Despite using the best available methods 
(including propensity score matching on a large range of characteristics), the study was 
unable to replicate hazard ratios (HRs) that were compatible with a major RCT; namely 
0.70 (0.60-0.82). Instead, estimates from their observational study suggested a harmful 
effect of spironolactone; 1.32 (1.18-1.47). Discordance between these results may 
reflect residual confounding arising from aspects of the treatment allocation in clinical 
practice that were not measured or recorded within the observational dataset. 
A common source of residual confounding within analyses of primary care data is the 
severity of the condition, which is often apparent to the GP but may not be well 
captured within the dataset. For example, in the case of the spironolactone study, 
although all study subjects had heart failure that was sufficiently severe to require 
treatment with high dose loop diuretics, reliable indicators of disease severity were not 
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available. By contrast, the GP will have examined the patient for symptoms (such as 
breathlessness, tiredness and ankle swelling) as well as using test results (including 
electrocardiogram, echocardiogram and blood tests for relevant biomarkers including 
natriuretic peptides) to guide treatment decisions (National Institute for Health and 
Clinical Excellence, 2010). Much of this information will not have been recorded in a 
way that could be factored into the analysis: for example, Doppler echocardiogram test 
results may include a measure of blood flow through the heart, but equivalent 
information is likely to be absent or incompletely captured (e.g. “Doppler studies 
abnormal”) in medical codes. 
Although confounding by indication should always be of concern when estimating 
effectiveness with observational data, there are certain conditions under which this type 
of confounding can be better controlled. Routinely captured information describing the 
severity of the condition and well defined algorithms guiding the selection of treatment 
are likely to facilitate control of confounding by indication (Freemantle et al., 2013). This 
thesis focuses on primary prevention of CVD, a condition for which the risk of future 
events can be estimated in primary care using CVD risk scores such as Framingham or 
QRisk2 (Hippisley-Cox et al., 2008;D'Agostino et al., 2008).  The risk score for a patient 
may help the GP decide on whether or not they should prescribe statin. Therefore, 
statin prescribing for primary CVD may be less prone to confounding by indication than 
conditions such as heart failure because information on components of the CVD risk 
score are captured in electronic health records. Furthermore, because annual CVD 
screening is recommended for people with SMI, data on CVD covariates are likely to 
be relatively well recorded for this patient group (Osborn et al., 2011). 
4 Other types of confounding and bias 
Bias may also arise when the timing of exposure or start of follow up is not equal 
across comparison groups: particularly when the comparison group is untreated 
because it may be unclear how the start of follow up should be defined. As confounding 
is a diverse and complex issue, I will outline the ways in which this type of bias may be 
reduced by discussing smaller subtopics: selecting appropriate comparison groups, 
new-user designs, as well as addressing differences in the characteristics of 
comparison groups and the importance of selecting a valid index date.  
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5 Selecting appropriate comparison groups for cohort studies  
Comparison groups should be as similar as possible in all aspects except for the 
intervention under investigation. Identifying the exposed group (such as statin users) is 
usually relatively straightforward, but choosing an appropriate comparison group in a 
cohort study is often more complex as a large portion of the unexposed individuals 
(non-statin users) may not be eligible for treatment. For example, as CVD events are 
rare in people under the age of 30 years few people under that age would be 
prescribed a statin. Therefore, it would be more sensible to include people who are 
older than 30 years in a study examining drugs prescribed to manage CVD risk. 
Applying strict inclusion and exclusion criteria also increases the similarity between 
study subjects and may therefore help to produce more precise estimates of effect. 
However, it should be recognised that there is a trade-off between increasing the 
similarity of the study subjects and the generalisability of the results, which are specific 
to individuals who are comparable to the  study population (McKee et al., 1999). 
6 New-user study designs 
New-user designs begin by follow-up of individuals from the time that they first initiate a 
given treatment and exclude individuals who started treatment before entry into the 
study (Ray, 2003). The major benefits of this approach are twofold: bias arising from 
inadequate control for factors that are changed by exposure (for example reductions in 
cholesterol following statin use) is avoided and the potential to miss outcomes arising 
soon after exposure is minimised. 
The new-user approach is also advantageous when the effect of treatment is not fixed 
over time, but varies relative to the time of initiation. For example, the risk of coronary 
heart disease (CHD) in women using hormone replacement therapy (versus no 
treatment or placebo) is elevated amongst treated women during the first 2 years, but 
the risk is equivalent to that of non-users when a longer timeframe is considered (Ray, 
2003). In this example, incident and prevalent users differ with respect to CHD risk and 
should not be combined. Another study comparing the results from a RCT of statins 
and approximately equivalent observational studies showed that including a greater 
proportion of prevalent users decreased the similarity of the observational estimates 
relative to the trial results (Danaei et al., 2012). 
As part of a bigger study, Danaei and colleagues investigated the impact of statin 
prescribing on primary prevention of CHD in prevalent statin users versus individuals 
who were never prescribed a statin (Danaei et al., 2013). The authors calculated an 
 
 
101 
 
adjusted HR of 1.42 (1.16-1.73) suggesting a harmful effect of statins that is unlikely to 
be plausible given the results from RCTs (Taylor et al., 2013). This anomalous result is 
likely to reflect insufficient adjustment for confounders (such as cholesterol 
concentration) that are changed by statin use as well as selecting statin users who had 
a higher risk of CVD  than individuals who had never been prescribed a statin. 
Furthermore, attempts to restrict the exposed group to long term users (e.g. individuals 
with persistent statin use over a 1 year period) may introduce selection bias because 
only individuals who have survived and adhered to the medication for at least a year (in 
this example) will be included in such a study (Danaei et al., 2013).  By contrast, 
defining the exposed group (e.g. statin users) to include individuals with a minimum 
duration of treatment will exclude people who received a sub-clinical dosage of the 
intervention. This type of restriction has the advantage of conveying information about 
the likely impact of optimal treatment (and is therefore more likely to reflect efficacy 
(The Cochrane Collaboration, 2015)).  However, this adds the disadvantage of tending 
to over-estimate the real-world impact of rolling out the intervention. 
7 Addressing differences in the characteristics of comparison groups: 
propensity score matching and regression  
As described above, in clinical practice many treatments are given based on the 
prescriber’s judgement of future risk of adverse health outcomes. This means that 
direct comparison of treated and untreated individuals is likely to generate biased 
results, often with treatment appearing to be harmful (Freemantle et al., 2013) because 
of imbalances in the risk profiles of the comparison groups. For example, it is likely that 
people who are prescribed a statin will be at higher risk of CVD risk than people who 
are not prescribed a statin. Possible solutions to this imbalance include adjusting for 
confounding variables, although this may not resolve imbalances in confounders that 
have not been measured and which may have influenced either clinician or patient 
preferences for a given treatment. For example, information on diet and physical 
activity is not systematically captured in primary care data, but these factors are likely 
to influence the choice of different options for managing CVD risk for a given patient. 
Other routinely recorded variables, such as body mass index (BMI) and blood 
pressure, may provide an indication of some unmeasured factors and can therefore 
help to reduce unmeasured confounding. 
Matching can help to remove imbalances in measured confounders that make up the 
matching criteria and may also produce comparison groups that are more similar in 
terms of related - but unmeasured - indicators. For example, by matching on age, 
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gender, socio-economic status and level of comorbidity it may be possible to achieve 
comparison groups that are more similar in terms of other unmeasured characteristics 
(e.g. specific aspects of lifestyle). In the event that it is feasible i) to capture all 
confounding, and ii) to identify unexposed individuals, it becomes possible to estimate 
an unbiased estimate of effect. However, increasing the number of matching variables 
reduces the availability of suitable comparison individuals and can quickly become 
unworkable: for example, applying 10 age categories, two gender categories, five 
binary diagnosis categories, five binary drug therapies and five cost-of-care categories 
results in 102,400 potential groups (10x2x25x25x5). Exhaustive matching therefore 
becomes impossible and may dramatically reduce the number of individuals who can 
be included in the study, thereby negatively impacting upon sample size and 
generalisability (Seeger et al., 2007).  
Another potential method for addressing imbalances in measured confounders without 
the need for such complex matching criteria is the propensity score. A propensity score 
is an estimate of an individual’s probability of receiving a treatment given the 
distribution of their measured covariate data (Rosenbaum and Rubin, 1983). The 
propensity score can thereby be used as the sole criterion for matching (to select) or 
adjusting (to balance) comparison groups with respect to their indication for treatment. 
Instead of matching on all of the individual component variables, the propensity score 
simplifies the matching process as it does not require a perfect match on each variable 
and enables a greater portion of individuals to be included in the study. Propensity 
scores are increasingly used in observational studies because – within strata of the 
propensity score – individuals are similar (exchangeable) in terms of the observed 
variables that constitute the propensity score.  Although using a propensity score to 
adjust for differences measured confounding can be beneficial, bias can still arise due 
to unmeasured confounding (Bosco et al., 2010). 
Despite the increasing popularity of using propensity scores in observational studies, 
the methodology does not appear to outperform traditional regression methods. A 
systemic review that compared results from observational studies that adjusted for 
confounding using a propensity score and (separately) traditional regression concluded 
that both methods gave similar results (Shah et al., 2005). The effect estimates 
calculated using traditional regression and propensity score methods were highly 
concordant (kappa = 0.79 (0.65–0.92)), with propensity scores producing estimates 
that were, on average, 6% closer to the null (Shah et al., 2005).  Furthermore, specific 
estimates for the effectiveness of statins (versus no treatment) for primary prevention 
of coronary heart disease (CHD) found almost identical HRs and confidence intervals 
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derived from either traditional regression or propensity score methods (0.89 (0.73-1.09) 
and 0.88 (0.72-1.08), respectively) (Danaei et al., 2012).  
8 Selecting a valid index date 
Another source of bias within observational studies arises when the timing of exposure 
or follow up differs between comparison groups. This type of bias is problematic where 
a treated group is compared to an untreated group; as it may be unclear how the start 
of follow-up should be defined for the untreated individuals. The selection of a valid 
index date is even more important if it forms part of the criteria used to define a 
baseline period in which time-varying confounders are measured (e.g. cholesterol 
measured in the twelve months prior to the index date). Methods to support selecting a 
valid index date for comparison individuals who did not receive treatment include 
choosing a date (often randomly) within the time period during which they were eligible 
to receive treatment (Seeger, 2014;Seeger et al., 2007;Hernan et al., 2008).  
9 Approaches for handling missing data 
Some covariate data in primary care records are not complete. In particular, cholesterol 
concentration (estimated from a blood sample) may be measured in line with national 
policies - including health checks offered to individuals with risk factors such as 
diabetes - or when clinically indicated.  Cholesterol data are therefore unobserved 
within a given calendar year for a substantial proportion of individuals (ranging from 
>80% prior to 2002 to <40% after 2010 (Chapter 5)). Local testing policies may also 
impact upon the ascertainment of data such as cholesterol concentration. For example, 
total cholesterol concentration is universally measured to determine the lipid profile of a 
blood sample; however, the high density-lipoprotein cholesterol (HDL-C) fraction is not 
measured by all NHS clinical laboratories. The proportion of missing data is therefore 
generally higher for HDL-C than total cholesterol. Other partially observed data include 
blood pressure, weight, height and smoking status. Unlike cholesterol, this information 
is often collected at the time of patient registration ((Marston et al., 2014), Chapter 5 
section 7.1.2), and also on regular basis for people with long-term conditions such as 
diabetes, CVD and SMI (National Institute for Health and Clinical Excellence, 2012). 
However, for people without chronic conditions these health indicators are not routinely 
recorded at regular time points after registration. 
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9.1 Types of missing data 
There are three assumptions regarding the type of missingness within partially 
observed data, which have important implications for the likely viability of strategies 
such as complete case analysis (where data are restricted to records with fully 
obsereved covariate data) or imputation for missing handling data (Sterne et al., 2009). 
9.1.1 Data are Missing Completely At Random (MCAR):  
MCAR describes data where missingness of a variable Y is independent of both values 
of Y and the fully observed covariate X, such that individuals with missing data do not 
differ systematically from those with fully observed data.  This type of missingness is 
the only scenario when performing a complete case analysis will consistently yield 
unbiased results (although complete-case analysis of datasets with very low 
proportions of missing data is unlikely to give strongly biased results). 
9.1.2 Data are Missing At Random (MAR):  
If Y is MAR, missingness is independent of values of Y but associated with covariate X 
and missing at completely at random after conditioning on X.  For example, in a dataset 
comprising age (fully observed) and blood pressure (partially observed) missing values 
of blood pressure may increase with older age, but be MCAR within individuals who are 
the same age.  However, without knowing the values of the missing data it is not 
possible to prove whether the assumption of MAR is correct. It may, however, be 
reasonable to assume data are MAR and impute missing values using an imputation 
model that explains the pattern of missingness. 
9.1.3 Data are Missing Not At Random (MNAR):  
In the event that the pattern of missing data for Y is associated with the value of Y (e.g. 
missing low values of blood pressure), then the type of missingness is not random 
(MNAR) and – even after conditioning on covariate X – would be difficult to handle 
without additional information on the value of Y. 
A practical implication of clinically indicated data collection is that the distribution of 
observed and missing data is likely to be associated with other factors such as patient 
characteristics and calendar time; for example, reflecting changes in screening policy. 
This pattern of missingness is not compatible with data being MCAR and must instead 
be assumed to reflect data that are MAR or MNAR.  Multiple imputation can be used to 
handle data that are MAR, although the success of this method is dependent on 
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specifying an imputation model that that incorporates variables (such as the presence 
of diabetes) that explain the pattern of missingness (Sterne et al., 2009).  I explore 
patterns of missing CVD data in Chapter 5 and evaluate if it is plausible that data were 
MAR in Chapter 7. 
There are a range of methods available for handling missing data including complete 
case analysis or other ad hoc missing data methods (Carpenter and Kenward, 2013). 
However, when correctly implemented, multiple imputation performs better than these 
methods because it becomes possible to analyse data that are MAR for all individuals 
and also provides more accurate measures of the uncertainty around the effect 
estimate (Sterne et al., 2009). There is a growing selection of tools to help impute 
missing data in longitudinal datasets, including the Stata MI (Multiple Imputation) suite 
of commands and twofold FCS (fully conditional specification) algorithm, which have 
been developed and tested using CVD data extracted from THIN (Nevalainen et al., 
2009;Welch and Bartlett, 2013). 
Multiple imputation results in many (typically 5-10) copies of the imputed dataset and 
can be challenging to combine with some methods for controlling confounding: for 
example, propensity scores. This is because each of the imputed datasets comprise 
different estimates of the unobserved value. Current methods for combining multiple 
imputation and propensity score matching are imperfect, although strategies such as 
incorporating missing data patterns into the score or randomly selecting one possible 
score per patient have been attempted (Hayes and Groner, 2008). By contrast, 
methods for undertaking regression analysis with multiple imputed datasets are well 
established and feasible using standard statistical software packages such as Stata, R 
or SAS. 
10 Summary 
Confounding (by indication) and missing data pose major challenges for the use of 
observational data for causal inference. However, there are a range of techniques to 
aid the selection of appropriate comparison groups and to undertake analyses that 
account for differences in the characteristics and follow up time that can help to reduce 
confounding. Methods for handling missing data are rapidly advancing but are not yet 
fully compatible with propensity score matching. However, methods for undertaking 
traditional regression analysis with an imputed dataset are now well developed and 
supported in most statistical software packages. 
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11 Methods for analysing observational data to estimate the 
causal effects of statins: three case studies in populations 
without SMI 
I will now outline three studies (Boxes 1-3 and Table 11-1) that have used different 
methodological approaches (namely matching with propensity score adjustment, 
multivariable regression and a series of staggered cohort studies) to estimate causal 
effects of statins using large primary care databases. These studies have been highly 
influential on my choice of study design and also provide a useful frame of reference 
for explaining how the design and methods of my proposed study have developed. 
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Box 1 
Title: Smeeth, L., Douglas, I., Hall, A., Hubbard, R., Evans, S. Effect of statins on a 
wide range of health outcomes: a cohort study validated by comparison with 
randomized trials Br J Clin Pharmacol 2008 67(1): 99-109 
Aim: to replicate the Heart Protection Study using part of a cohort that was analysed to 
identify the pleiotropic (cholesterol-independent) effects of statins using data from 
THIN. 
Methods: Data were extracted for individuals aged 40-80 years who had a diagnosis of 
atherosclerosis (before or within the study period) and contributed data between 
January 1995 and December 2006. Due to the high CVD risk amongst this group, the 
first 12 months of follow-up after the index date was excluded from the analysis. People 
with a history of MI or stroke, or a previous statin prescription prior to the index date 
(statin initiation or randomly generated start date) were excluded. The outcomes 
examined were time to fatal or non-fatal MI or stroke, and all-cause mortality. 
Imbalances in the characteristics of exposed and unexposed individuals were 
minimised by adjusting for a propensity score for being prescribed statin and imposing 
tight matching criteria: up to five non-statin users were selected from the same practice 
and matched to each statin user on the basis of sex and five-year age band. The dates 
of registration also had to be compatible, with registration occurring at least 12 months 
prior to the index date. Additionally, all individuals needed to consult the GP during the 
6 months before or after the index date. In the primary analysis individuals were 
analysed according to their exposure status at the index date; regardless of later 
changes in exposure (starting or stopping statin therapy). A sensitivity analysis 
investigated the impact of curtailing follow up time for individual’s whose exposure 
status changed after the index date. 
Results: Adjusted HRs and 95% CI for mortality, MI and stroke were 0.78 (0.74, 0.82), 
0.86 (0.76, 0.97) and 0.86 (0.77, 0.97), respectively. The sensitivity analysis 
investigating changes in exposure after the index date did not produce significantly 
different results to the main analysis. 
Conclusions: The study identified similar effect sizes for statin prescribing on 
mortality, MI and stroke to the Heart Protection study. 
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Box 2 
Title: Hippisley-Cox, J., Coupland, C., Unintended effects of statins in men and women 
in England and Wales: population based cohort study using the QResearch database 
BMJ 2010 20;340:c219 
Aim: To quantify the unintended effects of statins according to type, dose, and duration 
of use, using a large UK primary care database (QResearch). 
Methods: Data were extracted for an open cohort of new statin users and previously 
unexposed individuals who were aged 30-84 years. The exposure status of these 
individuals was defined by whether or not each individual was prescribed a statin over 
the course of the study period of 6.5 years (1 January 2002-30 June 2008). Entry into 
the cohort occurred at either the earliest start date (the latest of: January 2002, 
registration plus twelve months, 30th birthday) for non-statin users or on the date of the 
first statin prescription after the earliest start date for statin users. A range of outcomes 
(cataract, fracture, cancer (by type: breast, prostate, lung, colon, melanoma, 
oesophageal, gastric, renal), liver dysfunction, venous thromboembolism, dementia, 
rheumatoid arthritis, Parkinson’s disease, acute renal failure, myopathy) were studied, 
and the number needed to treat or harm (NNT/NNH) was calculated for each of these 
outcomes. Multiple imputation was used to replace missing values for BMI and 
smoking status, which were used in the main analysis. Analyses were stratified by 
gender and adjusted for a range of variables including age, BMI, Townsend score, 
smoking status and the presence of treatment or conditions such as cancer, 
hypertension or depression. Where appropriate, non-linear functions of continuous 
variables were included in the models as fractional polynomials.  
Results: Data describing the characteristics of exposed and unexposed individuals in 
the cohort at baseline are presented in the publication. These data appear to show 
imbalances in some baseline characteristics such as age, gender, comorbidity and the 
presence of liver function test results between statin users and non-users. Statins were 
associated with increased risk of myopathy, cataract, acute renal failure and liver 
dysfunction and reduced risk of oesophageal cancer, but not associated with the other 
outcomes under investigation. A dose-response effect was apparent for liver 
dysfunction and acute renal failure. 
Conclusions: The results suggest that statins are associated with greater risk of 
myopathy, cataract, acute renal failure and liver dysfunction, and a reduced risk of 
oesophageal cancer, in comparison to no statin exposure.  
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Box 3 
Title: Danaei G., Rodriguez G., Cantero O., Logan R., Hernan M., Observational data 
for comparative effectiveness research: an emulation of randomised trials to estimate 
the effect of statins on primary prevention of CHD Stat Methods Res. 2013 22(1): 70-96 
Aim: To mimic recruitment into a series of non-randomised cohort studies (termed 
“trials” by the authors) of statins that run at staggered intervals using primary care data 
from THIN. 
Methods: Individuals aged 55-84 years who had not been prescribed a statin during 
the prior 24 months were eligible for inclusion in one or more “trials” that were initiated 
each month over an 83 month period. Each month a new “trial” enrolled individuals who 
either i) were prescribed a statin during that month (to form the exposed cohort) or ii) 
did not initiate statin therapy that month (the unexposed comparison group). Thus a 
total of 83 distinct “trials” were developed and pooled using the robust sandwich 
estimator (to account for the same individuals being incorporated in several “trials”). 
Individuals who stopped being prescribed a statin entered later “trials” after a 24 month 
washout period from the last day of statin therapy. The authors explored the impact of 
using different measures of treatment effectiveness and efficacy (akin to the intention 
to treat, per protocol and as-treated analyses often incorporated into RCTs) and they 
applied a variety of methods for reducing confounding (statistical adjustment for 
confounders, propensity score inverse probability weighting). 
Results: The fully adjusted HR for the effect of statins on CHD in the main intention to 
treat analysis was 0.89 (0.73, 1.09), whereas the unadjusted estimate was 1.37 (1.14, 
1.66). Fully adjusted results from per protocol and as-treated analyses were 0.86 (0.59, 
1.27) and 0.73 (0.50, 1.06), respectively. Comparison of prevalent statin users versus 
never users yielded a HR of 1.31 (1.04, 1.66). The main intention to treat analysis did 
not exclude any follow up time, however, a sensitivity analysis undertaken by the 
authors showed that when between 3 and 12 months of follow up time was excluded 
the effect estimate for statin prescribing and CHD was protective with a 95% 
confidence interval that excluded one. 
Conclusions: The authors show that an effect estimate that is compatible with the 
results from randomised controlled trials can be calculated by emulating a trial with 
observational data, although the confidence intervals around these estimates were 
wide (e.g. 0.50 to 1.06). They also show that comparison of prevalent statin users and 
never users results in a biased estimate of effect. 
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Table 11-1: Key characteristics of three observational studies investigating the 
effects of statin therapy 
First author Smeeth Hippisley-Cox Danaei 
Title Effect of statins on a wide 
range of health outcomes: 
a cohort study validated 
by comparison with 
randomized trials 
Unintended effects 
of statins in men 
and women in 
England and 
Wales: population 
based cohort study 
using the 
QResearch 
database 
Observational data for 
comparative effectiveness 
research: an emulation of 
randomised trials to estimate 
the effect of statins on 
primary prevention of CHD 
Objective To assess the effect of 
statins on a range of 
health outcomes and to  
replicate the Heart 
Protection Study 
To quantify the 
unintended effects 
of statins 
according to type, 
dose, and duration 
of use 
To test the limitations of a 
study design that aims to 
emulate a series of 
randomised controlled trials 
of statins 
Study 
design 
Prospective open cohort 
study using routinely 
collected data 
Prospective open 
cohort study using 
routinely collected 
data 
Series of prospective 
staggered cohort studies 
(“trials”) using routinely 
collected data 
Population Individuals aged 40-80 
years between January 
1995 and December 2006 
who were registered with 
a THIN practice and had a 
diagnosis of 
atherosclerosis: 30,024 
statin initiators and a 
matched sample of 53,598 
non-initiators 
Individuals aged 
30-84 years 
registered with GP 
surgeries reporting 
to the QResearch 
database: 225,922 
statin initiators and 
1,778,770 non-
initiators  
Individuals aged 55-84 years 
in the year 2000 who were 
registered with a THIN 
practice and had no prior 
history of CHD or other 
specified conditions. 
Individuals were excluded if 
they had a prescription for a 
statin in the 24 months prior 
to enrolment: 13,599 new 
initiators of statins and 
831,201 non-initiators  
Intervention Receiving a prescription of 
simvastatin, atorvastatin, 
pravastatin, rosuvastatin, 
fluvastatin or cerivastatin 
at any point during follow 
up 
Receiving a 
prescription of 
simvastatin, 
atorvastatin, 
pravastatin, 
rosuvastatin or 
fluvastatin at any 
point during follow-
up 
Any statin prescription 
during the one month 
exposure period at the start 
of each “trial”.  
Comparison No statin prescription at or 
before the index date 
No statin 
prescription during 
follow-up 
No statin prescription during 
the one month exposure 
window at the start of each 
“trial” 
Primary 
Outcome/s 
First recorded occurrence 
of MI, stroke or death 
First recorded 
occurrence of 
CVD, moderate or 
serious myopathic 
events 
First recorded occurrence of 
MI or death from CHD 
Follow-up Median 4.4 years plus a 
12 month washout period 
post index date 
Maximum duration 
of 6.5 years 
Average: 26 months 
(initiators) and 30 months 
(non-initiators)  
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12 Development of the study design to estimate the 
effectiveness of statins for primary prevention of CVD 
events in people with SMI 
This section of the thesis documents how the study design that I implemented in the 
main analysis (Chapter 6) was influenced – and is justified - by the strengths and 
weaknesses of each of the three case studies led by Smeeth (Box 1 (Smeeth et al., 
2009)), Hippisley-Cox (Box 2 (Hippisley-Cox and Coupland, 2010) and Danaei (Box 3 
(Danaei et al., 2013)). 
12.1 Considerations around propensity scores and matching 
My initial plans for my study design were strongly influenced by the methods of Smeeth 
and colleagues. They used a propensity score in combination with judicious eligibility 
and matching criteria to select statin exposed and unexposed individuals with 
atherosclerosis who were free of CVD at baseline and did not have a prior statin 
prescription. However, I believe that the success of Smeeth’s study is in part due to the 
large pool of individuals (30,024 statin initiators and 53,598 people who did not initiate 
treatment) included in the study which thus enabled the use of restrictive eligibility 
criteria. For my study, achieving an adequate sample size was likely to be more difficult 
because the prevalence of schizophrenia and bipolar disorder is relatively low and 
yields a population of around 24,000 individuals (including only 3,000 that were 
prescribed a statin) in THIN. 
To assess the feasibility of replicating a study similar to that undertaken by Smeeth – 
within a population of individuals with a diagnosis of SMI - I examined the number of 
people registered with each GP surgery by strata of gender and age-band that received 
or did not receive a statin prescription during the study period. As the pool of 
individuals with SMI is much smaller than the population used by Smeeth, I 
investigated wider strata of age-band (10 years versus 5 years): these broader strata 
would not be sufficient to balance differences in age-related CVD risk between 
exposed and unexposed individuals, but were useful for exploring the feasibility of 
using more precise matching criteria. The results of these exploratory analyses 
suggested that, on average, for each person who was prescribed a statin, there were 
3.2 individuals of the same 10-year age band and gender within the same practice who 
were not prescribed a statin. This ratio of possible matches for statin users and non-
users (3.2 when using 10-year age bands) was less than 5, which is usually considered 
optimal in terms of efficient gains in power (Hennessy et al., 1999). Therefore, 
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matching individuals on the basis of narrower age bands (e.g. 5 years), gender and 
practice was unlikely to yield sufficient numbers of suitably matched individuals and 
would be even further reduced by restricting matching to individuals with compatible 
dates of registration at their practice. In addition, because the majority of prescribing 
occurred during the latter part of the study period (Chapter 3, section 4), the ratio of 
unexposed to exposed individuals decreased substantially over the study period and it 
became progressively more difficult to find appropriate matches for exposed 
individuals. I therefore concluded that it was not possible to replicate Smeeth’s 
methods within a population of people with SMI in THIN. 
Smeeth’s study is well designed and is successful in reproducing the results of the 
Heart Protection Study, however, there are some aspects of the design where 
modifications could be considered. The eligibility and matching criteria (GP practice, 
gender, 5-year age-band and time of registration) are used in combination with a 
propensity score, which in turn was used to adjust (not match) for differences in the 
scores of exposed and unexposed individuals. However, the authors had to make 
some assumptions regarding missing data in order to define some of the variables in 
the propensity score; which may have misclassified some individuals.  For example, in 
Smeeth’s study cholesterol was dichotomised into individuals with dyslipidaemia versus 
no record of dyslipidaemia, which will include many individuals who were not tested. 
Whilst this practice is common and generally accepted for symptomatic conditions, it is 
probably less appropriate for measures such as dyslipidaemia that are not usually 
apparent without testing and do not have a well-defined high risk threshold. The 
proportion of individuals who did not have available data on cholesterol was not 
reported in Smeeth’s study. However, other research using data from THIN suggests 
an annual incidence rate for cholesterol monitoring of 7% in adults aged 40 rising to 23-
25% in 60-80 year olds during the period 1999-2008, meaning that in a given year data 
were missing for 75-93% of individuals (Welch, 2012). As the prevalence of 
dyslipidaemia in the general population aged 40 years or more is in the region of 50-
70% (Townsend et al., 2012), it is possible that a significant minority of those who had 
not had their cholesterol monitored were misclassified as having normal lipids in this 
study. 
I considered - at length - the possibility of developing a propensity score for being 
prescribed a statin in my main analysis and using this to select statin users and non-
users with SMI who were matched within strata of the propensity score. This method 
was particularly appealing because - within matched strata of the propensity score - 
estimates of effect for individuals who received treatment (termed Average Treatment 
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effect on the Treated (ATT)) are equivalent to the treatment effect in both treated and 
untreated individuals (termed Average Treatment Effect (ATE)) (Austin, 2011;Austin, 
2008;Austin et al., 2007). These stratum-specific estimates can be weighted to reflect 
the whole population and pooled to estimate the ATE for the whole study population 
(Imbens, 2004). However, as described previously (section 9.1.3), it is not currently 
possible to use propensity score matching with multiple imputation and I was unable to 
find any satisfactory means of combining these methods within the literature.  
Multiple imputation helps to reduce selection bias because the analysis is not restricted 
to individuals with complete data (Sterne et al., 2009). Methods for handling missing 
data were a particular priority in my study because of the likely associations between 
missing data and statin prescribing, physical (including CVD risk) and mental health.  In 
addition, the limited size of the study population and relatively large amount of missing 
data add further justification for using multiple imputation in preference to other 
methods for handling data. Furthermore, multiple imputation has been successfully 
implemented to investigate CVD risk in individuals with SMI (Osborn et al., 2015).  For 
these reasons I shifted my attention to study designs that used standard regression 
methods, which have been shown to produce similar effect estimates to using a 
propensity score, as described in the section 7 above. 
12.2  Considerations around selection of exposed and unexposed 
individuals 
One example of a study that uses multiple imputation in combination with regression 
methods is the study by Hippisley-Cox and Coupland. This study is strong in many 
respects, particularly in terms of the application of a new-user design, handling 
unobserved data (on BMI and smoking status) and the use of regression to adjust for 
differences in a large range of baseline confounders. However, the way in which statin 
exposure is defined may have introduced some bias.  
The study by Hippisley-Cox and Coupland examined a relatively long time period (6.5 
years), with a new statin prescription at any point during this period leading to the 
classification of an individual as exposed. This way of selecting exposed and 
unexposed groups of individuals could have the unintended effect of identifying people 
who are systematically different because the design requires individuals who were not 
prescribed a statin to remain free of statin prescriptions throughout the whole study 
period (6 years). Indeed in Hippisley-Cox’s study, the unexposed individuals appear to 
be more healthy at baseline (i.e. less likely to require a statin) than exposed individuals. 
Imbalances in baseline characteristics are particularly apparent for: age (mean 57 
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years amongst exposed and 42 among unexposed) and the proportion with a liver 
function test (58.1% among exposed and 9.1% among unexposed), as well as a 
generally higher prevalence of comorbid conditions such as type two diabetes (21.1% 
in the exposed group versus 1% in the unexposed) (Hippisley-Cox and Coupland, 
2010). 
Selecting index dates for individuals is difficult when no placebo or other intervention is 
provided, and is particularly important if it defines a baseline period in which time-
varying confounders are measured (e.g. blood pressure measured in the six months 
prior to the index date). In their study, Hippisley-Cox and Coupland defined the date of 
entry as follows: non-statin users: earliest start date (after January 2002, registration 
plus 12 months, 30th birthday etc.), statin users: first statin prescription date. However, 
this leaves the study vulnerable to bias arising from the relatively earlier entry of non-
statin users into the study; because statin user entry is delayed until the first 
prescription after the earliest start date.  
Because statin users must be alive and event free in the period before they receive a 
statin, this creates an “immortal time period” before the index date – that is excluded 
from the study for statin users but not non-statin users. This is problematic because an 
event (and the associated follow-up time) that occurs during the “immortal time” can 
only contribute to the unexposed cohort (overestimating the event rate in the 
unexposed arm), even though the individual is later prescribed a statin (Suissa, 2007). 
In instances when exposed and unexposed study populations are analysed in their 
entirety, or equally sampled, it is possible to correct the biased rate in the unexposed 
study group by including the “immortal time” for the statin users in the denominator. 
However, in studies where the exposed and unexposed populations are not equally 
sampled, this may introduce bias that is larger than that arising from excluding the 
“immortal time” preceding the index date (Rothman and Suissa, 2008).  
It is difficult to determine the extent to which confounding by indication – and any 
impact arising from differences in the entry of exposed and unexposed individuals into 
the cohort – may have impacted upon the results of this study. It is likely that defining 
statin exposure on the basis of prescriptions over the whole study period will tend to 
select a non-statin user group that is relatively healthier than statin users: and this 
scenario is compatible with the imbalance in CVD covariates reported by the authors.  
However, these imbalances may be largely addressed in the analysis through the 
application of multivariable regression (as undertaken by the authors) to adjust for 
differences in measured covariates.  By contrast, it is likely that the misclassification of 
the unexposed “immortal time” for individuals in the statin arm will have contributed to 
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an over-estimation of the event rate in the unexposed arm, thus biasing the results 
away from the null, although it is unclear what the possible magnitude of bias might be. 
12.3 Considerations around the timing of exposure and follow-up  
Methods that impose equivalent times of entry for both exposed and unexposed 
individuals may help to reduce bias and confounding: Seeger, Kurth and Walker used 
this approach to examine the effectiveness of statins (Seeger et al., 2007). The authors 
stratified the study into six month blocks of time and looked at whether statins were 
prescribed during each time block to determine an individual’s exposure status (Figure 
12-1). Individuals were followed-up from either the index prescription date, or (for 
unexposed individuals) a random date within the six month time-window until censoring 
or an event. An intention-to-treat approach was used to analyse the data such that all 
individuals irrespectively of whether statin exposure later changed (e.g. prescribing 
stopped) were analysed according to statin prescribing at the index date. The authors 
used these time criteria in conjunction with propensity matching and “candidacy” 
requirements, with the latter requiring all individuals to have dyslipidaemia recorded in 
the prior six months (Seeger et al., 2007). 
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Figure 12-1: Study design incorporating a series of staggered cohorts (used with 
permission)(Seeger, 2014) 
 
Danaei and Hernan have recently proposed a new kind of study design that uses a 
similar approach – ensuring that the start of follow-up time is balanced across the two 
exposure groups – to the study developed by Seeger and colleagues. Danaei’s study 
analyses data on a series of staggered cohorts that are initiated at one month intervals 
in order to imitate multiple non-randomised trials. The authors divided the study period 
into one month windows of time in which all individuals initiating a statin that month 
were defined as exposed and all other individuals were unexposed: all individuals with 
statin prescription in the prior two years were excluded. The study population was then 
followed-up from the start of the one month window until a first CVD event or censoring 
occurred.  
Using a series of staggered cohorts enables unexposed individuals from previous 
cohorts to form the study population for future cohorts, as well as allowing newly 
eligible individuals to be added into subsequent studies. The multiple staggered 
cohorts that are unique to this design have several advantages over other study types: 
the selection of exposed and unexposed individuals was done at the same time point 
but, by having multiple staggered cohort studies, an individual’s exposure status to 
statins could vary over time. Allowing the exposure status to change at different time 
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points has some advantages over alternative strategies such as conditioning on future 
exposure or using a long baseline time period to define exposed and unexposed 
individuals. Both these scenarios potentially introduce bias because the unexposed 
individuals can never become exposed (and are therefore likely to differ to unexposed 
individuals), which may lead to selecting a healthier set of unexposed individuals as 
was demonstrated by the differences in baseline characteristics in the study by 
Hippisley Cox and Copeland. 
The method developed by Danaei should theoretically make it possible to select an 
unexposed group that is more similar to the exposed group than other study designs 
exemplified by Hippisley-Cox and Smeeth. Furthermore, this design makes the 
selection of an index date for unexposed individuals straightforward (as the start of the 
trial is the same for both exposed and unexposed individuals) and should avoid 
introducing “immortal time” bias. However, it should be stressed that issues of 
confounding by indication are not fully addressed by the introduction of multiple 
staggered cohorts alone. Other methods are required to correct inevitable differences 
in measured baseline confounders for exposed and unexposed individuals.  
On balance, the study design developed by Danaei and Hernan appears pragmatic for 
use with my dataset from THIN as the design aims to reduce selection bias, makes 
good use of the data and overcomes the problem of selecting an index date for 
unexposed individuals and is compatible with multiple imputation to estimate 
unobserved covariate data. However, this study design does not offer a perfect solution 
and the limitations of the methodology are further evaluated in the discussion chapter 
(Chapter 7).  
13 Summary of the proposed study design 
A detailed specification of the study design that I chose to address my main research 
question is given in Chapter 6. 
In summary, the effectiveness of statins for primary prevention of CVD events in people 
with SMI will be investigated using a study design that most closely resembles the 
methods used by Danaei. 
14 Exploratory work and next steps 
In preparation for undertaking the main study, I performed two exploratory studies to 
investigate patterns of CVD screening and statin prescribing in individuals with and 
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without SMI (Chapter 5). I investigated patterns of CVD screening to better understand 
patterns of missing covariate data and thereby inform the imputation model used in the 
main analysis (Chapter 6). In addition, I investigated patterns of statin prescribing to 
people with and without SMI, in order to support comparison with results – such as 
those estimated by Smeeth and Danaei - for people without SMI. Analyses of both 
CVD screening and statin prescribing are also of public health interest, because they 
provide an indication of the uptake of physical health checks and whether statin 
prescribing is comparable amongst people with and without SMI. 
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Chapter 5 : Exploring patterns of CVD screening and 
statin prescribing in primary care to individuals with 
SMI 
1 Chapter content 
This chapter examines patterns of screening for prevention of cardiovascular disease 
(CVD) and statin prescribing in individuals with and without severe mental illness (SMI) 
using data from The Health Improvement Network (THIN). In addition to assessing the 
impact of health policy on the uptake of CVD screening, this work is important because 
it characterises the pattern of missing CVD covariate data. These patterns of missing 
data are used to inform the imputation model that supports the later phases of my PhD 
work investigating the effectiveness of statin prescribing. In this chapter I first introduce 
background information on the clinical care pathway, fundamental policies and key 
publications regarding CVD screening and statin prescribing in primary care in the 
United Kingdom (UK) for individuals with and without SMI. I then describe the rationale 
for the study and outline the study aims and objectives. These objectives focus on 
different parts of the clinical care pathway, namely i) uptake of physical health checks 
and ii) rates of statin prescribing; with a focus on people who have been screened and 
therefore have CVD covariate data recorded. This second part of the study is also 
extended to evaluate whether the rate of statin prescribing differs in people with and 
without SMI after either stratifying on, or adjusting for differences, in estimated CVD 
risk scores between these groups. The results and limitations of these studies are 
discussed with reference to published literature. Finally the implications of the study 
results are outlined with respect to the planning of the main analysis and for policy and 
practice.  
This work was peer-reviewed and subsequently accepted for presentation at the 
following conferences (associated abstracts are outlined in the appendix, section 23): 
- Primary Care Mental Health Annual Conference (March 2014 - Exeter): poster 
presentation 
- UK Society of Academic Primary Care (SAPC) annual conference (July 2014 - 
Edinburgh) where it received the 2014 SAPC Travel Award to present an 
extended version of the original oral presentation at the North American Primary 
Care Research Group Annual Conference (November 2014 – New York) 
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- International Society for Pharmaco-Epidemiology Annual Conference (October 
2014 - Taipei): oral presentation (Blackburn et al., 2014a)  
2 CVD screening and statin prescribing: UK primary care 
policies 
Primary prevention of CVD in primary care settings is initiated through a multi-step 
process, in which a physical health check is used to screen and identify people who are 
likely to benefit from interventions to manage CVD risk (Figure 2-1).  
 
 
121 
 
Figure 2-1: Clinical care pathway for CVD screening and statin prescribing for primary prevention of CVD in UK primary care 
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A physical health check aims to facilitate estimation of a CVD risk score - such as 
Framingham (D'Agostino et al., 2008) or QRisk2 (Hippisley-Cox et al., 2008) - by 
measuring the information that is needed to calculate an individual’s risk of developing 
CVD over a ten year period. In the case of the Framingham risk score, this information 
is age, gender, diabetes, smoking status, blood pressure, use of medication for 
hypertension and either body mass index (BMI) or total cholesterol and high density-
lipoprotein-cholesterol (HDL-C) concentration in combination (as outlined in Chapter 3 
section 3.2.6). Other risk scores – including QRisk2 – may also use additional 
information on ethnicity, geographical region, family history of CVD, chronic kidney 
disease (CKD) and rheumatoid arthritis ((Hippisley-Cox et al., 2008)). In addition, both 
Framingham and QRisk2 risk scores include information on the presence of atrial 
fibrillation, which is associated with a three-fold greater risk of stroke but has a low 
prevalence (<0.5%) amongst people without pre-existing CVD (DeWilde et al., 2006). 
Online interfaces to calculate an individual’s risk score are freely available (e.g. 
http://qrisk.org/) and have also been integrated into software - such as Vision – that is 
routinely used by General Practitioners (GPs). Within Vision software CVD risk scores 
are automatically estimated using the most recently recorded patient data available 
(Abegunde, 2010).  
According to national guidelines, “high” CVD risk has historically been defined as a 
≥20% likelihood of having a CVD event over a 10 year period (National Institute for 
Health and Clinical Excellence, 2008b), but was re-defined in July 2014 to a ≥10% risk 
over a 10 year period (National Institute for Health and Clinical Excellence, 2014b)). 
Both sets of guidelines acknowledge that people with SMI may have additional risk 
factors (e.g. smoking more heavily) relative to the general population and that risk 
scores may therefore underestimate risk: however, they do not explicitly define 
bespoke guidance for statin prescribing to people with SMI.  
Recent policy developments are outlined in Figure 2-2.  
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Figure 2-2: CVD screening and prescribing policy developments in individuals with SMI and the UK general population. 
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QOF; Quality and Outcomes Framework, NICE; National Institute for Health and Clinical Excellence 
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In 2004 the Quality and Outcomes Framework (QOF) was implemented, and this 
strategy helped to promote annual physical health checks for people on the SMI 
register (National Institute for Health and Clinical Excellence, 2006;National Institute for 
Health and Clinical Excellence, 2009). However, financial incentives for GPs to 
measure specific components of the physical health check (blood pressure, BMI, 
diabetes, cholesterol and smoking status) were not implemented until 2012 (National 
Institute for Health and Clinical Excellence, 2012). These policy interventions have 
been associated with increased uptake of physical health checks in people with SMI 
(Osborn et al., 2011): however, the absolute uptake of screening remains low, with 
estimates suggesting that around one third of people with schizophrenia received a full 
health check in 2012 (Royal College of Psychiatrists, 2014). In the general population, 
the NHS Health Check was introduced in 2009 and advocates offering a similar 
physical health check to all adults aged 40-74 years on a five-yearly basis (Department 
of Health, 2015). The NHS Health Check includes measuring blood pressure, BMI, 
diabetes, cholesterol and smoking status (National Institute for Health and Clinical 
Excellence, 2012). 
2.1 CVD screening in people with SMI 
The provision of physical health checks to people with SMI in the UK has been 
explored using primary care data from THIN for the period 2000-2007 (Osborn et al., 
2011). The study compared the completeness of recording of CVD covariates in 18,696 
patients with SMI (primarily diagnoses of schizophrenia, bipolar disorder or 
schizoaffective disorder) and 95,512 gender and five-year age-band frequency 
matched comparison patients without a SMI diagnosis. Annual incident rate ratios 
(IRRs) (adjusted for age, sex, Townsend score for deprivation, consultation rate and 
whether the patient was newly registered) derived from the study showed that 
recording of  BMI, total cholesterol, blood pressure and glucose monitoring all 
increased over time and that the gap in uptake between people with and without SMI 
reduced during the study period. There were some important differences by age: in the 
most recent time period in the study (2007) the rate of uptake was approximately equal 
in patients aged 18-59 years with and without SMI, whereas the rate amongst older 
patients with SMI was 20-35% lower than people without SMI (Osborn et al., 2011). 
2.2 Statin prescribing to individuals with SMI 
In the UK, statins are one of three major groups of pharmacological interventions for 
reducing CVD risk in and are considered to be cost-effective for primary prevention in 
high risk individuals in the general population (Taylor et al., 2013). At present, little is 
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known about patterns of statin prescribing to individuals with SMI and how this 
compares with the general population. I was unable to find any studies investigating the 
provision of statin therapy specifically for primary prevention of CVD in people with 
SMI. However, a meta-analysis of three studies examining statin prescribing for a 
mixture of primary and secondary prevention of CVD found that people with SMI were 
almost 40% less likely to access statin therapy than people without mental illness (odds 
ratio (OR) 0.61 (0.39-0.94)) (Mitchell et al., 2012). 
3 Rationale for investigating CVD screening and statin 
prescribing in individuals with and without SMI 
The risk of CVD morbidity and associated mortality is much higher amongst people 
with schizophrenia and bipolar disorder relative to individuals without SMI: those aged 
between 50 and 74 have approximately two-fold risk (IRR 1.86 and 95% CI 1.63-2.12) 
(Osborn et al., 2007a) and improved management of CVD risk is needed. Historically, 
there has been substantial inequality in the uptake of physical health checks to older 
people with SMI (Osborn et al., 2011) and under-provision of interventions for disease 
prevention (Mitchell et al., 2012). Statins are clinically and cost-effective for preventing 
CVD in the general population, however, the uptake of statin therapy for primary 
prevention of CVD in people with SMI is not known.  
I set out to characterise differences in statin prescribing patterns in people with and 
without SMI for two reasons: i) to evaluate the viability of using estimates of statin 
effectiveness in the general population as an external validity check for the later 
phases of my PhD research. ii) To inform the development of the imputation model 
used to develop the dataset for the main analysis investigating the effectiveness of 
statins. 
4 Aim 
This chapter aims to explore patterns of CVD risk screening and to describe 
differences in the prescribing of statins to people with and without SMI who do not have 
a pre-existing CVD condition. 
4.1 Objectives 
1) Investigate the rate of physical health checks and describe how rates differ in 
people with and without SMI 
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2) Investigate rates of statin prescribing in people who have been prescribed a 
statin for the first time 
3) i) Describe how rates of new statin prescribing differ in people with and without 
SMI within a given timeframe 
ii) Amongst people who have had a CVD screen, investigate whether the rate of 
statin prescribing differs in people with and without SMI after accounting for 
differences in estimated CVD risk 
5 Methods:  
5.1 Data Source 
THIN was the data source for this study: an extended description of the database and 
indicators of the reliability of the data are outlined in Chapter 3. 
5.2 Inclusion and exclusion criteria 
A retrospective cohort study was developed: data for all GP surgeries were extracted 
for people with a diagnosis of schizophrenia or bipolar disorder (case definitions 
outlined in Chapter 3 and code lists included in the appendix; section 20) for the period 
1st January 2002 to 31st December 2012. Ten times as many comparison individuals 
from the same practice who did not have a SMI diagnosis were frequency-matched by 
age (±5 years at study start) and gender to individuals with SMI. People were excluded 
from the comparison cohort if they had a diagnosis of bipolar disorder, schizophrenia, 
other type of non-organic psychosis or had a record indicating that they were on the 
SMI register. 
Inclusion Criteria: people aged 30-99 years old who; i) were permanently registered 
with the GP practice (Patflag A and C) ii) consulted their GP within the study period and 
iii) had data reported after practice acceptable mortality rate (AMR) and acceptable 
computer usage (ACU) dates (further detail outlined in Chapter 3 section 3.2).  
Exclusion Criteria: people who; i) had a diagnosis of CVD prior to the start of the 
study ii) were prescribed a statin prior to start of the study. 
Entry into the study was at the latest of:  
i) 1st January 2002  
ii) 30th birthday 
iii) date of registration plus 6 months 
 
 
127 
 
iv) date of practice AMR or ACU (Horsfall et al., 2012;Maguire et al., 2009) 
Exit from the study occurred at the earliest of:  
i) 31st December 2012 
ii) 100
th
 birthday  
iii) out of practice transfer 
iv) first statin prescription 
v) first CVD event  
vi) death 
Individuals were not eligible to enter the study until six months after the date of 
registration: this was in order to exclude people with prevalent diagnoses of CVD or 
who were continuing statin treatment from when they were registered with another 
general practice. I used this cut-off based on another study which demonstrated that 
incidence rates for the majority of acute conditions – including MI – stabilize within six 
months of the date of registration (Lewis et al., 2005). 
People below the age of 30 years were not included in the cohort because the risk of 
CVD is very low and because UK policy for management of CVD focuses on people 
aged 40 and above. In addition, the majority of people who develop SMI are diagnosed 
before the age of 30 (Kirkbride et al., 2012) and diagnoses may be missed or less 
accurate at substantially younger ages. The upper age limit (100 years) should help 
exclude people with erroneously recorded age and to ensure that the cohort age range 
is representative of those with SMI.  
Additional criteria for objectives 3i and 3ii: It was necessary to apply extra inclusion 
criteria for objectives 3i and 3ii, which investigated statin prescribing to individuals 
within the time period 1
st
 January 2007-31
st
 December 2012. The time period (2007-
2012) was selected because UK policy introduced in 2009 advocates offering an NHS 
health check to the general population aged 40-74 on a five-yearly basis and it would 
therefore be anticipated that everyone in the target population should be offered a 
health check over the course of a six year period. By contrast, people with SMI should 
be offered a health check annually. In addition, objective 3ii restricted the cohort to 
people aged 30-74 years for whom a full CVD screen had been undertaken. A full CVD 
screen was defined as one or more records of: weight or lipids (total cholesterol and 
HDL-C) and blood pressure within the 6 year period 1st January 2007-31st December 
2012, plus at least one adult record of height and smoking status recorded before the 
end of follow-up. People aged 75 years and older were excluded from the cohort data 
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analysed for objective 3ii because Framingham risk scores can only reliably be 
calculated for people aged 30-74 years (D'Agostino et al., 2008).  
Study variables (Chapter 3 section 3.2 and appendix; section 20) 
– Core individual data: age, sex and Townsend score for deprivation 
– CVD risk covariates: blood pressure, weight, height, total and HDL-C 
concentration, diabetes and smoking status 
– Presence of SMI: Read codes for bipolar disorder or schizophrenia  
– Exposure to statins: one or more statin prescriptions 
Data on covariates such as blood pressure were included for each individual from the 
twelve months prior to entering the study until the end of follow up. The distribution of 
categorical and continuous variables was compared using χ2 and Mann-Whitney tests 
respectively, with the latter selected on the basis that data were not required to have a 
normal distribution (which was important because the values of covariates such as 
cholesterol cannot be negative and therefore tend to have a distribution that is skewed 
towards higher values). 
6 Analysis  
Figure 6-1 presents an overview of the time periods investigated for each of the three 
objectives, which are outlined in greater depth in the following text. 
Figure 6-1: Overview of the time periods investigated by different parts of the 
analysis 
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Objective 1) Temporal changes in the recording of CVD risk factors in people 
with and without SMI (2002-2012) 
Annual rates of the recording of CVD risk factors were calculated separately for each 
year by dividing the number of people with one or more recorded physical health 
indicators (height, weight, blood pressure, cholesterol, smoking status) in the 12 month 
period by the total number of people who were under follow up during the same 
calendar year. Four separate age groups (30-39, 40-59, 60-74, 75-99 years), which are 
compatible with age groups targeted by policies for the general population or people 
with SMI, were considered. Wilson’s method (Brown et al., 2001) was used to calculate 
95% confidence intervals (CI) that were bounded within 0 and 1 in order to estimate the 
proportion who had a physical health check. 
New patient registration is a key time point for capturing information on health 
indicators (Marston et al., 2014): the proportion of people who had a measurement of 
weight, blood pressure, cholesterol or smoking status recorded in primary care was 
calculated for each calendar year from the time of registration. This method was 
repeated for people with and without SMI who were newly registered in three years 
(2005, 2007 or 2010) that were selected to cover a broad cross-section of time after the 
introduction of QOF. 
The uptake of a full physical health screen was assessed. A full physical health screen 
was defined as at least one adult record of smoking status (during follow-up) plus one 
or more records within a given calendar year of: 
 Systolic blood pressure  
And one of:  
 Total cholesterol and HDL-C (laboratory CVD risk score)  
 BMI (office CVD risk score)  
The proportion screened was estimated by dividing the number of people in the 12 
month period with data for these covariates by the total number of people who were 
under follow-up during the same calendar year. Measuring smoking status should be 
part of the CVD screening process, however, I dropped the requirement for an annual 
record because smoking status appeared to be routinely collected at the time of patient 
registration rather than annually (see Figure 7-7).  
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Objective 2) Temporal changes in rates of new statin prescriptions to people with 
and without SMI (2002-2012) 
Annual rates of new statin prescriptions were calculated by dividing the number of 
people with a first statin prescription in a given 12 month period by the total person-
time at risk during the same period. Data were analysed by age-group (30-39, 40-59, 
60-74, 75-99 years). 
Objective 3i) Investigate differences in the rate of new statin prescriptions to 
people with and without SMI (2007 to 2012) 
Poisson regression models were used to calculate IRRs separately for the four age 
groups (30-39, 40-59, 60-74, 75-99 years) for the period January 1st 2007 to December 
31st 2012, with new statin prescriptions as the outcome. Likelihood ratio testing was 
used to assess evidence of an association between statin prescribing and SMI in a 
model that was adjusted for Townsend quintile of deprivation, gender and age in five 
year age bands (to account for additional confounding by age). 
Objective 3ii) Investigate the rate of new statin prescriptions amongst people 
who had a full physical health check between 2007 and 2012 
Estimated 10 year CVD risk was calculated for each individual using records from 
January 1st 2007 to December 31st 2012. CVD covariates for each individual were 
pooled from all time points that preceded statin prescribing between 2007 and 2012: 
where multiple measurements were available for the same patient, the mean of these 
values was calculated to contribute to the risk score. The method used to estimate 
CVD risk scores is outlined in the section 3.2.6 of Chapter 3. 
Estimated CVD risk was used to stratify individuals into risk strata of 5-percentile 
intervals (<5%, 5-9%, 10-14% etc.) between 0-29% and 10-percentile intervals 
thereafter. The proportion of people who were prescribed a statin during the study 
period was calculated for the each of the SMI cohorts within strata of CVD risk and 
plotted against the proportion of people who were prescribed a statin. 
Evidence for differences in the rate of statin prescribing to people with and without SMI 
was formally tested using Poisson regression models that were adjusted for estimated 
CVD risk. Preliminary analysis of the proportion of people who were prescribed a statin 
plotted against estimated CVD risk suggested a non-linear relationship that could be 
modelled using restricted cubic splines (Harrell, 2001) and further illustrated in previous 
work that I have undertaken (Blackburn et al., 2014b). Splines are a collection of linear 
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and cubic functions joined at one or more breakpoints, which are termed knots. This 
analysis used a restricted cubic spline with three knots (placed at recommended 
intervals of 10th, 50th and 90th percentiles (Harrell, 2001)) that was incorporated into 
Poisson regression models for the rate of new statin prescribing in people with and 
without SMI. The spline variables were calculated using the Stata package mkspline2 
and the fit of the spline to the underlying data was checked by visualising the spline 
using postrcspline (Buis, 2009). Likelihood ratio testing was used to assess evidence of 
an interaction between SMI and the spline terms for CVD risk.  
7 Results 
A flowchart outlining case numbers for people included and excluded from the study is 
outlined in Figure 7-1. A total of 11,669 people with a diagnosis of schizophrenia and 
9,645 people with a diagnosis of bipolar disorder were identified for inclusion in the 
study between January 1st 2002 and December 31st 2012. A total of 115,544 and 
93,307 age and gender frequency-matched people who did not have a SMI diagnosis 
formed the comparison groups for the schizophrenia and bipolar cohorts, respectively.  
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Figure 7-1: Dataflow for data extraction for people with and without SMI 
No. retained
9,453,011
8,765,664 687,347
4,190,343 4,575,321
4,190,079 264
3,597,759 592,320
3,596,949 810
3,568,143 28,806
3,471,379 96,764
No. excluded: 3,450,065 No. excluded: 3,262,528
SMI No. retained No. retained
Schizophrenia 11,669 115,544
Bipolar disorder 9,645 93,307
Schizophrenia comparison group
Bipolar disorder comparison group
No. excluded
Permanently registered at the practice: patflag A/C
Aged <=99 years old at start of follow-up
No record of CVD before start of follow-up
No record of statin therapy before start of follow-up
No SMI
Description
Initial number of individuals
Townsend Score not missing
Under follow-up during 2002-2012
Valid record of sex and date of birth
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The median duration of follow up was shorter amongst people with SMI. People with a 
diagnosis of schizophrenia were followed up for an average of 4.2 years (interquartile 
range (IQR): 1.8-7.9 years) versus 5.3 (IQR: 2.3-9.6) in the comparison group. People 
with a diagnosis of bipolar disorder were followed up for an average of 4.5 years (IQR: 
1.9-8.5) versus 5.6 years (IQR: 2.4-10.0) in the comparison group. 
7.1 Objective 1) Temporal changes the recording of physical health 
checks 
7.1.1 Separate components of the CVD risk score 
The proportion of people who had at least one measurement per year for weight, blood 
pressure, total cholesterol or HDL-C-concentration increased substantially over the 
study period ( 
Figure 7-2 to Figure 7-9) for the period 1st January 2002 to 31st December 2012). The 
next section describes the recording of physical health checks in over calendar time for 
each of the components of the Framingham risk score. In general, the rate of uptake of 
physical health checks has increased since 2002 both for people with and without SMI: 
however, the magnitude of increase has been greater amongst people with SMI. 
Stratifying uptake by age (30-39, 40-59, 60-74, 75-99 years) and type of SMI 
(schizophrenia or bipolar disorder) has highlighted differences in the rate of recording 
of physical health measures between sub-groups.  
7.1.1.1 Blood pressure 
Amongst people with a diagnosis of SMI, 25-40% had a blood pressure measurement 
taken in 2002 an uptake increased over time to 60-75% in 2012 ( 
Figure 7-2). During the same time period the uptake of blood pressure monitoring in 
people without SMI started at a similar level (20-40% in 2002) and remained fairly 
constant in people aged 30-39 and 40-59 years; but rose by approximately 10% in 
people aged 60-74 and 75-99 years.  
The proportion of people who had a record of systolic blood pressure recorded within 
each calendar year between 2002 and 2012 was consistently highest amongst people 
aged 30-39 and 40-59 years who had a diagnosis of SMI than people without SMI. The 
rate of uptake of blood pressure measurements occurred more slowly amongst people 
over 60 years of age and only reached comparable levels in the oldest age group (75-
99 years) amongst people with and without SMI after 2012.  
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Figure 7-2: Annual measurement of blood pressure recorded in people with 
schizophrenia (above) or bipolar disorder (below) compared to people without 
SMI
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7.1.1.2 Weight 
Amongst people with SMI, approximately one fifth had a weight measurement taken in 
2002 compared to 50-60% in 2012 (Figure 7-3). During the same time period the 
uptake of weight monitoring in people without SMI was at a similar level (15-20% in 
2002) and increased by approximately 10% between 2002 and 2006 and remained at 
relatively constant levels thereafter.  
The proportion of people who had a record of weight was consistently highest amongst 
people aged 30-39 and 40-59 years with a diagnosis of SMI. The rate of uptake of 
weight monitoring was slower amongst people over 60 years of age and only reached 
comparable levels in the oldest age group (75-99 years) amongst people with and 
without SMI after 2006.  
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Figure 7-3: Annual measurement of weight recorded in people with 
schizophrenia (above) or bipolar disorder (below) compared to people without 
SMI 
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7.1.1.3 Total cholesterol 
The uptake of total cholesterol monitoring in people with SMI increased markedly 
between 2002 and 2012 from no more than 10% in 2002 to 30-60% in 2012 (Figure 
7-4). The rate of annual cholesterol monitoring increased most sharply in people with 
SMI between 2010 and 2012 and uptake approximately doubled during this time 
period. Total cholesterol monitoring also increased in people without SMI, but at a 
slower and smoother rate: in 2002 approximately 10% had a total cholesterol 
measurement taken, increasing to 20-25% by 2012. 
Patterns of cholesterol monitoring were generally similar for both SMI groups; however, 
uptake amongst people with schizophrenia appeared to lag behind people with bipolar 
disorder. This trend was particularly evident for the oldest age group (75-99 years) for 
which levels of cholesterol monitoring in people with and without SMI reached 
comparable levels in 2009 for the bipolar disorder cohort and 2011 for the 
schizophrenia cohort. 
Cholesterol monitoring during 2012 was more common amongst people with SMI than 
those without for all age groups: absolute uptake was greatest in people aged 40-74 
years with the largest relative increase in the youngest age group (30-39 years). 
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Figure 7-4: Annual measurement of total cholesterol recorded in people with 
schizophrenia (above) or bipolar disorder (below) compared to people without 
SMI 
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7.1.1.4 HDL-C 
HDL-C testing (Figure 7-5) followed a very similar pattern to total cholesterol 
monitoring, although uptake of HDL-C monitoring was consistently slightly (2-5%) lower 
than for total cholesterol. 
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Figure 7-5: Annual measurement of high density lipoprotein-cholesterol recorded 
in people with schizophrenia (above) or bipolar disorder (below) compared to 
people without SMI 
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7.1.1.5 Smoking 
The pattern of recording suggests that only a minority (<20%) of people had smoking 
status recorded each year between 2002 and 2010 (Figure 7-6). However, the 
proportion of people who had smoking status recorded in 2011 and 2012 was 
substantially higher: up to 50% amongst people with SMI and 10-20% amongst people 
without SMI.  
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Figure 7-6: Annual measurement of smoking status recorded in people with 
schizophrenia (above) or bipolar disorder (below) compared to people without 
SMI 
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7.1.2 Recording of physical health data relative to the time of registration 
Figure 7-7 confirms that the recording of physical health data on weight, blood pressure 
and smoking status was most complete in the year of registration, and that amongst 
people with SMI, the completeness of this information improved year on year. The 
figures also show that at the time of registration, people with or without SMI had 
approximately equal levels of recording. However, after the year of registration people 
with SMI were more likely to have physical health measurements recorded than people 
without SMI. 
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Figure 7-7: The proportion of people with or without SMI who had one or more records of (clockwise from top left); A) weight, B) systolic 
blood pressure, C) total cholesterol or D) smoking status, per calendar year following registration 
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7.1.3 Combinations of components of the CVD risk score 
The proportion of people who had measurements for the collection of covariates 
needed to estimate the office version of the 10 year Framingham CVD risk score for a 
given year is outlined in Figure 7-8. Over the study period, the proportion of people for 
whom a CVD risk score could be estimated (using  BMI) increased amongst people 
with SMI from <20% in 2002 to 50% of people aged 30-39 years, 60% aged 40-59 
years, 50-60% aged 60-74 years and approximately 40% aged 75-99 years in 2012. 
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Figure 7-8: Annual recording of the set of covariates required to estimate BMI 
CVD risk in people with schizophrenia (above) or bipolar disorder (below) 
compared to people without SMI 
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Figure 7-9 outlines proportion of people who had measurements for the collection of 
covariates needed to estimate the laboratory version of the 10 year Framingham CVD 
risk score for a given year. Over the course of the study period the proportion of people 
for whom a CVD risk score could be estimated (using lipid measurements) increased 
amongst people with SMI from <10% in 2002 to 30-35% of people aged 30-39 years, 
50% aged 40-59years, 40-50% aged 60 in 2012. 
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Figure 7-9: Annual recording of the set of covariates required to estimate 
laboratory CVD risk in people with schizophrenia (above) or bipolar disorder 
(below) compared to people without SMI 
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7.2 Objective 2: Temporal changes in new statin prescriptions (January 
2002- December 2012) 
Figure 7-10 outlines the rate of new statin prescribing by age group to people with and 
without SMI for the period January 2002 to December 2012. During this period rates 
were relatively static in people aged 30-39 years and 40-59 years, with an increase in 
prescribing between 2010 and 2012 amongst those with SMI, but not those without 
SMI. Prescribing rates were higher amongst people aged 30-39 years and 40-59 years 
who had a diagnosis of SMI than comparison people without SMI. The rate of 
prescribing was highest amongst people aged 60-74 years: for this age group 
prescribing rates peaked in 2006 for people with and without SMI. There was 
substantial overlap in the rate of statin prescribing for people with and without SMI who 
were aged 60-74 years or 75-99 years. 
C 
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Figure 7-10: the rate of statin prescribing (per 1000 person years) in people with 
schizophrenia (above) or bipolar disorder (below) compared to people without 
SMI for the period 2002-2012  
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7.3 Objective 3) Investigate differences in new statin prescriptions to 
people with and without SMI (2007 to 2012) 
7.3.1 Characteristics of the cohort: 
A total of 8,779 people with a diagnosis of schizophrenia and 7,690 people with a 
diagnosis of bipolar disorder and ten times as many people without SMI (87,709 and 
76,846, respectively) were identified for inclusion in the study between 2007 and 2012 
(Table 7-1). Table 7-1 describes the characteristics of the cohort for the period 2007-
2012. People with SMI were more likely to have a higher level of deprivation, larger 
BMI, and a greater proportion had diabetes and were smokers (p<0.001 in all 
instances). Mean cholesterol concentration was similar in people with and without 
bipolar disorder (p=0.8) and slightly lower (p<0.001 for a difference of 0.1mmol/L) in 
people with schizophrenia relative to those without SMI; which reflects lower HDL-C 
concentration amongst people with SMI (p<0.001 for a difference of 0.1mmol/L in both 
cohorts). Mean systolic blood pressure was lower in people with SMI (p<0.001 for a 
difference of 4mmHg in both cohorts). 
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Table 7-1: Summary statistics for people with a diagnosis of schizophrenia or bipolar disorder compared to age and gender frequency 
matched people without a SMI: data for the period 2007-2012 
Characteristic 
 
n=8,779 n=87,709 n=7,690 n=76,846 
  
Schizophrenia (%) No SMI (%) Bipolar disorder (%) No SMI (%) 
Age at study start 
(years) 
30-39 2,521 (29) 25,249 (29) 2,538 (33) 25,414 (33) 
40-59 3,859 (44) 38,816 (44) 3,507 (46) 35,104 (46) 
60-74 1,657 (19) 16,395 (19) 1,131 (15) 11,251 (15) 
75-99 742 (8) 7,249 (8) 514 (7) 5,077 (7) 
Median age at start  
in years [IQR] 
 48.5 
[38.5-
61.5] 
48.5 
[38.5-
61.0] 
45.8 
[37.5-
57.5] 
45.5 
[37.1-
57.5] 
 
Sex Males 5,176 (59) 51,721 (59) 3,031 (39) 30,266 (39) 
Townsend score for 
deprivation 
1 997 (11) 18,629 (21) 1,465 (19) 18,957 (25) 
2 1,207 (14) 17,487 (20) 1,444 (19) 16,905 (22) 
3 1,734 (20) 18,698 (21) 1,665 (22) 16,491 (21) 
4 2,323 (26) 17,651 (20) 1,726 (22) 14,420 (19) 
5 2,518 (29) 15,244 (17) 1,390 (18) 10,073 (13) 
Diabetes Yes 812 (9) 4,614 (5) 579 (8) 3,546 (5) 
Smoker Yes 4,725 (54) 25,519 (29) 3,505 (46) 21,037 (27) 
Not recorded 156 (2) 3,352 (4) 71 (1) 2,192 (3) 
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Table 7-1 continued 
Characteristic n=8,779 n=87,709 n=7,690 n=76,846 
 Schizophrenia (%) No SMI (%) Bipolar disorder (%) No SMI (%) 
Mean cholesterol 
(mmol/L) 5.4 (1.1)* 5.5 (1.1)* 5.5 (1.1)* 5.5 (1.1)* 
Not recorded 3,174 (36) 47,455 (54) 2,587 (34) 43,267 (56) 
Mean HDL-C (mmol/L) 1.3 (0.4)* 1.4 (0.4)* 1.4 (0.4)* 1.5 (0.4)* 
Not recorded 3,693 (42) 51,950 (59) 3,011 (39) 46,979 (61) 
Mean SBP (mmHg) 129 (15)* 133 (16)* 128 (15)* 131 (16)* 
Not recorded 1,137 (13) 21,452 (24) 759 (10) 16,623 (22) 
Mean BMI (kg/m
2
) 27.7 (5.9)* 27.1 (5.3)* 27.8 (5.6)* 27.0 (5.5)* 
Not recorded 1,943 (22) 35,712 (41) 1,409 (18) 29,746 (39) 
*Figure in brackets indicates standard deviation rather than percentage. IQR; inter-quartile range, SBP; systolic blood pressure. Where multiple measurements were 
available for the same individual, the mean (continuous variables) or mode (categorical variables) was retained in the dataset.  
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7.3.2 Differences in new statin prescriptions to people with and without SMI 
(2007 to 2012) 
The crude rate and incidence rate ratios (adjusted for sex, five-year age-band and 
Townsend score for deprivation) for new statin prescribing during the period 2007-2012 
are outlined in Table 7-2.  
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Table 7-2: IRRs for new statin prescriptions in people with and without SMI between 2007 and 2012: results from multivariable Poisson 
regression models 
SMI type Age group (years) 
SMI No SMI Adjusted IRR 
Crude rate 95% CI Crude rate 95% CI aIRR* 95% CI p value 
Schizophrenia 
30-39 10.51 (8.09-13.7) 2.13 (1.78-2.55) 4.48 3.25-6.19 <0.001 
40-59 32.57 (29.6-35.9) 16.40 (15.8-17.1) 1.87 1.68-2.08 <0.001 
60-74 48.30 (42.9-54.3) 51.04 (49.3-52.8) 0.91 0.80-1.02 0.114 
75-99 31.21 (24.9-39.1) 37.63 (35.5-39.9) 0.79 0.62-1.00 0.049 
Bipolar disorder 
30-39 7.65 (5.67-10.3) 1.91 (1.61-2.31) 3.85 2.70-5.49 <0.001 
40-49 25.07 (22.4-28.0) 12.82 (12.2-13.4) 1.87 1.65-2.11 <0.001 
60-74 59.72 (52.7-67.6) 44.38 (42.5-46.3) 1.32 1.16-1.51 <0.001 
75-99 34.81 (27.0-44.8) 36.79 (34.2-39.5) 0.92 0.71-1.20 0.531 
* IRRs for statin prescribing and SMI adjusted for 5-year age-band, gender and Townsend score for deprivation 
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The absolute rate of new statin prescribing in people with SMI ranged from 8 per 1000 
person-years in 30-39 years olds to 60 per 1000 person-years in 60-74 years olds. 
Amongst people without SMI, rates of new statin prescribing were comparatively lower 
in younger people and similar or slightly higher in older people. 
After adjusting for 5 year age band, gender and Townsend score, IRRs for statin 
prescribing during the period 2007 to 2012 were significantly higher amongst people 
with a diagnosis of bipolar disorder than comparison people for all but the oldest age 
group (75-99 years), for which there was no evidence of a difference in prescribing rate 
(p=0.5). The greatest relative difference in prescribing rate was for people aged 30-39 
years, where rates were 3-4 fold higher in people with bipolar disorder than comparison 
people (adjusted IRR of 3.9 (2.7-5.5), p<0.001). Relative rates of prescribing to people 
with bipolar disorder were approximately doubled amongst people aged 40-59 years 
(adjusted IRR of 1.9 (1.7-2.1), p<0.001) and 30% higher for people aged 60-74 years 
(adjusted IRR of 1.3 (1.2-1.5), p<0.001), relative to comparison people without SMI 
(Table 7-2). 
A similar – but more pronounced - pattern of prescribing was evident for people with a 
diagnosis of schizophrenia (Table 7-2), for whom relative rates of prescribing were 
nearly five-fold higher amongst people aged 30-39 years (adjusted IRR of 4.5 (3.3-6.2), 
p<0.001) and almost doubled in people aged 40-59 years (adjusted IRR of 1.9 (1.7-
2.1), p<0.001). Rates of prescribing were equivalent in people aged 60-74 years with 
schizophrenia compared to those without SMI (adjusted IRR of 0.9 (0.8-1.0), p=0.1). 
However, there was evidence of significantly lower rates of statin prescribing to people 
with schizophrenia in the oldest age group (75-99 years), relative to people without SMI 
(adjusted IRR of 0.8 (0.6-1.0)).  
7.3.3 Amongst people who have had a CVD screen, investigate whether the rate 
of statin prescribing differs in people with and without SMI after 
accounting for differences in estimated CVD risk (2007-2012) 
A total of 8,037 people with a diagnosis of schizophrenia and 7,176 with a diagnosis of 
bipolar disorder (and 80,460 and 71,769 comparison people, respectively) who were 
aged between 30 and 74 years of age were identified for the period 2007 to 2012 (link 
back to Table 7-1).  
Due to missing data, it was only possible to estimate CVD risk scores for a total of 
9034 (59%) people with SMI (schizophrenia: 4,697 (58%) or bipolar disorder: 4,337 
(60%)) and 58,153 (38%) without SMI. Of these, 20% (1775 of 9034) with SMI and 
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23% (13,380 of 58,153) without SMI had a CVD risk score of 20% or greater (p<0.001). 
A total of 37% (651 of 1,775) of people with SMI who had a risk score of 20% or higher 
were prescribed a statin, which compares to 43% (n=5,748 of 13,380) in people without 
SMI (p<0.001). 
Figure 7-11 outlines the relationship between estimated CVD risk and the proportion of 
people who were prescribed a statin aged 30-74 years (and who had sufficient data to 
estimate CVD risk using the lipid version of the Framingham equation).  
The proportion of people who were prescribed a statin at risk scores below 20% (which 
was the recommended threshold for statin prescribing at the time of data collection) 
was similar for people with and without SMI. However a lower proportion of people with 
high risk scores - and who had schizophrenia - prescribed a statin relative to people 
without SMI. For example, for people who had a risk score in excess of 40%, 39% 
(95% CI: 31-47) with schizophrenia (n= 50 of 129) were prescribed a statin versus 55% 
(95% CI: 51-58) without SMI (n= 520 of 952). 
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Figure 7-11: the proportion of people who were prescribed a statin, by 10 year CVD risk (%) 
 
 
 
159 
 
IRRs for new statin prescription show that, after adjusting for estimated CVD risk 
score, the rate of prescribing did not differ significantly between people with or 
without SMI. The adjusted IRRs were 0.97 (95% CI; 0.90-1.05) for people with 
schizophrenia and 1.00 (95% CI; 0.92-1.10) for bipolar disorder, relative to 
comparison people.  Further detail regarding the spline model is outlined in the 
appendix; section 22. 
8 Discussion 
8.1 Key results 
The key findings of this study are that annual rates of CVD screening in people with 
SMI are now at or above equitable levels relative to people without SMI. Despite 
these improvements, there were many people (40-60%) who had insufficient 
physical health data recorded to estimate a CVD risk score. The increased rate of 
CVD screening has been accompanied by increases in statin prescribing in people 
with SMI – particularly those aged 40-59 and 60-74 years – relative to people 
without SMI. However, the oldest people (75-99 years) with schizophrenia remain 
less likely to be prescribed a statin relative to people without SMI. 
8.2 Uptake of physical health checks amongst people with and 
without SMI 
The recording rate of covariates used to estimate 10 year CVD risk has rapidly 
increased over time (particularly after the introduction of QOF), with the greatest rise 
seen amongst people with SMI who were aged 30-59 years. However, uptake of 
physical health checks is not universal and a substantial proportion (40-60% 
depending on age group and type of CVD risk score) of people with SMI had 
insufficient data to estimate CVD risk. However, it should be noted that the uptake 
of physical health checks during the period 2007-2012 was relatively lower in people 
without SMI. 
The results of this study echo findings from the National Audit of Schizophrenia, 
which found that two thirds of people with a diagnosis of schizophrenia were not 
given a full physical health check during the 12 month period ending in 2013 (Royal 
College of Psychiatrists, 2014). Few studies have investigated the uptake of 
physical health checks in people who do not have a pre-existing CVD condition and 
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who have a SMI diagnosis: the results from this chapter are novel, but comparison 
with other studies is limited. 
Osborn et al. used primary care data from THIN to investigate differences in the rate 
of physical health checks between January 2000 and December 2007 in people with 
and without SMI who did not have an existing CVD condition (Osborn et al., 2011). 
My study and the work by Osborn et al. use similar methodologies and have the 
same data source (although the study by Osborn applied additional criteria – such 
as a date range for confirming the diagnosis of SMI - to define the study population): 
it is therefore unsurprising that the overall patterns of screening are similar. 
However, the results I have presented in this chapter are more contemporary and 
assess the collective availability of health parameters required to estimate CVD risk, 
not just individual factors. 
Two other studies have sought to estimate differences in uptake of physical health 
checks for people with SMI, relative to people without SMI. Roberts et al. examined 
the proportion of patients registered at 22 UK GP practices who had six health 
parameters (blood pressure, weight, cholesterol, smoking status, alcohol 
consumption and family history of heart disease) recorded between April 1998 and 
December 2000. The study found that patients with a diagnosis of schizophrenia 
were approximately half as likely have a record of blood pressure or cholesterol 
concentration compared to age- and gender-matched patients from either the 
general population or the asthma register. In comparison to asthma patients (but not 
the general population patient sample), people with schizophrenia were much less 
likely (OR: 0.37, p=0.001) to have had smoking status recorded (Roberts et al., 
2007). Direct comparison to my study is difficult because the time periods are 
different: however, there is agreement from both studies that physical health 
measurements have historically been less frequently provided to people with SMI, 
although my results show marked improvement in more recent years. 
A different study (Hardy et al., 2013) opted to use people with a diagnosis of 
diabetes as the comparison group for people with SMI. The study team undertook a 
retrospective audit of the uptake of full physical health checks (defined as 
measurement of blood pressure, BMI, blood glucose or HbA1c and cholesterol 
within a 15 month period) across five primary care centres in Northampton between 
September 2009 and August 2010. People with SMI were identified through the 
register or from prescribing records for antipsychotic medication. People with 
diabetes were identified through the Quality Management Analysis System (which 
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determines payment of GP surgeries as part of the national contract). The study 
found that 21% of people with SMI received a full health check (with recording of 
individual components varying between 63% (blood pressure) and 35% 
(HbA1c/blood glucose)). This compared to 96% of patients with diabetes receiving 
an equivalent screen, thus giving a crude odds ratio of 90.4 (95% CI: 64.5-126.6) 
that favoured screening in diabetic patients relative to people with SMI.  
The same study investigated the distribution of full physical health checks by age 
and found that this proportion increased with advancing age amongst people with 
SMI: 16-35 years; 11%, 36-55 years; 22% and 56 years+; 31% (n=386) (Hardy et 
al., 2013). Whilst this result appears at odds with my findings of lower rates of 
screening amongst older people with schizophrenia, there are several factors that 
may explain these differences. In particular, Hardy et al. did not exclude people with 
pre-existing CVD. Although it is not possible determine the proportion of people with 
an existing CVD diagnosis from the publication, physical health checks are more 
frequently carried out amongst people with a CVD diagnosis, and CVD diagnoses 
are more frequent in older people. 
The results of my study suggest that disparities in the provision of physical health 
checks have decreased over time such that people with SMI are now more likely to 
be screened than those without this condition. However, despite these 
improvements, there are many people for whom it is not possible to estimate CVD 
risk. I identified age as being associated with uptake of health checks: younger 
people with SMI were more likely to be screened than older people. This study has 
enabled me to explore patterns of physical health checks and to develop an 
understanding of some of the mechanisms (such as new patient registration) 
through which physical health data are collected. These factors will be essential for 
more detailed exploration of unobserved (i.e. missing) covariate data that will 
support development of a multiple imputation model used in the main analys is 
regarding the effectiveness of statins in people with SMI. 
8.3 Rates of new prescriptions of statins to people with and without 
SMI 
Rates of new statin prescriptions have fluctuated over time and after 2010 were 
more frequently prescribed to people with SMI than comparable people without SMI. 
Age was strongly associated with the likelihood of receiving a new statin 
prescription, with prescribing rates amongst younger people (aged 30-59 years) with 
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SMI being twice as high as rates in the comparison group. By contrast, older adults 
(60-99 years) with schizophrenia (but not bipolar disorder) had reduced rates of 
prescribing, which were 9% lower than for comparison people. 
In my study, the frequency with which new statin prescriptions were issued was 
much higher (2-5 times) in younger people with SMI than comparison people 
without SMI. However, rates of new statin prescribing were the same or lower in 
older people with SMI, with significant disparity in prescribing for people with 
schizophrenia. Although inequalities in the provision of statins to older people with 
schizophrenia have (to the best of my knowledge) not been investigated elsewhere, 
it is recognised that older people with a mental health condition are at risk of greater 
inequality in other forms of health provision (Karim et al., 2005;Davies, 
2011;Lawrence and Kisely, 2010;Green and Benzeval, 2013). However, it is difficult 
to interpret the clinical implications of lower rates of statin prescribing to the over 
75s because the guidance on statin prescribing at the time of the data collection 
was unclear for this age group (National Institute for Health and Clinical Excellence, 
2008b). 
Amongst the subset of people for whom a CVD risk score could be calculated 
(assumed to be those who participated in screening), the proportion who received a 
statin increased with increasing estimated risk. After taking into account estimated 
CVD risk score, there was no evidence that rates of new statin prescribing differed 
between people with or without SMI who had been screened: this suggests that the 
increased frequency of statin prescribing in people with SMI is proportionate to the 
higher CVD risk of the group. This could suggest that the decision-making process 
governing statin prescribing after a physical health check is similar regardless of 
SMI status. However, my results may not reflect trends at time points earlier than 
2007.  
In addition, the descriptive analysis of CVD risk and statin prescribing amongst 
people who were screened indicated that the proportion of people with high CVD 
risk who were prescribed a statin was lower amongst people with a diagnosis of 
schizophrenia than people without SMI. Although this difference was not statistically 
significant across the whole spectrum of CVD risk, the discrepancy in prescribing 
could warrant further investigation. Amongst people with SMI who had a CVD 
screen, only a minority (37%) of those with an estimated risk of 20% or higher were 
prescribed a statin, which suggests a concerning level of under-treatment. However, 
this figure is broadly similar to figures for the general population (Wu et al., 
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2013;Artac et al., 2013) and is likely to reflect both GP and patient perceptions and 
preferences for cardiovascular management. 
In addition, other studies have indicated that lower provision of statins to people with 
SMI may be at least partly driven by GP prescribing preferences. A recent study 
randomly assigned one of three sets of vignettes to all GPs in a single region in 
Scotland (Macklin and Morrison, 2011).  Each vignette set outlined details for two 
patients with a CVD risk score of 20% (using the Joint British Hypertension Society 
Risk Calculator), which differed only in terms of each patient’s status as having; type 
1 versus type 2 diabetes, schizophrenia versus epilepsy, or being retired versus 
unemployed.  The results (obtained from 56/133 GPs initially approached) showed 
that 37% of GPs surveyed recommended prescribing statins to an individual with 
schizophrenia, which was similar to individuals with epilepsy (31%).  This figure was 
markedly lower than for individuals with diabetes (type 1 diabetes (88%) versus type 
2 diabetes (85%)), but similar for people who were not working (retired (33%) 
versus unemployed (23%)) (Macklin and Morrison, 2011). 
8.4 Limitations of the study 
The low proportion of high risk people who were prescribed a statin in this study 
may reflect some important limitations: 
8.4.1 Imperfect replication of the risk score estimated by the GP 
Vision software has a built-in application that estimates a patient’s CVD risk score 
based on risk factors that have been measured at recent time points (Abegunde, 
2010): however, this estimate is not routinely captured in THIN data. Although there 
are designated Read codes for estimated CVD risk, these fields were not well 
populated and I therefore opted to calculate risk scores from available data held in 
other parts of each electronic patient record (as described in Chapter 3). As a result, 
my estimates of CVD risk might differ to scores calculated by the GP in real life, 
since a number of risk algorithms are available (Hippisley-Cox et al., 2010;Conroy et 
al., 2003;D'Agostino et al., 2008) as well as different criteria for selecting covariate 
data. In particular, risk scores estimated by GP software packages do not routinely 
restrict measurements to those taken within a specific time period (e.g. the 6 year 
calendar period used in my study) but will default to using the most recently 
recorded measurements. 
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The Framingham Risk score (which I used in this study) tends to overestimate CVD 
risk in European populations (Brindle et al., 2003), which may have contributed to 
the apparently low levels of statin prescribing to people at and above the 20% 
threshold. I considered using the QRISK2 algorithm (Hippisley-Cox et al., 2008) to 
estimate CVD risk; however, this was not possible because full details of the 
algorithm (coefficients and baseline population risk) were not freely available at the 
time of undertaking the study. 
8.4.2 Use of lifestyle modification 
National guidelines for lipid management recommend that people with raised CVD 
risk should try to modify their lifestyle through changes to diet and physical activity 
before initiating a statin (National Institute for Health and Clinical Excellence, 
2008b). However, these recommendations are not routinely recorded in primary 
care data such as THIN. It is therefore possible that people with high CVD risk who 
were not prescribed a statin were advised by their GP to change aspects of their 
lifestyle such as diet.  
8.4.3 Use of other lipid modifying drugs 
This study has focused on statins and has not considered other types of lipid-
modifying drugs. Although statins account for over 90% of pharmacological 
interventions for lowering cholesterol in the UK (Wu et al., 2013), other drugs such 
as fibrates, may be used for lipid modification (Joint Formulary Committee, 2012). 
Later work will include an indicator denoting people who were prescribed non-statin 
lipid modifying drugs, which will be incorporated into multiple imputation and 
analysis models. 
8.4.4 Contraindications for statin prescribing 
I did not exclude people with a contraindicating condition such as acute liver 
disease, although this is unlikely to substantially impact upon my results (as the 
number of people to whom this applies is likely to be low). However, it will be 
necessary to exclude people with contraindicating conditions from the main analysis 
of my PhD work regarding the effectiveness of statins in people with SMI. 
8.4.5 Missing data on covariates 
I was only able to estimate risk scores for a subset of people (59% with SMI and 
38% without SMI) who were under follow up during the period January 2007-
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December 2012. Risk scores were estimated for all people who had covariate data 
on blood pressure, smoking status, total cholesterol and HDL-C during the during 
the six year period and were therefore assumed to have received a full CVD screen. 
However, it is important to note that people for whom it was possible to estimate a 
risk score are not likely to be representative of people with missing covariate data. 
In particular, it was not possible to estimate CVD risk scores for the majority of 
people without SMI, which may reflect both differences in screening policy in people 
with and without SMI (e.g. annual screening in people with SMI versus five yearly 
screening in the general population aged 40-75 years). 
8.5 Implications for my work on estimating the effectiveness of statins 
in people with SMI (Chapter 6) 
The results of this study indicate the importance and potential value of imputing 
missing CVD covariate data in order to select statin exposed and unexposed people 
with similar CVD risk scores. In addition, this study identified strong temporal trends 
in missing covariate data and statin prescribing. The design selected for the main 
study (estimating the effectiveness of statins – Chapter 6) stratifies people into a 
series of cohorts on the basis of whether or not they were prescribed a statin within 
a given calendar period. Because this approach explicitly selects people within the 
cohort on the basis of time it may therefore be well suited to analysing datasets - 
such as this one - where patterns of both prescribing and missing data are 
associated with calendar time. 
This study found that over half of people who had physical health measurements 
that indicated high ten-year CVD risk (>20%) were not prescribed a statin. Plausible 
reasons for these people not being prescribed a statin include the patient declining 
to be treated with a statin, or trying lifestyle modification first. In addition, the GP 
may not have directly estimated the CVD risk score and were therefore unaware 
that the patient’s risk score was above the prescribing threshold. Furthermore, the 
presence of contra-indicating conditions (such as liver disease or terminal illness) 
may preclude prescribing. This latter reason highlights the importance of applying 
rigorous inclusion and exclusion criteria in addition to incorporating confounding 
variables that are predictive of statin prescribing patterns. The main analysis will 
include covariate information on a much more extensive range of confounders, and 
should therefore be more able to adjust for differences in the characteristics of 
people who were prescribed a statin, relative to statin non-users (thereby 
decreasing the likelihood of confounding by indication). 
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In April 2014 the QOF target for measuring cholesterol for primary prevention of 
CVD was retired, thus removing the financial incentive for monitoring this physical 
health parameter (National Institute for Health and Clinical Excellence, 2012). 
Although measuring cholesterol in people who have been prescribed statin therapy 
is still considered to be best practice (National Institute for Health and Clinical 
Excellence, 2014b), the loss of the QOF target is likely to reduce rates of annual 
cholesterol monitoring. It is currently unclear what impact (if any) this will have on 
individual patients, but decreased completion of primary care data seems likely. For 
this reason, the current dataset from THIN (up to 2014) is likely to provide the most 
complete dataset regarding cholesterol concentration and therefore makes the 
timing for investigating the effectiveness of statins with primary care data optimal. 
8.6 Implications for policy and practice 
These results suggest that the observed higher rate of statin prescribing to people 
with SMI relative to people without SMI is proportionate given differences in CVD 
risk between the two groups. However, the results also suggest that high risk and 
older people with schizophrenia may potentially be an undertreated group. 
However, although current guidelines advocate statin prescribing to older people, 
previous guidance (in place at the time of data collection) did not promote 
prescribing to people aged over 75 years (National Institute for Health and Clinical 
Excellence, 2014b;National Institute for Health and Clinical Excellence, 2008b). In 
addition, older people - especially those with SMI - may be more difficult to both 
access and engage in preventative therapies. It may therefore be necessary to 
consider different approaches for improving the physical care of this demographic, 
for example through opportunistically undertaking physical checks in secondary 
care or during visits by community mental health staff.  
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Chapter 6 : The effectiveness of statins for primary 
prevention of CVD in people with SMI: a staggered 
cohort study in THIN 
1 Chapter content 
This chapter builds on material presented elsewhere in the thesis. Chapter 2 
evaluated the evidence-base for statin prescribing for primary prevention of 
cardiovascular disease (CVD) in people with severe mental illness (SMI). It also 
identified a need for research investigating the impact of statin prescribing on CVD 
events and over longer periods of time.  Chapters 3 and 4 detail the rationale for 
selecting the data source (The Health Improvement Network (THIN)), case 
definitions and type of methodology (staggered cohort study), respectively. The 
results of chapter 5 described the scale and temporal distribution of missing data on 
CVD covariates and confirmed that statins are prescribed with increasing frequency 
to individuals with SMI. This chapter outlines the method and results for the main 
analysis investigating the effectiveness of statins for primary prevention of CVD in 
people with SMI.  The primary outcome was combined first myocardial infarction 
(MI) and stroke events. The secondary outcomes were all-cause mortality, MI, 
stroke and change in total cholesterol concentration at 1 and 2 years after the index 
date. I describe the key results and interpret the main findings with reference to 
published literature and the likely limitations of the study. Finally, I suggest some 
preliminary conclusions, which are discussed in greater depth in Chapter 7. 
This work has been submitted for presentation at the UK Public Health England 
Applied Epidemiology Scientific Conference 2016 (March 2016 - Warwick). The 
associated abstract is outlined in the appendix; section 24.1. 
2 Statin prescribing for primary prevention of CVD in people 
with SMI 
Figure 2-1 outlines the clinical care pathway for CVD screening and statin 
prescribing in UK primary care. 
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Figure 2-1: Clinical care pathway for CVD screening and statin prescribing in UK primary care 
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Chapter 5 examined the processes that occur upstream of statin prescribing and 
identified that statins are now more frequently prescribed to people aged 30-74 
years with SMI than comparable individuals without SMI. The results from chapter 5 
also highlighted that in 2012 40-60% of individuals with SMI did not attend an 
annual physical health check. Furthermore, of the people for whom it was possible 
to estimate a CVD risk score, only a minority (37%) with risk scores at or above the 
recommended clinical threshold (≥20% over a 10 year period) were prescribed a 
statin.  These findings are of significance to this study because:  
– people who attended a physical health check may not be representative of 
those who did not attend  
 
– people who were prescribed a statin may not be representative of those who 
were not prescribed a statin; even amongst the subset of people who were 
screened and had a high CVD risk score 
In practical terms the implication of these findings are that restricting the analysis to 
people with fully observed covariate data (i.e. a complete case analysis) may 
produce biased results that are not representative of the full SMI population. This is 
because people with and without fully observed covariate data may differ with 
respect to characteristics such as severity of mental illness and their preference for 
taking a statin (factors which are imprecisely described by data from THIN).  
Furthermore, national policy identifies people with SMI as a population that is at 
high risk of developing CVD and for whom statin prescribing should be considered. 
This chapter therefore focuses on the association between statin prescribing and 
CVD events in all individuals with SMI, rather than only those who attended an 
annual physical health check. 
The importance of multiple imputation as a method for estimating unobserved 
values of CVD covariates was emphasised in Chapter 4 section 9.  Multiple 
imputation is likely to offer the best available method to facilitate extending the 
analysis beyond the subset of people with complete covariate data.  This is because 
multiple imputation uses the correlations within the observed covariate data to 
determine the underlying distribution from which imputed values are estimated 
(Sterne et al., 2009). 
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3 Rationale for investigating the effectiveness of statins in 
people with SMI 
The evidence-base for statin prescribing for primary prevention of CVD in people 
with SMI was outlined in Chapter 2.  In brief, randomised controlled trials (RCTs) 
have shown statins to be cost-effective for managing dyslipidaemia and preventing 
CVD events in high risk people (recently defined for the UK as ≥10% risk of CVD 
over a ten year period, but historically 20%: Chapter 5 section 2) (National Institute 
for Health and Clinical Excellence, 2014b;Gutierrez et al., 2012;Baigent et al., 
2005;Lazar et al., 2011;Taylor et al., 2013). However, people with SMI are under-
represented in statins trials and the effectiveness of statins may differ relative to the 
general and trial populations due to increased CVD risk, antipsychotic exposure and 
potentially lower medication adherence. 
4 Aim 
This study aims to estimate the effectiveness of statins in reducing CVD 
events in people with SMI. 
Objectives: 
To compare people with SMI who did (statin users), or did not (statin non-users), 
receive a statin prescription and to estimate the effect of statin prescribing on: 
1) combined first MI and stroke (primary outcome) 
2) combined first MI and stroke within clinically relevant sub-groups 
3) all-cause mortality 
4) first MI 
5) first stroke  
6) change in total cholesterol concentration 1 and 2 years after the index date 
5 Methods:  
This section describes the methods applied to the study: the rationale and 
justification of these methods was discussed in detail in Chapter 4. 
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5.1 Data Source 
The data source for this study is THIN: an extended description of the database, all 
case definitions and indicators of the reliability of the data were outlined in Chapter 
3. 
5.2 Study design 
5.2.1 Overview:  
The effect of statin prescribing on CVD events in people with SMI was evaluated 
using pooled data from five cohort studies in THIN that were initiated at two year 
intervals from 1st January 2002 to 1st January 2010 (Figure 5-1).  Each cohort study 
started with a twenty-four month exposure window (the duration of which was 
identified through exploratory work), in which the presence or absence of at least 
one statin prescription was used to classify an individual as a statin user or non-user 
(respectively) for that time period. Statin users and non-users were re-defined at the 
start (twenty-four month exposure window) of each subsequent cohort, meaning 
that an individual could contribute data to both statin user and non-user study 
groups. 
Figure 5-1: diagrammatic representation of the staggered cohort study design 
 
The duration of the exposure window (twenty-four months) was selected on the 
basis of exploratory work that investigated both the width of the confidence intervals 
(CI) around the effect estimate for the crude association between statin prescribing 
and CVD events and the feasibility of imputing missing data for each cohort.  
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Possible exposure windows of 6, 12 and 24 months were investigated, which would 
correspond to a study design comprising 20, 10 or 5 cohorts, respectively.   
In this study the term “case” is used to refer to statin users and non-users who were 
under follow-up. Given that each individual could contribute data to more than one 
cohort the total number of cases under follow-up across all five cohorts is larger 
than the total number of individuals. 
5.2.2 Inclusion and exclusion criteria for each staggered cohort 
A series of retrospective cohort studies were developed. Data for all GP surgeries 
were extracted for people with a diagnosis of schizophrenia or bipolar disorder 
(Chapter 3 section 3.2) for the period 1st January 2002 to 31st December 2013. 
Inclusion Criteria: people aged 40-84 years who; i) were permanently registered 
with the GP practice (Patflag A and C) ii) consulted their GP within the study period 
and iii) have data reported after practice acceptable mortality rate (AMR) and 
acceptable computer usage (ACU) dates (Horsfall et al., 2012;Maguire et al., 2009) 
(Chapter 3 section 3.2).    
Exclusion Criteria: individuals who; i) had a diagnosis of CVD (Chapter 3 section 
3.2) prior to the start of the study, ii) had been prescribed a statin in the twenty-four 
months prior to the start of the study or iii) had a statin contraindicating condition 
(terminal illness, raised liver enzymes or dementia) recorded before the start of the 
study.  Full code lists for these conditions are outlined in the appendix; section 20. 
Terminal illness was defined as Read codes held in medical records 
relating to the following conditions: terminal illness – late stage, last days of 
life, terminal care, palliative care, GSF supportive care, Liverpool care 
pathway, end of life advanced care plan, terminal care, end of life care,  
Raised liver enzymes was defined as: 3x the upper limit of the reference 
ranges for either alanine transaminase (ALT) or aspartate aminotransferase 
(AST) as indicated in addition health records (1001400006 and 1001400007, 
for ALT and AST respectively).  The threshold would ideally be defined using 
local reference ranges specific to the testing laboratory, but this approach 
was not pragmatic so general criteria were applied to exclude individuals 
with high threshold values.  For ALT and AST the current upper limits of the 
reference ranges for NHS Camden are 33 and 31 IU/L, respectively.  These 
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values were inflated by 25% and multiplied by 3 to give highly conservative 
values of 124 (ALT) and 116 IU/L (AST) for exclusion. These individuals 
were excluded because statins are contraindicated for people with elevated 
liver enzymes (Joint Formulary Committee, 2012). 
Dementia was defined as Read codes held in medical records relating to the 
following conditions: Alzheimer’s, dementia, other senile and presenile 
organic psychoses, presbyophrenic psychosis, senile psychosis,  
Entry into the study was at the latest of:  
v) Index date (see Section 5.3.1) 
vi) 40th birthday 
vii) date of registration plus 12 months 
viii) date of practice AMR or ACU 
Exit from the study occurred at the earliest of: 
vii) 31st December 2013 
viii) out of practice transfer 
ix) first CVD event 
x) death 
Individuals were not eligible to enter the study until 12 months after the date of 
registration. This was to ensure that people were under follow-up though-out the 
baseline period of 12 months (in which covariate data were measured – Chapter 3 
section 3.2) but also exclude people with prevalent diagnoses of CVD and prevalent 
statin users (Lewis et al., 2005).   
Individuals below the age of 40 years were not included in the cohort because the 
CVD event rate in this age group is very low.  The upper age limit (84 years) for 
people entering the cohort at baseline was applied because – at the time of data 
collection – guidance regarding initiation of statin prescribing to people aged older 
than 75 years was unclear and prescribing practice was likely to be inconsistent.  
However, once statin medication has been initiated there is no upper age limit at 
which discontinuing medication is advised, therefore no upper age limit was used to 
define follow-up. 
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The latest date that an individual could exit the cohort was 31
st
 December 2013, 
which was selected because this date marked the most current data available at the 
time and allowed a two year period after the last possible index date (31st December 
2011) to capture CVD and total cholesterol outcome data. 
5.3 Study variables 
5.3.1 Index date 
Statin users: Individuals who initiated a statin within the two year exposure period 
began follow-up on the day of their first statin prescription (the index date).   
Statin non-users: For individuals who did not receive a statin prescription (Chapter 
3 section 3.2) during the two year exposure period, the index date was a randomly 
selected day within the two year exposure period and within the follow up time of the 
individual. 
In the main analysis individuals were analysed on the basis of statin prescribing at 
the index date regardless of any subsequent changes in use (e.g. initiating a statin 
after the exposure period, or discontinuation of prescribing) and is broadly 
analogous to “intention to treat” analyses of trial data.  
5.3.2 Study outcomes 
Primary outcome: first MI or stroke (combined MI, haemorrhagic and ischaemic or 
unspecified stroke) (Chapter 3 section 3.2) 
Secondary outcomes: all cause-mortality, MI, stroke, change in total cholesterol 
concentration 1 and 2 years after the index date (Chapter 3 section 3.2) 
Chapter 3 introduced literature that aimed to assess the validity of CVD diagnoses 
recorded in THIN.  These studies indicated reasonable confidence in diagnoses of 
MI, stroke and all-cause mortality, but considerable uncertainty for other types of 
coronary heart disease (CHD) diagnoses (including angina and unstable angina), 
transient ischaemic attack (TIA) as well as unspecified diagnoses of CVD.  For this 
reason preliminary work for this study examined temporal trends by sub-groups of 
CVD diagnoses to assess whether there was any indication that prevalent 
diagnoses of CVD might be recorded.  On the basis of this work and published 
validation studies other types of CHD diagnoses were not included as an outcome 
measure in this study. 
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Exclusion of misclassified CVD events: Statin users and non-users who had a 
CVD event recorded within three months of the index date were excluded.  This was 
primarily to exclude individuals for whom statins were prescribed as secondary 
prevention: i.e. prescriptions after a CVD event, but where the CVD event date may 
have been incorrectly recorded in the patient’s notes such that the event appears to 
occur immediately after the index date.  This scenario may arise when a GP is 
notified of the CVD event via a discharge letter from secondary services, or at the 
point at which the patient obtains a statin prescription. 
An exclusion period of three months after the index date was selected on the basis 
that the rate of CVD events in individuals who were prescribed a statin was very 
high at time points close to the index date (Figure 5-2).  The rate of CVD events 
amongst statin users fell and fluctuated less after three months, suggesting that this 
was the minimum period that should be excluded.  Discussion with clinicians also 
suggested that three months was a plausible length of time for the GP to be formally 
notified of a CVD event and to update the electronic health record. 
Figure 5-2: The rate of CVD events in statin users relative to the date of first 
statin prescription 
 
Change in total cholesterol concentration in the 1 and 2 years after the index 
date: The impact of statin prescribing on lipid modification is of interest both as an 
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intermediate outcome for CVD risk reduction and as an indicator of statin 
medication adherence. In this analysis lipid modification was only investigated 
amongst people with complete baseline covariate data (i.e. complete case analysis) 
in order to avoid imputing either the outcome (total cholesterol concentration at 1 
and 2 years after the index date) or total cholesterol concentration at baseline; 
which is likely to be strongly correlated with cholesterol outcomes at 1 and 2 years. 
5.3.3 Covariates  
Data on all covariates were measured for each individual during the 24 month 
baseline period prior to entering the study and are summarised in Table 5-1: a 
proposed causal diagram and case definitions were outlined in Chapter 3 section 
3.2.  
Covariates were: age, sex, type of SMI, blood pressure, weight, height, total 
cholesterol and high density lipoprotein-cholesterol (HDL-C) concentration, 
diabetes, smoking status, Townsend score, antihypertensive use, non-statin lipid 
modification, heavy drinking, familial hypercholesterolaemia, hypothyroidism, 
chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), 
asthma, atrial fibrillation, predominant antipsychotic, mood stabilizing drug, anti-
depressant drug, annual consultation rate, cancer diagnosis, health authority region. 
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Table 5-1: Variables considered for inclusion in the imputation and analysis models 
  Variable Value 
F
u
ll
y
 o
b
s
e
rv
e
d
 
Index date Date 
CVD event MI or stroke 
Date of death Date 
Time to event Nelson–Aalen estimates 
Statin prescriptions Type and date prescribed 
Start date 
Date 
End date 
5 year age band 5 year age band (between 40 and 84 years) 
Sex Male / Female 
SMI type Bipolar disorder / Schizophrenia 
Diabetes No/Yes at or before baseline 
P
a
rt
ia
ll
y
 o
b
s
e
rv
e
d
 
Total cholesterol 
Mean during baseline (mmol/L) 
HDL-C 
Systolic blood pressure 
Mean during baseline  (mm/Hg) 
Diastolic blood pressure 
Weight Mean during baseline (kilograms) 
Height Adult height (centimetres) 
Smoking status Never, Ex, Current 
Townsend score 1-5 (5=most deprived) 
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Table 5-1 continued 
  Variable Value 
F
u
ll
y
 o
b
s
e
rv
e
d
 
Antihypertensive 
No/Yes at or before baseline 
Non-statin lipid modification 
Heavy drinking 
Familial hypercholesterolaemia 
Hypothyroidism 
CKD 
COPD 
Asthma 
Atrial fibrillation 
Predominant antipsychotic No/Yes and generation (first or second) during baseline 
Mood stabilizing drug No/Yes and class (lithium, valproate, carbamazepine, lamotragine) during baseline 
Anti-depressant drug No/Yes and class (SSRI, tricyclic, monoamine oxidase inhibitor, other) during baseline 
Annual consultation rate Quartiles of consultation rate during baseline 
Cancer diagnosis No/Yes and type in 5 years before the index date 
Health authority A-M including Scotland, Northern Ireland and Wales 
Shaded cells indicate essential variables or covariates; non-shaded cells are additional covariates
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5.4 Multiple imputation of unobserved covariate data 
Complete cases: Individuals were defined as complete cases if they had a record 
of systolic blood pressure, weight and total cholesterol concentration measured in 
the 12 months before the index date in addition to a record of height (at age 21 
years or older) and smoking status recorded at any time point. 
Imputation of missing data: Unobserved covariate data were estimated using 
multiple imputation to generate ten imputed datasets for the full study population.  
The MI suite of commands in Stata was used to estimate missing covariate data 
and analyse the imputed datasets.  Data were separately imputed by gender in 
each of the five cohorts because CVD risk differs markedly between men and 
women, even after accounting for other factors such as age (Osborn et al., 
2015).  The imputation model used mean time-varying data for each year from three 
years either side of the index date to estimate unobserved records for the baseline 
period (twelve months before the index date) (Figure 5-3).   
Figure 5-3: Temporal relationships between the index date, baseline year (BL), 
and imputation variables (up to three years before (Y-3) and after (Y+3) the 
index date). 
 
Final imputation model: MI chained (Stata version 12) was used to produce 10 
imputed datasets for each cohort.  The imputation model included measurements of 
total cholesterol, blood pressure, height and weight in log form.  
Variables being imputed: log of cholesterol concentration at baseline and at +/-3 
years, log of height, log of weight at baseline and +/-3 years, log of systolic blood 
pressure at baseline and +/- 3 years, Townsend score, smoking status. Although 
only baseline measurements were included in the analysis model (see section 6) a 
chained equations approach was used to impute data for the three years either side 
of baseline immediately prior to estimating missing baseline values. 
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Fully observed variables: statin exposure at the index date, CVD event indicator, 
Nelson-Aalen estimates, indicators for statin prescribing at 1 and 2 years after the 
index date, sex, SMI diagnosis and baseline estimates of: 5 year age-band, 
diabetes status, heavy drinking, antihypertensive use, non-statin lipid modifying 
drug use, anti-depressant use, antipsychotic use and type/generation of 
antipsychotic, mood stabilizing drug use, quartiles of annual consultation rate, 
cancer diagnosis, hypothyroidism, familial hypercholesterolaemia, CKD, COPD, 
health authority region. Further detail regarding the specification of these variables 
is included in Table 5-1 and Chapter 3 section 3.2. 
5.4.1 Developing and checking the specification of the multiple imputation 
model 
Initial exploratory analyses confirmed that each of the covariates identified from the 
literature (Table 5-1) was associated with missing data and/or the observed data 
value. 
 Requirements of the imputation model specification: The selection of a multiple 
imputation model to estimate unobserved covariate data for use in the final analysis 
was constrained by several factors that are specific to the study design and the 
research question.  These factors were that:  
i) the imputed dataset should support estimation of the office version of the 
Framingham risk score (described in detail in Chapter 3 section 3.2.6); 
with the ideal dataset allowing estimation of the laboratory version of the 
Framingham risk score 
ii) the same combination of variables should be included in the imputation 
model for each of the 5 time periods (cohorts) 
iii) the imputation model should incorporate essential variables on statin 
exposure, CVD outcomes (both the event indicator and time component) 
and all other variables included in the final analysis model (White et al., 
2011). 
5.4.1.1 Developing the imputation model 
Figure 5-4 describes the process used to specify the imputation model. The 
imputation model was developed using a forwards elimination approach starting 
with a basic model incorporating essential variables.  Additional variables were 
added to this model in order of anticipated importance for patterns and values of 
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missing data.  Where the addition of a variable resulted in failure of the imputation 
model to converge it was omitted.  The proportion of missing data for variables  
included in the Framingham risk score (Chapter 3 section 3.2.6) increased over time 
(Chapter 5 section 7.1): it was therefore anticipated that the earliest time periods 
would limit the complexity of the imputation model, relative to more recent data.  For 
example, HDL-C was recorded for less than 5% of individuals in 2002, but was 
available for over 60% of individuals in 2012.  Similarly the pattern of recording for 
smoking status had changed over time such than in earlier years only current 
smokers had a record, whereas never- and ex-smoking statuses were much more 
commonly recorded for recent time points. The basic imputation model was 
therefore developed using data from the earliest cohorts and then applied to data 
from later cohorts. 
Essential variables in the imputation model: The process outlined in Figure 5-4 
started with a basic imputation model for each cohort, which included the following 
essential variables: age (in 5 year bands), statin prescribing at the index date and 1 
and 2 years after the index date, diabetes status, systolic blood pressure, total 
cholesterol concentration, height, weight, smoking status, CVD events and the 
associated Nelson-Aalen cumulative hazard function estimate (White and Royston, 
2009).  Time varying indicators marking whether an individual was prescribed a 
statin at one and two years after the index date were added to the imputation model.  
This improved the potential of the model to impute cholesterol concentration 
correctly at time periods after baseline in response to the initiation or cessation of 
statin therapy after the index date.   
Additional variables in the imputation model: Other variables (termed Xi in 
Figure 5-4) that were identified from the literature as being correlated with CVD 
events and statin therapy were sequentially added to the model in order of 
anticipated importance.  The order of importance was specified as follows: HDL-C, 
diastolic blood pressure, Townsend score, antihypertensive use, heavy drinking, 
non-statin lipid modifying drug use, antipsychotic use, antidepressant use, mood 
stabilising drug use, hypothyroidism, familial hypercholesterolaemia, consultation 
rate during baseline, cancer diagnoses, antipsychotic type and generation, CKD, 
COPD, asthma, atrial fibrillation, health authority region. 
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Figure 5-4: Flowchart for the process of developing the imputation model 
 
Cohort n denotes the cohort which was initiated at the earliest calendar time period (i.e. 
January 2002-December 2003).  
Cohort n+1 denotes the next cohort in the sequence (e.g. January 2004-December 2005). 
The basic imputation model* incorporated essential variables as follows: age (in 5 year 
bands), statin prescribing at the index date and 1 and 2 years after the index date, diabetes 
status, blood pressure, total cholesterol concentration, height, weight, smoking status,  CVD 
events and the associated Nelson-Aalen cumulative hazard function estimate. 
Each additional variable (xi) was added in the following order: HDL-C, diastolic blood 
pressure and Townsend score for deprivation, antihypertensive use, heavy drinking, non-
statin lipid modifying drug use, antipsychotic use, antidepressant use, mood stabilising drug 
use, hypothyroidism, familial hypercholesterolaemia, quartiles of consultation rate during 
baseline, cancer diagnoses, antipsychotic type and generation, CKD, COPD, asthma, atrial 
fibrillation, health authority region. 
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Data on smoking status was difficult to impute as a time-varying variable and 
resulted in an imputation model that was incompatible (unstable at >3 imputations) 
with each of the other essential variables in the model.  Smoking status was 
therefore imputed as a time-fixed variable in which the highest recorded smoking 
status (ordered as never<ex-smoker<current smoker) for each individual was 
retained in the dataset.  Whilst this definition of smoking is fairly satisfactory for 
individuals classed as never and ex-smokers, it may overestimate CVD risk for 
individuals classified as current smokers who later stopped smoking.  However, 
manual review of records for ex-smokers suggested that many had a mixture of 
current and ex-smoker records, which is indicative of multiple failed cessation 
attempts and thus reflects a CVD risk profile that is more similar to a smoker than a 
non-smoker. The mode of classification used is further justified by the practical 
advantage that the resulting imputation model was highly stable and could support 
the inclusion of all other essential variables. 
Imputing HDL-C was not possible for early time periods (the model did not 
converge), reflecting a very low proportion of people that had a measurement of 
HDL-C recorded (e.g. 5% in 2002). However, given information on other covariates 
such as total cholesterol concentration, height and weight, imputed values of HDL-C 
near the start of the study would be unlikely to be informative because data were 
missing for 95% of individuals.  Because it was not possible to impute HDL-C, the 
laboratory version of the Framingham risk score could not be estimated from the 
imputed dataset, instead CVD risk profile was reported using the office version of 
the Framingham risk score. 
Imputation model checking:  The standard output (example outlined in the 
appendix sections 25 and 26) obtained from execution of MI impute in Stata was 
checked for any indication of model instability or misspecification. The plausibility of 
imputed values for total cholesterol, height, weight, systolic blood pressure and 
smoking status were carefully assessed for each cohort and across the full dataset 
(all five cohorts) as follows:   
 Data that were imputed in log form were back-transformed in order to make 
assessment of the biological plausibility of these values easier to determine 
 
 The range and distribution of imputed values was assessed relative to the 
observed (complete) data; particular attention was given to values of total 
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cholesterol at baseline and other time points 
 
 Complete and imputed data were also investigated by estimating CVD risk 
scores within strata of age (40-59, 60-69, 70-74, 75-84 years) and gender.  
In addition, the coefficients obtained for regression of estimated risk score 
on (continuous) age in years (separately for men and women) was used as a 
further means of gauging the compatibility of the complete and imputed 
datasets 
 
 Multivariable regression models (output included in the appendix; Table 8 
and Table 9) were used to assess the similarity of correlations within 
complete and imputed datasets between each of the variables included in 
the main analysis and statin prescribing or CVD events for the association. 
These associations were also useful for sense-checking complete and 
imputed data for well-established correlations such as increasing CVD risk 
and advancing age 
6 Analysis 
Descriptive analysis: the characteristics of statin users and non-users were 
described using data for the complete cases and the imputed dataset.  Observed 
and imputed cholesterol data at 1 and 2 years after the index date were investigated 
but these variables were not incorporated into the final analysis models.  However, 
these estimates are of interest because change in cholesterol concentration is an 
intermediate outcome for CVD and may be indicative of statin medication 
adherence. 
Calculating average treatment effect: Data for each of the five cohort studies 
were pooled to obtain average causal effect estimates for the whole study 
period.  Incident rate ratios (IRRs) for the association between statin prescribing and 
combined MI and stroke were estimated using a Poisson regression model with 
receipt of a statin prescription as the exposure and first MI or stroke event as the 
outcome: follow up time was used as an offset.  As the same individual could be 
included in more than one cohort it was necessary to combine the effect estimates 
using the ‘robust sandwich estimator’ to calculate conservative estimates of 
variance.   
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In addition to calculating the crude IRR, the Poisson model was adjusted for a panel 
of essential (SMI condition, age, gender, diabetes status, blood pressure, BMI, total 
cholesterol concentration, smoking status and year of cohort initiation) and 
additional covariates. Additional covariates were added to the analysis model in 
order of their perceived importance as confounders of the causal association 
between statin use and CVD events. The order was as follows: antihypertensive 
drug use, psychological drug use (antipsychotics, antidepressant and mood 
stabilizer use), consultation rate, Townsend score and comorbid conditions (familial 
hypercholesterolaemia, non-statin lipid modification, CKD, COPD, hypothyroidism, 
heavy drinking, asthma, atrial fibrillation, cancer). The pooled dataset was reviewed 
to understand what impact each of the essential covariates and all additional 
variables in the final model had on the crude effect estimate and were presented as 
a Forest plot. 
Systolic blood pressure and total cholesterol were included in the analysis model on 
their original scale (mmHg and mmol/L, respectively): however, the full multivariable 
model was reviewed for evidence of improved specification (using Wald tests and 
reviewing the effect estimates and associated standard error) after including these 
variables in log form.  In addition, the impact of substituting age bands with different 
transformations of age (continuous or log of age) and the inclusion of an interaction 
term between age and sex was assessed for the complete case analysis by 
reviewing the effect estimates and using likelihood ratio testing. Evidence of 
improved model specification through the inclusion of transformed variables and 
interaction terms in the complete case analysis was used to guide the development 
of the imputation model. 
Calculating cohort-specific estimates of effect: Data for each cohort were 
analysed separately to calculate crude and adjusted effect estimates for statin 
prescribing and combined MI and stroke for each time period.   
Secondary outcomes: all-cause mortality, fatal and non-fatal stroke, fatal and 
non-fatal MI, cholesterol concentration 1 and 2 years after the index date: The 
primary analysis was repeated for: all-cause mortality (any record of death), first 
stroke (haemorrhagic or ischaemic stroke) and first MI to identify whether the 
effectiveness of statins was substantially altered for each of these outcomes.   
Changes in total cholesterol concentration measured during the 1 and 2 years after 
the index date (i.e. 1-365 or 366-730 days after the index date, respectively) were 
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evaluated for statin users and non-users in individuals with complete data at 
baseline. For this analysis, linear regression models with total cholesterol at one or 
two years after the index date were developed using the same array of covariates 
as for the main analysis. Change in cholesterol as an outcome for individuals who 
did not have complete data was not assessed because the imputation model was 
developed to impute covariate rather than outcome data. 
Sub-group analyses: Sub-group analyses were conducted by repeating the main 
analysis (primary outcome of combined MI and stroke) within strata of: high 10 year 
CVD risk (≥10%, ≥15%, ≥20% and ≥25%) at baseline, gender and type of SMI 
(bipolar disorder or schizophrenia). In order to increase the similarity of risk scores 
between statin users and non-users individuals with the top 5% (by gender) of CVD 
risk scores were excluded from the CVD risk analysis. 
7 Results 
7.1 Exploratory work 
7.1.1 Selecting the CVD outcomes included in the study 
Figure 7-1 shows the rate of first CVD events by type (MI, stroke or CHD excluding 
MI) over time.  The grey vertical line indicates the calendar year 2002 (the start of 
the first staggered cohort study).  There was moderate variation in the rate of first 
CVD events over time. Although not conclusive, the peak in CHD diagnoses in 2003 
could potentially be indicative of a catch-up exercise (i.e. recording prevalent CVD 
diagnoses) in anticipation of the introduction of the Quality and Outcomes 
Framework (QOF) in 2004. 
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Figure 7-1: CVD event rate (per 1000 person years) in people with SMI by type 
of CVD diagnosis 
The grey vertical line indicates the calendar year 2002 
7.1.2 Selecting the duration of the exposure window 
An exposure window of 24 months was required for the imputation model to be 
compatible with data for each of the cohorts. This was because the imputation 
model would not converge for some of the cohorts when a shorter exposure window 
(of 6 or 12 months) was specified, which is likely to reflect issues of perfect 
prediction arising from the small number of CVD events within sub-groups of statin 
use and gender (White et al., 2011). 
7.2 Descriptive results 
7.2.1 Study population 
A total of 16,854 individuals with a diagnosis of schizophrenia or bipolar disorder 
from five cohorts spanning from January 2002 to December 2011 were included in 
the pooled dataset.  On average each individual was included in 2.7 cohorts such 
that data for a total of 45,830 cases (total statin users and non-users under follow-
up) were available for analysis (Table 7-1). The majority of individuals (96%) 
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contributed data to the statin non-users arm of at least one cohort and a total of 
2913 (17%) people were prescribed a statin during the study period.   
The complete case analysis was conducted on a subset of 6915 cases, which had 
data on all essential covariates during the baseline period (reflecting 5321 
individuals who contributed data to an average of 1.3 cohorts: (Table 7-1)). 
Table 7-1: Summary of the number of cases and individuals in the study 
population, classified by statin exposure 
Subset of data Total Statin Users Statin non-users 
Full 
population 
Total cases under follow-up* 45,824 2,944 6% 42,886 94% 
People** 16,850 2,913 17% 16,098 96% 
Mean cohorts per person 2.72 1.01  2.66  
Complete 
cases 
Total cases under follow-up* 6,915 1,714 25% 5,201 75% 
People** 5,321 1,706 32% 4,017 75% 
Mean cohorts per person 1.30 1.00  1.29  
 
*Total cases under follow up describes the number of statin users and non-users that were 
included in the pooled datasets derived from combining cohorts for different time periods.  
**Because the same individual could be included as both a statin user and non-user (at 
different time points) the combined percentage of people who were statin users or statin non-
users exceeds 100%. 
 
Of the 2,944 statin prescriptions issued at the index date, 2,938 (83%) were for 
simvastatin, 395 (13%) for atorvastatin and the remaining 111 (4%) for pravastatin 
(n=46), rosuvastatin (n=45), fluvastatin (n=16) or cerivastatin (n=4). 
The number of statin users and non-users and the associated event rate for MI and 
stroke that were included in each of the five cohort studies is outlined in Figure 7-2 
describes the flow of individuals between adjacent cohorts (e.g. 6,493 individuals 
who were statin non-users in 2002/3 were included in the 2004/5 cohort in addition 
to 2,830 newly eligible individuals). 
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Figure 7-2: Flowchart of statin users and non-users contributing data to each of the five cohorts in the full population 
2002 / 3 2004 / 5 2006 / 7 2008/ 9 2010 / 11 2012 / 13 N
Statin: 252 → → → → → 12 5.7 (3.2-10.1)
No statin: 7640 → → → → → 309 5.2 (4.6-5.8)
↓
Statin: 568 → → → → 29 7.4 (5.2-10.7)
No statin: 8490 → → → → 248 4.3 (3.8-4.9)
↓
Statin: 721 → → → 26 6.4 (4.4-9.4)
No statin: 8744 → → → 177 3.7 (3.2-4.3)
↓
Statin: 674 → → 11 3.9 (2.2-7.0)
No statin: 8892 → → 129 3.6 (3.1-4.3)
↓
Statin: 596 → 5 3.2 (2.3-3.7)
No statin: 8481 → 64 2.9 (2.3-3.7)
Statin: 2944 83 5.7 (4.6-7.1)
No statin: 42880 927 4.2 (3.9-4.5)
Total: 45824 1,010
*Crude event rates (and associated 95% CI) per 1000 person-years
7617
Newly     → 
eligible                               
           1757       + 7372
Newly     → 
eligible                               
           2154       + 7492
Newly     → 
eligible                               
           2073       +
Eligible  →                             8036
Newly     → 
eligible                               
2830         + 6493
MI and stroke
Time period Crude Rate*
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Table 7-2 reports the number and rate of events within each cohort separately for 
MI and stroke. 
Table 7-2: The number and rate of events within each cohort for MI and stroke 
in the full population 
Time period Exposure 
at index 
date 
MI Stroke 
 
N Crude Rate* N Crude Rate* 
        
2002/3 
Statin 4 1.9 (0.7-5.0) 8 3.8 (1.9-7.5) 
No statin 108 1.8 (1.5-2.2) 201 3.4 (2.9-3.9) 
        
2004/5 
Statin 10 2.6 (1.4-4.8) 19 4.9 (3.1-7.6) 
No statin 88 1.5 (1.2-1.9) 160 2.8 (2.4-3.3) 
        
2006/7 
Statin 11 2.7 (1.5-4.9) 15 3.7 (2.2-6.2) 
No statin 59 1.2 (1.0-1.6) 118 2.5 (2.1-3.0) 
        
2008/9 
Statin 5 1.8 (0.7-4.3) 6 2.5 (1.0-4.7) 
No statin 41 1.2 (0.8-1.6) 88 2.1 (2.0-3.0) 
        
2010/11 
Statin 1 0.6 (0.1-4.5) 4 2.5 (1.0-6.8) 
No statin 20 0.9 (0.6-1.4) 44 2.0 (1.5-2.7) 
        
All cohorts 
Statin 31 2.1 (1.5-3.0) 52 3.6 (2.7-4.7) 
No statin 316 1.4 (1.3-1.6) 611 2.8 (2.5-3.0) 
 
Total 347 
  
663 
  
*Crude event rates (and associated 95% CI) per 1000 person-years 
7.2.2 Characteristics of the study population 
Table 7-3 describes the baseline characteristics of statin users and non-users 
included in the complete case and full population analyses.  
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Of note, total cholesterol concentration at baseline differed in statin users and non-
users for both the complete cases (6.2 and 5.3mmol/L in statin users and non-
users, respectively) and those with imputed data (6.4 and 5.4mmol/L in statin users 
and non-users, respectively). Values of total cholesterol recorded in the year after 
statin initiation were reduced by 1.7mmol/L (27%) in both the observed and imputed 
datasets.  By contrast, amongst statin non-users total cholesterol recorded in the 
year after the index date was decreased by 0.08mmol/L (1%) in the observed data 
and 0.02mmol/L in the imputed dataset (0.4%). 
The distribution of estimated CVD risk scores was different for statin users and non-
users, with baseline risk being higher (on average) for statin users. The 
characteristics of the full study population (investigated using imputed data) were 
similar to the complete cases; however, the proportion of individuals with diabetes 
was much higher in the subset with complete data (22% versus 8% in statin non-
users and 45% versus 35% in statin users). As diabetics are in general more 
intensively monitored in primary care, this difference was anticipated. Table 7-3 
outlines estimated CVD risk scores within strata of age-band and gender and Figure 
7-3 depicts histograms of the distribution of the risk scores for statin users and non-
users. 
In addition to differences in CVD risk score, the number of face-to-face 
consultations during baseline differed for statin users and non-users: on average 
statin users consulted more frequently.  Statin users were also relatively more likely 
to be more deprived, be prescribed an antihypertensive, antidepressant and to have 
familial hypercholesterolaemia (for which statin therapy is indicated).  There were 
smaller absolute differences for the proportion of statin users and non-users who 
were prescribed mood stabilisers, non-statin lipid modifying drugs or who had a 
diagnosis of asthma, COPD, atrial fibrillation, cancer, hypothyroidism, CKD or being 
a heavy drinker (Table 7-3). 
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Table 7-3: Characteristics of the study population at baseline 
  Characteristic at baseline   Complete cases Full population 
      Statin - IQR Statin + IQR Statin - IQR Statin + IQR 
  Total cases under follow-up*   5201 
 
1714 
 
42886 
 
2944 
   Bipolar   50% 
 
49% 
 
51% 
 
50% 
   Median age (years)   55 (48, 64) 58 (50, 65) 54 (47, 64) 59 (51, 67) 
  Male   47% 
 
51% 
 
45% 
 
48% 
   Diabetes (yes)   22% 
 
45% 
 
8% 
 
35% 
   Median Sys BP (mmHg)**   131 (120, 141) 136 (125, 147) 130 (120, 141) 137 (126, 148) 
  Median BMI**   28 (25, 33) 30 (26, 34) 27 (24, 31) 30 (26, 34) 
  Median cholesterol conc (mmol/L)**   5.3 (4.7, 6.0) 6.2 (5.5, 7.1) 5.4 (4.8, 6.2) 6.4 (5.6, 7.2) 
  Smoker**   58% 
 
65% 
 
55% 
 
61% 
       
          Median BMI CVD risk score   
        
Women 
40-49 years   6 (4, 10) 10 (7, 16) 5 (4, 7) 10 (6, 14) 
50-59 years   11 (8, 15) 19 (12, 26) 10 (7, 14) 17 (11, 24) 
60-74 years   20 (13, 30) 29 (19, 42) 17 (12, 25) 25 (17, 38) 
75-84 years***   34 (23, 49) 36 (27, 56) 26 (18, 36) 34 (24, 48) 
Men 
40-49 years   14 (10, 20) 20 (15, 28) 12 (9, 16) 19 (14, 26) 
50-59 years   26 (18, 35) 33 (23,42) 22 (16, 30) 32 (22,41) 
60-74 years   41 (29, 55) 47 (35, 59) 36 (26, 47) 45 (34, 57) 
75-84 years***   58 (45, 71) 62 (48, 80) 49 (39, 63) 58 (48, 79) 
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Table 7-3 continued Characteristic at baseline   Complete cases Full population 
      Statin - % Statin + % Statin - % Statin + % 
  Total cases under follow-up*   5201 
 
1714 
 
42886 
 
2944 
 
Annual consultation rate 
<4   630 12% 150 9% 10906 25% 322 11% 
4-6   1024 20% 323 19% 9310 22% 568 19% 
7-12   1679 32% 561 33% 11506 27% 942 32% 
>13   1868 26% 680 40% 11158 26% 1112 38% 
Antipsychotic use 
None   1926 37% 649 38% 20061 47% 1178 40% 
First generation   1091 21% 384 22% 8932 21% 630 21% 
Second generation   2184 42% 681 40% 13886 32% 1136 39% 
Townsend score 
1 (least deprived)   813 16% 238 14% 7280 17% 448 15% 
2   823 16% 253 15% 7419 17% 462 16% 
3   987 19% 336 20% 8653 20% 595 20% 
4   1278 25% 380 22% 9731 23% 626 21% 
5 (most deprived)   1214 23% 469 27% 9101 21% 755 26% 
Not recorded   86 2% 38 2% 969 2% 58 2% 
Year of cohort 
2002   268 5% 98 6% 7752 18% 285 10% 
2004   592 11% 336 20% 8718 20% 605 21% 
2006   1024 20% 453 26% 8901 21% 747 25% 
2008   1387 27% 427 25% 8994 21% 697 24% 
2010   1930 37% 400 23% 8521 20% 610 21% 
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Table 7-3 continued Characteristic at baseline   Complete cases Full population 
      Statin - % Statin + % Statin - % Statin + % 
  Total cases under follow-up*   5201 
 
1714 
 
42886 
 
2944 
 Antihypertensive use (yes)   1201 23% 1065 62% 5685 13% 961 33% 
Antidepressant use (yes)   2156 41% 801 47% 17252 40% 1371 47% 
Mood stabiliser use (yes)   1815 35% 538 31% 13166 31% 922 31% 
Asthma (yes)   596 11% 211 12% 4387 10% 336 11% 
COPD (yes)   224 4% 85 5% 1300 3% 132 4% 
Familial hypercholesterolaemia (yes)   38 0.7% 173 10% 77 0.2% 302 10% 
Atrial fibrillation (yes)   59 1.0% 16 0.9% 406 1.0% 41 1.4% 
Cancer diagnosis in past year (yes)   80 2% 22 1.2% 607 1.4% 39 1.3% 
Hypothyroidism (yes)   47 0.9% 21 1.2% 342 0.8% 34 1.2% 
CKD (yes)   424 8% 102 6% 1398 3% 188 6% 
Heavy drinker (yes)   933 18% 293 17% 5994 14% 469 16% 
Non-statin lipid modification (yes)   66 1.3% 34 2% 196 0.5% 51 2% 
*Total cases under follow up describes the number of statin users and non-users that were included in the pooled datasets derived from combining cohorts for different time periods  
**Denotes variables where unobserved baseline values were imputed in the full population dataset  
***Framingham risk score not validated for individuals aged >74 years  
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Figure 7-3: Distribution of CVD risk scores (top: complete cases and below: 
full population) 
 
CVD risk scores in the full population were estimated using imputed values of blood pres sure, BMI and 
smoking status where these values were not recorded during baseline.
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8 Average treatment effect of statin prescribing on MI and stroke  
The crude rate of first MI and stroke per 1000 person-years of follow-up was 5.74 
(4.62, 7.11) in statin users and 4.17 (3.91, 4.45) in statin non-users (Figure 7-2, 
previous) in the full population.  The impact of adding covariates to the model is 
outlined in Figure 8-1.  The crude IRR for the association between statin prescribing 
and MI and stroke events was 1.39 (1.11, 1.74) for the full study population: the 
addition of all essential covariates to the model reduced the IRR to 0.92 (0.89, 
1.18).  This estimate were further reduced to 0.89 (0.68, 1.15) after adjustment for 
all additional covariates. Inclusion of transformed versions of continuous variables 
(age, total cholesterol, systolic blood pressure, BMI) in the model did not have a 
marked impact upon the effect estimates or associated 95% CI for the association 
between statin prescribing and MI and stroke events. 
Figure 8-1: Crude and adjusted IRRs for statin prescribing and MI and stroke 
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*Fully adjusted model baseline covariates: age and sex, diabetes, total cholesterol concentration**, 
BMI**, systolic blood pressure**, smoking status**, SMI type, year of cohort start, antihypertensive use, 
antidepressant use, consultation rate, antipsychotic use and type, mood-stabiliser use, Townsend 
score, asthma, COPD, hypothyroidism, CKD, atrial fibrillation, familial hypercholesterolaemia, heavy 
drinking, non-statin lipid modification, cancer, hypothyroidism. 
**Denotes variables where unobserved baseline values were imputed 
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The fully adjusted IRR for the primary outcome (0.89) suggests that statin 
prescribing may be associated with a 10% reduction in the rate of first MI and stroke 
in people with SMI. However, because the 95% CI around the point estimate were 
wide (0.68-1.15), there is insufficient evidence to conclude that the lower rate of 
CVD events amongst statin users could not have arisen by chance. 
8.1 Cohort-specific effects of statin prescribing on MI and stroke 
Fully adjusted IRRs for the association between statin prescribing and MI and stroke 
are outlined for each of the five cohorts and for the pooled dataset in Figure 8-2.  
Although there was some variation in the point estimates for a given cohort (which 
ranged from 0.68 in 2002 to 1.19 in 2004), the associated 95% CI were wide and 
there were no outliers with respect to the pooled result for all years. 
Figure 8-2: Adjusted IRRs for statin prescribing and CVD events for each of 
the cohort studies  
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*Fully adjusted model baseline covariates: age and sex, diabetes, total cholesterol concentration**, 
BMI**, systolic blood pressure**, smoking status**, SMI type, year of cohort start, antihypertensive use, 
antidepressant use, consultation rate, antipsychotic use and type, mood-stabiliser use, Townsend 
score, asthma, COPD, hypothyroidism, CKD, atrial fibrillation, familial hypercholesterolaemia, heavy 
drinking, non-statin lipid modification, cancer, hypothyroidism. 
**Denotes variables where unobserved baseline values were imputed 
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8.2 Secondary outcomes:  
8.2.1 Average treatment effect of statin prescribing on all-cause mortality 
The crude rate of all-cause-mortality per 1000 person-years of follow-up was 19.6 
(17.4, 22.0) in statin users and 19.3 (18.7, 19.8) in statin non-users in the full 
population.  The crude IRR for the association between statin prescribing and all-
cause mortality was 1.02 (0.90, 1.14) and was reduced to 0.89 (0.78, 1.02) after 
adjusting for all covariates. 
8.2.2 Average treatment effect of statin prescribing on first MI 
The crude rate of first MI per 1000 person-years of follow-up was 2.14 (1.51, 3.05) 
in statin users and 1.42 (1.27, 1.59) in statin non-users in the full population.  The 
crude IRR for the association between statin prescribing and first MI was 1.51 (1.04, 
2.18) and was reduced to 0.75 (0.48, 1.15) after adjusting for all covariates. 
8.2.3 Average treatment effect of statin prescribing on first stroke 
The crude rate of first stroke per 1000 person-years of follow-up was 3.60 (2.74, 
4.72) in statin users and 2.75 (2.50, 2.98) in statin non-users in the full population.  
The crude IRR for the association between statin prescribing and first stroke was 
1.31 (0.99, 1.74) and was reduced to 0.96 (0.68, 1.15) after adjusting for all 
covariates. 
8.2.4 Change in total cholesterol and 1 and 2 years after the index date in 
complete cases 
A total of 82% and 73% of the 1714 statin users had measurements of total 
cholesterol recorded within the 1 and 2 years after the index date, respectively.  By 
comparison, 55% and 69% of statin non-users had a measurement of cholesterol 
recorded within the 1 and 2 years after the index date, respectively.  Mean total 
cholesterol at baseline was almost 1mmol/L lower in statin non-users than statin 
users. 
On average, the total cholesterol concentration of individuals who were prescribed a 
statin was decreased by 1.7mmol/L at both 1 and 2 years after the index date: mean 
cholesterol concentration at 1 and 2 years did not substantially change in individuals 
who were not prescribed a statin (Figure 8-3). 
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Figure 8-3: Change in total cholesterol concentration (mmol/L) at 1 year after 
the index date 
 
In statin users total cholesterol was decreased by 1.7mmol/L (27%) from baseline 
concentrations of 6.3 to 4.6mmol/L at both 1 and 2 years after baseline (Table 8-1).  
By contrast, amongst statin non-users mean total cholesterol in each individual was 
slightly decreased by 0.1mmol/L (2%) from baseline concentrations of 5.4mmol/l to 
5.3mmol/L at both 1 and 2 years after baseline.   
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Table 8-1: summary statistics for change in total cholesterol within 1 and 2 
years of the index date 
Group Description of metric Baseline 1 year  2 years  
Statin non-
users 
Number under follow-up 5201 2865 3002 
Mean cholesterol concentration mmol/L (SD) 5.4 (1.0) 5.3 (1.0) 5.3 (1.0) 
Change from baseline mmol/L (%) -- -0.1 (-2%) -0.1 (-2%) 
Statin 
users 
Number under follow-up 1714 1409 1253 
Mean cholesterol concentration mmol/L (SD) 6.3 (1.2) 4.6 (1.0) 4.6 (1.1) 
Change from baseline mmol/L (%) -- -1.7 (-27%) -1.7 (-27%) 
 
A linear regression model for the crude change in cholesterol by statin exposure 
confirmed that statin use was associated with a 1.7mmol/L (95% CI; 1.6, 1.7) 
decrease in cholesterol concentration, relative to non-users at both 1 and 2 years 
after the index date. The fully adjusted model produced lower estimates of 
1.3mmol/L (95% CI; 1.2, 1.4) and 1.2mmol/L (95% CI; 1.1, 1.3) decreases at 1 and 
2 years after the index date, respectively.   
In the fully adjusted model statin use was the most important predictor of change in 
cholesterol concentration at both time points (coefficients of -0.36 and -0.41 at 1 and 
2 years, respectively). A range of other variables were more weakly associated with 
change in cholesterol (model outputs outlined in the appendix; Table 6 and Table 7): 
including baseline cholesterol concentration, age, gender, and presence of familial 
hypercholesterolaemia, diabetes, non-statin lipid modification, type of antipsychotic 
used and hypothyroidism. 
8.3 Sub-group analyses 
8.3.1 Average treatment effect of statin prescribing on MI and stroke in the 
subgroup of cases at high risk of CVD 
Within the subset of cases with estimated 10 year CVD risk scores indicating high 
risk the fully adjusted IRRs for statin prescribing and first MI and stroke were as 
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follows: ≥10% CVD risk score; 0.93 (95% CI; 0.69, 1.26), ≥15%; 0.90 (95% CI; 0.67, 
1.21), ≥20%; 0.82 (95% CI; 0.59, 1.13) and ≥25%; 0.73 (95% CI; 0.52, 1.05).     
8.3.2 Average treatment effect of statin prescribing on MI and stroke within 
strata of gender 
Fully adjusted IRRs for the association between statin prescribing and first MI and 
stroke within strata of gender were as follows: men; 0.96 (95% CI; 0.65, 1.42) and 
women; 0.84 (95% CI; 0.58, 1.20). 
8.3.3 Average treatment effect of statin prescribing on MI and stroke within 
strata of mental illness type 
Fully adjusted IRRs for the association between statin prescribing and first MI and 
stroke within strata of mental illness type were as follows: schizophrenia; 0.85 (95% 
CI; 0.60, 1.20) and bipolar disorder; 0.89 (95% CI; 0.60, 1.32). 
9 Complete case analysis 
A parallel set of results to those presented for the full population are outlined in the 
appendix (Table 9) for complete cases.  Fully adjusted IRRs for the association 
between statin prescribing and combined MI and stroke were 0.88 (95% CI; 0.58, 
1.36). Estimates for the association between statin prescribing and secondary 
outcomes were as follows: 1.02 (95% CI; 0.82, 1.27) for all-cause mortality, 0.85 
(95% CI; 0.49, 1.48) for stroke and 0.93 (95% CI; 0.47, 1.83) for MI. 
10 Key results 
The results from this study provide consistent evidence that statin prescribing to 
people with SMI may be beneficial, with statistically significant reductions in total 
cholesterol (of 1.2mmol/L for up to 2 years, p<0.001) and non-significant reductions 
in the rate of combined MI and stroke (0.89; 95% CI; 0.68-1.15) and all-cause 
mortality (0.89 with 95% CI; 0.78, 1.02). 
11 Comparison with the literature 
Figure 11-1 summarises key results for statin prescribing and the rate of MI, stroke 
and all-cause mortality derived from this study relative to published estimates from 
meta-analysis of RCTs (outlined in Chapter 2) (Taylor et al., 2011) and 
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observational studies of the general population without SMI (outlined in Chapter 4) 
(Smeeth et al., 2009). 
Figure 11-1: Summary of the key results for the association between statin 
prescribing and the rate of MI, stroke and all-cause mortality derived from this 
study relative to reference values 
Fully adjusted*
All cause mortality
Stroke
MI
Non SMI RCT (CHD)
Non SMI RCT (CVD)
Non SMI RCT (death)
Non SMI Observational study (MI)
Non SMI Observational study (stroke)
Non SMI Observational study (death)
Primary outcome
Secondary outcomes
Reference values
Crude
.5 1 1.5 2
IRR for statin prescribing and outcome
Reference values derived from published estimates. Non SMI RCT (Taylor et al., 2011): 
CHD; 0.73 (0.67, 0.80)  n=48049, CVD; 0.75 (0.70, 0.81)  n=23805, death; 0.86 (0.79, 0.94)  
n=48060.  Non SMI observational study (Smeeth et al., 2009): MI; 0.87 (0.77, 0.98) 
n=61291, stroke; 0.86 (0.77, 0.96) n=71564, death; 0.79 (0.75, 0.83) n=83622. 
 
11.1 MI and stroke 
The fully adjusted IRRs for the association between statin prescribing and the rate 
of MI and stroke were 0.89 (0.68, 1.15).  This point estimate is similar to that derived 
from observational studies in the general population (MI; 0.87 (0.77, 0.98), stroke; 
0.86 (0.77, 0.96), CHD; 0.89 (0.73, 1.09)) (Smeeth et al., 2009;Danaei et al., 2013).  
Additional analyses within sub-groups of people with a high risk of CVD, by gender 
and type of mental illness all resulted in consistent and broadly comparable 
estimates of effect.   
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The point estimates (but not the 95% CI) suggest a protective effect of statin 
prescribing on stroke (0.96) and MI (0.75), with a larger potential magnitude of effect 
on MI.  The interpretation of these results is further evaluated in the context of 
published validation studies (outlined in Chapter 3) in the discussion chapter 
(Chapter 7). 
11.2 All-cause mortality 
The point estimate from this study for the association between statin prescribing and 
all-cause mortality in the full population was 0.89 (95% CI; 0.78, 1.02). For purposes 
of comparison with five-year mortality in RCTs, this IRR can be expressed as an 
adjusted odds ratio of 0.92 (95% CI; 0.79, 1.07); which is broadly similar to the 
results obtained from the meta-analysis of RCTs in the general population, notably 
0.86 (95% CI; 0.79, 0.94) (Taylor et al., 2013).  However, it should be noted that 
direct comparison of these estimates requires caution because the duration of 
follow-up varied in my study whereas the trials included in the meta-analysis were of 
fixed length (usually 5 years). The IRR is therefore the more appropriate measure of 
effect. Furthermore, the proportion of participants who died in the trials was almost 
half that of my study population: the mortality rate reported in the meta-analysis 
was: statin group; 4.4% and placebo; 5.1% (Taylor et al., 2013). In the current study 
9.6% of statin users and 10% of statin non-users died. By contrast, the 
observational study by Smeeth and colleagues identified a greater reduction in 
statin-associated mortality (IRR of 0.79 (0.75, 0.83)), which may reflect generally 
higher frequencies of death in their study; particularly in statin non-users (21% of 
statin non-users died compared to 11% of statin users) (Smeeth et al., 2009).   
11.3 Impact of statins on total cholesterol  
Statin use was associated with a mean decrease in total cholesterol concentration 
at 1 and 2 years after the index date of 1.3 and 1.2mmol/L respectively (equivalent 
to a 20-21% decrease from the index date), after adjusting for differences in the 
baseline characteristics of statin users and non-users.  RCTs with a minimum of six 
months of follow up in people without SMI have identified a similar net decrease in 
total cholesterol of 1.05mmol/L (95% CI; 0.76, 1.35), with variation between 
difference types and dosage of statin (Taylor et al., 2013).  The estimates from my 
study lie between those obtained from published studies in people with SMI: to date, 
only two studies that incorporate a statin non-user arm have been published 
(Chapter 2).  These both were small with short follow-up (12 weeks).  The non-
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randomised study compared changes in lipid levels during a 12 week period in 52 
individuals taking 10mg rosuvastatin daily and 48 individuals not taking statins: total 
cholesterol concentration was decreased by an additional 2.9mmol/L (35%) in statin 
users (De Hert M. et al., 2006).  The RCT of 60 individuals randomised to receive 
40mg pravastatin daily or no statin for a 12 weeks reported smaller decreases in 
total cholesterol of 0.5mmol/L (11%) in statin use. The study also examined 
changes in cholesterol at 6 weeks after baseline and established that the reduction 
in total cholesterol was greater at 6 weeks than 12 weeks, which may indicate 
issues with the long term effectiveness of statins (Vincenzi et al., 2014). 
The cholesterol reduction observed in this study lies approximately at the mid-point 
between the two published studies. This result is not unexpected given 20-40mg 
simvastatin (the most commonly prescribed statin within the population investigated 
by my study) has an intermediate level of cholesterol-lowering activity relative to 
10mg rosuvastatin and 40mg pravastatin when tested in the general population over 
a period of 1-3 years (Weng et al., 2010).  My results provide the first evidence that 
medication adherence amongst individuals with SMI is sustained at sufficient levels 
to reduce cholesterol concentration by over 1mmol/L for up to 2 years.  However, an 
important limitation of this finding is that the results apply only to individuals who 
had complete data at baseline and who had one or more measurements of total 
cholesterol recorded in the 2 years after the index date.  Although the ascertainment 
of cholesterol outcome data was good for statin users (73-82%) it is likely that 
unobserved cholesterol measurements may not be missing at random as individuals 
who are less compliant may be less willing to have a blood test. In addition, 
outcome data were less available for statin non-users (55-57%) and may also be 
missing not at random, although it is well established from other trials of statins that 
cholesterol concentration is unlikely to change substantially in the control arm. 
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12 Statistical power and sample size 
It is possible to calculate a crude estimate4 of the standard error arising due to 
Poisson counting error alone in this study using the number of events amongst 
statin users. Given the number of MI (n=31) and stroke (n=52) events amongst 
statin users the results would be likely to be null unless the point estimate for the 
IRR was smaller than 0.65 (MI), 0.73 (stroke) or 0.78 (combined MI and stroke).  On 
the same basis, estimates for the 95% confidence interval for all-cause mortality 
(given 284 deaths amongst statin users) are unlikely to yield significant results 
unless the point estimate for the IRR was less than 0.88.   
These figures are based on minimum estimates of the standard error within the 
study: RCTs carried out in high risk individuals without SMI suggest that reductions 
of up to 25% in MI or stroke are attributable to statins. The sample size for my study 
was therefore unlikely to yield statistically significant results for MI and stroke (either 
combined or separately). However, the study is likely to have been sufficiently 
powered to detect a statistically significant effect of statin prescribing on all-cause 
mortality at an equivalent level to previous observational studies of people without 
SMI  who have diagnosed atherosclerosis (0.79, 0.75-0.83) (Smeeth et al., 2009) 
and from RCTs of people without SMI (0.86, 0.79, 0.94) (Taylor et al., 2013). 
13 Control of confounding 
The use of observational data for studies that compare treated and untreated arms 
is likely to result in comparison groups that differ in terms of their risk for the 
condition being medicated.  Although this study employed strategies to increase the 
comparability of statin user and non-user groups (for example by excluding 
individuals with contraindications for statin therapy) the profiles of statin users and 
non-users differed at baseline; with statin users having greater CVD risk and a 
crude MI and stroke event rate.  These baseline differences were anticipated and 
their impact was greatly reduced by using a multivariable regression model that 
adjusted for a wide range of confounding variables that were known to be 
associated with both prescribing and CVD outcomes. However, this approach can 
                                                 
4
 The minimum standard error of IRR is driven by Poisson counting error, which is equal to 
the square root of the mean (estimated as the number of events in statin users).  The half 
width of the 95% CI around its central limit can therefore be estimated as 1.96 multiplied by 
the square root of the mean divided by the mean.  For example, there were 31 cases of MI 
in statin users, the half width of the 95% CI can therefore be estimated as 1.96*(√31/31) = 
0.35 (or 35%) 
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only reduce bias arising from differences in measured confounders: the results are 
therefore likely to be biased to some extent by residual confounding arising from 
unmeasured factors such as the severity of mental illness.  Nevertheless, the point 
estimates for combined (0.89) and separate MI (0.75), stroke (0.96) and all-cause 
mortality (0.89) in the full population provide evidence that the impact of 
confounding by indication has been minimised. 
14 Role of missing data 
The results of statin effectiveness on CVD outcomes described by this study have 
focused on data for the full population with imputed values of covariate data (on 
blood pressure, total cholesterol, smoking status, weight and height) where these 
measurements were unobserved at baseline. Results for the full population have 
been given greater prominence because of concerns that data on complete cases 
might not be representative: although it is reassuring to note that results from the 
complete case analysis were similar to the full population for the primary outcome 
(0.88 (95% CI; 0.58, 1.36) and (0.89; 95% CI; 0.68-1.15), respectively). Application 
of multiple imputation improved the precision of the estimate, which reflects the 
inclusion of all cases in the analysis. 
Individuals who were not prescribed a statin but who had complete baseline data 
made up only a small proportion (12%) of total statin non-users included in the full 
analysis.  Furthermore, the unadjusted rates of CVD events and mortality in statin 
users and non-users (summarised in the appendix; Table 25) indicate important 
differences between individuals with and without full covariate data at baseline.  It 
was therefore important to extend the analysis beyond individuals for whom 
complete data was available. Comparison of complete and multiple imputed 
datasets suggests that the imputation model appeared to be functioning well in 
terms of generating plausible values, particularly with respect to unobserved values 
of cholesterol in statin users and non-users at time points after the index date.  
Some misspecification of the model is inevitable, however, because a minority of 
potentially important variables, such as the severity of mental illness, are not 
recorded.  The absence of these variables weakens the legitimacy of assuming that 
data are missing at random, although it should be noted that proxies such as 
psychiatric medication use may help to capture comparable information.   
Full consideration of the impact of missing data and the strengths and limitations of 
the strategies that I have implemented in this analysis are reviewed with reference 
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to patterns of physical health screening (Chapter 5) in the discussion chapter 
(Chapter 7). 
15 Conclusions 
The results from this study provide evidence that the potential impact of statin 
prescribing to people with SMI may have a magnitude of effect that is similar to the 
general population. This study identified statistically significant reductions in total 
cholesterol (of 1.2mmol/L up to 2 years, p<0.001) and non-significant reductions in 
the rate of combined MI and stroke (0.89; 95% CI; 0.68-1.15) and all-cause mortality 
(0.89 with 95% CI; 0.78, 1.02).  There was no evidence of strong effect modification 
within strata of clinical sub-groups (by SMI type, gender or people with high CVD 
risk). 
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Chapter 7 : Discussion 
“It is clear that patients with schizophrenia and other mental disorders are not accessing 
adequate treatment for their cardiovascular diseases.  What is less clear is the level at 
which these patients are being failed by the system – whether somatic disorders are not 
being recognized, cardiovascular drugs are not being prescribed, or patients are not taking 
the drugs… …we suspect that all these mechanisms may be at work but our data are not 
able to address this question.” 
(Laursen et al., 2013) 
1 Chapter Content 
This quote describes a snapshot of psychiatric cardiovascular medicine as it was in 
September 2012 at the start of my PhD and – by chance – the time at which 
Thomas Laursen and colleagues submitted their manuscript (from which the quote 
is derived) to the journal.  My thesis did not set out to answer these questions 
specifically but they provide a framework with which to position and discuss the 
findings of this thesis. This chapter discusses my research findings in terms of the 
level at which inequalities in cardiovascular health may arise in people with severe 
mental illness (SMI) in the context of provision of physical health checks, statin 
prescribing and the effectiveness of statins for primary prevention of cardiovascular 
disease (CVD). As part of this evaluation I summarise the major findings of this 
thesis and the evidence as it was at the time of embarking upon the work. I then 
discuss the broader interpretation of these findings and evaluate their significance in 
relation to each other and the literature – including evidence that has recently been 
published. I also explore whether individuals with the greatest physical health needs 
are engaged in CVD screening, which was not central to my research objectives but 
has important implications for the interpretation of the results. I weigh up the 
strengths and weaknesses of the research undertaken and reflect upon how these 
factors limit the findings.  Finally I appraise the contribution made by my PhD 
research to the evidence-base, and discuss the implications for policy and future 
research. 
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2 Summary of key findings 
This thesis aimed to explore the effectiveness of statins for primary prevention of 
CVD in people with SMI by examining the following objectives (Chapter 1 section 9): 
1. Evaluate the evidence-base for statin prescribing for prevention of CVD in 
people with SMI (Chapter 2) 
 
2. Describe the strengths and limitations of using UK primary care data to 
investigate the impact of statin prescribing on CVD in people with SMI 
(Chapter 3) 
 
3. Explore methods to reduce confounding and handle missing data to support 
estimates of effectiveness derived from primary care data (Chapter 4) 
 
4. Investigate the uptake of CVD screening and statin prescribing in UK 
primary care amongst people with and without SMI (Chapter 5) 
 
5. Estimate the effectiveness of statin prescribing in UK primary care for 
prevention of CVD in people with SMI (Chapter 6) 
 
6. Discuss the collective interpretation of the findings from these objectives and 
their significance in terms of policy, practice and research (Chapter 7) 
The major findings were that statin prescribing was associated with statistically 
significant reductions in total cholesterol of 1.2mmol/L (with 95% confidence 
intervals (CI) of 1.1-1.3) for up to 2 years.  The reduction in total cholesterol is 
coherent and consistent with the non-significant reductions in the estimate of the 
rate of combined myocardial infarction (MI) and stroke and all-cause mortality 
observed amongst statin uses in the main analysis: incident rate ratios (IRRs) of 
0.89 (95% CI; 0.68-1.15) for MI and stroke and 0.89 (95% CI; 0.78, 1.02) for all-
cause mortality. 
Earlier phases of the research outlined in this thesis investigated the uptake of CVD 
screening and statin prescribing in UK primary care amongst people with and 
without SMI. This work established that current provision of CVD screening and 
statin prescribing is increasingly accessed by individuals with SMI, relative to people 
without SMI.  However, although the provision of CVD screening has improved 
markedly over time, uptake is not universal and in 2012 over 40% of people with 
SMI did not attend an annual physical health check. Older people with 
schizophrenia were identified as a group among whom statins were prescribed 
inequitably relative to people without SMI, and under-treatment may be an issue.  
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3 A disadvantaged starting point: SMI and the social 
determinants of health 
The association between premature death and SMI has been documented for over 
a century, with the role played by lifestyle, healthcare access and medication in 
individuals with psychosis being explored in more recent decades (De Hert et al., 
2011a;De Hert et al., 2011b;Felker et al., 1996). The relationship between SMI and 
CVD is driven by increased rates of conventional risk factors (such as smoking, 
poor diet and low levels of physical activity) in combination with factors specific to 
psychosis (such as diagnostic overshadowing, the side-effects of some types of 
antipsychotic medication and possible genetic associations) that may exacerbate 
physical health conditions or delay their diagnosis.  However, the source of these 
factors is deeply rooted in the social determinants of health including social 
gradient, stress, social exclusion and unemployment, which are adversely 
associated with both mental and physical health (World Health Organization, 2003).  
In other words, SMI and social disadvantage are inextricably linked and it is 
important to recognise that treating downstream physical health conditions is 
unlikely to fully rectify this disadvantaged starting point.   
Nevertheless, the burden of CVD amongst individuals with SMI is considerable and 
at least partly avoidable.  The risk of CVD events is at least doubled amongst 
people with schizophrenia and bipolar disorder, with a further doubling of the 
subsequent risk of death following a CVD event relative to  those without similar 
mental health conditions (De Hert et al., 2011a;De Hert et al., 2011b;Osborn et al., 
2007a;Nordentoft et al., 2013). Approximately one third (Brown et al., 2010) of the 
13-30 year deficit in life expectancy experienced by people with SMI relative to the 
general population has been attributed to CVD (Lahti et al., 2012;Tiihonen et al., 
2009;Hennekens et al., 2005;Colton and Manderscheid, 2006), making this 
condition a prime target for reducing health inequalities in people with SMI. Effective 
interventions for primary prevention of CVD are therefore needed to improve the 
physical health prognosis for people with SMI. 
4 Uptake of physical health checks 
Policy in the United Kingdom (UK) has evolved to better manage physical health 
conditions in individuals with schizophrenia and bipolar disorder: SMI registers were 
established at general practice-level in 2003 and financial incentives introduced 
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thereafter for providing physical health checks to people on the register (National 
Institute for Health and Clinical Excellence, 2006;National Institute for Health and 
Clinical Excellence, 2009;National Institute for Health and Clinical Excellence, 
2012). Since the introduction of these measures, the proportion of individuals with 
schizophrenia or bipolar disorder who had one or more physical health parameters 
recorded in primary care has risen each year and the level of disparity relative to 
individuals without SMI has declined (Osborn et al., 2011). However, the latest 
published data (for the year 2007) suggested that individuals with SMI who were 
over the age of 60 years were significantly less likely than those without SMI to have 
a physical health check (Osborn et al., 2011).   
Thesis Objective 4 - outlined in Chapter 5 section 7.1 - provided an extension to the 
study published by Osborn and colleagues by investigating the recording of CVD 
covariates both in isolation and in combinations that support the estimation of CVD 
risk using scores such as Framingham (D'Agostino et al., 2008).  This work 
established that the increasing uptake of physical health checks reported by Osborn 
and colleagues has continued such that individuals aged 30-39 and 40-59 years 
with SMI are now more likely to have measurements of blood pressure, total 
cholesterol, weight and smoking status recorded than individuals without a 
comparable mental health condition who were of the same age and gender.  The 
uptake of physical health screening in adults aged 60-74 and 75-99 years with an 
SMI diagnosis has also increased over time to reach a greater level than similar 
individuals without mental illness. Rates of screening amongst the oldest people 
with SMI were much slower to improve and only reached comparable levels to 
people without SMI between 2008 and 2010. These results provide new assurance 
that CVD monitoring in people with SMI now occurs at levels that are at least 
equivalent to similar people without SMI and mark substantial progress given the 
historic disparity in screening. However, the uptake of CVD screening amongst 
people with SMI is not universal: in 2012 over 40% of individuals aged 30-74 and 
almost 60% aged 75-99 years did not have sufficient measurements recorded in 
their electronic health records to support estimation of CVD risk. This is of particular 
concern as it is unclear whether participation in screening is inversely correlated 
with health needs: I return to this issue later in this chapter.  
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5 Provision of statin prescribing for primary prevention of 
CVD 
Health assessments are a check point at which interventions for improving physical 
health can be implemented.  These assessments measure individual CVD risk 
factors and allow an individual’s likelihood of developing CVD to be estimated over 
a given timeframe. CVD risk is estimated in general practice using a range of 
algorithms including the Framingham Risk Score (recommended until 2014) 
(D'Agostino et al., 2008) and QRisk (Hippisley-Cox et al., 2008) and estimated risk 
is used to guide clinical management.  Individuals found to be at high risk of CVD 
(defined as 20% risk over a ten year period until 2014 and 10% thereafter) should 
be managed using lifestyle modification either alone or – if insufficient progress has 
been made towards reducing CVD risk - in combination with pharmacological 
interventions. Statins form the mainstay of these pharmacological interventions and 
are prescribed on the basis of CVD risk rather than lipid concentration alone 
(National Institute for Health and Clinical Excellence, 2008b;National Institute for 
Health and Clinical Excellence, 2014b). The primary pharmacological action of 
statins inhibits the synthesis of low density lipoprotein cholesterol (LDL-C), thereby 
slowing the deposition of lipids onto blood vessel walls and gradually reducing the 
lipid core of existing plaques (Maron et al., 2000). In addition, statins have anti-
inflammatory properties that are beneficial in preventing CVD through a mechanism 
that is independent of the pathway that reduces LDL-C concentration (Antonopoulos 
et al., 2012). Some researchers have reported that these anti-inflammatory 
properties may also be beneficial for reducing symptoms of psychosis and statins 
are therefore a potential target for new therapies for psychosis itself (Vincenzi et al., 
2014). The role of statins for primary prevention of CVD in people with SMI has 
been the particular focus of this thesis because statin use is clinically and cost 
effective in the general population but the evidence-base for people with SMI was 
unclear (Taylor et al., 2013). 
Thesis Objective 4 - outlined in Chapter 5 section 7.2 - investigated the uptake of 
statin prescribing in UK primary care in individuals with and without SMI. This work 
is important because the impact of increased CVD screening on interventions such 
as statin prescribing was not previously known. These results provide the first 
evidence that, in recent years, the rate of statin prescribing is 21% lower in the 
oldest individuals (75-99 years) with schizophrenia, relative to controls without SMI. 
This is despite evidence that those with schizophrenia in this age group are being 
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screened at least as often as their counterparts without SMI, suggesting that this 
difference is not explained by a difference in older people with schizophrenia 
attending for screening; for example due to negative symptoms of schizophrenia.  
By contrast, the results for people with bipolar disorder and younger individuals with 
schizophrenia suggest that statins are prescribed to at a similar or higher rate to 
individuals who do not have an SMI diagnosis.   
Amongst the subset of people who had all component parts of the physical health 
check measured within a six-year period there was no evidence of a difference in 
the rate of statin prescribing to people with or without SMI after adjusting for 
estimated CVD risk score (Chapter 5, section 7.3). However, although not 
statistically significant, descriptive work for the relationship between CVD risk and 
statin prescribing amongst screening participants suggested that a small number of 
individuals with schizophrenia who had high CVD risk (exceeding 30%) were less 
likely to receive a statin than people without SMI who had a comparable CVD risk 
score. This result is not conclusive but may justify further investigation to evaluate 
evidence for a high-risk and undertreated group for whom preventative care is 
inadequate. 
6 What is known about the effectiveness of statins for 
primary prevention of CVD in people with SMI? 
Thesis Objective 1 (Chapter 2) aimed to evaluate the evidence-base for statin 
prescribing for prevention of CVD in people with SMI. Evidence in support of statin 
prescribing for the general population is almost exclusively derived from randomised 
controlled trials (RCTs) of statins (Taylor et al., 2013).  This evidence-base was not 
readily transferable to people with SMI because this population was excluded from 
many of the original trials of statins and may differ in terms of CVD risk profile, 
antipsychotic exposure and statin medication adherence. 
To establish what was known about the effectiveness of statins for primary 
prevention of CVD in people with SMI I undertook a systematic review of published 
literature and registered trials; which revealed a paucity of evidence. The systematic 
review did not identify any information on CVD events, mortality or long term statin 
use in people with SMI. However, the search did find two studies that included both 
statin user and non-user comparison groups (De Hert M. et al., 2006;Vincenzi et al., 
2014), and three other single arm studies have also been published (Ojala et al., 
2008;Landry et al., 2008;Hanssens et al., 2007).  In addition, three trials were 
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registered but not published: two were terminated due to recruitment problems and 
the remaining study was completed and had negative results (Brar, J. Personal 
Communication, 23/4/2012).   
The two studies with comparison groups provide evidence from observational (De 
Hert M. et al., 2006) and experimental (Vincenzi et al., 2014) study designs and 
show that statin therapy is associated with significant reductions in total cholesterol 
and LDL-C over the course of a 12 week period.  The magnitude of the decrease 
differed substantially between the two studies. Total cholesterol was decreased by 
11% (0.5mmol/L) in the trial of 40mg pravastatin versus placebo and 35% 
(2.9mmol/L) in the observational study of 10mg rosuvastatin. LDL-C was decreased 
by 20% (0.6mmol/L) with pravastatin and 49% (2.0mmol/L) with rosuvastatin, most 
likely reflecting differences in the biological activity of the statins investigated and 
lipid concentrations at baseline.  One of the studies measured lipid fractions at both 
6 and 12 weeks after randomisation of pravastatin or placebo and reported that 
reductions in total cholesterol and LDL-C waned between these two time points, 
thus raising concerns over the long term effectiveness and medication adherence to 
statin therapy (Vincenzi et al., 2014). 
7 Are statins effective for primary prevention of CVD in 
people with SMI? 
Thesis Objective 5 (Chapter 6) aimed to estimate the effectiveness of statin 
prescribing in UK primary care for prevention of CVD in people with SMI. The main 
analysis investigated CVD outcomes in people who were prescribed a statin during 
a given two-year period and compared them to people who were not prescribed a 
statin. Statin use was associated with a mean decrease in total cholesterol 
concentration at 1 and 2 years after the index date of 1.3 and 1.2mmol/L, 
respectively (equivalent to a 20-21% decrease from the index date), after adjusting 
for differences in the baseline characteristics of statin users and non-users. This 
result is consistent with results from RCTs in people without SMI (Taylor et al., 
2013) and with the two studies identified by the systematic review (outlined above) 
(De Hert M. et al., 2006;Vincenzi et al., 2014).  
The primary outcome was combined incident MI and stroke, which was non-
significantly reduced by 11% (IRR 0.89; 95% CI; 0.68-1.15) in the main analysis.  
The rate of all-cause mortality was also non-significantly reduced (0.89 with 95% CI; 
0.78, 1.02) amongst statin users relative to non-users.  These estimates are broadly 
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similar to those from other observational studies (MI; 0.87 (0.77, 0.98), stroke; 0.86 
(0.77, 0.96), CHD; 0.89 (0.73, 1.09)) (Smeeth et al., 2009;Danaei et al., 2013) and 
RCTs (CHD; 0.73 (0.67, 0.80), CVD; 0.75 (0.70, 0.81)) (Taylor et al., 2013). The 
point estimates for MI, stroke and all-cause mortality identified in the main study are 
coherent with the decrease in total cholesterol concentration that was attributable to 
statin use: all confirm a cardio-protective effect of statins that is broadly similar to 
the effect of statins in the general population (Danaei et al., 2013;Smeeth et al., 
2009). 
Changes in cholesterol concentration are on the causal pathway between statin 
prescribing and CVD events, and are the endpoint for many trials because 
differences in continuous outcomes are more efficiently measured relative to binary 
events such as mortality (Campbell et al., 1995).  Furthermore, trials of very long 
duration or sample size would be required to examine mortality. Other studies have 
shown that the impact of statin prescribing on CVD events increases with extended 
use: reductions of 0.6mmol/L of total cholesterol are associated with a 7% decrease 
in ischaemic heart disease during the first two years of therapy and >20% 
decreases thereafter (Law, 2003). The decreased total cholesterol concentrations 
attributed to statin therapy in people with SMI are therefore likely to translate into 
long term clinically meaningful reductions in CVD. 
8 Possible correlation between severity of mental illness 
and CVD risk  
It important to consider the possibility that - even though statin prescribing appears 
to be effective for lowering intermediate CVD outcomes – the current clinical 
pathway for CVD screening and statin prescribing may not adequately reach people 
with SMI who are at high risk of CVD. Individuals with SMI are as likely to take up 
the offer of CVD screening as people without a comparable mental health diagnosis 
(Osborn et al., 2003). However, it is not clear whether there is any correlation 
between the severity of mental illness and willingness to participate with CVD 
screening amongst people with SMI. Studies investigating physical health screening 
for other types of conditions have reported lower participation amongst individuals 
requiring the highest level of mental health support (Werneke et al., 2006).  
If a similar association (i.e. decreasing engagement with increasing severity of 
mental illness) exists for cardiovascular health then individuals with poorer mental 
health could be less likely to be screened, be prescribed a statin and could also 
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have worse CVD outcomes. In such case, results from the complete case analysis 
would not be generalizable to the subset of people with the poorest health because 
missing covariate data could be indicative of poorer mental and physical health. A 
similar pattern is evident for the general population, where uptake of primary care 
health checks is inversely correlated with modifiable CVD risk (i.e. people with 
missing data are more likely to have poorer health), thus limiting the benefits of 
screening (Waller et al., 1990;Artac et al., 2013). This pattern of uptake is described 
by the Inverse Care Law and has been observed in many areas of healthcare (Hart, 
1971). 
The existence of a sizable group of high risk individuals who were not engaged in 
CVD screening might be indicated by results from the imputed data analysis 
suggesting greater effectiveness of statins relative to the complete case analysis. 
This was not borne-out by results for the primary outcome, which had very similar 
point estimates in both the full population and in the complete case analysis: 0.89 
(95% CI; 0.68-1.15) versus 0.88 (95% CI; 0.58-1.36). However, comparison 
between the rate of all-cause mortality among non-statin users in the full population 
(crude rate of 19.3 (18.7-19.8) per 1000 person years) and complete cases (16.8 
(15.1-18.6) per 1000 person years) could potentially be compatible with the 
existence of an unscreened subgroup of high risk individuals; although the 
magnitude of difference is relatively small. A potential barrier to identifying a 
hypothetical population of high risk individuals with missing covariate data is 
insufficiently accurate or precise imputed data values, which could result in biased 
effect estimates and wide 95% CIs. The relevance of a group of individuals who 
have a high level of CVD risk but are not engaged in screening is discussed further 
in the Policy and Research Implications sections at the end of this chapter. 
9 Discussion of the strengths and weaknesses of the work 
presented in this thesis (relating to Objectives 2 and 3) 
9.1 Use of observational data 
The strengths and limitations of using an observational study design over 
experimental options such as an RCT were outlined in Chapter 3 section 2.1. The 
analyses presented in this thesis have drawn upon electronic patient records which 
provide longitudinal data on a large and representative cohort of individuals with a 
diagnosis of SMI or comparable individuals without SMI. THIN data are a record of 
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healthcare interactions and the care that was actually delivered and, as such, are an 
excellent resource for investigating the uptake of physical health checks and statin 
prescribing in UK primary care. By contrast, investigating the causal effect of statins 
is more challenging with this type of data. One consequence of analysing data 
where statin assignment is not random is that the association between being 
prescribed the drug and the risk of future CVD events is confounded. Nevertheless, 
the point estimates for statin prescribing derived from the main analysis suggest 
acceptable control of confounding, although some bias due to unmeasured 
confounders such as diet and severity of mental illness was unavoidable. 
9.2 Misclassification bias 
The Framingham risk score was used as a means of estimating the absolute risk of 
CVD for an individual. In the main analysis risk scores were used for the purpose of 
assessing differences in the CVD risk profiles of statin users and non-users only, 
and were not used to address any imbalances.  By contrast, in the study 
investigating statin prescribing amongst the subset of individuals who had all 
components of the physical health check recorded within a six year period, risk 
scores were used to adjust for differences in CVD risk between individuals with and 
without SMI (Chapter 5 section 7.3).  Since the start of my PhD new work in this 
area has established that CVD risk scores that incorporate factors specific to mental 
illness have superior discrimination to the Framingham risk score (Osborn et al., 
2015). A practical implication of this research for my work is that CVD risk scores 
may underestimate risk in individuals with SMI relative to people without similar 
mental health conditions. 
For example, risk scores specific to individuals with SMI may include information on 
psychiatric medication, which are not included in the Framingham risk score 
(Osborn et al., 2015).  Furthermore, there is likely to be misclassification of 
information on some factors such as smoking, which are included in the 
Framingham risk score as a binary indicator (smoker/not a smoker). Because 
individuals with SMI are known to smoke more heavily than smokers in the general 
population (Williams and Foulds, 2007;Williams and Ziedonis, 2004;Dixon et al., 
2007) the risk of smoking-related morbidity (including CVD) will tend to be under-
estimated for this group.  It is therefore possible that the equivalent patterns of statin 
prescribing, attained after adjusting for estimated CVD risk, may translate into 
under-provision in real terms because CVD risk is under-estimated in people with 
SMI, relative to people without SMI. 
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9.3 Missing data 
The potential for missing data to bias the results of the main study was described in 
Chapter 3 sections 3.2.11 and 5.2.6, and Chapter 5 section 9. Covariate data that 
were either partially or entirely missing were a limitation of the data source and have 
strongly shaped the choice of study design. Factors such as diet, severity of mental 
illness and genetics (e.g. familial hypercholesterolaemia), which may be associated 
with both statin prescribing and the risk of CVD events (as described in Chapters 1 
and 3), are not directly captured by the data held in THIN.  However, it is likely that 
some – but not all - of the causal effect of these factors is correlated with 
information on traditional CVD covariates (including lipid profile and body mass 
index (BMI)) or related characteristics such as psychiatric medication and 
comorbidity. However, adjusting for a greater number of covariates can have 
unintended consequences and increases the risk of over-adjustment.  In this study 
over-adjustment is likely to be most problematic for variables that are associated 
with medication adherence and therefore lie on the causal pathway between statin 
prescribing and CVD events (Schisterman et al., 2009).  In this type of scenario 
over-adjustment usually biases results towards the null (Rothman and Greenland, 
1998).  For this reason the variables included in the main analysis model were 
added sequentially and the impact on the IRR was carefully reviewed (Chapter 6 
section 8): there was no evidence that one or more variables were associated with 
inflating either the point estimate or associated 95% CI. 
Some important factors – such as total cholesterol concentration – were not fully 
observed: the pattern of missingness had strong temporal correlations and was also 
associated with statin prescribing. The methods that I used to impute data in the 
main analysis were well adapted to these conditions because the staggered cohort 
design explicitly stratifies individuals on the basis of calendar time and statin 
exposure.  This approach enables data for each time point (cohort) to be imputed 
separately but still incorporated time-varying data from three years before and after 
baseline in the imputation model. Review of the distribution of the values that were 
imputed, relative to values that were recorded, suggested that the model was well 
specified. However, some potentially important variables, such as GP surgery and 
high density lipoprotein-cholesterol (HDL-C) were not included in the imputation or 
analysis model.  This was because it was not possible to develop an imputation 
model that included HDL-C (as outlined in Chapter 6) and because a multi-level 
multiple imputation model that accommodated clustering by GP surgery would be 
extremely computationally demanding and was therefore be impractical given the 
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need to impute data separately for each of the five cohorts. Despite these 
limitations, the approach used for handling missing data was carefully researched 
and implemented and offers distinct advantages over complete case analysis or ad 
hoc forms of imputation. 
9.4 Study design 
The primary purpose of undertaking an analysis using multiple imputed data for the 
whole population of individuals with SMI was to analyse data for which information 
on the outcome was available, but covariate data were missing. The advantages of 
this type of analysis relative to a complete case analyse are twofold: it is possible to 
analyse the full sample of data and to estimate the effect for the whole population, 
rather than a subset of potentially unrepresentative individuals. As a consequence, 
the study was able to estimate the average treatment effect of statin prescribing for 
all individuals with SMI aged 40-84 years. The average treatment effect is distinct 
from the effect in the treated and estimates the impact of treating the whole 
population rather than the impact in treated individuals. This estimate is now of 
particular value because current guidance states that statin prescribing should be 
considered for individuals aged 40-84 years with a QRisk score of 10% or above 
(National Institute for Health and Clinical Excellence, 2014b).  To put this into 
context, in the main study that I undertook 94% of men aged over 40 years and 83% 
of women aged over 50 years had an estimated Framingham risk score that 
exceeded 10% and could therefore be eligible for statin prescribing.   
A major disadvantage of the staggered cohort design is that it is more complex to 
understand than other study designs.  However, in essence, the design of each 
cohort (illustrated in Figure 5-1 of Chapter 6) is simple: 1) individuals with a prior 
diagnosis of CVD or statin exposure in the 2 years before baseline are excluded, 2) 
exposure is defined on the basis of whether or not a statin is prescribed during the 
baseline period and 3) follow-up begins at the start of the baseline period and ends 
at first CVD event or censoring (out-of-practice transfer, death or the end of the 
study period).  Nevertheless, once several cohorts are considered, it quickly 
becomes difficult to visualise the dataflow.  
A further weakness of the methodology is that it does not appear to be possible to 
do a formal sample size calculation which correctly accounts for the inclusion of the 
same individual in multiple cohorts. Arguably, a sample size calculation is not 
essential for undertaking a database study, because no additional resource is 
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expended – nor is patient burden increased - by using a larger subset of the 
dataset, so it is often reasonable to analyse as many records as possible.  However, 
in the event of obtaining marginal or non-significant results (as was the case for the 
primary outcome in my study), a sample size calculation enables assessment of 
whether or not the result is likely to be due to chance and can therefore be useful for 
directing future work.   
In my study I overcame this problem by crudely estimating the half-width of the 95% 
CI using the minimum estimate of standard error for the number of events in statin 
users (Chapter 6 section 12).  Although not precise (in part because the normal 
distribution was used to estimate the Poisson distribution), these estimates 
suggested that the study was underpowered to detect an effect size of less than 
22% for combined MI and stroke and 12% for all-cause mortality, which are similar 
effect sizes to those from RCTs in people without SMI (Taylor et al., 2013).  There is 
no straightforward solution for increasing the sample size for this study.  However, 
possible approaches are extending the dataset (for example by combining with 
other data sources) and/or confirming the validity of other types of CVD outcomes 
are outlined in the Methodological Implications section at the end of this chapter. 
9.5 “Intention to treat” analytical approach 
The main analysis adopted an analytical approach that was akin to an “intention to 
treat” analysis in an RCT, which was pragmatic given that the study aimed to 
estimate the actual (rather than optimal) impact of prescribing. However, selection 
of the statin user group on the basis of one or more statin prescriptions at the index 
date has an important bearing on the results because prescribing and medication 
usage are not equivalent. For instance, some individuals will not fill the prescription 
at the pharmacy and others will pick up the medication but not take it as directed. In 
addition, it has been possible to buy low dose statin therapy (simvastatin 10mg) 
over the counter in the UK for about a decade. It is therefore possible that some 
individuals may have started statin therapy independently of their GP, although 
these numbers are likely to be low because the additional costs of over-the-counter 
medication are borne by the patient. Non-compliance with treatment (for both statin 
users and non-users) may therefore have impacted upon the results. The most 
common scenario for non-compliance is likely to be statin users not taking 
medication (and therefore being under-medicated), although statin drop-in (i.e. 
prescriptions made after the index date) and over-the-counter purchase of 
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simvastatin may also occur. All these scenarios are likely to attenuate the 
measurable impact of statin prescribing. 
Medication adherence is often highlighted as a source of differences in 
effectiveness between observational studies and RCTs, with trials usually expected 
to yield greater estimates of effect than equivalent observational studies. For 
example, a meta-analysis evaluating non-adherence to statin therapy estimated that 
one year after initiating statin therapy approximately half of patients participating in 
observational studies were compliant compared to 90% in RCTs (Lemstra et al., 
2012). These differences in adherence are usually attributed to selection bias 
(arising at the time of enrolment) and the combined impact of additional monitoring 
that is carried out as part of the trial and because RCTs usually aim to recruit a 
clinically similar group with less complex health needs than the target patient group 
in clinical practice. To date, there is relatively little research on physical health 
medication adherence in individuals with SMI and there are no published studies for 
statin adherence. It is therefore not possible to evaluate whether statin medication 
adherence in people with SMI is likely to differ substantially relative the general 
population, although the comparable reduction in total cholesterol at 1 and 2 years 
after the index date provides tentative evidence that adherence may be broadly 
similar to the general population. 
9.6 Inclusion and exclusion criteria 
Case definitions and the justification of the criteria used in each of the analyses 
described in this thesis were outlined in Chapter 3 (section 3.2). The inclusion and 
exclusion criteria applied to the main study as a consequence of these case 
definitions were selected with the purpose of optimising the number of people who 
were potentially eligible for statin therapy for primary prevention of CVD.  This 
approach was pragmatic given the limited study population size, relatively low rate 
of CVD events and desire to ensure that the results were generalizable to the whole 
SMI population. 
However, there were some aspects of the inclusion and exclusion criteria which, 
with the benefit of hindsight, were not ideal.  Of note, the main study did not exclude 
people with familial hypercholesterolaemia, which is a limitation because the clinical 
pathway for statin prescribing and prognosis for this condition is distinct from that of 
routine primary CVD prevention (National Institute for Health and Clinical 
Excellence, 2008a). However, this decision reflected uncertainty around identifying 
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people with possible familial hypercholesterolaemia, which was determined on the 
basis of Read codes or a total cholesterol concentration of >7.5mmol/L, which 
reflects national guidance for the general population, but may be a less reliable 
indicator of the condition amongst people with SMI because this group is at greater 
risk of antipsychotic-associated dyslipidaemia (Chapter 1 section 5.3).  
The inclusion of people with familial hypercholesterolaemia (according to the 
definition used in this study) is not likely to substantially impact upon estimates of 
the effectiveness of statins because the true prevalence of familial 
hypercholesterolaemia is low (~0.2%) (Marks et al., 2003) and statistical adjustment 
was made for differences in the presence of this condition and baseline total 
cholesterol concentration.  However, it should be noted that people classified as 
having familial hypercholesterolaemia in this study were over-represented amongst 
statin users (10% versus 0.2%, although the absolute number of cases in both 
groups was small: 379 (0.8%)).  
9.7 CVD outcomes 
This study investigated a relatively uncommon primary outcome (MI and stroke) in a 
population of limited size and therefore was a trade-off between maximising the 
quality or quantity of CVD endpoints.  I investigated the feasibility of including 
coronary heart disease (CHD) events in the primary outcome (with MI and stroke) 
but was concerned that this might result in including misclassified prevalent cases, 
potentially reflecting the introduction of the Quality and Outcomes Framework 
(QOF) (National Institute for Health and Clinical Excellence, 2012).  For this reason I 
chose to select only outcomes that were known to have a high level of validity 
(indicated by positive predictive value: Chapter 3 section 5.2.3).  The advantage of 
this approach is that it was possible to obtain plausible and informative point 
estimates from the study, but this gain in validity was made at the expense of 
decreased precision. 
 
 
223 
 
Summary of findings: 
The final section of this thesis summarises the collective interpretation of the results 
and how these findings could feed into health policy and future research. The 
implications of this work are presented in the context of the questions raised by 
Laursen and colleagues in 2012 (quote at start of chapter) that relate to the level at 
which inequalities in cardiovascular health among people with SMI arise. 
10 At what level do inequalities in cardiovascular health arise 
in people with SMI? 
This thesis aimed to evaluate the effectiveness of statins for primary prevention of 
CVD in people with SMI.  The collective body of work examines the processes that 
occur upstream of primary CVD diagnoses, which include CVD screening and statin 
prescribing. Investigating patterns of screening and statin prescribing through 
comparison of individuals with and without SMI offers two major benefits.  Firstly, by 
increasing our understanding of the level at which inequalities in cardiovascular 
health to people with SMI may arise. Secondly, by characterising patterns of 
missing data and statin prescribing, thus informing the design of the final study of 
effectiveness and enabling the results to be interpreted with respect to estimates for 
the general population.   
Results from the screening study show that substantial improvements have been 
made with increased CVD screening in people with SMI: the proportion of 
individuals who did not have physical health information recorded has declined from 
90% to 40% over a ten year period.  This marks a substantial improvement in 
uptake of physical health checks following the introduction of QOF, but suggests 
that many people with SMI are not yet engaged in CVD screening. Amongst the 
subset of people who were screened, statin prescribing was broadly equivalent to 
individuals with and without SMI who had similar levels of CVD risk.  However, 
because risk scores may not adequately capture CVD risk in individuals with SMI, it 
is possible that current patterns of prescribing to screened people do not reflect (but 
under-estimate) cardiovascular need. In other words, although absolute levels of 
CVD screening and prescribing were higher amongst individuals with SMI, provision 
may still be suboptimal relative to people without SMI. 
My work provides the first evidence that statin prescribing is associated with a 20% 
reduction in total cholesterol concentration at two years after the first statin 
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prescription – which is important because it demonstrates longer term medication 
use than had been previously reported. However, it was not possible to satisfactorily 
quantify the effectiveness of statins in preventing CVD events; partly because the 
number of events amongst statins users was small and the 95% CI were therefore 
too wide to rule out a null effect.  Similarly, although the main study was likely to be 
adequately powered to detect a statin-associated reduction in all-cause mortality at 
a similar level to that observed in RCTs, I did not identify a reduction that was 
significant at the 5% level. Crude estimation of the width of the half CI around the 
point estimate identified from the main analysis did however confirm that the upper 
limit of the 95% CI was likely to be limited by sample size (Chapter 6 section 12).  
These results provide good evidence that statin prescribing is associated with 
meaningful reductions in total cholesterol concentration and that prescribing is not 
adversely associated with CVD events or all-cause mortality. In conjunction with 
published evidence on the long term impact of reductions in total cholesterol 
concentration (Law et al., 2003), it is likely that statins have a broadly similar level of 
effectiveness in people with and without SMI. However, further evidence is required 
to confirm precise estimates of the magnitude of effect on CVD events. 
Collectively, these results suggest advances in CVD management for people with 
SMI. However, there is scope for improvement: annually, over 40% of individuals 
with SMI had insufficient information recorded in their electronic patient record to 
estimate CVD risk. Furthermore, there was some indication that older individuals 
may be less frequently prescribed a statin than people without SMI. Other 
individuals – particularly those with schizophrenia – did participate in physical health 
checks and had records indicating high CVD risk and eligibility for statin therapy, but 
were not prescribed a statin. This observation may reflect unawareness of the 
patient’s risk score by the GP or some resistance towards statin therapy on the part 
of the clinician and/or patient. 
11 Methodological implications 
This study highlighted the limitations and opportunities for using primary care data 
to investigate less common events within a relatively small patient group. My study 
was challenged by a relatively low rate of validated CVD outcomes in the SMI 
population and more research in this area is needed. More precise estimates of 
effectiveness of statins on preventing MI, stroke and all-cause mortality could be 
obtained by pooling data from several primary care databases including THIN, 
Clinical Practice Research Datalink (CPRD) and QResearch. Alternatively, the use 
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of linked primary and secondary care data could assist with the validation of CVD 
events (for example confirming which CHD events resulted in a hospital admission) 
and thereby produce more precise estimates for CVD events and statin prescribing. 
I needed to design a study which was compatible with multiple imputation and that 
was appropriate for investigating treatment versus no treatment.  Although the study 
design appears to have functioned well, there was an important trade-off in terms of 
the ease with which the results can be communicated relative to traditional study 
designs. A preferable approach (as outlined in Chapter 4) might have been to 
integrate methods for improving covariate balance between statin users and non-
users (e.g. propensity score matching) and multiple imputation. At present we lack 
the methods to combine these features and further investment in this area of 
research could facilitate the use of more accessible study designs. 
12 Policy implications 
12.1 Statin prescribing to people with SMI is likely to be beneficial 
The statistically significant reductions in total cholesterol (of 1.2mmol/L) at 1 and 2 
years after initiating a statin identified by this study provide evidence that statin 
prescribing is effective for lipid modification in people with SMI. In addition, this 
study identified non-significant reductions in CVD events and all-cause mortality. 
These results confirm that statins are not harmful with respect to CVD events or 
mortality and provide suggestive evidence that the long-term impact of prescribing 
to people with SMI may carry similar benefits to the general population (Law et al., 
2003;Rahilly-Tierney et al., 2009;Penning-van Beest et al., 2007).  On balance, the 
findings of this thesis therefore provide greater evidence to support the use of statin 
prescribing for primary CVD prevention in people with SMI.   
The screening results outlined in this thesis observed substantial increases in the 
uptake of CVD screening in people with SMI, which were temporally associated with 
the introduction of QOF.  This finding suggests that QOF has been successful in 
helping to reduce inequalities in the uptake of physical health checks between 
people with and without SMI. However, because the uptake of physical health 
checks amongst people with SMI is not universal, there remains some uncertainty 
regarding the effectiveness of the current clinical care pathway with respect to 
targeting people who would derive the greatest benefit from statin prescribing. 
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12.2 Improving the uptake of CVD screening amongst individuals with 
SMI 
Health checks are an attractive and seemingly intuitive intervention to improve CVD 
prevention and management.  However, the clinical and cost effectiveness of such 
schemes relies upon sufficient uptake amongst individuals with the capacity to 
benefit from interventions: reflecting CVD risk, willingness to engage in both 
screening and subsequent interventions, and the effectiveness of intervention. To 
date, the clinical and cost-effectiveness of CVD screening to individuals with SMI 
has not been evaluated (Tosh et al., 2010) and the value of similar strategies in the 
general population is contested (McCartney, 2013;Braillon et al., 2015).   
NHS Health Checks were first introduced in 2008 to offer comprehensive 5-yearly 
physical health screening to all individuals in England aged 40-75 years. The 
scheme was implemented under the assumption that uptake would be at least 75%, 
whereas current estimates indicate that less than 50% participate (Dalton and 
Soljak, 2012;Artac et al., 2013). Advocates argue that health checks increase 
pharmacological management of CVD risk and result in significant reductions in 
blood pressure, cholesterol concentration and CVD risk scores; particularly in high 
risk patients (Lauritzen et al., 2014;Si et al., 2014). Critics emphasise the modest 
reductions in CVD risk factors (Si et al., 2014;Robson et al., 2015;Artac et al., 
2013), which are driven by pharmacological management rather than changes in 
lifestyle (Jorgensen et al., 2014). A lack of evidence indicating reduced CVD 
morbidity or mortality (Krogsboll et al., 2012a;Krogsboll et al., 2012b), potential 
harms associated with screening (Gotzsche et al., 2014) and the multi-billion pound 
price tag associated with implementation (Braillon et al., 2015) cast further doubt on 
the value of NHS Health Checks. Worse still, there is suggestion of an inverse 
association between uptake and need (Waller et al., 1990;Bender et al., 
2014;Krogsboll et al., 2012a;Krogsboll et al., 2012b), meaning that the scheme may 
widen health inequalities (Capewell and Graham, 2010).   
Physical health checks amongst individuals with SMI focus on a high risk group with 
specific health needs and are therefore likely to result in greater health gains than 
less targeted schemes. However, health benefits may be achieved at the expense 
of greater inequality if the uptake of screening is inversely correlated with need.  
Results from Chapter 5 demonstrate that, whilst the provision of CVD screening has 
improved markedly over time, uptake is not universal. This is important because 
there was an indication that the rate of all-cause mortality was higher in the full 
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population of people with SMI than those who were screened.  It is therefore 
possible that some people who do not participate in screening may have poor 
physical health. Although my study can only offer suggestive evidence on the 
physical health needs of individuals who did not have complete covariate data, the 
implication that individuals with particularly poor physical health are not participating 
in screening is concerning and needs further attention.  Furthermore, whilst it 
appears that QOF has increased uptake of physical health checks amongst people 
with SMI, it is unclear what – if any – impact the recent removal of some QOF 
targets, particularly for cholesterol, may have on management of CVD and 
evaluation of this policy change is needed. 
13 Research Implications 
13.1 Identifying how participation in CVD screening to individuals with 
SMI can be increased 
Preferences for different approaches to CVD prevention in people with SMI are 
complex and the acceptability of options such as monitoring by community mental 
health teams and blood tests may play a role in limiting the uptake of screening 
(Wright et al., 2006).  Emerging evidence (Zomer et al., 2015) suggests that use of 
specific CVD risk scores for individuals with SMI may offer significant benefits in 
terms of better identifying those at high risk of CVD.  Furthermore, as one of the 
SMI-specific CVD risk scores which was found to be cost-effective does not require 
a blood test, it may facilitate increased uptake of CVD screening (Osborn et al., 
2015).  
Recording the correct information for estimation of CVD risk may also hinder 
screening and can be facilitated by integrating tools that aid structured data capture 
with the primary care information system (Yeomans et al., 2014).  At present there 
is no evidence to suggest an improved model for providing health checks to people 
with SMI. However, increased uptake might be achieved through improved 
implementation at GP surgeries (for example using tools to aid data capture and 
using risk scores that do not require a blood test) in addition to offering health 
checks within secondary care to the small but important minority of individuals who 
do not routinely access primary care (Reilly et al., 2012). Central to the success of 
such a strategy would be increased integration of physical and mental health teams 
to ensure that health checks result in appropriate action. 
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13.2 Prescribing statins to individuals with the greatest capacity to 
benefit 
Although statin prescribing does appear to be effective for lipid modification for 
people with SMI and may therefore improve cardiovascular health, the current 
strategy for prescribing may miss some individuals at high risk of CVD; particularly 
individuals with schizophrenia.  It is unclear what factors may be driving this process 
and further qualitative and quantitative work is required to better characterise 
individuals who are likely to be missed and to ascertain the types of intervention that 
are appropriate for this group of individuals.  In addition, it may be possible to 
achieve greater benefits from statin prescribing through further studies to determine 
optimal timings and dosages for people with SMI.  For example, given the earlier 
age of CVD onset within this group, it may be advantageous to explore whether 
starting pharmacological intervention in younger individuals is worthwhile. 
My study identified that statins were prescribed to less than half of people who had 
all components of the physical health check recorded over a six-year period and 
had an estimated Framingham risk score of 20% or higher. This finding raises the 
question of why these individuals were not prescribed a statin. Perhaps the most 
likely explanation is that the GP had not actively estimated a risk score for the 
patient and was therefore unaware of the patient’s potential eligibility for statin 
prescribing. There may therefore be a role for tailoring GP software to highlight 
when sufficient information is available to estimate a risk score (e.g. by including an 
alert in a visible but unobtrusive part of the patient’s electronic health record), and 
whether this score is likely to be at or above the threshold for prescribing. However, 
given the vast burden of competing priorities that GP consultations must already 
address, further research is required to ascertain acceptable and effective forms for 
such prompts to take. 
UK guidance promotes the role of lifestyle modification prior to initiating statin 
therapy, and it is likely that some of the high CVD risk individuals identified in my 
study were encouraged to consider this approach (National Institute for Health and 
Clinical Excellence, 2014b). However, given evidence from the general population 
(Jorgensen et al., 2014), it is likely that statin prescribing would offer CVD benefits 
over and above interventions that aim to change lifestyle. UK guidance advocates 
shared decision making between the patient and GP for statin prescribing (National 
Institute for Health and Clinical Excellence, 2008b;National Institute for Health and 
Clinical Excellence, 2014b): the absence of prescribing to eligible individuals may 
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therefore occur when one or both parties are reluctant to pursue this line of risk 
management.   
Although, information arising from the decision process can theoretically be 
captured in free text held in electronic patient records, this information is likely to be 
infrequently available, difficult to interpret and was therefore not considered in my 
study. Further qualitative work is required to understand the extent and basis of 
resistance to statin medication on the part of both GPs and people with SMI. In 
particular, better understanding of whether the primary concerns relate to 
perceptions of side-effects, medication adherence or other health beliefs is needed.  
It is likely that there are many individuals who – if able to implement and maintain 
lifestyle changes to lower cholesterol - would obtain greater benefit (including those 
that are not specific to CVD) than could be achieved through statin therapy alone. 
However, effective means of supporting lifestyle modification among people with 
SMI have not been established and further work is needed in this area (Burton et 
al., 2015). In particular, the results from the PRIMROSE RCT will help to provide a 
fuller picture of how statin therapy can be used to compliment strategies for 
improving medication adherence, stopping smoking, increasing physical activity and 
promoting healthy eating.  In combination, these interventions will help to reduce the 
inequalities in CVD that are experienced by people with SMI. 
14 Conclusions 
The findings of this thesis are that the evidence to support statin prescribing for 
primary CVD prevention in people with SMI greatly outweighs the paucity of 
evidence that opposes prescribing to this group. This thesis provides new evidence 
to show that statin prescribing is associated with clinically relevant reductions in 
total cholesterol and that these reductions may translate into long term benefits in 
terms of CVD events and mortality. However, the results from this thesis do not 
provide conclusive evidence on the magnitude of effectiveness in people with SMI 
and this may have implications for the cost-effectiveness of statin therapy. Although 
there is good evidence to suggest that substantial progress has been made towards 
reducing inequalities in the uptake of physical health checks amongst people with 
SMI; uptake is not universal.  For this reason, there remains some uncertainty 
regarding the effectiveness of the current clinical care pathway with respective to 
targeting people who would derive the greatest benefit from statin prescribing. Statin 
therapy is therefore a valuable component of care for primary prevention of CVD in 
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people with SMI. However, further policy intervention and research is required to 
ensure that statins are prescribed to individuals with the greatest capacity to benefit, 
which encompasses factors such as medication adherence and side-effects relative 
to other pharmacological or lifestyle interventions.  
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16 Appendices: 
17 Tailored literature search terms for each database 
17.1 Search terms for querying MedLine  
Domain 1) (“cardio*” mp.) OR (“metabolic*” mp.) OR (“lipid*” mp.) OR (“cholesterol*” mp.) 
OR (exp CVDs/) OR (exp Cholesterol/) OR (exp Lipids/) OR (exp Dyslipidemias/) OR (exp 
Hyperlipidemias/) OR (exp Metabolic Syndrome X/) 
Domain 2) (“Hydroxymethylglutaryl-CoA Reductase Inhibitor*” mp.) OR (“statin*” mp.) OR 
(exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/) 
Domain 3) (“Bipolar” mp.) OR (“mania*” mp.) OR (“manic*” mp.) OR (“hypomanic*” mp.) OR 
(“psychotic” mp.) OR (“postpsychotic” mp.) OR (“post psychotic” mp.) OR (“schizoaffective” 
mp.) OR (“psychosis” mp.) OR (“psychoses” mp.) OR (exp Bipolar Disorder/) OR (exp 
Schizophrenia/) OR (exp Psychotic Disorders/) OR (exp Antipsychotic Agents/) 
Multipurpose search (mp.)=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, 
rare disease supplementary concept, unique identifier, exp = exploded term 
17.2 Search terms for querying EMBASE  
Domain 1) (exp CVD/) OR (exp cholesterol/) OR (exp lipid/) OR (exp dyslipidemia/) OR (exp 
hyperlipidemia/) OR (exp metabolic syndrome X/) OR (“cardio*” mp.) OR (“metabolic*” mp.) 
OR (“lipid*” mp.) OR (“cholesterol*” mp.)  
Domain 2) (exp hydroxymethylglutaryl coenzyme A reductase Inhibitor/) OR (exp “statin 
(protein)”) OR (“Hydroxymethylglutaryl-CoA Reductase Inhibitor*” mp.) OR (“statin*” mp.) 
Domain 3) (exp b ipolar disorder/) OR (exp schizophrenia/) OR (exp psychosis/) OR (exp 
neuroleptic agent/) OR (“Bipolar” mp.) OR (“mania*” mp.) OR (“manic*” mp.) OR 
(“hypomani*” mp.) OR (“psychotic” mp.) OR (“postpsychotic” mp.) OR (“postpsychotic” mp.) 
OR (“rapid cycling”) OR (“schizoaffective” mp.) OR (“psychosis” mp.) OR (“psychoses” mp.) 
Multipurpose search (mp.)=title, abstract, subject headings, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, device trade 
name, keyword, exp = exploded term 
17.3 Search terms for querying PsycInfo 
Domain 1) (exp Cardiovascular Disorders/) OR (exp Cholesterol/) OR (exp Lipids/) OR (exp 
Lipid Metabolism Disorders/) OR (exp Metabolic Disorders/) OR (exp Metabolic Syndrome/) 
OR (“cardio*” mp.) OR (“metabolic*” mp.) OR (“lipid*” mp.) OR (“cholesterol*” mp.)  
Domain 2) (exp “Statins”) (“Hydroxymethylglutaryl-CoA Reductase Inhibitor*” mp.) OR 
(“statin*” mp.)  
Domain 3) (exp Bipolar Disorder/) OR (exp Schizophrenia/) OR (exp Psychosis/) OR (exp 
Neuroleptic drugs/) OR (“Bipolar” mp.) OR (“mania*” mp.) OR (“manic*” mp.) OR 
(“hypomani*” mp.) OR (“psychotic” mp.) OR (“postpsychotic” mp.) OR (“post psychotic” mp.) 
OR (“rapid cycling” mp.) OR (“schizoaffective” mp.) OR (“psychosis” mp.) OR (“psychoses” 
mp.) 
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Multipurpose search (mp.)=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures, exp = exploded term  
17.4 Search terms for querying CINAHL 
Domain 1) (MH “CVD+”) OR (MH “lipid+”) OR (MH “cholesterol+”) OR (MH 
“hyperlipidaemia+”) OR cardio* OR lipid* OR cholesterol* OR dyslipid* OR hyperlipid* OR 
metabolic* 
Domain 2) (MH “statin”) OR (Hydroxymethylglutaryl-CoA Reductase Inhibitor*) OR statin* 
Domain 3) (MH “b ipolar disorder”) OR (MH “schizophrenia”) OR (MH “anti psychotic 
agents”) OR bipolar OR mania* OR manic* Or hypomani* OR psychotic OR postpsychotic 
OR (post psychotic) OR (rapid cycling) OR schizoaffective OR psychosis OR psychoses 
MH = medical heading 
17.5 Tailored literature search terms for querying NHS evidence 
Domain 1) ((cardio*) OR (cholesterol*) OR (lipid*) OR (metabolic*))  
 
Domain 2) ((statin*) OR (“Hydroxymethylglutaryl-CoA Reductase Inhibitor*”)) 
 
Domain 3) ((Bipolar) OR (mania*) OR (manic*) Or (hypomani*) OR (psychotic) OR 
(postpsychotic) OR (“post psychotic”) OR (“rapid cycling”) OR (schizoaffective) OR 
(psychosis) OR (psychoses)) 
 
Domain 4) Information type =‘primary research’ 
18 Systematic review abstract submitted to SAPC 
Title: Systematic review of the evidence for the effectiveness of statins for the 
primary prevention of cardiovascular disease in people with severe mental illness.  
The Problem: Cardiovascular–related mortality and morbidity are twofold higher 
amongst individuals with severe mental illness (including schizophrenia and bipolar 
disorder) than the general population; thus highlighting the need for improved 
cardiovascular care for this group.  Statins are a cost-effective means of preventing 
cardiovascular disease in the general population. However, the evidence-base for 
statin use in people with severe mental illness is unclear and may differ to the 
general population because of interaction with antipsychotic medication or patterns 
of medication adherence. 
The Approach: We aimed to identify studies evaluating the impact of statin 
therapy on the primary prevention of cardiovascular disease in individuals with 
severe mental illness. A systematic search was conducted using five 
complimentary databases (EMBASE, MedLine, CINAHL, NHS Evidence, PsycInfo) 
and five major trials registries (CENTRAL, International Standard Randomised 
Controlled Trial Register, US National Institutes of Health service, UK National 
Institute for Health Research Register,UK Clinical Research Network study portfolio 
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database).  Search terms included synonyms, free text and wildcard terms for: 1) 
cardiovascular disease, 2) statins and 3) severe mental illness.  All results were 
independently screened for relevance by two reviewers. 
Findings: A total of 1994 citations were screened to yield six potentially relevant 
registered trials and four non-randomised studies.  Of the trials, one is currently 
recruiting, one has been completed but results are not yet available, three were 
terminated early with no available results and one has been completed, with 
negative results and has not been published.  Of the four non-randomised studies, 
only one incorporated a statin unexposed comparison group: results from this 
study suggest that statins can produce meaningful reductions in total cholesterol (-
35% (±6), p<0.001) and low density lipoprotein cholesterol (-49% (±8), p<0.001) in 
individuals with severe mental illness. However, the strength of these findings are 
limited by relatively small sample size (n=100) from a single centre, type of statin 
investigated (rosuvastatin) and short duration of follow up (3 months).  
Consequences: There is an extremely limited pool of evidence assessing the 
effectiveness of statins in people with severe mental illness, with some evidence of 
publication bias, no results currently available from randomised controlled trials 
and only one study incorporating a statin-free comparison arm.  Further evidence is 
required to support effective primary prevention of cardiovascular disease amongst 
individuals with severe mental illness. 
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19 Estimating CVD risk scores 
Table 19-1: Published regression Coefficients for the laboratory version of 
the Framingham risk score for CVD (D'Agostino et al., 2008) 
Variable Coefficient 
Women (10 year baseline survival: So(10)=0.95012) 
    Log of age 2.32888 
    Log of total cholesterol 1.20904 
    Log of HDL cholesterol −0.70833 
    Log of SBP if not treated 2.76157 
    Log of SBP if treated 2.82263 
    Smoking 0.52873 
    Diabetes 0.69154 
Men (10 year baseline survival: So(10)=0.88936) 
    Log of age 3.06117 
    Log of total cholesterol 1.1237 
    Log of HDL cholesterol −0.93263 
    Log of SBP if not treated 1.93303 
    Log of SBP if treated 1.99881 
    Smoking 0.65451 
    Diabetes 0.57367 
SBP; systolic blood pressure 
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Table 19-2: Published regression Coefficients for the desk version of the 
Framingham risk score for CVD (D'Agostino et al., 2008) 
Variable Coefficient 
Women (10 year baseline survival: So(10)= 0.94833) 
    Log of age 2.72107 
    Body mass index 0.51125 
    Log of SBP if not treated 2.81291 
    Log of SBP if treated 2.88267 
    Smoking 0.61868 
    Diabetes 0.77763 
Men (10 year baseline survival: So(10)= 0.88431) 
    Log of age 3.11296 
    Body mass index 0.79277 
    Log of SBP if not treated 1.85508 
    Log of SBP if treated 1.92672 
    Smoking 0.70953 
    Diabetes 0.53160 
SBP; systolic blood pressure 
 
 
 
20 Drug and Read Code Lists 
20.1 SMI 
Description (SMI) Med Code SMI Type 
H/O: schizophrenia 1464.00 schizophrenia 
H/O: manic depressive disorder 146D.00 bipolar 
H/O: psychosis 146H.00 other 
On national service framework mental health 9H6..00 register 
On severe mental illness register 9H8..00 register 
Non-organic psychoses E1...00 other 
Schizophrenic disorders E10..00 schizophrenia 
Simple schizophrenia E100.00 schizophrenia 
Schizophrenia simplex E100.11 schizophrenia 
Unspecified schizophrenia E100000 schizophrenia 
Subchronic schizophrenia E100100 schizophrenia 
Chronic schizophrenic E100200 schizophrenia 
Acute exacerbation of subchronic schizophrenia E100300 schizophrenia 
Acute exacerbation of chronic schizophrenia E100400 schizophrenia 
Schizophrenia in remission E100500 schizophrenia 
Simple schizophrenia NOS E100z00 schizophrenia 
Hebephrenic schizophrenia E101.00 schizophrenia 
Unspecified hebephrenic schizophrenia E101000 schizophrenia 
Subchronic hebephrenic schizophrenia E101100 schizophrenia 
Chronic hebephrenic schizophrenia E101200 schizophrenia 
Acute exacerbation of subchronic hebephrenic schizophrenia E101300 schizophrenia 
Acute exacerbation of chronic hebephrenic schizophrenia E101400 schizophrenia 
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Description (SMI) Med Code SMI Type 
Hebephrenic schizophrenia in remission E101500 schizophrenia 
Hebephrenic schizophrenia NOS E101z00 schizophrenia 
Catatonic schizophrenia E102.00 schizophrenia 
Unspecified catatonic schizophrenia E102000 schizophrenia 
Subchronic catatonic schizophrenia E102100 schizophrenia 
Chronic catatonic schizophrenia E102200 schizophrenia 
Acute exacerbation of subchronic catatonic schizophrenia E102300 schizophrenia 
Acute exacerbation of chronic catatonic schizophrenia E102400 schizophrenia 
Catatonic schizophrenia in remission E102500 schizophrenia 
Catatonic schizophrenia NOS E102z00 schizophrenia 
Paranoid schizophrenia E103.00 schizophrenia 
Unspecified paranoid schizophrenia E103000 schizophrenia 
Subchronic paranoid schizophrenia E103100 schizophrenia 
Chronic paranoid schizophrenia E103200 schizophrenia 
Acute exacerbation of subchronic paranoid schizophrenia E103300 schizophrenia 
Acute exacerbation of chronic paranoid schizophrenia E103400 schizophrenia 
Paranoid schizophrenia in remission E103500 schizophrenia 
Paranoid schizophrenia NOS E103z00 schizophrenia 
Acute schizophrenic episode E104.00 schizophrenia 
Oneirophrenia E104.11 other 
Latent schizophrenia E105.00 schizophrenia 
Unspecified latent schizophrenia E105000 schizophrenia 
Subchronic latent schizophrenia E105100 schizophrenia 
Chronic latent schizophrenia E105200 schizophrenia 
Acute exacerbation of subchronic latent schizophrenia E105300 schizophrenia 
Acute exacerbation of chronic latent schizophrenia E105400 schizophrenia 
Latent schizophrenia in remission E105500 schizophrenia 
Latent schizophrenia NOS E105z00 schizophrenia 
Residual schizophrenia E106.00 schizophrenia 
Restzustand - schizophrenia E106.11 schizophrenia 
Schizo-affective schizophrenia E107.00 schizophrenia 
Cyclic schizophrenia E107.11 schizophrenia 
Unspecified schizo-affective schizophrenia E107000 schizophrenia 
Subchronic schizo-affective schizophrenia E107100 schizophrenia 
Chronic schizo-affective schizophrenia E107200 schizophrenia 
Acute exacerbation subchronic schizo-affective schizophrenia E107300 schizophrenia 
Acute exacerbation of chronic schizo-affective schizophrenia E107400 schizophrenia 
Schizo-affective schizophrenia in remission E107500 schizophrenia 
Schizo-affective schizophrenia NOS E107z00 schizophrenia 
Other schizophrenia E10y.00 schizophrenia 
Cenesthopathic schizophrenia E10y.11 schizophrenia 
Atypical schizophrenia E10y000 schizophrenia 
Coenesthopathic schizophrenia E10y100 schizophrenia 
Other schizophrenia NOS E10yz00 schizophrenia 
Schizophrenia NOS E10z.00 schizophrenia 
Affective psychoses E11..00 other 
Bipolar psychoses E11..11 bipolar 
Depressive psychoses E11..12 other 
Manic psychoses E11..13 bipolar 
Manic disorder, single episode E110.00 bipolar 
Hypomanic psychoses E110.11 bipolar 
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Description (SMI) Med Code SMI Type 
Single manic episode, unspecified E110000 bipolar 
Single manic episode, mild E110100 bipolar 
Single manic episode, moderate E110200 bipolar 
Single manic episode, severe without mention of psychosis E110300 bipolar 
Single manic episode, severe, with psychosis E110400 bipolar 
Single manic episode in partial or unspecified remission E110500 bipolar 
Single manic episode in full remission E110600 bipolar 
Manic disorder, single episode NOS E110z00 bipolar 
Recurrent manic episodes E111.00 bipolar 
Recurrent manic episodes, unspecified E111000 bipolar 
Recurrent manic episodes, mild E111100 bipolar 
Recurrent manic episodes, moderate E111200 bipolar 
Recurrent manic episodes, severe without mention psychosis E111300 bipolar 
Recurrent manic episodes, severe, with psychosis E111400 bipolar 
Recurrent manic episodes, partial or unspecified remission E111500 bipolar 
Recurrent manic episodes, in full remission E111600 bipolar 
Recurrent manic episode NOS E111z00 bipolar 
Single major depressive episode, severe, with psychosis E112400 other 
Recurrent major depressive episodes, severe, with psychosis E113400 other 
Bipolar affective disorder, currently manic E114.00 bipolar 
Manic-depressive - now manic E114.11 bipolar 
Bipolar affective disorder, currently manic, unspecified E114000 bipolar 
Bipolar affective disorder, currently manic, mild E114100 bipolar 
Bipolar affective disorder, currently manic, moderate E114200 bipolar 
Bipolar affect disord, currently manic, severe, no psychosis E114300 bipolar 
Bipolar affect disord, currently manic,severe with psychosis E114400 bipolar 
Bipolar affect disord,currently manic, part/unspec remission E114500 bipolar 
Bipolar affective disorder, currently manic, full remission E114600 bipolar 
Bipolar affective disorder, currently manic, NOS E114z00 bipolar 
Bipolar affective disorder, currently depressed E115.00 bipolar 
Manic-depressive - now depressed E115.11 bipolar 
Bipolar affective disorder, currently depressed, unspecified E115000 bipolar 
Bipolar affective disorder, currently depressed, mild E115100 bipolar 
Bipolar affective disorder, currently depressed, moderate E115200 bipolar 
Bipolar affect disord, now depressed, severe, no psychosis E115300 bipolar 
Bipolar affect disord, now depressed, severe with psychosis E115400 bipolar 
Bipolar affect disord, now depressed, part/unspec remission E115500 bipolar 
Bipolar affective disorder, now depressed, in full remission E115600 bipolar 
Bipolar affective disorder, currently depressed, NOS E115z00 bipolar 
Mixed bipolar affective disorder E116.00 bipolar 
Mixed bipolar affective disorder, unspecified E116000 bipolar 
Mixed bipolar affective disorder, mild E116100 bipolar 
Mixed bipolar affective disorder, moderate E116200 bipolar 
Mixed bipolar affective disorder, severe, w ithout psychosis E116300 bipolar 
Mixed bipolar affective disorder, severe, w ith psychosis E116400 bipolar 
Mixed bipolar affective disorder, partial/unspec remission E116500 bipolar 
Mixed bipolar affective disorder, in full remission E116600 bipolar 
Mixed bipolar affective disorder, NOS E116z00 bipolar 
Unspecified bipolar affective disorder E117.00 bipolar 
Unspecified bipolar affective disorder, unspecified E117000 bipolar 
Unspecified bipolar affective disorder, mild E117100 bipolar 
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Description (SMI) Med Code SMI Type 
Unspecified bipolar affective disorder, moderate E117200 bipolar 
Unspecified bipolar affective disorder, severe, no psychosis E117300 bipolar 
Unspecified bipolar affective disorder,severe with psychosis E117400 bipolar 
Unspecified bipolar affect disord, partial/unspec remission E117500 bipolar 
Unspecified bipolar affective disorder, in full remission E117600 bipolar 
Unspecified bipolar affective disorder, NOS E117z00 bipolar 
Other and unspecified manic-depressive psychoses E11y.00 bipolar 
Unspecified manic-depressive psychoses E11y000 bipolar 
Atypical manic disorder E11y100 bipolar 
Other mixed manic-depressive psychoses E11y300 bipolar 
Other and unspecified manic-depressive psychoses NOS E11yz00 bipolar 
Other and unspecified affective psychoses E11z.00 other 
Unspecified affective psychoses NOS E11z000 other 
Other affective psychosis NOS E11zz00 other 
Paranoid states E12..00 other 
Simple paranoid state E120.00 other 
Chronic paranoid psychosis E121.00 other 
Sander's disease E121.11 other 
Paraphrenia E122.00 other 
Shared paranoid disorder E123.00 other 
Folie a deux E123.11 other 
Other paranoid states E12y.00 other 
Paranoia querulans E12y000 other 
Other paranoid states NOS E12yz00 other 
Paranoid psychosis NOS E12z.00 other 
Other nonorganic psychoses E13..00 other 
Reactive psychoses E13..11 other 
Reactive depressive psychosis E130.00 other 
Psychotic reactive depression E130.11 other 
Acute hysterical psychosis E131.00 other 
Acute paranoid reaction E133.00 other 
Bouffee delirante E133.11 other 
Psychogenic paranoid psychosis E134.00 other 
Other reactive psychoses E13y.00 other 
Psychogenic stupor E13y000 other 
Brief reactive psychosis E13y100 other 
Other reactive psychoses NOS E13yz00 other 
Nonorganic psychosis NOS E13z.00 other 
Psychotic episode NOS E13z.11 other 
Other specified non-organic psychoses E1y..00 other 
Non-organic psychosis NOS E1z..00 other 
Schizotypal personality E212200 schizophrenia 
[X]Schizophrenia, schizotypal and delusional disorders Eu2..00 schizophrenia 
[X]Schizophrenia Eu20.00 schizophrenia 
[X]Paranoid schizophrenia Eu20000 schizophrenia 
[X]Paraphrenic schizophrenia Eu20011 schizophrenia 
[X]Hebephrenic schizophrenia Eu20100 schizophrenia 
[X]Disorganised schizophrenia Eu20111 schizophrenia 
[X]Catatonic schizophrenia Eu20200 schizophrenia 
[X]Catatonic stupor Eu20211 schizophrenia 
[X]Schizophrenic catalepsy Eu20212 schizophrenia 
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Description (SMI) Med Code SMI Type 
[X]Schizophrenic catatonia Eu20213 schizophrenia 
[X]Schizophrenic flexibilatis cerea Eu20214 schizophrenia 
[X]Undifferentiated schizophrenia Eu20300 schizophrenia 
[X]Atypical schizophrenia Eu20311 schizophrenia 
[X]Post-schizophrenic depression Eu20400 schizophrenia 
[X]Residual schizophrenia Eu20500 schizophrenia 
[X]Chronic undifferentiated schizophrenia Eu20511 schizophrenia 
[X]Restzustand schizophrenic Eu20512 schizophrenia 
[X]Simple schizophrenia Eu20600 schizophrenia 
[X]Other schizophrenia Eu20y00 schizophrenia 
[X]Cenesthopathic schizophrenia Eu20y11 schizophrenia 
[X]Schizophreniform disord NOS Eu20y12 schizophrenia 
[X]Schizophrenifrm psychos NOS Eu20y13 schizophrenia 
[X]Schizophrenia, unspecified Eu20z00 schizophrenia 
[X]Schizotypal disorder Eu21.00 schizophrenia 
[X]Latent schizophrenic reaction Eu21.11 schizophrenia 
[X]Borderline schizophrenia Eu21.12 schizophrenia 
[X]Latent schizophrenia Eu21.13 schizophrenia 
[X]Prepsychotic schizophrenia Eu21.14 schizophrenia 
[X]Prodromal schizophrenia Eu21.15 schizophrenia 
[X]Pseudoneurotic schizophrenia Eu21.16 schizophrenia 
[X]Pseudopsychopathic schizophrenia Eu21.17 schizophrenia 
[X]Schizotypal personality disorder Eu21.18 schizophrenia 
[X]Persistent delusional disorders Eu22.00 other 
[X]Delusional disorder Eu22000 other 
[X]Paranoid psychosis Eu22011 other 
[X]Paranoid state Eu22012 other 
[X]Paraphrenia - late Eu22013 schizophrenia 
[X]Sensitiver Beziehungswahn Eu22014 other 
[X]Paranoia Eu22015 other 
[X]Delusional misidentification syndrome Eu22100 other 
[X]Capgras syndrome Eu22111 other 
[X]Cotard syndrome Eu22200 other 
[X]Other persistent delusional disorders Eu22y00 other 
[X]Delusional dysmorphophobia Eu22y11 other 
[X]Involutional paranoid state Eu22y12 other 
[X]Paranoia querulans Eu22y13 other 
[X]Persistent delusional disorder, unspecified Eu22z00 other 
[X]Acute and transient psychotic disorders Eu23.00 other 
[X]Acute polymorphic psychot disord without symp of schizoph Eu23000 other 
[X]Bouffee delirante Eu23011 other 
[X]Cycloid psychosis Eu23012 other 
[X]Acute polymorphic psychot disord with symp of schizophren Eu23100 other 
[X]Bouffee delirante w ith symptoms of schizophrenia Eu23111 other 
[X]Cycloid psychosis with symptoms of schizophrenia Eu23112 schizophrenia 
[X]Acute schizophrenia-like psychotic disorder Eu23200 other 
[X]Brief schizophreniform disorder Eu23211 other 
[X]Brief schizophrenifrm psych Eu23212 other 
[X]Oneirophrenia Eu23213 other 
[X]Schizophrenic reaction Eu23214 schizophrenia 
[X]Other acute predominantly delusional psychotic disorders Eu23300 other 
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Description (SMI) Med Code SMI Type 
[X]Psychogenic paranoid psychosis Eu23312 other 
[X]Other acute and transient psychotic disorders Eu23y00 other 
[X]Acute and transient psychotic disorder, unspecified Eu23z00 other 
[X]Brief reactive psychosis NOS Eu23z11 other 
[X]Reactive psychosis Eu23z12 other 
[X]Induced delusional disorder Eu24.00 other 
[X]Folie a deux Eu24.11 other 
[X]Induced paranoid disorder Eu24.12 other 
[X]Induced psychotic disorder Eu24.13 other 
[X]Schizoaffective disorders Eu25.00 schizophrenia 
[X]Schizoaffective disorder, manic type Eu25000 schizophrenia 
[X]Schizoaffective psychosis, manic type Eu25011 schizophrenia 
[X]Schizophreniform psychosis, manic type Eu25012 schizophrenia 
[X]Schizoaffective disorder, depressive type Eu25100 schizophrenia 
[X]Schizoaffective psychosis, depressive type Eu25111 schizophrenia 
[X]Schizophreniform psychosis, depressive type Eu25112 schizophrenia 
[X]Schizoaffective disorder, mixed type Eu25200 schizophrenia 
[X]Cyclic schizophrenia Eu25211 schizophrenia 
[X]Mixed schizophrenic and affective psychosis Eu25212 schizophrenia 
[X]Other schizoaffective disorders Eu25y00 schizophrenia 
[X]Schizoaffective disorder, unspecified Eu25z00 schizophrenia 
[X]Schizoaffective psychosis NOS Eu25z11 schizophrenia 
[X]Other nonorganic psychotic disorders Eu2y.00 other 
[X]Chronic hallucinatory psychosis Eu2y.11 other 
[X]Unspecified nonorganic psychosis Eu2z.00 other 
[X]Psychosis NOS Eu2z.11 other 
[X]Manic episode Eu30.00 bipolar 
[X]Bipolar disorder, single manic episode Eu30.11 bipolar 
[X]Hypomania Eu30000 bipolar 
[X]Mania w ithout psychotic symptoms Eu30100 bipolar 
[X]Mania w ith psychotic symptoms Eu30200 bipolar 
[X]Mania w ith mood-congruent psychotic symptoms Eu30211 bipolar 
[X]Mania w ith mood-incongruent psychotic symptoms Eu30212 bipolar 
[X]Manic stupor Eu30213 bipolar 
[X]Other manic episodes Eu30y00 bipolar 
[X]Manic episode, unspecified Eu30z00 bipolar 
[X]Mania NOS Eu30z11 bipolar 
[X]Bipolar affective disorder Eu31.00 bipolar 
[X]Manic-depressive illness Eu31.11 bipolar 
[X]Manic-depressive psychosis Eu31.12 bipolar 
[X]Mainc-depressive reaction Eu31.13 bipolar 
[X]Bipolar affective disorder, current episode hypomanic Eu31000 bipolar 
[X]Bipolar affect disorder cur epi manic wout psychotic symp Eu31100 bipolar 
[X]Bipolar affect disorder cur epi manic with psychotic symp Eu31200 bipolar 
[X]Bipolar affect disorder cur epi mild or moderate depressn Eu31300 bipolar 
[X]Bipol aff disord, curr epis sev depress, no psychot symp Eu31400 bipolar 
[X]Bipolar affect dis cur epi severe depres with psyc symp Eu31500 bipolar 
[X]Bipolar affective disorder, current episode mixed Eu31600 bipolar 
[X]Bipolar affective disorder, currently in remission Eu31700 bipolar 
[X]Other bipolar affective disorders Eu31y00 bipolar 
[X]Bipolar II disorder Eu31y11 bipolar 
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Description (SMI) Med Code SMI Type 
[X]Recurrent manic episodes Eu31y12 bipolar 
[X]Bipolar affective disorder, unspecified Eu31z00 bipolar 
[X]Severe depressive episode with psychotic symptoms Eu32300 other 
[X]Single episode of major depression and psychotic symptoms Eu32311 other 
[X]Single episode of psychogenic depressive psychosis Eu32312 other 
[X]Single episode of psychotic depression Eu32313 other 
[X]Single episode of reactive depressive psychosis Eu32314 other 
[X]Major depression, severe w ith psychotic symptoms Eu32800 other 
[X]Manic-depress psychosis,depressd,no psychotic symptoms Eu33213 bipolar 
[X]Recurrent depress disorder cur epi severe with psyc symp Eu33300 other 
[X]Endogenous depression with psychotic symptoms Eu33311 other 
[X]Manic-depress psychosis,depressed type+psychotic symptoms Eu33312 bipolar 
[X]Recurr severe episodes/major depression+psychotic symptom Eu33313 other 
[X]Recurr severe episodes/psychogenic depressive psychosis Eu33314 other 
[X]Recurrent severe episodes of psychotic depression Eu33315 other 
[X]Recurrent severe episodes/reactive depressive psychosis Eu33316 other 
[X]Affective psychosis NOS Eu3z.11 other 
[X]Hysterical psychosis Eu44.14 other 
[X]Symbiotic psychosis Eu84314 other 
Profile of mood states, bipolar ZRby100 bipolar 
Schizophrenic language ZS7C611 schizophrenia 
[V]Personal history of schizophrenia ZV11000 schizophrenia 
[V]Personal history of manic-depressive psy ZV11111 bipolar 
[V]Personal history of manic-depressive psy ZV11112 bipolar 
20.2 CVD 
description (CVD) MedCode CVD Type Incident 
H/O: cerebrovascular disease 1477.00 CVD unspecif ied n 
H/O: cardiovascular disease 14A..00 CVD unspecif ied n 
H/O: myocardial infarct <60 14A3.00 MI n 
H/O: myocardial infarct >60 14A4.00 MI n 
H/O: angina pectoris 14A5.00 angina n 
H/O: CVA/stroke 14A7.00 ischaemic/unspecif ied 
stroke 
n 
H/O: CVA 14A7.11 ischaemic/unspecif ied 
stroke 
n 
H/O: stroke 14A7.12 ischaemic/unspecif ied 
stroke 
n 
H/O: heart disease NOS 14AA.00 CHD unspecif ied n 
H/O: TIA 14AB.00 TIA n 
H/O: Myocardial infarction in last year 14AH.00 MI n 
H/O: Angina in last year 14AJ.00 angina n 
H/O: Stroke in last year 14AK.00 ischaemic/unspecif ied 
stroke 
n 
H/O: Treatment for ischaemic heart disease 14AL.00 CHD unspecif ied n 
History of myocardial infarction 14AT.00 MI n 
H/O: CVS disease NOS 14AZ.00 CVD unspecif ied n 
ECG: myocardial ischaemia 322..00 MI y 
ECG:shows myocardial ischaemia 3222.00 MI y 
ECG: myocardial ischaemia NOS 322Z.00 MI y 
ECG: myocardial infarction 323..00 MI y 
ECG: old myocardial infarction 3232.00 MI n 
 
 
270 
 
description (CVD) MedCode CVD Type Incident 
ECG: antero-septal infarct. 3233.00 MI y 
ECG:posterior/inferior infarct 3234.00 MI y 
ECG: subendocardial infarct 3235.00 MI y 
ECG: lateral infarction 3236.00 MI y 
ECG: myocardial infarct NOS 323Z.00 MI y 
Angina control - good 662K000 angina n 
Angina control - poor 662K100 angina n 
Angina control - improving 662K200 angina n 
Angina control - worsening 662K300 angina n 
Angina control NOS 662Kz00 angina n 
Coronary artery operations 792..00 surgery y 
Coronary artery bypass graft operations 792..11 surgery y 
Saphenous vein graft replacement of coronary 
artery 
7920.00 surgery y 
Saphenous vein graft bypass of coronary artery 7920.11 surgery y 
Saphenous vein graft replacement of one 
coronary artery 
7920000 surgery y 
Saphenous vein graft replacement of two 
coronary arteries 
7920100 surgery y 
Saphenous vein graft replacement of three 
coronary arteries 
7920200 surgery y 
Saphenous vein graft replacement of four+ 
coronary arteries 
7920300 surgery y 
Saphenous vein graft replacement of coronary 
artery OS 
7920y00 surgery y 
Saphenous vein graft replacement coronary 
artery NOS 
7920z00 surgery y 
Other autograft replacement of coronary artery 7921.00 surgery y 
Other autograft bypass of coronary artery 7921.11 surgery y 
Autograft replacement of one coronary artery 
NEC 
7921000 surgery y 
Autograft replacement of two coronary arteries 
NEC 
7921100 surgery y 
Autograft replacement of three coronary arteries 
NEC 
7921200 surgery y 
Autograft replacement of four of more coronary 
arteries NEC 
7921300 surgery y 
Other autograft replacement of coronary artery 
OS 
7921y00 surgery y 
Other autograft replacement of coronary artery 
NOS 
7921z00 surgery y 
Allograft replacement of coronary artery 7922.00 surgery y 
Allograft bypass of coronary artery 7922.11 surgery y 
Allograft replacement of one coronary artery 7922000 surgery y 
Allograft replacement of two coronary arteries 7922100 surgery y 
Allograft replacement of three coronary arteries 7922200 surgery y 
Allograft replacement of four or more coronary 
arteries 
7922300 surgery y 
Other specified allograft replacement of 
coronary artery 
7922y00 surgery y 
Allograft replacement of coronary artery NOS 7922z00 surgery y 
Prosthetic replacement of coronary artery 7923.00 surgery y 
Prosthetic bypass of coronary artery 7923.11 surgery y 
Prosthetic replacement of one coronary artery 7923000 surgery y 
Prosthetic replacement of two coronary arteries 7923100 surgery y 
Prosthetic replacement of three coronary 
arteries 
7923200 surgery y 
Prosthetic replacement of four or more coronary 
arteries 
7923300 surgery y 
Other specified prosthetic replacement of 
coronary artery 
7923y00 surgery y 
 
 
271 
 
description (CVD) MedCode CVD Type Incident 
Prosthetic replacement of coronary artery NOS 7923z00 surgery y 
Revision of bypass for coronary artery 7924.00 surgery y 
Revision of bypass for one coronary artery 7924000 surgery y 
Revision of bypass for two coronary arteries 7924100 surgery y 
Revision of bypass for three coronary arteries 7924200 surgery y 
Revision of bypass for four or more coronary 
arteries 
7924300 surgery y 
Revision of connection of thoracic artery to 
coronary artery 
7924400 surgery y 
Revision of implantation of thoracic artery into 
heart 
7924500 surgery y 
Other specified revision of bypass for coronary 
artery 
7924y00 surgery y 
Revision of bypass for coronary artery NOS 7924z00 surgery y 
Connection of mammary artery to coronary 
artery 
7925.00 surgery y 
Creation of bypass from mammary artery to 
coronary artery 
7925.11 surgery y 
Double anastomosis of mammary arteries to 
coronary arteries 
7925000 surgery y 
LIMA sequential anastomosis 7925011 surgery y 
RIMA sequential anastomosis 7925012 surgery y 
Double implant of mammary arteries into 
coronary arteries 
7925100 surgery y 
Single anast mammary art to left ant descend 
coronary art 
7925200 surgery y 
Single anastomosis of mammary artery to 
coronary artery NEC 
7925300 surgery y 
LIMA single anastomosis 7925311 surgery y 
RIMA single anastomosis 7925312 surgery y 
Single implantation of mammary artery into 
coronary artery 
7925400 surgery y 
Connection of mammary artery to coronary 
artery OS 
7925y00 surgery y 
Connection of mammary artery to coronary 
artery NOS 
7925z00 surgery y 
Connection of other thoracic artery to coronary 
artery 
7926.00 surgery y 
Double anastom thoracic arteries to coronary 
arteries NEC 
7926000 surgery y 
Double implant thoracic arteries into coronary 
arteries NEC 
7926100 surgery y 
Single anastomosis of thoracic artery to 
coronary artery NEC 
7926200 surgery y 
Single implantation thoracic artery into coronary 
artery NEC 
7926300 surgery y 
Connection of other thoracic artery to coronary 
artery OS 
7926y00 surgery y 
Connection of other thoracic artery to coronary 
artery NOS 
7926z00 surgery y 
Transposition of coronary artery NEC 7927300 surgery y 
Exploration of coronary artery 7927400 surgery y 
Open angioplasty of coronary artery 7927500 surgery y 
Other specified other open operation on 
coronary artery 
7927y00 surgery y 
Other open operation on coronary artery NOS 7927z00 surgery y 
Transluminal balloon angioplasty of coronary 
artery 
7928.00 surgery y 
Percutaneous balloon coronary angioplasty 7928.11 surgery y 
Percut transluminal balloon angioplasty one 
coronary artery 
7928000 surgery y 
Percut translum balloon angioplasty mult 
coronary arteries 
7928100 surgery y 
Percut translum balloon angioplasty bypass 
graft coronary a 
7928200 surgery y 
Percut translum cutting balloon angioplasty 7928300 surgery y 
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coronary artery 
Transluminal balloon angioplasty of coronary 
artery OS 
7928y00 surgery y 
Transluminal balloon angioplasty of coronary 
artery NOS 
7928z00 surgery y 
Other therapeutic transluminal operations on 
coronary artery 
7929.00 surgery y 
Percutaneous transluminal laser coronary 
angioplasty 
7929000 surgery y 
Percut transluminal coronary thrombolysis w ith 
streptokinase 
7929100 surgery y 
Percut translum coronary thrombolytic therapy- 
streptokinase 
7929111 surgery y 
Percut translum inject therap subst to coronary 
artery NEC 
7929200 surgery y 
Rotary blade coronary angioplasty 7929300 surgery y 
Insertion of coronary artery stent 7929400 surgery y 
Insertion of drug-eluting coronary artery stent 7929500 surgery y 
Percutaneous transluminal atherectomy of 
coronary artery 
7929600 surgery y 
Other therapeutic transluminal op on coronary 
artery OS 
7929y00 surgery y 
Other therapeutic transluminal op on coronary 
artery NOS 
7929z00 surgery y 
Diagnostic transluminal operations on coronary 
artery 
792A.00 surgery y 
Diagnostic transluminal operation on coronary 
artery OS 
792Ay00 surgery y 
Diagnostic transluminal operation on coronary 
artery NOS 
792Az00 surgery y 
Repair of coronary artery NEC 792B.00 surgery y 
Endarterectomy of coronary artery NEC 792B000 surgery y 
Other specified repair of coronary artery 792By00 surgery y 
Repair of coronary artery NOS 792Bz00 surgery y 
Other replacement of coronary artery 792C.00 surgery y 
Replacement of coronary arteries using multiple 
methods 
792C000 surgery y 
Other specified replacement of coronary artery 792Cy00 surgery y 
Replacement of coronary artery NOS 792Cz00 surgery y 
Other bypass of coronary artery 792D.00 surgery y 
Other specified other bypass of coronary artery 792Dy00 surgery y 
Other bypass of coronary artery NOS 792Dz00 surgery y 
Other specified operations on coronary artery 792y.00 surgery y 
Coronary artery operations NOS 792z.00 surgery y 
Perc translumin balloon angioplasty stenting 
coronary artery 
793G.00 surgery y 
Perc translum ball angio insert 1-2 drug elut 
stents cor art 
793G000 surgery y 
Perc tran ball angio ins 3 or more drug elut 
stents cor art 
793G100 surgery y 
Perc translum balloon angioplasty insert 1-2 
stents cor art 
793G200 surgery y 
Percutaneous cor balloon angiop 3 more stents 
cor art NEC 
793G300 surgery y 
OS perc translumina balloon angioplast stenting 
coronary art 
793Gy00 surgery y 
Perc translum balloon angioplasty stenting 
coronary art NOS 
793Gz00 surgery y 
Transluminal operations on cardiac conduit 793H.00 surgery y 
Percutaneous transluminal balloon dilation 
cardiac conduit 
793H000 surgery y 
Rotary blade angioplasty 7A54500 surgery y 
Peroperative angioplasty 7A6G100 surgery y 
Prosthetic graft patch angioplasty 7A6H300 surgery y 
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Percutaneous transluminal angioplasty of 
vascular graft 
7A6H400 surgery y 
Delivery of rehabilitation for acute cardiac 
disorders 
7P24000 CVD unspecif ied n 
Delivery of rehabilitation for stroke 7P24200 ischaemic/unspecif ied 
stroke 
n 
Transient ischaemic attack clinical management 
plan 
8CRB.00 TIA y 
Admit ischaemic heart disease emergency 8H2V.00 CHD unspecif ied y 
Stroke / transient ischaemic attack referral 8HBJ.00 ischaemic/unspecif ied 
stroke 
y 
Ref to multidisciplinary stroke function 
improvement service 
8HHM.00 ischaemic/unspecif ied 
stroke 
n 
Referral to stroke clinic 8HTQ.00 ischaemic/unspecif ied 
stroke 
n 
Seen in stroke clinic 9N0p.00 ischaemic/unspecif ied 
stroke 
n 
DNA - Did not attend stroke clinic 9N4X.00 ischaemic/unspecif ied 
stroke 
n 
Amaurosis fugax F423600 ischaemic/unspecif ied 
stroke 
y 
Ischaemic heart disease G3...00 CHD unspecif ied y 
Arteriosclerotic heart disease G3...11 CHD unspecif ied y 
Atherosclerotic heart disease G3...12 CHD unspecif ied y 
IHD - Ischaemic heart disease G3...13 CHD unspecif ied y 
Acute myocardial infarction G30..00 MI y 
Attack - heart G30..11 MI y 
Coronary thrombosis G30..12 MI y 
Cardiac rupture following myocardial infarction 
(MI) 
G30..13 MI y 
Heart attack G30..14 MI y 
MI - acute myocardial infarction G30..15 MI y 
Thrombosis - coronary G30..16 MI y 
Silent myocardial infarction G30..17 MI y 
Acute anterolateral infarction G300.00 MI y 
Other specified anterior myocardial infarction G301.00 MI y 
Acute anteroapical infarction G301000 MI y 
Acute anteroseptal infarction G301100 MI y 
Anterior myocardial infarction NOS G301z00 MI y 
Acute inferolateral infarction G302.00 MI y 
Acute inferoposterior infarction G303.00 MI y 
Posterior myocardial infarction NOS G304.00 MI y 
Lateral myocardial infarction NOS G305.00 MI y 
True posterior myocardial infarction G306.00 MI y 
Acute subendocardial infarction G307.00 MI y 
Acute non-Q wave infarction G307000 MI y 
Acute non-ST segment elevation myocardial 
infarction 
G307100 MI y 
Inferior myocardial infarction NOS G308.00 MI y 
Acute Q-wave infarct G309.00 MI y 
Mural thrombosis G30A.00 MI y 
Acute posterolateral myocardial infarction G30B.00 MI y 
Acute transmural myocardial infarction of 
unspecif site 
G30X.00 MI y 
Acute ST segment elevation myocardial 
infarction 
G30X000 MI y 
Other acute myocardial infarction G30y.00 MI y 
Acute atrial infarction G30y000 MI y 
Acute papillary muscle infarction G30y100 MI y 
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Acute septal infarction G30y200 MI y 
Other acute myocardial infarction NOS G30yz00 MI y 
Acute myocardial infarction NOS G30z.00 MI y 
Other acute and subacute ischaemic heart 
disease 
G31..00 MI y 
Postmyocardial infarction syndrome G310.00 MI y 
Dressler's syndrome G310.11 MI y 
Preinfarction syndrome G311.00 unstable angina/ACS y 
Crescendo angina G311.11 unstable angina/ACS y 
Impending infarction G311.12 unstable angina/ACS y 
Unstable angina G311.13 unstable angina/ACS y 
Angina at rest G311.14 unstable angina/ACS y 
Myocardial infarction aborted G311000 CHD unspecif ied y 
MI - myocardial infarction aborted G311011 CHD unspecif ied y 
Unstable angina G311100 unstable angina/ACS y 
Angina at rest G311200 unstable angina/ACS y 
Refractory angina G311300 unstable angina/ACS y 
Worsening angina G311400 unstable angina/ACS y 
Acute coronary syndrome G311500 unstable angina/ACS y 
Preinfarction syndrome NOS G311z00 unstable angina/ACS y 
Coronary thrombosis not resulting in myocardial 
infarction 
G312.00 unstable angina/ACS y 
Other acute and subacute ischaemic heart 
disease 
G31y.00 unstable angina/ACS y 
Acute coronary insufficiency G31y000 unstable angina/ACS y 
Microinfarction of heart G31y100 unstable angina/ACS y 
Subendocardial ischaemia G31y200 unstable angina/ACS y 
Transient myocardial ischaemia G31y300 unstable angina/ACS y 
Other acute and subacute ischaemic heart 
disease NOS 
G31yz00 unstable angina/ACS y 
Old myocardial infarction G32..00 MI n 
Healed myocardial infarction G32..11 MI n 
Personal history of myocardial infarction G32..12 MI n 
Angina pectoris G33..00 angina y 
Angina decubitus G330.00 angina y 
Nocturnal angina G330000 angina y 
Angina decubitus NOS G330z00 angina y 
Prinzmetal's angina G331.00 angina y 
Variant angina pectoris G331.11 angina y 
Coronary artery spasm G332.00 unstable angina/ACS y 
Angina pectoris NOS G33z.00 angina y 
Status anginosus G33z000 angina y 
Stenocardia G33z100 unstable angina/ACS y 
Syncope anginosa G33z200 angina y 
Angina on effort G33z300 angina y 
Ischaemic chest pain G33z400 CHD unspecif ied y 
Post infarct angina G33z500 angina y 
New onset angina G33z600 angina y 
Stable angina G33z700 angina y 
Angina pectoris NOS G33zz00 angina y 
Other chronic ischaemic heart disease G34..00 CHD unspecif ied y 
Coronary atherosclerosis G340.00 CHD unspecif ied y 
Triple vessel disease of the heart G340.11 CHD unspecif ied y 
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Coronary artery disease G340.12 CHD unspecif ied y 
Single coronary vessel disease G340000 CHD unspecif ied y 
Double coronary vessel disease G340100 CHD unspecif ied y 
Atherosclerotic cardiovascular disease G342.00 CHD unspecif ied y 
Ischaemic cardiomyopathy G343.00 CHD unspecif ied y 
Silent myocardial ischaemia G344.00 MI y 
Other specified chronic ischaemic heart disease G34y.00 angina y 
Chronic coronary insufficiency G34y000 angina y 
Chronic myocardial ischaemia G34y100 angina y 
Other specified chronic ischaemic heart disease 
NOS 
G34yz00 angina y 
Other chronic ischaemic heart disease NOS G34z.00 angina y 
Asymptomatic coronary heart disease G34z000 CHD unspecif ied y 
Subsequent myocardial infarction G35..00 MI y 
Subsequent myocardial infarction of anterior 
wall 
G350.00 MI y 
Subsequent myocardial infarction of inferior wall G351.00 MI y 
Subsequent myocardial infarction of other sites G353.00 MI y 
Subsequent myocardial infarction of unspecified 
site 
G35X.00 MI y 
Certain current complication follow acute 
myocardial infarct 
G36..00 MI y 
Haemopericardium/current comp folow acut 
myocard infarct 
G360.00 MI y 
Atrial septal defect/curr comp folow acut 
myocardal infarct 
G361.00 MI y 
Ventric septal defect/curr comp fol acut 
myocardal infarctn 
G362.00 MI y 
Ruptur cardiac wall w 'out haemopericard/cur 
comp fol ac MI 
G363.00 MI y 
Ruptur chordae tendinae/curr comp fol acute 
myocard infarct 
G364.00 MI y 
Rupture papillary muscle/curr comp fol acute 
myocard infarct 
G365.00 MI y 
Thrombosis atrium,auric append&vent/curr 
comp foll acute MI 
G366.00 MI y 
Postoperative myocardial infarction G38..00 MI y 
Postoperative transmural myocardial infarction 
anterior wall 
G380.00 MI y 
Postoperative transmural myocardial infarction 
inferior wall 
G381.00 MI y 
Postoperative transmural myocardial infarction 
other sites 
G382.00 MI y 
Postoperative transmural myocardial infarction 
unspec site 
G383.00 MI y 
Postoperative subendocardial myocardial 
infarction 
G384.00 MI y 
Postoperative myocardial infarction, unspecified G38z.00 MI y 
Other specified ischaemic heart disease G3y..00 CHD unspecif ied y 
Ischaemic heart disease NOS G3z..00 CHD unspecif ied y 
Post infarction pericarditis G501.00 MI y 
Cerebrovascular disease G6...00 ischaemic/unspecif ied 
stroke 
y 
Intracerebral haemorrhage G61..00 haemorrhagic stroke y 
CVA - cerebrovascular accid due to intracerebral 
haemorrhage 
G61..11 haemorrhagic stroke y 
Stroke due to intracerebral haemorrhage G61..12 haemorrhagic stroke y 
Cortical haemorrhage G610.00 haemorrhagic stroke y 
Internal capsule haemorrhage G611.00 haemorrhagic stroke y 
Basal nucleus haemorrhage G612.00 haemorrhagic stroke y 
Cerebellar haemorrhage G613.00 haemorrhagic stroke y 
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Pontine haemorrhage G614.00 haemorrhagic stroke y 
Bulbar haemorrhage G615.00 haemorrhagic stroke y 
External capsule haemorrhage G616.00 haemorrhagic stroke y 
Intracerebral haemorrhage, intraventricular G617.00 haemorrhagic stroke y 
Intracerebral haemorrhage, multiple localized G618.00 haemorrhagic stroke y 
Intracerebral haemorrhage in hemisphere, 
unspecified 
G61X.00 haemorrhagic stroke y 
Left sided intracerebral haemorrhage, 
unspecified 
G61X000 haemorrhagic stroke y 
Right sided intracerebral haemorrhage, 
unspecified 
G61X100 haemorrhagic stroke y 
Intracerebral haemorrhage NOS G61z.00 haemorrhagic stroke y 
Precerebral arterial occlusion G63..00 ischaemic/unspecif ied 
stroke 
y 
Infarction - precerebral G63..11 ischaemic/unspecif ied 
stroke 
y 
Stenosis of precerebral arteries G63..12 CVD unspecif ied y 
Basilar artery occlusion G630.00 ischaemic/unspecif ied 
stroke 
y 
Carotid artery occlusion G631.00 ischaemic/unspecif ied 
stroke 
y 
Stenosis, carotid artery G631.11 CVD unspecif ied y 
Thrombosis, carotid artery G631.12 ischaemic/unspecif ied 
stroke 
y 
Vertebral artery occlusion G632.00 ischaemic/unspecif ied 
stroke 
y 
Multiple and bilateral precerebral arterial 
occlusion 
G633.00 ischaemic/unspecif ied 
stroke 
y 
Other precerebral artery occlusion G63y.00 ischaemic/unspecif ied 
stroke 
y 
Cerebral infarct due to thrombosis of 
precerebral arteries 
G63y000 ischaemic/unspecif ied 
stroke 
y 
Cerebral infarction due to embolism of 
precerebral arteries 
G63y100 ischaemic/unspecif ied 
stroke 
y 
Precerebral artery occlusion NOS G63z.00 ischaemic/unspecif ied 
stroke 
y 
Cerebral arterial occlusion G64..00 ischaemic/unspecif ied 
stroke 
y 
CVA - cerebral artery occlusion G64..11 ischaemic/unspecif ied 
stroke 
y 
Infarction - cerebral G64..12 ischaemic/unspecif ied 
stroke 
y 
Stroke due to cerebral arterial occlusion G64..13 ischaemic/unspecif ied 
stroke 
y 
Cerebral thrombosis G640.00 ischaemic/unspecif ied 
stroke 
y 
Cerebral infarction due to thrombosis of 
cerebral arteries 
G640000 ischaemic/unspecif ied 
stroke 
y 
Cerebral embolism G641.00 ischaemic/unspecif ied 
stroke 
y 
Cerebral embolus G641.11 ischaemic/unspecif ied 
stroke 
y 
Cerebral infarction due to embolism of cerebral 
arteries 
G641000 ischaemic/unspecif ied 
stroke 
y 
Cerebral infarction NOS G64z.00 ischaemic/unspecif ied 
stroke 
y 
Brainstem infarction NOS G64z.11 ischaemic/unspecif ied 
stroke 
y 
Cerebellar infarction G64z.12 ischaemic/unspecif ied 
stroke 
y 
Brainstem infarction G64z000 ischaemic/unspecif ied 
stroke 
y 
Wallenberg syndrome G64z100 ischaemic/unspecif ied 
stroke 
y 
Lateral medullary syndrome G64z111 ischaemic/unspecif ied 
stroke 
y 
Left sided cerebral infarction G64z200 ischaemic/unspecif ied 
stroke 
y 
Right sided cerebral infarction G64z300 ischaemic/unspecif ied y 
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stroke 
Infarction of basal ganglia G64z400 ischaemic/unspecif ied 
stroke 
y 
Transient cerebral ischaemia G65..00 TIA y 
Transient ischaemic attack G65..12 TIA y 
Vertebro-basilar insufficiency G65..13 CVD unspecif ied y 
Basilar artery syndrome G650.00 CVD unspecif ied y 
Insufficiency - basilar artery G650.11 CVD unspecif ied y 
Vertebral artery syndrome G651.00 ischaemic/unspecif ied 
stroke 
y 
Vertebro-basilar artery syndrome G651000 CVD unspecif ied y 
Subclavian steal syndrome G652.00 ischaemic/unspecif ied 
stroke 
y 
Carotid artery syndrome hemispheric G653.00 ischaemic/unspecif ied 
stroke 
y 
Multiple and bilateral precerebral artery 
syndromes 
G654.00 ischaemic/unspecif ied 
stroke 
y 
Vertebrobasilar insufficiency G656.00 CVD unspecif ied y 
Other transient cerebral ischaemia G65y.00 TIA y 
Transient cerebral ischaemia NOS G65z.00 TIA y 
Impending cerebral ischaemia G65z000 CVD unspecif ied y 
Intermittent cerebral ischaemia G65z100 TIA y 
Transient cerebral ischaemia NOS G65zz00 TIA y 
Stroke and cerebrovascular accident 
unspecified 
G66..00 ischaemic/unspecif ied 
stroke 
y 
CVA unspecified G66..11 ischaemic/unspecif ied 
stroke 
y 
Stroke unspecified G66..12 ischaemic/unspecif ied 
stroke 
y 
CVA - Cerebrovascular accident unspecified G66..13 ischaemic/unspecif ied 
stroke 
y 
Middle cerebral artery syndrome G660.00 ischaemic/unspecif ied 
stroke 
y 
Anterior cerebral artery syndrome G661.00 CVD unspecif ied y 
Posterior cerebral artery syndrome G662.00 CVD unspecif ied y 
Brain stem stroke syndrome G663.00 ischaemic/unspecif ied 
stroke 
y 
Cerebellar stroke syndrome G664.00 ischaemic/unspecif ied 
stroke 
y 
Pure motor lacunar syndrome G665.00 ischaemic/unspecif ied 
stroke 
y 
Pure sensory lacunar syndrome G666.00 ischaemic/unspecif ied 
stroke 
y 
Left sided CVA G667.00 ischaemic/unspecif ied 
stroke 
y 
Right sided CVA G668.00 ischaemic/unspecif ied 
stroke 
y 
Other cerebrovascular disease G67..00 CVD unspecif ied y 
Cerebral atherosclerosis G670.00 CVD unspecif ied y 
Precerebral atherosclerosis G670.11 CVD unspecif ied y 
Generalised ischaemic cerebrovascular disease 
NOS 
G671.00 CVD unspecif ied y 
Acute cerebrovascular insufficiency NOS G671000 CVD unspecif ied y 
Chronic cerebral ischaemia G671100 CVD unspecif ied y 
Generalised ischaemic cerebrovascular disease 
NOS 
G671z00 CVD unspecif ied y 
Cereb infarct due cerebral venous thrombosis, 
nonpyogenic 
G676000 ischaemic/unspecif ied 
stroke 
y 
Occlusion/stenosis cerebral arts not result 
cerebral infarct 
G677.00 CVD unspecif ied y 
Occlusion and stenosis of middle cerebral artery G677000 ischaemic/unspecif ied 
stroke 
y 
Occlusion and stenosis of anterior cerebral 
artery 
G677100 ischaemic/unspecif ied 
stroke 
y 
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Occlusion and stenosis of posterior cerebral 
artery 
G677200 ischaemic/unspecif ied 
stroke 
y 
Occlusion and stenosis of cerebellar arteries G677300 ischaemic/unspecif ied 
stroke 
y 
Occlusion+stenosis of multiple and bilat 
cerebral arteries 
G677400 ischaemic/unspecif ied 
stroke 
y 
Small vessel cerebrovascular disease G679.00 CVD unspecif ied y 
Other cerebrovascular disease OS G67y.00 CVD unspecif ied y 
Other cerebrovascular disease NOS G67z.00 CVD unspecif ied y 
Late effects of cerebrovascular disease G68..00 CVD unspecif ied y 
Sequelae of intracerebral haemorrhage G681.00 haemorrhagic stroke n 
Sequelae of other nontraumatic intracranial 
haemorrhage 
G682.00 ischaemic/unspecif ied 
stroke 
n 
Sequelae of cerebral infarction G683.00 ischaemic/unspecif ied 
stroke 
n 
Sequelae/other + unspecified cerebrovascular 
diseases 
G68W.00 ischaemic/unspecif ied 
stroke 
n 
Sequelae of stroke,not specfd as h'morrhage or 
infarction 
G68X.00 CVD unspecif ied n 
Cereb infarct due unsp occlus/stenos precerebr 
arteries 
G6W..00 ischaemic/unspecif ied 
stroke 
y 
Cerebrl infarctn due/unspcf occlusn or 
sten/cerebrl artrs 
G6X..00 CVD unspecif ied y 
Other specified cerebrovascular disease G6y..00 CVD unspecif ied y 
Cerebrovascular disease NOS G6z..00 CVD unspecif ied y 
[X]Ischaemic heart diseases Gyu3.00 CHD unspecif ied y 
[X]Other forms of angina pectoris Gyu3000 angina y 
[X]Other current complicatns following acute 
myocard infarct 
Gyu3100 MI y 
[X]Other forms of acute ischaemic heart disease Gyu3200 CHD unspecif ied y 
[X]Other forms of chronic ischaemic heart 
disease 
Gyu3300 angina y 
[X]Acute transmural myocardial infarction of 
unspecif site 
Gyu3400 MI y 
[X]Subsequent myocardial infarction of other 
sites 
Gyu3500 MI y 
[X]Subsequent myocardial infarction of 
unspecified site 
Gyu3600 MI y 
[X]Cerebrovascular diseases Gyu6.00 CVD unspecif ied y 
[X]Other intracerebral haemorrhage Gyu6200 haemorrhagic stroke y 
[X]Cerebrl infarctn due/unspcf occlusn or 
sten/cerebrl artrs 
Gyu6300 ischaemic/unspecif ied 
stroke 
y 
[X]Other cerebral infarction Gyu6400 ischaemic/unspecif ied 
stroke 
y 
[X]Occlusion and stenosis of other precerebral 
arteries 
Gyu6500 ischaemic/unspecif ied 
stroke 
y 
[X]Occlusion and stenosis of other cerebral 
arteries 
Gyu6600 ischaemic/unspecif ied 
stroke 
y 
[X]Other specified cerebrovascular diseases Gyu6700 CVD unspecif ied y 
[X]Other cerebrovascular disorders in diseases 
CE 
Gyu6A00 CVD unspecif ied y 
[X]Sequelae of other nontraumatic intracranial 
haemorrhage 
Gyu6B00 haemorrhagic stroke n 
[X]Sequelae of stroke,not specfd as h'morrhage 
or infarction 
Gyu6C00 ischaemic/unspecif ied 
stroke 
n 
[X]Sequelae/other + unspecified cerebrovascular 
diseases 
Gyu6D00 ischaemic/unspecif ied 
stroke 
n 
[X]Intracerebral haemorrhage in hemisphere, 
unspecified 
Gyu6F00 haemorrhagic stroke y 
[X]Cereb infarct due unsp occlus/stenos 
precerebr arteries 
Gyu6G00 ischaemic/unspecif ied 
stroke 
y 
Coronary artery bypass graft occlusion SP07600 surgery y 
Discharge from stroke serv ZLEP.00 ischaemic/unspecif ied 
stroke 
n 
[V]Personal history of stroke ZV12511 ischaemic/unspecif ied 
stroke 
n 
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[V]Presence of aortocoronary bypass graft ZV45700 surgery n 
[V]Presence of coronary angioplasty implant 
and graft 
ZV45800 surgery n 
[V]Presence of coronary artery bypass graft ZV45K00 surgery n 
[V]Presence of coronary artery bypass graft - 
CABG 
ZV45K11 surgery n 
[V]Status following coronary angioplasty NOS ZV45L00 surgery n 
20.3 Statins 
Statin generic name Drug Code 
FLUVASTATIN 24 hr mr tabs 80mg 82002998 
FLUVASTATIN 24 hr mr tabs 80mg 82073998 
FLUVASTATIN 24 hr mr tabs 80mg 82907998 
SIMVASTATIN tabs 80mg 83030998 
SIMVASTATIN sf oral susp 40mg/5ml 83099998 
PRAVASTATIN oral liq 83899998 
SIMVASTATIN (IPU) tabs 5mg 85181998 
SIMVASTATIN oral liq 85440998 
SIMVASTATIN sf oral susp 20mg/5ml 86020998 
ROSUVASTATIN tabs 5mg 86467998 
ROSUVASTATIN tabs 5mg 86468998 
SIMVASTATIN + EZETIMIBE tabs 80mg + 10mg 86787998 
SIMVASTATIN + EZETIMIBE tabs 40mg + 10mg 86788998 
SIMVASTATIN + EZETIMIBE tabs 20mg + 10mg 86789998 
EZETIMIBE + SIMVASTATIN tabs 10mg + 80mg 86791998 
EZETIMIBE + SIMVASTATIN tabs 10mg + 80mg 86794998 
EZETIMIBE + SIMVASTATIN tabs 10mg + 40mg 86795998 
EZETIMIBE + SIMVASTATIN tabs 10mg + 40mg 86796998 
EZETIMIBE + SIMVASTATIN tabs 10mg + 20mg 86797998 
EZETIMIBE + SIMVASTATIN tabs 10mg + 20mg 86798998 
SIMVASTATIN tabs 10mg 87373998 
SIMVASTATIN tabs 40mg 87416998 
SIMVASTATIN tabs 20mg 87417998 
SIMVASTATIN tabs 10mg 87418998 
SIMVASTATIN tabs 40mg 87916998 
SIMVASTATIN tabs 20mg 87917998 
SIMVASTATIN tabs 10mg 87918998 
ROSUVASTATIN tabs 10mg 88534998 
CERIVASTATIN tabs 300micrograms 89153996 
CERIVASTATIN tabs 200micrograms 89153997 
CERIVASTATIN tabs 100micrograms 89153998 
CERIVASTATIN tabs 300micrograms 89154996 
CERIVASTATIN tabs 200micrograms 89154997 
CERIVASTATIN tabs 100micrograms 89154998 
ATORVASTATIN tabs 40mg 89306996 
ATORVASTATIN tabs 20mg 89306997 
ATORVASTATIN tabs 10mg 89306998 
ATORVASTATIN tabs 40mg 89311996 
ATORVASTATIN tabs 20mg 89311997 
ATORVASTATIN tabs 10mg 89311998 
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Statin generic name Drug Code 
ATORVASTATIN tabs 80mg 90309998 
ATORVASTATIN tabs 80mg 90310998 
ROSUVASTATIN tabs 20mg 90973998 
FLUVASTATIN 24 hr mr tabs 80mg 91194998 
SIMVASTATIN sf oral susp 40mg/5ml 92110990 
SIMVASTATIN sf oral susp 20mg/5ml 92154990 
FLUVASTATIN caps 40mg 92206990 
FLUVASTATIN caps 20mg 92207990 
SIMVASTATIN tabs 80mg 92220998 
FLUVASTATIN caps 40mg 92274990 
FLUVASTATIN caps 20mg 92275990 
SIMVASTATIN tabs 80mg 92278990 
ROSUVASTATIN tabs 20mg 92408998 
ROSUVASTATIN tabs 10mg 92409998 
ROSUVASTATIN tabs 40mg 92410998 
CERIVASTATIN tabs 800micrograms 92447997 
CERIVASTATIN tabs 400micrograms 92447998 
CERIVASTATIN tabs 800micrograms 92448997 
CERIVASTATIN tabs 400micrograms 92448998 
SIMVASTATIN tabs 80mg 92471998 
SIMVASTATIN tabs 80mg 92504990 
ROSUVASTATIN tabs 40mg 92539998 
FLUVASTATIN 24 hr mr tabs 80mg 92650990 
FLUVASTATIN caps 40mg 92651990 
FLUVASTATIN caps 20mg 92652990 
FLUVASTATIN caps 40mg 92659990 
FLUVASTATIN caps 20mg 92660990 
FLUVASTATIN caps 40mg 92664990 
FLUVASTATIN caps 20mg 92665990 
FLUVASTATIN 24 hr mr tabs 80mg 92804996 
FLUVASTATIN caps 40mg 92804997 
FLUVASTATIN caps 20mg 92804998 
FLUVASTATIN caps 40mg 92805997 
FLUVASTATIN caps 20mg 92805998 
SIMVASTATIN tabs 40mg 93230990 
SIMVASTATIN tabs 20mg 93231990 
SIMVASTATIN tabs 10mg 93232990 
PRAVASTATIN tabs 40mg 93243996 
PRAVASTATIN tabs 20mg 93243997 
PRAVASTATIN tabs 10mg 93243998 
PRAVASTATIN tabs 40mg 93244996 
PRAVASTATIN tabs 20mg 93244997 
PRAVASTATIN tabs 10mg 93244998 
SIMVASTATIN sf oral susp 20mg/5ml 93504990 
SIMVASTATIN tabs 40mg 93619996 
SIMVASTATIN tabs 20mg 93619997 
SIMVASTATIN tabs 10mg 93619998 
SIMVASTATIN tabs 40mg 93620996 
SIMVASTATIN tabs 20mg 93620997 
SIMVASTATIN tabs 10mg 93620998 
SIMVASTATIN tabs 80mg 93870990 
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Statin generic name Drug Code 
SIMVASTATIN tabs 40mg 93871990 
SIMVASTATIN tabs 20mg 93872990 
SIMVASTATIN tabs 10mg 93873990 
SIMVASTATIN tabs 80mg 94196990 
SIMVASTATIN tabs 40mg 94197990 
SIMVASTATIN tabs 20mg 94198990 
SIMVASTATIN tabs 10mg 94199990 
PRAVASTATIN tabs 40mg 94321990 
PRAVASTATIN tabs 20mg 94322990 
PRAVASTATIN tabs 10mg 94323990 
PRAVASTATIN tabs 40mg 94324990 
PRAVASTATIN tabs 20mg 94325990 
PRAVASTATIN tabs 10mg 94326990 
PRAVASTATIN tabs 40mg 94327990 
PRAVASTATIN tabs 20mg 94328990 
PRAVASTATIN tabs 10mg 94329990 
PRAVASTATIN tabs 40mg 94363990 
PRAVASTATIN tabs 20mg 94364990 
PRAVASTATIN tabs 10mg 94365990 
PRAVASTATIN tabs 40mg 94392990 
PRAVASTATIN tabs 20mg 94393990 
PRAVASTATIN tabs 10mg 94394990 
SIMVASTATIN tabs 40mg 94406990 
SIMVASTATIN tabs 20mg 94407990 
SIMVASTATIN tabs 10mg 94408990 
PRAVASTATIN tabs 40mg 94702990 
PRAVASTATIN tabs 20mg 94703990 
PRAVASTATIN tabs 10mg 94704990 
PRAVASTATIN tabs 40mg 94777990 
PRAVASTATIN tabs 20mg 94778990 
PRAVASTATIN tabs 10mg 94779990 
PRAVASTATIN tabs 40mg 94781990 
PRAVASTATIN tabs 20mg 94782990 
PRAVASTATIN tabs 10mg 94783990 
PRAVASTATIN tabs 40mg 94787990 
PRAVASTATIN tabs 20mg 94788990 
PRAVASTATIN tabs 10mg 94789990 
PRAVASTATIN tabs 40mg 94794990 
PRAVASTATIN tabs 20mg 94795990 
PRAVASTATIN tabs 10mg 94796990 
PRAVASTATIN tabs 40mg 94802990 
PRAVASTATIN tabs 20mg 94803990 
PRAVASTATIN tabs 10mg 94804990 
PRAVASTATIN tabs 40mg 94805990 
PRAVASTATIN tabs 20mg 94806990 
PRAVASTATIN tabs 10mg 94807990 
PRAVASTATIN tabs 40mg 94811990 
PRAVASTATIN tabs 20mg 94812990 
PRAVASTATIN tabs 10mg 94813990 
PRAVASTATIN tabs 40mg 94829990 
PRAVASTATIN tabs 20mg 94830990 
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Statin generic name Drug Code 
PRAVASTATIN tabs 10mg 94831990 
PRAVASTATIN tabs 40mg 94849990 
PRAVASTATIN tabs 20mg 94850990 
PRAVASTATIN tabs 10mg 94851990 
SIMVASTATIN tabs 40mg 94919990 
SIMVASTATIN tabs 20mg 94920990 
SIMVASTATIN tabs 10mg 94921990 
SIMVASTATIN tabs 80mg 94927990 
SIMVASTATIN tabs 80mg 95185990 
SIMVASTATIN tabs 40mg 95277990 
SIMVASTATIN tabs 20mg 95278990 
SIMVASTATIN tabs 10mg 95279990 
SIMVASTATIN tabs 40mg 95372990 
SIMVASTATIN tabs 20mg 95373990 
SIMVASTATIN tabs 10mg 95374990 
SIMVASTATIN tabs 40mg 95405990 
SIMVASTATIN tabs 20mg 95406990 
SIMVASTATIN tabs 10mg 95408990 
SIMVASTATIN tabs 40mg 95414990 
SIMVASTATIN tabs 20mg 95415990 
SIMVASTATIN tabs 10mg 95416990 
SIMVASTATIN tabs 80mg 95442990 
SIMVASTATIN tabs 40mg 95443990 
SIMVASTATIN tabs 20mg 95444990 
SIMVASTATIN tabs 10mg 95445990 
SIMVASTATIN tabs 80mg 95448990 
SIMVASTATIN tabs 40mg 95449990 
SIMVASTATIN tabs 20mg 95450990 
SIMVASTATIN tabs 10mg 95451990 
SIMVASTATIN tabs 40mg 95471990 
SIMVASTATIN tabs 20mg 95472990 
SIMVASTATIN tabs 10mg 95473990 
SIMVASTATIN tabs 40mg 95474990 
SIMVASTATIN tabs 20mg 95475990 
SIMVASTATIN tabs 10mg 95476990 
SIMVASTATIN tabs 40mg 95478990 
SIMVASTATIN tabs 20mg 95479990 
SIMVASTATIN tabs 10mg 95480990 
SIMVASTATIN tabs 40mg 95481990 
SIMVASTATIN tabs 20mg 95482990 
SIMVASTATIN tabs 10mg 95483990 
SIMVASTATIN tabs 40mg 95486990 
SIMVASTATIN tabs 20mg 95487990 
SIMVASTATIN tabs 10mg 95488990 
SIMVASTATIN tabs 40mg 95493990 
SIMVASTATIN tabs 20mg 95494990 
SIMVASTATIN tabs 10mg 95495990 
SIMVASTATIN tabs 80mg 95500990 
SIMVASTATIN tabs 40mg 95501990 
SIMVASTATIN tabs 20mg 95502990 
SIMVASTATIN tabs 10mg 95508990 
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SIMVASTATIN tabs 40mg 95549990 
SIMVASTATIN tabs 20mg 95550990 
SIMVASTATIN tabs 10mg 95551990 
20.4 Non-statin lipid modifying drugs 
Non-statin lipid modifying drug generic name Drug Code 
NICOTINIC ACID 1000mg m/r tab 87850998 
Nicotinic acid 1g modified-release tablets 87853998 
Ciprofibrate 100mg tablets 97723998 
GEMFIBROZIL 600mg tablets 97247997 
Colestyramine sugar free pdr 91316998 
CLOFIBRATE 500mg capsules 98455998 
Fenofibrate 200mg capsules 94188997 
ISPAG HSK 3.5g ornge s/f gran 89617998 
Colestyramine 4g oral powder sachets sugar free 96134990 
FENOFIBRATE 200mg capsules 90649998 
Colestipol with aspartame granules 94605998 
Nicotinic acid 375mg + 500mg + 750mg Modified-release tablet 87849998 
CIPROFIBRATE 100mg tablets 97433979 
FENOFIBRATE 200mg capsules 94189997 
FISH OIL(CONC) 1g capsules 97078998 
Gemfibrozil 300mg capsules 96295998 
Gemfibrozil 600mg tablets 97808989 
BEZAFIBRATE 400mg m/r tablets 83187998 
FENOFIBRATE 267mg capsules 88297996 
Colestyramine with aspartame 4g sugar free powder 90653998 
Bezafibrate 200mg tablets 96656990 
Fenofibrate 100mg Capsule 94188998 
Colestyramine 4g oral powder sachets 96678998 
Probucol 250mg tablet 95401998 
Colesevelam 625mg tablets 84268998 
Bezafibrate 200mg tablets 96685989 
BEZAFIBRATE 400mg m/r tablets 89401998 
Clofibrate 500mg capsules 96642998 
FENOFIBRATE 200mg capsules 88297997 
Acipimox 250mg capsules 94883998 
BEZAFIBRATE 400mg m/r tablets 89089998 
CHOLESTYRAMINE POW 94827992 
NICOFURANOSE 250mg e/c tabs 98108998 
Colestyramine 4g oral powder sachets sugar free 93541998 
NICOTINIC ACID 500 MG TAB 97800992 
ACIPIMOX 250mg capsules 94882998 
COLESTY+ASPART 4g/sach s/f pdr 93542998 
Colestyramine 4g oral powder sachets sugar free 95847990 
Nicotinic acid 50mg tablets 99725990 
Ezetimibe 10mg tablets 92292998 
Eicosapentaenoic acid 460mg / Docosahexaenoic acid 380mg capsules 89800998 
FISH OIL(CONC) oral liquid 97078997 
Fenofibrate micronised 200mg capsules 96021990 
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Non-statin lipid modifying drug generic name Drug Code 
BEZAFIBRATE 400mg m/r tablets 97895997 
COLESEVELAM 625mg tablets 84267998 
BEZAFIBRATE 400mg m/r tablets 95805998 
COLESTIPOL HCl GRA 93851992 
Fenofibrate micronised 160mg tablets 92460998 
COLESTIPOL orang 5g/sach grans 87760998 
Bezafibrate 200mg tablets 95952998 
Nicotinic acid 50mg tablets 98066997 
BEZAFIBRATE 400mg m/r tablets 99014998 
NICOTINIC ACID starter pack 87848998 
Fenofibrate micronised 200mg capsules 92549990 
Eicosapentaenoic acid 170mg/g / Docosahexaenoic acid 115mg/g oral 
liquid 
94925997 
Gemfibrozil 600mg tablets 96295997 
Bezafibrate 400mg modified-release tablets 95952997 
Nicotinic acid 100mg Tablet 98066996 
BEZAFIBRATE 400mg m/r tablets 87025998 
Fenofibrate micronised 267mg capsules 88298997 
Colestyramine 4g oral powder sachets sugar free 97655990 
GEMFIBROZIL 300mg capsules 97247998 
FISH OIL(CONC) oral emulsion 97078996 
BEZAFIBRATE 200mg tablets 83188998 
COLESTIPOL granules 5g sachet 94661998 
Bezafibrate 400mg modified-release tablets 96685990 
Nicotinic acid 750mg modified-release tablets 87854998 
CHOLESTYRAMINE 325 MG CAP 94112992 
Fenofibrate micronised 200mg capsules 88298996 
NICOTINIC ACID 750mg m/r tabs 87851998 
Colestipol 5g granules sachets sugar free 94662998 
CIPROFIBRATE 100mg tablets 97751998 
NICOTINIC ACID 500mg m/r tabs 87852998 
EZETIMIBE 10mg tablets 92293998 
COLESTYRAMINE powder 4g/sachet 99197998 
NICOTINC/LAROP 1g/20mg m/r tab 82655998 
Bezafibrate 200mg tablets 93838990 
Eicosapentaenoic acid 170mg / Docosahexaenoic acid 115mg capsules 94925998 
Fenofibrate micronised 67mg capsules 88298998 
FENOFIBRATE 160mg m/r tablets 94799998 
Nicofuranose 250mg Tablet 95728998 
HEXOPAL 200 MG TAB 95098992 
Nicotinic acid 25mg Tablet 98066998 
FENOFIBRATE 67mg capsules 88297998 
Nicotinic acid 500mg modified-release tablets 87855998 
FENOFIBRATE 100mg capsules 94189998 
COLESTIPOL orang 5g/sach grans 94661997 
Bezafibrate 400mg modified-release tablets 97595979 
Nicotinic acid 1g / Laropiprant 20mg modified-release tablets 83594998 
BEZAFIBRATE 200mg tablets 97895998 
PROBUCOL 250mg tablets 99456998 
Eicosapentaenoic acid 460mg / Docosahexaenoic acid 380mg capsules 92329998 
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20.5 Diabetes 
Diabetes description Med Code Incident 
Diabetic lipid lowering diet 13AB.00 0 
Diabetic weight reducing diet 13AC.00 0 
Diabetic diet 13B1.00 0 
Diabetic association member 13Y1.00 0 
H/O: diabetes mellitus 1434.00 0 
H/O: Admission in last year for diabetes foot problem 14F4.00 0 
Retinal abnormality - diabetes related 2BBF.00 0 
O/E - diabetic maculopathy present both eyes 2BBL.00 0 
O/E - diabetic maculopathy absent both eyes 2BBM.00 0 
O/E - right eye background diabetic retinopathy 2BBP.00 0 
O/E - left eye background diabetic retinopathy 2BBQ.00 0 
O/E - right eye preproliferative diabetic retinopathy 2BBR.00 0 
O/E - left eye preproliferative diabetic retinopathy 2BBS.00 0 
O/E - right eye proliferative diabetic retinopathy 2BBT.00 0 
O/E - left eye proliferative diabetic retinopathy 2BBV.00 0 
O/E - right eye diabetic maculopathy 2BBW.00 0 
O/E - left eye diabetic maculopathy 2BBX.00 0 
O/E - right eye stable treated prolif diabetic retinopathy 2BBk.00 0 
O/E - left eye stable treated prolif diabetic retinopathy 2BBl.00 0 
O/E - sight threatening diabetic retinopathy 2BBo.00 0 
Foot abnormality - diabetes related 2G51000 0 
O/E - Right diabetic foot at risk 2G5A.00 0 
O/E - Left diabetic foot at risk 2G5B.00 0 
Foot abnormality - diabetes related 2G5C.00 0 
O/E - Right diabetic foot at low risk 2G5E.00 0 
O/E - Right diabetic foot at moderate risk 2G5F.00 0 
O/E - Right diabetic foot at high risk 2G5G.00 0 
O/E - Right diabetic foot - ulcerated 2G5H.00 0 
O/E - Left diabetic foot at low risk 2G5I.00 0 
O/E - Left diabetic foot at moderate risk 2G5J.00 0 
O/E - Left diabetic foot at high risk 2G5K.00 0 
O/E - Left diabetic foot - ulcerated 2G5L.00 0 
O/E - right chronic diabetic foot ulcer 2G5V.00 0 
O/E - left chronic diabetic foot ulcer 2G5W.00 0 
Education score - diabetes 3881.00 0 
Diabetes well being questionnaire 3882.00 0 
Diabetes treatment satisfaction questionnaire 3883.00 0 
Insulin tolerance test 4545.00 0 
Diabetic monitoring 66A..00 0 
Follow-up diabetic assessment 66A2.00 0 
Has seen dietician - diabetes 66A8.00 0 
Understands diet - diabetes 66A9.00 0 
Injection sites - diabetic 66AA.11 0 
Diabetic drug side effects 66AG.00 0 
Diabetic treatment changed 66AH.00 0 
Conversion to insulin 66AH000 0 
Diabetic - good control 66AI.00 0 
Diabetic - poor control 66AJ.00 0 
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Diabetes description Med Code Incident 
Brittle diabetes 66AJ100 0 
Diabetic - poor control NOS 66AJz00 0 
Diabetic - cooperative patient 66AK.00 0 
Diabetic-uncooperative patient 66AL.00 0 
Diabetic - follow-up default 66AM.00 0 
Date diabetic treatment start 66AN.00 0 
Date diabetic treatment stopp. 66AO.00 0 
Diabetes: practice programme 66AP.00 0 
Diabetes management plan given 66AR.00 0 
Diabetic annual review 66AS.00 0 
Annual diabetic blood test 66AT.00 0 
Diabetes care by hospital only 66AU.00 0 
Diabetic foot risk assessment 66AW.00 0 
Diabetes: shared care in pregnancy - diabetol and obstet 66AX.00 0 
Diabetic diet - good compliance 66AY.00 0 
Diabetic monitoring NOS 66AZ.00 0 
Diabetic diet - poor compliance 66Aa.00 0 
Diabetic foot examination 66Ab.00 0 
Diabetic peripheral neuropathy screening 66Ac.00 0 
Patient diabetes education review 66Af.00 0 
Insulin needles changed daily 66Ag.00 0 
Insulin needles changed for each injection 66Ah.00 0 
Diabetic 6 month review 66Ai.00 0 
Insulin needles changed less than once a day 66Aj.00 0 
Diabetic monitoring - lower risk albumin excretion 66Ak.00 0 
Diabetic monitoring - higher risk albumin excretion 66Al.00 0 
Insulin dose changed 66Am.00 0 
Diabetes type 1 review 66An.00 0 
Diabetes type 2 review 66Ao.00 0 
Diabetic pre-pregnancy counselling 6761.00 0 
Health education - diabetes 679L.00 0 
Patient offered diabetes structured education programme 679R.00 0 
Diab mellit insulin-glucose infus acute myocardial infarct 889A.00 0 
Diabetic crisis monitoring 8A12.00 0 
Diabetic stabilisation 8A13.00 0 
Diabetes medication review 8B3l.00 0 
Patient on maximal tolerated therapy for diabetes 8BL2.00 0 
Pt advised re diabetic diet 8CA4100 0 
Diabetic leaflet given 8CE0.00 0 
Transition of diabetes care options discussed 8CP2.00 0 
Diabetes clinical management plan 8CR2.00 0 
Diabetes care plan agreed 8CS0.00 0 
Admit diabetic emergency 8H2J.00 0 
Non-urgent diabetic admission 8H3O.00 0 
Referral to diabetologist 8H4F.00 0 
Refer, diabetic liaison nurse 8H7C.00 0 
Referral to diabetes nurse 8H7f.00 0 
Refer to diabetic foot screener 8H7r.00 0 
Diabetic retinopathy 12 month review 8HBG.00 0 
Diabetic retinopathy 6 month review 8HBH.00 0 
Referral to diabetic register 8HHy.00 0 
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Diabetology D.V. requested 8HKE.00 0 
Diabetology D.V. done 8HLE.00 0 
Listed for Diabetology admissn 8HME.00 0 
Referral to diabetes preconception counselling clinic 8HTe.00 0 
Referral to multidisciplinary diabetic clinic 8HTi.00 0 
Referral to diabetic eye clinic 8HTk.00 0 
Private referral to diabetologist 8HVU.00 0 
Discharged from care of diabetes specialist nurse 8Hg4.00 0 
Referral to diabetes structured education programme 8Hj0.00 0 
Family/carer referral to diabetes structured education prog 8Hj1.00 0 
Referral for diabetic retinopathy screening 8Hl1.00 0 
Referral to community diabetes specialist nurse 8Hl4.00 0 
Diabetic foot examination declined 8I3W.00 0 
Diabetic retinopathy screening refused 8I3X.00 0 
Patient held diabetic record declined 8I57.00 0 
Diabetic retinopathy screening not indicated 8I6F.00 0 
Diabetic foot examination not indicated 8I6G.00 0 
Patient held diabetic record issued 9360.00 0 
Patient consent given for addition to diabetic register 93C4.00 0 
Informed consent for diabetes national audit 9M00.00 0 
Informed dissent for diabetes national audit 9M10.00 0 
Seen in diabetic nurse consultant clinic 9N0m.00 0 
Seen in community diabetes specialist clinic 9N0n.00 0 
Seen in community diabetic specialist nurse clinic 9N0o.00 0 
Seen in diabetic clinic 9N1Q.00 0 
Seen in diabetic foot clinic 9N1i.00 0 
Seen in multidisciplinary diabetic clinic 9N1o.00 0 
Seen in diabetic eye clinic 9N1v.00 0 
Seen by diabetologist 9N2d.00 0 
Seen by diabetic liaison nurse 9N2i.00 0 
DNA - Did not attend diabetic clinic 9N4I.00 0 
Did not attend diabetic retinopathy clinic 9N4p.00 0 
Attending diabetes clinic 9NM0.00 0 
Under care of diabetologist 9NN8.00 0 
Under care of diabetes specialist nurse 9NN9.00 0 
Under care of diabetic foot screener 9NND.00 0 
Diabetes monitoring admin. 9OL..00 0 
Diabetes clinic administration 9OL..11 0 
Attends diabetes monitoring 9OL1.00 0 
Refuses diabetes monitoring 9OL2.00 0 
Diabetes monitoring default 9OL3.00 0 
Diabetes monitoring 1st letter 9OL4.00 0 
Diabetes monitoring 2nd letter 9OL5.00 0 
Diabetes monitoring 3rd letter 9OL6.00 0 
Diabetes monitor.verbal invite 9OL7.00 0 
Diabetes monitor.phone invite 9OL8.00 0 
Diabetes monitor. check done 9OLA.00 0 
Diabetes monitored 9OLA.11 0 
Attended diabetes structured education programme 9OLB.00 0 
Family/carer attended diabetes structured education prog 9OLC.00 0 
Diabetic patient unsuitable for digital retinal photography 9OLD.00 0 
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Diabetes monitoring admin.NOS 9OLZ.00 0 
Exception reporting: diabetes quality indicators 9h4..00 0 
Excepted from diabetes qual indicators: Patient unsuitable 9h41.00 0 
Excepted from diabetes quality indicators: Informed dissent 9h42.00 0 
Diabetes mellitus with ketoacidosis C101.00 0 
Diabetes mellitus, juvenile type, w ith ketoacidosis C101000 0 
Diabetes mellitus, adult onset, with ketoacidosis C101100 0 
Other specified diabetes mellitus w ith ketoacidosis C101y00 0 
Diabetes mellitus NOS with ketoacidosis C101z00 0 
Diabetes mellitus with hyperosmolar coma C102.00 0 
Diabetes mellitus, juvenile type, w ith hyperosmolar coma C102000 0 
Diabetes mellitus, adult onset, with hyperosmolar coma C102100 0 
Diabetes mellitus NOS with hyperosmolar coma C102z00 0 
Diabetes mellitus with ketoacidotic coma C103.00 0 
Diabetes mellitus, juvenile type, w ith ketoacidotic coma C103000 0 
Diabetes mellitus, adult onset, with ketoacidotic coma C103100 0 
Other specified diabetes mellitus w ith coma C103y00 0 
Diabetes mellitus NOS with ketoacidotic coma C103z00 0 
Diabetes mellitus with renal manifestation C104.00 0 
Diabetic nephropathy C104.11 0 
Diabetes mellitus, juvenile type, w ith renal manifestation C104000 0 
Diabetes mellitus, adult onset, with renal manifestation C104100 0 
Other specified diabetes mellitus w ith renal complications C104y00 0 
Diabetes mellitis with nephropathy NOS C104z00 0 
Diabetes mellitus with ophthalmic manifestation C105.00 0 
Diabetes mellitus, juvenile type, + ophthalmic manifestation C105000 0 
Diabetes mellitus, adult onset, + ophthalmic manifestation C105100 0 
Other specified diabetes mellitus w ith ophthalmic complicatn C105y00 0 
Diabetes mellitus NOS with ophthalmic manifestation C105z00 0 
Diabetes mellitus with neurological manifestation C106.00 0 
Diabetic amyotrophy C106.11 0 
Diabetes mellitus with neuropathy C106.12 0 
Diabetes mellitus with polyneuropathy C106.13 0 
Diabetes mellitus, juvenile, + neurological manifestation C106000 0 
Diabetes mellitus, adult onset, + neurological manifestation C106100 0 
Other specified diabetes mellitus w ith neurological comps C106y00 0 
Diabetes mellitus NOS with neurological manifestation C106z00 0 
Diabetes mellitus with peripheral circulatory disorder C107.00 0 
Diabetes mellitus with gangrene C107.11 0 
Diabetes with gangrene C107.12 0 
Diabetes mellitus, juvenile +peripheral circulatory disorder C107000 0 
Diabetes mellitus, adult, + peripheral circulatory disorder C107100 0 
Diabetes mellitus, adult with gangrene C107200 0 
IDDM with peripheral circulatory disorder C107300 0 
NIDDM with peripheral circulatory disorder C107400 0 
Other specified diabetes mellitus w ith periph circ comps C107y00 0 
Diabetes mellitus NOS with peripheral circulatory disorder C107z00 0 
Insulin-dependent diabetes mellitus w ith renal complications C108000 0 
Type I diabetes mellitus w ith renal complications C108011 0 
Type 1 diabetes mellitus w ith renal complications C108012 0 
Insulin-dependent diabetes mellitus w ith ophthalmic comps C108100 0 
 
 
289 
 
Diabetes description Med Code Incident 
Type I diabetes mellitus w ith ophthalmic complications C108111 0 
Type 1 diabetes mellitus w ith ophthalmic complications C108112 0 
Insulin-dependent diabetes mellitus w ith neurological comps C108200 0 
Type I diabetes mellitus w ith neurological complications C108211 0 
Type 1 diabetes mellitus w ith neurological complications C108212 0 
Insulin dependent diabetes mellitus with multiple complicatn C108300 0 
Type I diabetes mellitus w ith multiple complications C108311 0 
Type 1 diabetes mellitus w ith multiple complications C108312 0 
Unstable insulin dependent diabetes mellitus C108400 0 
Unstable type I diabetes mellitus C108411 0 
Unstable type 1 diabetes mellitus C108412 0 
Insulin dependent diabetes mellitus with ulcer  C108500 0 
Type I diabetes mellitus w ith ulcer C108511 0 
Type 1 diabetes mellitus w ith ulcer C108512 0 
Insulin dependent diabetes mellitus with gangrene C108600 0 
Type I diabetes mellitus w ith gangrene C108611 0 
Type 1 diabetes mellitus w ith gangrene C108612 0 
Insulin dependent diabetes mellitus with retinopathy C108700 0 
Type I diabetes mellitus w ith retinopathy C108711 0 
Type 1 diabetes mellitus w ith retinopathy C108712 0 
Insulin dependent diabetes mellitus with mononeuropathy C108B00 0 
Type I diabetes mellitus w ith mononeuropathy C108B11 0 
Type 1 diabetes mellitus w ith mononeuropathy C108B12 0 
Insulin dependent diabetes mellitus with polyneuropathy C108C00 0 
Type I diabetes mellitus w ith polyneuropathy C108C11 0 
Type 1 diabetes mellitus w ith polyneuropathy C108C12 0 
Insulin dependent diabetes mellitus with nephropathy C108D00 0 
Type I diabetes mellitus w ith nephropathy C108D11 0 
Type 1 diabetes mellitus w ith nephropathy C108D12 0 
Insulin dependent diabetes mellitus with hypoglycaemic coma C108E00 0 
Type I diabetes mellitus w ith hypoglycaemic coma C108E11 0 
Type 1 diabetes mellitus w ith hypoglycaemic coma C108E12 0 
Insulin dependent diabetes mellitus with diabetic cataract C108F00 0 
Type I diabetes mellitus w ith diabetic cataract C108F11 0 
Type 1 diabetes mellitus w ith diabetic cataract C108F12 0 
Insulin dependent diab mell with peripheral angiopathy C108G00 0 
Type I diabetes mellitus w ith peripheral angiopathy C108G11 0 
Type 1 diabetes mellitus w ith peripheral angiopathy C108G12 0 
Insulin dependent diabetes mellitus with arthropathy C108H00 0 
Type I diabetes mellitus w ith arthropathy C108H11 0 
Type 1 diabetes mellitus w ith arthropathy C108H12 0 
Insulin dependent diab mell with neuropathic arthropathy C108J00 0 
Type I diabetes mellitus w ith neuropathic arthropathy C108J11 0 
Type 1 diabetes mellitus w ith neuropathic arthropathy C108J12 0 
Other specified diabetes mellitus w ith multiple comps C108y00 0 
Unspecified diabetes mellitus with multiple complications C108z00 0 
Non-insulin-dependent diabetes mellitus with renal comps C109000 0 
Type II diabetes mellitus w ith renal complications C109011 0 
Type 2 diabetes mellitus w ith renal complications C109012 0 
Non-insulin-dependent diabetes mellitus with ophthalm comps C109100 0 
Type II diabetes mellitus w ith ophthalmic complications C109111 0 
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Type 2 diabetes mellitus w ith ophthalmic complications C109112 0 
Non-insulin-dependent diabetes mellitus with neuro comps C109200 0 
Type II diabetes mellitus w ith neurological complications C109211 0 
Type 2 diabetes mellitus w ith neurological complications C109212 0 
Non-insulin-dependent diabetes mellitus with multiple comps C109300 0 
Type II diabetes mellitus w ith multiple complications C109311 0 
Type 2 diabetes mellitus w ith multiple complications C109312 0 
Non-insulin dependent diabetes mellitus with ulcer C109400 0 
Type II diabetes mellitus w ith ulcer C109411 0 
Type 2 diabetes mellitus w ith ulcer C109412 0 
Non-insulin dependent diabetes mellitus with gangrene C109500 0 
Type II diabetes mellitus w ith gangrene C109511 0 
Type 2 diabetes mellitus w ith gangrene C109512 0 
Non-insulin-dependent diabetes mellitus with retinopathy C109600 0 
Type II diabetes mellitus w ith retinopathy C109611 0 
Type 2 diabetes mellitus w ith retinopathy C109612 0 
Non-insulin dependent diabetes mellitus with mononeuropathy C109A00 0 
Type II diabetes mellitus w ith mononeuropathy C109A11 0 
Type 2 diabetes mellitus w ith mononeuropathy C109A12 0 
Non-insulin dependent diabetes mellitus with polyneuropathy C109B00 0 
Type II diabetes mellitus w ith polyneuropathy C109B11 0 
Type 2 diabetes mellitus w ith polyneuropathy C109B12 0 
Non-insulin dependent diabetes mellitus with nephropathy C109C00 0 
Type II diabetes mellitus w ith nephropathy C109C11 0 
Type 2 diabetes mellitus w ith nephropathy C109C12 0 
Non-insulin dependent diabetes mellitus with hypoglyca coma C109D00 0 
Type II diabetes mellitus w ith hypoglycaemic coma C109D11 0 
Type 2 diabetes mellitus w ith hypoglycaemic coma C109D12 0 
Non-insulin depend diabetes mellitus with diabetic cataract C109E00 0 
Type II diabetes mellitus w ith diabetic cataract C109E11 0 
Type 2 diabetes mellitus w ith diabetic cataract C109E12 0 
Non-insulin-dependent d m with peripheral angiopath C109F00 0 
Type II diabetes mellitus w ith peripheral angiopathy C109F11 0 
Type 2 diabetes mellitus w ith peripheral angiopathy C109F12 0 
Non-insulin dependent diabetes mellitus with arthropathy C109G00 0 
Type II diabetes mellitus w ith arthropathy C109G11 0 
Type 2 diabetes mellitus w ith arthropathy C109G12 0 
Non-insulin dependent d m with neuropathic arthropathy C109H00 0 
Type II diabetes mellitus w ith neuropathic arthropathy C109H11 0 
Type 2 diabetes mellitus w ith neuropathic arthropathy C109H12 0 
Hyperosmolar non-ketotic state in type 2 diabetes mellitus C109K00 0 
Malnutrition-related diabetes mellitus C10A.00 0 
Malnutrition-related diabetes mellitus with coma C10A000 0 
Malnutrition-related diabetes mellitus with ketoacidosis C10A100 0 
Malnutrition-related diabetes mellitus with renal complicatn C10A200 0 
Malnutrit-related diabetes mellitus wth ophthalmic complicat C10A300 0 
Malnutrition-related diabetes mellitus wth neuro complicatns C10A400 0 
Malnutritn-relat diabetes melitus wth periph circul complctn C10A500 0 
Malnutrition-related diabetes mellitus with multiple comps C10A600 0 
Malnutrition-related diabetes mellitus without complications C10A700 0 
Malnutrit-related diabetes mellitus with unspec complics C10AW00 0 
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Malnutrit-relat diabetes mellitus with other spec comps C10AX00 0 
Diabetes mellitus induced by steroids C10B.00 0 
Steroid induced diabetes mellitus without complication C10B000 0 
Type 1 diabetes mellitus w ith renal complications C10E000 0 
Type I diabetes mellitus w ith renal complications C10E011 0 
Insulin-dependent diabetes mellitus w ith renal complications C10E012 0 
Type 1 diabetes mellitus w ith ophthalmic complications C10E100 0 
Type I diabetes mellitus w ith ophthalmic complications C10E111 0 
Insulin-dependent diabetes mellitus w ith ophthalmic comps C10E112 0 
Type 1 diabetes mellitus w ith neurological complications C10E200 0 
Type I diabetes mellitus w ith neurological complications C10E211 0 
Insulin-dependent diabetes mellitus w ith neurological comps C10E212 0 
Type 1 diabetes mellitus w ith multiple complications C10E300 0 
Type I diabetes mellitus w ith multiple complications C10E311 0 
Insulin dependent diabetes mellitus with multiple complicat C10E312 0 
Type 1 diabetes mellitus w ith ulcer C10E500 0 
Type I diabetes mellitus w ith ulcer C10E511 0 
Insulin dependent diabetes mellitus with ulcer  C10E512 0 
Type 1 diabetes mellitus w ith gangrene C10E600 0 
Type I diabetes mellitus w ith gangrene C10E611 0 
Insulin dependent diabetes mellitus with gangrene C10E612 0 
Type 1 diabetes mellitus w ith retinopathy C10E700 0 
Type I diabetes mellitus w ith retinopathy C10E711 0 
Insulin dependent diabetes mellitus with retinopathy C10E712 0 
Type 1 diabetes mellitus w ith mononeuropathy C10EB00 0 
Type I diabetes mellitus w ith mononeuropathy C10EB11 0 
Insulin dependent diabetes mellitus with mononeuropathy C10EB12 0 
Type 1 diabetes mellitus w ith polyneuropathy C10EC00 0 
Type I diabetes mellitus w ith polyneuropathy C10EC11 0 
Insulin dependent diabetes mellitus with polyneuropathy C10EC12 0 
Type 1 diabetes mellitus w ith nephropathy C10ED00 0 
Type I diabetes mellitus w ith nephropathy C10ED11 0 
Insulin dependent diabetes mellitus with nephropathy C10ED12 0 
Type 1 diabetes mellitus w ith hypoglycaemic coma C10EE00 0 
Type I diabetes mellitus w ith hypoglycaemic coma C10EE11 0 
Insulin dependent diabetes mellitus with hypoglycaemic coma C10EE12 0 
Type 1 diabetes mellitus w ith diabetic cataract C10EF00 0 
Type I diabetes mellitus w ith diabetic cataract C10EF11 0 
Insulin dependent diabetes mellitus with diabetic cataract C10EF12 0 
Type 1 diabetes mellitus w ith peripheral angiopathy C10EG00 0 
Type I diabetes mellitus w ith peripheral angiopathy C10EG11 0 
Insulin dependent diab mell with peripheral angiopathy C10EG12 0 
Type 1 diabetes mellitus w ith arthropathy C10EH00 0 
Type I diabetes mellitus w ith arthropathy C10EH11 0 
Insulin dependent diabetes mellitus with arthropathy C10EH12 0 
Type 1 diabetes mellitus w ith neuropathic arthropathy C10EJ00 0 
Type I diabetes mellitus w ith neuropathic arthropathy C10EJ11 0 
Insulin dependent diab mell with neuropathic arthropathy C10EJ12 0 
Type 1 diabetes mellitus w ith persistent proteinuria C10EK00 0 
Type I diabetes mellitus w ith persistent proteinuria C10EK11 0 
Type 1 diabetes mellitus w ith persistent microalbuminuria C10EL00 0 
 
 
292 
 
Diabetes description Med Code Incident 
Type I diabetes mellitus w ith persistent microalbuminuria C10EL11 0 
Type 1 diabetes mellitus w ith ketoacidosis C10EM00 0 
Type I diabetes mellitus w ith ketoacidosis C10EM11 0 
Type 1 diabetes mellitus w ith ketoacidotic coma C10EN00 0 
Type I diabetes mellitus w ith ketoacidotic coma C10EN11 0 
Type 1 diabetes mellitus w ith exudative maculopathy C10EP00 0 
Type I diabetes mellitus w ith exudative maculopathy C10EP11 0 
Type 1 diabetes mellitus w ith gastroparesis C10EQ00 0 
Type 2 diabetes mellitus w ith renal complications C10F000 0 
Type II diabetes mellitus w ith renal complications C10F011 0 
Type 2 diabetes mellitus w ith ophthalmic complications C10F100 0 
Type II diabetes mellitus w ith ophthalmic complications C10F111 0 
Type 2 diabetes mellitus w ith neurological complications C10F200 0 
Type II diabetes mellitus w ith neurological complications C10F211 0 
Type 2 diabetes mellitus w ith multiple complications C10F300 0 
Type II diabetes mellitus w ith multiple complications C10F311 0 
Type 2 diabetes mellitus w ith ulcer C10F400 0 
Type II diabetes mellitus w ith ulcer C10F411 0 
Type 2 diabetes mellitus w ith gangrene C10F500 0 
Type II diabetes mellitus w ith gangrene C10F511 0 
Type 2 diabetes mellitus w ith retinopathy C10F600 0 
Type II diabetes mellitus w ith retinopathy C10F611 0 
Type 2 diabetes mellitus w ith mononeuropathy C10FA00 0 
Type II diabetes mellitus w ith mononeuropathy C10FA11 0 
Type 2 diabetes mellitus w ith polyneuropathy C10FB00 0 
Type II diabetes mellitus w ith polyneuropathy C10FB11 0 
Type 2 diabetes mellitus w ith nephropathy C10FC00 0 
Type II diabetes mellitus w ith nephropathy C10FC11 0 
Type 2 diabetes mellitus w ith hypoglycaemic coma C10FD00 0 
Type II diabetes mellitus w ith hypoglycaemic coma C10FD11 0 
Type 2 diabetes mellitus w ith diabetic cataract C10FE00 0 
Type II diabetes mellitus w ith diabetic cataract C10FE11 0 
Type 2 diabetes mellitus w ith peripheral angiopathy C10FF00 0 
Type II diabetes mellitus w ith peripheral angiopathy C10FF11 0 
Type 2 diabetes mellitus w ith arthropathy C10FG00 0 
Type II diabetes mellitus w ith arthropathy C10FG11 0 
Type 2 diabetes mellitus w ith neuropathic arthropathy C10FH00 0 
Type II diabetes mellitus w ith neuropathic arthropathy C10FH11 0 
Hyperosmolar non-ketotic state in type 2 diabetes mellitus C10FK00 0 
Type 2 diabetes mellitus w ith persistent proteinuria C10FL00 0 
Type II diabetes mellitus w ith persistent proteinuria C10FL11 0 
Type 2 diabetes mellitus w ith persistent microalbuminuria C10FM00 0 
Type II diabetes mellitus w ith persistent microalbuminuria C10FM11 0 
Type 2 diabetes mellitus w ith ketoacidosis C10FN00 0 
Type II diabetes mellitus w ith ketoacidosis C10FN11 0 
Type 2 diabetes mellitus w ith ketoacidotic coma C10FP00 0 
Type II diabetes mellitus w ith ketoacidotic coma C10FP11 0 
Type 2 diabetes mellitus w ith exudative maculopathy C10FQ00 0 
Type II diabetes mellitus w ith exudative maculopathy C10FQ11 0 
Type 2 diabetes mellitus w ith gastroparesis C10FR00 0 
Secondary pancreatic diabetes mellitus C10G.00 0 
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Secondary pancreatic diabetes mellitus w ithout complication C10G000 0 
Diabetes mellitus induced by non-steroid drugs C10H.00 0 
DM induced by non-steroid drugs without complication C10H000 0 
Insulin autoimmune syndrome C10J.00 0 
Insulin autoimmune syndrome without complication C10J000 0 
Type A insulin resistance C10K.00 0 
Type A insulin resistance without complication C10K000 0 
Fibrocalculous pancreatopathy C10L.00 0 
Fibrocalculous pancreatopathy without complication C10L000 0 
Lipoatrophic diabetes mellitus C10M.00 0 
Lipoatrophic diabetes mellitus without complication C10M000 0 
Secondary diabetes mellitus C10N.00 0 
Secondary diabetes mellitus without complication C10N000 0 
Cystic fibrosis related diabetes mellitus C10N100 0 
Diabetes mellitus with other specified manifestation C10y.00 0 
Diabetes mellitus, juvenile, + other specified manifestation C10y000 0 
Diabetes mellitus, adult, + other specified manifestation C10y100 0 
Other specified diabetes mellitus w ith other spec comps C10yy00 0 
Diabetes mellitus NOS with other specified manifestation C10yz00 0 
Diabetes mellitus with unspecified complication C10z.00 0 
Diabetes mellitus, juvenile type, + unspecified complication C10z000 0 
Diabetes mellitus, adult onset, + unspecified complication C10z100 0 
Other specified diabetes mellitus w ith unspecified comps C10zy00 0 
Diabetes mellitus NOS with unspecified complication C10zz00 0 
[X]Malnutrit-relat diabetes mellitus with other spec comps Cyu2100 0 
[X]Malnutrit-related diabetes mellitus w ith unspec complics Cyu2200 0 
[X]Unspecified diabetes mellitus w ith renal complications Cyu2300 0 
Autonomic neuropathy due to diabetes F171100 0 
Diabetic mononeuritis multiplex F345000 0 
Diabetic mononeuritis NOS F35z000 0 
Polyneuropathy in diabetes F372.00 0 
Diabetic polyneuropathy F372.11 0 
Diabetic neuropathy F372.12 0 
Acute painful diabetic neuropathy F372000 0 
Chronic painful diabetic neuropathy F372100 0 
Asymptomatic diabetic neuropathy F372200 0 
Myasthenic syndrome due to diabetic amyotrophy F381300 0 
Diabetic amyotrophy F381311 0 
Diabetic mononeuropathy F3y0.00 0 
Diabetic retinopathy F420.00 0 
Background diabetic retinopathy F420000 0 
Proliferative diabetic retinopathy F420100 0 
Preproliferative diabetic retinopathy F420200 0 
Advanced diabetic maculopathy F420300 0 
Diabetic maculopathy F420400 0 
Advanced diabetic retinal disease F420500 0 
Non proliferative diabetic retinopathy F420600 0 
High risk proliferative diabetic retinopathy F420700 0 
High risk non proliferative diabetic retinopathy F420800 0 
Diabetic retinopathy NOS F420z00 0 
Diabetic iritis F440700 0 
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Diabetic cataract F464000 0 
Diabetic peripheral angiopathy G73y000 0 
Nephrotic syndrome in diabetes mellitus K01x100 0 
[X]Glomerular disorders in diabetes mellitus Kyu0300 0 
Diabetes mellitus during pregnancy/childbirth/puerperium L180.00 0 
Diabetes mellitus - unspec whether in pregnancy/puerperium L180000 0 
Diabetes mellitus during pregnancy - baby delivered L180100 0 
Diabetes mellitus in puerperium - baby delivered L180200 0 
Diabetes mellitus during pregnancy - baby not yet delivered L180300 0 
Diabetes mellitus in pueperium - baby previously delivered L180400 0 
Pre-existing diabetes mellitus, insulin-dependent L180500 0 
Pre-existing diabetes mellitus, non-insulin-dependent L180600 0 
Pre-existing malnutrition-related diabetes mellitus L180700 0 
Diabetes mellitus arising in pregnancy L180800 0 
Gestational diabetes mellitus L180811 0 
Gestational diabetes mellitus L180900 0 
Pre-existing diabetes mellitus, unspecified L180X00 0 
Diabetes mellitus in pregnancy/childbirth/puerperium NOS L180z00 0 
[X]Pre-existing diabetes mellitus, unspecified Lyu2900 0 
Cellulitis in diabetic foot M037200 0 
Ischaemic ulcer diabetic foot M271000 0 
Neuropathic diabetic ulcer - foot M271100 0 
Mixed diabetic ulcer - foot M271200 0 
Diabetic cheiroarthropathy N030000 0 
Diabetic cheiropathy N030011 0 
Diabetic Charcot arthropathy N030100 0 
[D]Gangrene of toe in diabetic R054200 0 
[D]Widespread diabetic foot gangrene R054300 0 
Dietary advice for diabetes mellitus ZC2C800 0 
Dietary advice for type I diabetes ZC2C900 0 
Diet advice for insulin-dependent diabetes ZC2C911 0 
Dietary advice for type II diabetes ZC2CA00 0 
Dietary advice non-insulin-dependent diabetes ZC2CA11 0 
Dietary advice for gestational diabetes ZC2CB00 0 
Under care of diabetic liaison nurse ZL22500 0 
Referral to diabetes nurse ZL62500 0 
Referral to diabetic liaison nurse ZL62600 0 
Seen by diabetic liaison nurse ZLA2500 0 
Discharge by diabetic liaison nurse ZLD7500 0 
Diabetes clinic satisfaction questionnaire ZRB4.00 0 
CSQ - Diabetes clinic satisfaction questionnaire ZRB4.11 0 
Diabetes treatment satisfaction questionnaire ZRB5.00 0 
DTSQ - Diabetes treatment satisfaction questionnaire ZRB5.11 0 
Diabetes wellbeing questionnaire ZRB6.00 0 
DWBQ - Diabetes wellbeing questionnaire ZRB6.11 0 
Education score - diabetes ZRBa.00 0 
Perceived control of insulin-dependent diabetes ZRbH.00 0 
[V]Dietary counselling in diabetes mellitus ZV65312 0 
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Smoking description Med Code Smoker type 
Tobacco consumption 137..00 Current smoker 
Smoker - amount smoked 137..11 Current smoker 
Never smoked tobacco 1371.00 Never smoker 
Non-smoker 1371.11 Never smoker 
Trivial smoker - < 1 cig/day 1372.00 Current smoker 
Occasional smoker 1372.11 Current smoker 
Light smoker - 1-9 cigs/day 1373.00 Current smoker 
Moderate smoker - 10-19 cigs/d 1374.00 Current smoker 
Heavy smoker - 20-39 cigs/day 1375.00 Current smoker 
Very heavy smoker - 40+cigs/d 1376.00 Current smoker 
Ex-trivial smoker (<1/day) 1377.00 Ex smoker 
Ex-light smoker (1-9/day) 1378.00 Ex smoker 
Ex-moderate smoker (10-19/day) 1379.00 Ex smoker 
Ex-heavy smoker (20-39/day) 137A.00 Ex smoker 
Ex-very heavy smoker (40+/day) 137B.00 Ex smoker 
Keeps trying to stop smoking 137C.00 Current smoker 
Admitted tobacco cons untrue ? 137D.00 Current smoker 
Ex-smoker - amount unknown 137F.00 Ex smoker 
Trying to give up smoking 137G.00 Current smoker 
Pipe smoker 137H.00 Current smoker 
Cigar smoker 137J.00 Current smoker 
Stopped smoking 137K.00 Ex smoker 
Recently stopped smoking 137K000 Ex smoker 
Current non-smoker 137L.00 Ex smoker 
Rolls own cigarettes 137M.00 Current smoker 
Ex pipe smoker 137N.00 Ex smoker 
Ex cigar smoker 137O.00 Ex smoker 
Cigarette smoker 137P.00 Current smoker 
Smoker 137P.11 Current smoker 
Smoking started 137Q.00 Current smoker 
Smoking restarted 137Q.11 Current smoker 
Current smoker 137R.00 Current smoker 
Ex smoker 137S.00 Ex smoker 
Date ceased smoking 137T.00 Ex smoker 
Smoking reduced 137V.00 Current smoker 
Cigarette consumption 137X.00 Current smoker 
Cigar consumption 137Y.00 Current smoker 
Tobacco consumption NOS 137Z.00 Current smoker 
Pipe tobacco consumption 137a.00 Current smoker 
Ready to stop smoking 137b.00 Current smoker 
Thinking about stopping smoking 137c.00 Current smoker 
Not interested in stopping smoking 137d.00 Current smoker 
Smoking restarted 137e.00 Current smoker 
Reason for restarting smoking 137f.00 Current smoker 
Cigarette pack-years 137g.00 Current smoker 
Minutes from waking to first tobacco consumption 137h.00 Current smoker 
Ex-cigarette smoker 137j.00 Ex smoker 
Ex roll-up cigarette smoker 137l.00 Ex smoker 
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No smokers in the household 13WK.00 Never smoker 
Smoking cessation milestones 13p..00 Current smoker 
Negotiated date for cessation of smoking 13p0.00 Current smoker 
Smoking status at 4 weeks 13p1.00 Current smoker 
Smoking free weeks 13p4.00 Ex smoker 
Smoking cessation programme start date 13p5.00 Current smoker 
Fagerstr test for nicotine dep 38DH.00 Current smoker 
Health ed. - smoking 6791.00 Current smoker 
Pregnancy smoking advice 67A3.00 Current smoker 
Lifestyle advice regarding smoking 67H1.00 Current smoker 
Brief intervention for smoking cessation 67H6.00 Current smoker 
Smoking cessation therapy 745H.00 Current smoker 
Nicotine replacement therapy using nicotine patches 745H000 Current smoker 
Nicotine replacement therapy using nicotine gum 745H100 Current smoker 
Nicotine replacement therapy using nicotine inhalator 745H200 Current smoker 
Nicotine replacement therapy using nicotine lozenges 745H300 Current smoker 
Smoking cessation drug therapy 745H400 Current smoker 
Other specified smoking cessation therapy 745Hy00 Current smoker 
Smoking cessation therapy NOS 745Hz00 Current smoker 
Nicotine replacement therapy 8B2B.00 Current smoker 
Over the counter nicotine replacement therapy 8B3Y.00 Current smoker 
Nicotine replacement therapy provided free 8B3f.00 Current smoker 
Nicotine replacement therapy provided by community pharmacis 8BP3.00 Current smoker 
Smoking cessation advice 8CAL.00 Current smoker 
Smoking cessation advice provided by community pharmacist 8CAg.00 Current smoker 
Referral to smoking cessation advisor 8H7i.00 Current smoker 
Stop smoking face to face follow-up 8HBM.00 Current smoker 
Referral to stop-smoking clinic 8HTK.00 Current smoker 
Referral to NHS stop smoking service 8HkQ.00 Current smoker 
Nicotine replacement therapy contraindicated 8I2I.00 Current smoker 
Nicotine replacement therapy refused 8I39.00 Current smoker 
Smoking cessation advice declined 8IAj.00 Current smoker 
Seen by smoking cessation advisor 9N2k.00 Current smoker 
DNA - Did not attend smoking cessation clinic 9N4M.00 Current smoker 
Ex-smoker annual review 9km..11 Ex smoker 
Non-smoker annual review 9kn..11 Never smoker 
Current smoker annual review 9ko..11 Current smoker 
Nicotine withdrawal E023.00 Current smoker 
Tobacco dependence E251.00 Current smoker 
Tobacco dependence, unspecified E251000 Current smoker 
Tobacco dependence, continuous E251100 Current smoker 
Tobacco dependence, episodic E251200 Current smoker 
Tobacco dependence in remission E251300 Ex smoker 
Tobacco dependence NOS E251z00 Current smoker 
[X]Mental and behavioural disorder due to use of tobacco Eu17.00 Current smoker 
[X]Mental and behav dis due to use of tobacco: harmful use Eu17100 Current smoker 
[X]Mental and behav dis due to use tobacco: dependence syndr Eu17200 Current smoker 
[X]Mental and behav dis due to use tobacco: w ithdrawal state Eu17300 Current smoker 
[X]Men & behav dis due tobacco: w ithdrawl state wth delirium Eu17400 Current smoker 
[X]Mental & behav dis due to use tobacco: psychotic disorder Eu17500 Current smoker 
[X]Mental and behav dis due to use tobacco: amnesic syndrome Eu17600 Current smoker 
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[X]Men & beh dis due tobacco: resid & late -onset psychot dis Eu17700 Current smoker 
[X]Men & behav dis due to use tobacco: oth men & behav dis  Eu17y00 Current smoker 
[X]Ment & behav dis due use tobacco: unsp ment & behav dis Eu17z00 Current smoker 
Advice on smoking ZG23300 Current smoker 
Fagerstrom test for nicotine dependence ZRBm200 Current smoker 
FTND - Fagerstrom test for nicotine dependence ZRBm211 Current smoker 
Motives for smoking scale ZRaM.00 Current smoker 
MFS - Motives for smoking scale ZRaM.11 Current smoker 
Occasions for smoking scale ZRao.00 Current smoker 
OFS - Occasions for smoking scale ZRao.11 Current smoker 
Reasons for smoking scale ZRh4.00 Current smoker 
RFS - Reasons for smoking scale ZRh4.11 Current smoker 
[V]Tobacco use ZV4K000 Current smoker 
[V]Tobacco abuse counselling ZV6D800 Current smoker 
20.7 Smoking cessation drugs 
Smoking cessation drug generic name Drug Code 
NICOTINE 84442998 
NICOTINE 84443998 
NICOTINE PATCHES 84466998 
NICOTINE PATCHES 84468998 
NICOTINE PATCHES 84469998 
VARENICLINE 85397998 
VARENICLINE 85398998 
VARENICLINE 85399998 
VARENICLINE 85400998 
VARENICLINE 85401998 
VARENICLINE 85403998 
NICOTINE 87919998 
NICOTINE 87920998 
NICOTINE 87922998 
NICOTINE 88005996 
NICOTINE 88005997 
NICOTINE 88005998 
NICOTINE 88288998 
NICOTINE 88291998 
NICOTINE 89110998 
NICOTINE 89112998 
NICOTINE 89863998 
MENTHYL VALERATE+QUININE&AROMATICS 90293998 
MENTHYL VALERATE+QUININE&AROMATICS 90295998 
NICOTINE 91162998 
NICOTINE 91248996 
NICOTINE 91248997 
NICOTINE 91248998 
NICOTINE 91384998 
NICOTINE 91848998 
BUPROPION 92309998 
BUPROPION 92311998 
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NICOTINE 92657998 
NICOTINE 92836998 
NICOTINE 92840996 
NICOTINE 92840997 
NICOTINE 92840998 
NICOTINE 92841997 
NICOTINE 92841998 
NICOTINE 92888990 
NICOTINE 92889990 
NICOTINE 92892997 
NICOTINE 92892998 
NICOTINE TRANSDERMAL PATCH 93447992 
NICOTINE 95727996 
NICOTINE 95727997 
NICOTINE 95727998 
NICOTINE TRANSDERMAL PATCH 30CM 96844992 
NICOTINE TRANSDERMAL PATCH 20CM 96845992 
NICOTINE TRANSDERMAL PATCH 96868992 
NICOTINE TRANSDERMAL PATCH 96869992 
NICOTINE TRANSDERMAL PATCH 96924992 
NICOTINE TRANSDERMAL PATCH 96930992 
NICOTINE 97673996 
NICOTINE 97673997 
NICOTINE 97673998 
NICOTINE 97737996 
NICOTINE 97737997 
NICOTINE 97737998 
NICOTINE 97739996 
NICOTINE 97739997 
NICOTINE 97739998 
NICOTINE 97740996 
NICOTINE 97740997 
NICOTINE 97740998 
NICOTINE 97763996 
NICOTINE 97763997 
NICOTINE 97763998 
NICOTINE 98082998 
NICOTINE 98430998 
NICOTINE 98581997 
NICOTINE 98581998 
NICOTINE 98904996 
NICOTINE 98904997 
NICOTINE 98904998 
20.8 Heavy drinking 
Alcohol use description Med Code Alcohol use type 
Moderate drinker - 3-6u/day 1364.00 Moderate/Heavy 
Heavy drinker - 7-9u/day 1365.00 Heavy 
Very heavy drinker - >9u/day 1366.00 Heavy 
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Alcohol intake above recommended sensible limits 136K.00 Moderate/Heavy 
Moderate drinker 136O.00 Moderate/Heavy 
Heavy drinker 136P.00 Heavy 
Very heavy drinker 136Q.00 Heavy 
Binge drinker 136R.00 Moderate/Heavy 
Harmful alcohol use 136T.00 Heavy 
Alcoholics anonymous 13Y8.00 Heavy 
H/O: liver disease 14C5.00 Heavy 
Compensation for liver failure 7L1f.00 Heavy 
Other specified compensation for liver failure 7L1fy00 Heavy 
Compensation for liver failure NOS 7L1fz00 Heavy 
Hepatitis status 6 months post treatment - enhanced serv 
adm 
9kX..00 Heavy 
Hepatitis status 6 months post treatment 9kX..11 Heavy 
Wernicke's encephalopathy C251.11 Heavy 
Wernicke's encephalopathy C253.00 Heavy 
Deficiency of coagulation factor due to liver disease D307000 Heavy 
Alcoholic psychoses E01..00 Heavy 
Alcohol amnestic syndrome E011.00 Heavy 
Korsakov's alcoholic psychosis E011000 Heavy 
Korsakov's alcoholic psychosis w ith peripheral neuritis E011100 Heavy 
Wernicke-Korsakov syndrome E011200 Heavy 
Alcohol amnestic syndrome NOS E011z00 Heavy 
Other alcoholic dementia E012.00 Heavy 
Alcoholic dementia NOS E012.11 Heavy 
Chronic alcoholic brain syndrome E012000 Heavy 
Alcohol w ithdrawal hallucinosis E013.00 Heavy 
Other alcoholic psychosis E01y.00 Heavy 
Alcohol w ithdrawal syndrome E01y000 Heavy 
Other alcoholic psychosis NOS E01yz00 Heavy 
Alcoholic psychosis NOS E01z.00 Heavy 
Alcohol dependence syndrome E23..00 Heavy 
Alcoholism E23..11 Heavy 
Alcohol problem drinking E23..12 Heavy 
Chronic alcoholism in remission E231300 Heavy 
Nondependent alcohol abuse E250.00 Moderate/Heavy 
Nondependent alcohol abuse, unspecified E250000 Heavy 
Nondependent alcohol abuse, episodic E250200 Heavy 
[X]Acute alcoholic drunkenness Eu10011 Heavy 
[X]Chronic alcoholism Eu10212 Heavy 
[X]Mental and behav dis due to use alcohol: w ithdrawal 
state 
Eu10300 Heavy 
[X]Men & behav dis due alcohl: w ithdrawl state with 
delirium 
Eu10400 Heavy 
[X]Delirium tremens, alcohol induced Eu10411 Heavy 
[X]Mental & behav dis due to use alcohol: psychotic 
disorder 
Eu10500 Heavy 
[X]Alcoholic hallucinosis Eu10511 Heavy 
[X]Alcoholic jealousy Eu10512 Heavy 
[X]Alcoholic psychosis NOS Eu10514 Heavy 
[X]Korsakov's psychosis, alcohol induced Eu10611 Heavy 
[X]Men & behav dis due alcoh: resid & late -onset psychot 
dis 
Eu10700 Heavy 
[X]Alcoholic dementia NOS Eu10711 Heavy 
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[X]Chronic alcoholic brain syndrome Eu10712 Heavy 
[X]Alcohol w ithdrawal-induced seizure Eu10800 Heavy 
Cerebral degeneration due to alcoholism F11x000 Heavy 
Alcoholic encephalopathy F11x011 Heavy 
Oesophageal varices in cirrhosis of the liver G852200 Heavy 
Oesophageal varices in alcoholic cirrhosis of the liver G852300 Heavy 
Acute hepatic failure J600000 Heavy 
Acute liver failure J600011 Heavy 
Subacute hepatic failure J601000 Heavy 
Cirrhosis and chronic liver disease J61..00 Heavy 
Acute alcoholic hepatitis J611.00 Heavy 
Alcoholic cirrhosis of liver J612.00 Heavy 
Florid cirrhosis J612.11 Heavy 
Laennec's cirrhosis J612.12 Heavy 
Alcoholic fibrosis and sclerosis of liver J612000 Heavy 
Alcoholic liver damage unspecified J613.00 Heavy 
Alcoholic hepatic failure J613000 Heavy 
Chronic hepatitis J614.00 Heavy 
Chronic persistent hepatitis J614000 Heavy 
Chronic active hepatitis J614100 Heavy 
Chronic aggressive hepatitis J614200 Heavy 
Recurrent hepatitis J614300 Heavy 
Chronic lobular hepatitis J614400 Heavy 
Chronic hepatitis unspecified J614y00 Heavy 
Chronic hepatitis NOS J614z00 Heavy 
Portal cirrhosis J615.11 Heavy 
Unilobular portal cirrhosis J615000 Heavy 
Multilobular portal cirrhosis J615100 Heavy 
Postnecrotic cirrhosis of liver J615111 Heavy 
Mixed portal cirrhosis J615200 Heavy 
Diffuse nodular cirrhosis J615300 Heavy 
Fatty portal cirrhosis J615400 Heavy 
Hypertrophic portal cirrhosis J615500 Heavy 
Capsular portal cirrhosis J615600 Heavy 
Cardiac portal cirrhosis J615700 Heavy 
Congestive cirrhosis J615711 Heavy 
Pipe-stem portal cirrhosis J615A00 Heavy 
Toxic portal cirrhosis J615B00 Heavy 
Xanthomatous portal cirrhosis J615C00 Heavy 
Portal cirrhosis unspecified J615y00 Heavy 
Macronodular cirrhosis of liver J615z11 Heavy 
Cirrhosis of liver NOS J615z13 Heavy 
Laennec's cirrhosis, non-alcoholic J615z14 Heavy 
Hepatic fibrosis J615z15 Heavy 
Alcoholic hepatitis J617.00 Heavy 
Chronic alcoholic hepatitis J617000 Heavy 
Portal fibrosis without cirrhosis J61y300 Heavy 
Hepatic fibrosis J61y400 Heavy 
Hepatic fibrosis with hepatic sclerosis J61y600 Heavy 
Chronic liver disease NOS J61z.00 Heavy 
[X] Hepatic failure J625.00 Heavy 
 
 
301 
 
Alcohol use description Med Code Alcohol use type 
[X] Liver failure J625.11 Heavy 
Other sequelae of chronic liver disease J62y.00 Heavy 
Hepatic failure NOS J62y.11 Heavy 
Liver failure NOS J62y.12 Heavy 
Hepatic failure J62y.13 Heavy 
Hepatitis unspecified J633.00 Heavy 
Toxic hepatitis J633000 Heavy 
Hepatitis unspecified NOS J633z00 Heavy 
Toxic liver disease J635.00 Heavy 
Toxic liver disease with cholestasis J635000 Heavy 
Toxic liver disease with hepatic necrosis J635100 Heavy 
Toxic liver disease with acute hepatitis J635200 Heavy 
Toxic liver disease with chronic persistent hepatitis J635300 Heavy 
Toxic liver disease with chronic lobular hepatitis J635400 Heavy 
Toxic liver disease with chronic active hepatitis J635500 Heavy 
Toxic liver disease with fibrosis and cirrhosis of liver J635600 Heavy 
Toxic liver disease, unspecified J635X00 Heavy 
Autoimmune hepatitis J63B.00 Heavy 
Granulomatous hepatitis, not elsewhere classified J63X.00 Heavy 
Nonspecific reactive hepatitis J63y100 Heavy 
Alcohol-induced chronic pancreatitis J671000 Heavy 
[X]Toxic liver disease with other disorders of liver  Jyu7000 Heavy 
[X]Other and unspecified cirrhosis of liver Jyu7100 Heavy 
[X]Other specified inflammatory liver diseases Jyu7200 Heavy 
[X]Toxic liver disease, unspecified Jyu7600 Heavy 
[X]Granulomatous hepatitis, not elsewhere classified Jyu7700 Heavy 
Dietary advice for liver disease ZC2CH11 Heavy 
20.9 Antipsychotics 
Antipsychotic generic drug name Drug Code Generation 
amisulpride 94546990 2 
amisulpride 88387998 2 
amisulpride 94846990 2 
amisulpride 94545990 2 
amisulpride 94544990 2 
amisulpride 90209998 2 
amisulpride 88383997 2 
amisulpride 91785990 2 
amisulpride 86433998 2 
amisulpride 88383998 2 
amisulpride 88387996 2 
amisulpride 88387997 2 
amisulpride 91425998 2 
amisulpride 94845990 2 
amisulpride 91083998 2 
amisulpride 94844990 2 
amisulpride 88383996 2 
amisulpride 91077998 2 
aripiprazole 87450998 2 
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Antipsychotic generic drug name Drug Code Generation 
aripiprazole 87452998 2 
aripiprazole 87448998 2 
aripiprazole 87449998 2 
aripiprazole 85835998 2 
aripiprazole 87089998 2 
aripiprazole 87090998 2 
aripiprazole 87453998 2 
aripiprazole 85832998 2 
aripiprazole 85836998 2 
aripiprazole 87451998 2 
aripiprazole 85834998 2 
aripiprazole 83903998 2 
aripiprazole 85833998 2 
aripiprazole 85837998 2 
asenapine 81172998 2 
asenapine 81170998 2 
benperidol 95980998 1 
benperidol 82225998 1 
benperidol 95979998 1 
benperidol 88885998 1 
chlorpromazine 94821992 1 
chlorpromazine 96691998 1 
chlorpromazine 97134992 1 
chlorpromazine 98062989 1 
chlorpromazine 96102992 1 
chlorpromazine 96689996 1 
chlorpromazine 97236990 1 
chlorpromazine 95200992 1 
chlorpromazine 97877998 1 
chlorpromazine 82892998 1 
chlorpromazine 96614992 1 
chlorpromazine 97880996 1 
chlorpromazine 95687990 1 
chlorpromazine 96689998 1 
chlorpromazine 98186990 1 
chlorpromazine 97871998 1 
chlorpromazine 93593998 1 
chlorpromazine 99010990 1 
chlorpromazine 97236988 1 
chlorpromazine 96674979 1 
chlorpromazine 97880997 1 
chlorpromazine 96691996 1 
chlorpromazine 97879998 1 
chlorpromazine 93587998 1 
chlorpromazine 95365990 1 
chlorpromazine 94107992 1 
chlorpromazine 98192988 1 
chlorpromazine 94761998 1 
chlorpromazine 97129992 1 
chlorpromazine 96690998 1 
chlorpromazine 94761997 1 
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Antipsychotic generic drug name Drug Code Generation 
chlorpromazine 94111992 1 
chlorpromazine 98192990 1 
chlorpromazine 93242998 1 
chlorpromazine 97236989 1 
chlorpromazine 97880998 1 
chlorpromazine 98062990 1 
chlorpromazine 98189990 1 
chlorpromazine 96689997 1 
chlorpromazine 98192989 1 
chlorpromazine 96690996 1 
chlorpromazine 96919990 1 
chlorpromazine 95364990 1 
chlorpromazine 99007990 1 
chlorpromazine 96691997 1 
chlorpromazine 97132992 1 
chlorpromazine 96919989 1 
chlorpromazine 93593997 1 
chlorprothixene 96686997 1 
clozapine 82802998 2 
clozapine 82800998 2 
clozapine 93595997 2 
clozapine 82803998 2 
clozapine 93596997 2 
clozapine 93596998 2 
clozapine 87020998 2 
clozapine 87341998 2 
clozapine 82801998 2 
clozapine 87340998 2 
clozapine 93595998 2 
clozapine 87019998 2 
clozapine 82799998 2 
thiopropazate 94891992 1 
droperidol 97343998 1 
droperidol 97343997 1 
droperidol 93675998 1 
droperidol 96303997 1 
droperidol 93674998 1 
droperidol 96303998 1 
droperidol 97334992 1 
flupentixol 98766997 1 
flupentixol 98766998 1 
flupentixol 97516998 1 
flupentixol 86421998 1 
flupentixol 94879998 1 
flupentixol 86422998 1 
flupentixol 86420998 1 
flupentixol 99775998 1 
flupentixol 96502996 1 
flupentixol 85614998 1 
flupentixol 99776998 1 
flupentixol 96503998 1 
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Antipsychotic generic drug name Drug Code Generation 
flupentixol 96502998 1 
flupentixol 85613998 1 
flupentixol 86423998 1 
flupentixol 96502997 1 
fluphenazine 99414998 1 
fluphenazine 96342992 1 
fluphenazine 85300998 1 
fluphenazine 85298998 1 
fluphenazine 96500998 1 
fluphenazine 85299998 1 
fluphenazine 98759998 1 
fluphenazine 99408998 1 
fluphenazine 96742990 1 
fluphenazine 93032992 1 
fluphenazine 96498997 1 
fluphenazine 99411998 1 
fluphenazine 85296998 1 
fluphenazine 85301998 1 
fluphenazine 97466992 1 
fluphenazine 96501996 1 
fluphenazine 96498998 1 
fluphenazine 96501998 1 
fluphenazine 99411996 1 
fluphenazine 96286990 1 
fluphenazine 85303998 1 
fluphenazine 85295998 1 
fluphenazine 85297998 1 
fluphenazine 99411997 1 
fluphenazine 85302998 1 
fluphenazine 85294998 1 
fluphenazine 96501997 1 
fluspirilene 96494998 1 
fluspirilene 99189998 1 
haloperidol 96265992 1 
haloperidol 95086992 1 
haloperidol 98544988 1 
haloperidol 97346998 1 
haloperidol 79934979 1 
haloperidol 97345997 1 
haloperidol 95242990 1 
haloperidol 96248998 1 
haloperidol 98625989 1 
haloperidol 97344997 1 
haloperidol 96245997 1 
haloperidol 91932990 1 
haloperidol 87190998 1 
haloperidol 92815998 1 
haloperidol 93695997 1 
haloperidol 96248997 1 
haloperidol 96249998 1 
haloperidol 81468998 1 
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Antipsychotic generic drug name Drug Code Generation 
haloperidol 96244998 1 
haloperidol 96247996 1 
haloperidol 81081998 1 
haloperidol 96249997 1 
haloperidol 96245998 1 
haloperidol 97346996 1 
haloperidol 98155990 1 
haloperidol 98360988 1 
haloperidol 96115990 1 
haloperidol 98625990 1 
haloperidol 97945997 1 
haloperidol 97946997 1 
haloperidol 97944997 1 
haloperidol 97945998 1 
haloperidol 97946996 1 
haloperidol 97944998 1 
haloperidol 97344998 1 
haloperidol 97568992 1 
haloperidol 98131989 1 
haloperidol 98154990 1 
haloperidol 96247998 1 
haloperidol 92815996 1 
haloperidol 98544990 1 
haloperidol 98625988 1 
haloperidol 96242997 1 
haloperidol 96247997 1 
haloperidol 83786998 1 
haloperidol 97135990 1 
haloperidol 83787998 1 
haloperidol 96889990 1 
haloperidol 96248996 1 
haloperidol 97346997 1 
haloperidol 93695998 1 
haloperidol 96249996 1 
haloperidol 96307992 1 
haloperidol 67935979 1 
haloperidol 96242998 1 
haloperidol 96246998 1 
haloperidol 98080990 1 
haloperidol 96758992 1 
haloperidol 91921998 1 
haloperidol 97135989 1 
haloperidol 98131990 1 
haloperidol 96889988 1 
haloperidol 92815997 1 
haloperidol 97946998 1 
haloperidol 81467998 1 
haloperidol 97945996 1 
levomepromazine 95919997 1 
levomepromazine 95918998 1 
levomepromazine 95919998 1 
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Antipsychotic generic drug name Drug Code Generation 
levomepromazine 98853998 1 
levomepromazine 96634979 1 
levomepromazine 98853997 1 
loxapine 94006996 1 
loxapine 94007996 1 
loxapine 94006997 1 
loxapine 94007998 1 
loxapine 94006998 1 
loxapine 94007997 1 
olanzapine 97433998 2 
olanzapine 86325998 2 
olanzapine 91618998 2 
olanzapine 89567998 2 
olanzapine 97995998 2 
olanzapine 89567996 2 
olanzapine 97111998 2 
olanzapine 90659997 2 
olanzapine 90659996 2 
olanzapine 87647998 2 
olanzapine 89567997 2 
olanzapine 91618997 2 
olanzapine 96421979 2 
olanzapine 91364998 2 
olanzapine 86324998 2 
olanzapine 80976998 2 
olanzapine 80981998 2 
olanzapine 80980998 2 
olanzapine 80970998 2 
olanzapine 81041998 2 
olanzapine 89569997 2 
olanzapine 82201998 2 
olanzapine 80971998 2 
olanzapine 80977998 2 
olanzapine 89569998 2 
olanzapine 80978998 2 
olanzapine 80969998 2 
olanzapine 80974998 2 
olanzapine 89569996 2 
olanzapine 90664998 2 
olanzapine 80979998 2 
olanzapine 80972998 2 
olanzapine 80973998 2 
olanzapine 85376998 2 
olanzapine 61579979 2 
olanzapine 90659998 2 
olanzapine 87646998 2 
olanzapine 85377998 2 
oxypertine 93699998 2 
oxypertine 95649998 2 
oxypertine 99530998 2 
oxypertine 95650998 2 
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Antipsychotic generic drug name Drug Code Generation 
paliperidone 81419998 2 
paliperidone 81418998 2 
paliperidone 84526998 2 
paliperidone 81424998 2 
paliperidone 84527998 2 
paliperidone 81421998 2 
paliperidone 84524998 2 
paliperidone 81422998 2 
paliperidone 81425998 2 
paliperidone 81420998 2 
paliperidone 84525998 2 
paliperidone 81423998 2 
paliperidone 84523998 2 
pericyazine 99362997 1 
pericyazine 95577996 1 
pericyazine 83020998 1 
pericyazine 97878992 1 
pericyazine 83019998 1 
pericyazine 99362996 1 
pericyazine 95577997 1 
pericyazine 95576998 1 
pericyazine 98865998 1 
pericyazine 95577998 1 
pericyazine 99362998 1 
perphenazine 99651998 1 
perphenazine 97786997 1 
perphenazine 97786998 1 
perphenazine 95575998 1 
perphenazine 95575997 1 
perphenazine 99651997 1 
perphenazine 95575996 1 
perphenazine 94164992 1 
perphenazine 98587998 1 
perphenazine 97877992 1 
pimozide 97342997 1 
pimozide 97342998 1 
pimozide 95516997 1 
pimozide 95516996 1 
pimozide 97342996 1 
pimozide 95516998 1 
pipotiazine 85410998 1 
pipotiazine 85411998 1 
pipotiazine 85413998 1 
pipotiazine 85409998 1 
pipotiazine 98622998 1 
pipotiazine 95503998 1 
promazine 98063990 1 
promazine 98063989 1 
promazine 95386996 1 
promazine 95386997 1 
promazine 95386998 1 
 
 
308 
 
Antipsychotic generic drug name Drug Code Generation 
promazine 98783998 1 
promazine 98786996 1 
promazine 97406989 1 
promazine 93708997 1 
promazine 93477997 1 
promazine 99093990 1 
promazine 95385997 1 
promazine 93708998 1 
promazine 99093988 1 
promazine 95385998 1 
promazine 96750992 1 
promazine 98786997 1 
promazine 93476998 1 
promazine 99117998 1 
promazine 93477998 1 
promazine 98786998 1 
quetiapine 81923998 2 
quetiapine 81924998 2 
quetiapine 83996998 2 
quetiapine 83492998 2 
quetiapine 88734996 2 
quetiapine 59469979 2 
quetiapine 83995998 2 
quetiapine 87907998 2 
quetiapine 59468979 2 
quetiapine 83994998 2 
quetiapine 83493998 2 
quetiapine 83993998 2 
quetiapine 88736998 2 
quetiapine 88938979 2 
quetiapine 88737996 2 
quetiapine 88737998 2 
quetiapine 83490998 2 
quetiapine 83491998 2 
quetiapine 88734997 2 
quetiapine 88733997 2 
quetiapine 88734998 2 
quetiapine 88733998 2 
quetiapine 87908998 2 
quetiapine 88736997 2 
quetiapine 59467979 2 
quetiapine 58638979 2 
quetiapine 88737997 2 
remoxipride 93344997 2 
remoxipride 93344998 2 
remoxipride 93335998 2 
remoxipride 93335997 2 
risperidone 88163998 2 
risperidone 98585996 2 
risperidone 96914992 2 
risperidone 92957990 2 
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Antipsychotic generic drug name Drug Code Generation 
risperidone 93240998 2 
risperidone 99649998 2 
risperidone 90395998 2 
risperidone 99637998 2 
risperidone 99649996 2 
risperidone 98585998 2 
risperidone 91676998 2 
risperidone 88164998 2 
risperidone 92107998 2 
risperidone 99649997 2 
risperidone 86984998 2 
risperidone 85042998 2 
risperidone 85039998 2 
risperidone 99637996 2 
risperidone 86983998 2 
risperidone 95519998 2 
risperidone 98585997 2 
risperidone 85040998 2 
risperidone 92089998 2 
risperidone 93240997 2 
risperidone 85038998 2 
risperidone 99637997 2 
risperidone 91374998 2 
risperidone 92023998 2 
risperidone 89908998 2 
risperidone 92953990 2 
risperidone 91968998 2 
risperidone 93240996 2 
risperidone 92491990 2 
risperidone 90396998 2 
sertindole 89812998 2 
sertindole 89812996 2 
sertindole 89811998 2 
sertindole 89812997 2 
sertindole 89809996 2 
sertindole 89809997 2 
sertindole 89809998 2 
sulpiride 90158998 2 
sulpiride 97966990 2 
sulpiride 97163989 2 
sulpiride 95226996 2 
sulpiride 95226997 2 
sulpiride 90805998 2 
sulpiride 97176998 2 
sulpiride 97163990 2 
sulpiride 98796998 2 
sulpiride 98796997 2 
sulpiride 97858990 2 
sulpiride 98149992 2 
sulpiride 95226998 2 
thiopropazate 98174992 1 
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Antipsychotic generic drug name Drug Code Generation 
thioproperazine 98173992 1 
thioproperazine 96492992 1 
thioridazine 99437997 1 
thioridazine 95173996 1 
thioridazine 95175996 1 
thioridazine 99437996 1 
thioridazine 95174997 1 
thioridazine 95174998 1 
thioridazine 99437998 1 
thioridazine 97715989 1 
thioridazine 97715990 1 
thioridazine 98899997 1 
thioridazine 95173997 1 
thioridazine 98404990 1 
thioridazine 98899998 1 
thioridazine 95174996 1 
thioridazine 98003988 1 
thioridazine 95175998 1 
thioridazine 92821997 1 
thioridazine 99436998 1 
thioridazine 96570992 1 
thioridazine 98403989 1 
thioridazine 95175997 1 
thioridazine 92821998 1 
thioridazine 95173998 1 
thioridazine 98403990 1 
thioridazine 98404988 1 
thioridazine 98899996 1 
thioridazine 98404989 1 
thioridazine 98003989 1 
thioridazine 98003990 1 
trifluoperazine 92623998 1 
trifluoperazine 99107997 1 
trifluoperazine 99109998 1 
trifluoperazine 95119996 1 
trifluoperazine 92623997 1 
trifluoperazine 95118997 1 
trifluoperazine 99108998 1 
trifluoperazine 95607992 1 
trifluoperazine 95119997 1 
trifluoperazine 95119998 1 
trifluoperazine 99109997 1 
trifluoperazine 99109996 1 
trifluoperazine 95118998 1 
trifluoperazine 98052990 1 
trifluoperazine 92623996 1 
trifluoperazine 98203992 1 
trifluoperazine 98052989 1 
trifluoperazine 95118996 1 
trifluoperazine 99108997 1 
trifluoperazine 99107998 1 
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trifluoperazine 98400990 1 
trifluoperazine 98206992 1 
trifluoperazine 99108996 1 
trifluoperazine 87435998 1 
trifluperidol 98204992 1 
trifluperidol 95116997 1 
trifluperidol 95117998 1 
trifluperidol 95117997 1 
trifluperidol 95116998 1 
zotepine 98190997 2 
zotepine 98190996 2 
zotepine 99337998 2 
zotepine 99337996 2 
zotepine 99337997 2 
zotepine 98190998 2 
zuclopenthixol 85607998 1 
zuclopenthixol 95071998 1 
zuclopenthixol 96629997 1 
zuclopenthixol 86333998 1 
zuclopenthixol 86335998 1 
zuclopenthixol 93520998 1 
zuclopenthixol 99821997 1 
zuclopenthixol 85609998 1 
zuclopenthixol 96629998 1 
zuclopenthixol 86334998 1 
zuclopenthixol 96629996 1 
zuclopenthixol 96628997 1 
zuclopenthixol 86332998 1 
zuclopenthixol 96628998 1 
zuclopenthixol 99821998 1 
zuclopenthixol 93519998 1 
zuclopenthixol 98767998 1 
zuclopenthixol 99821996 1 
20.10 Antidepressants 
Antidepressant generic drug name Drug 
code 
Antidepressant type 
Mirtazapine 45mg orodispersible tablets sugar free 58745979 Other 
Mirtazapine 15mg orodispersible tablets sugar free 58747979 Other 
Dosulepin 25mg/5ml oral solution 80274979 Tricyclic antidepressant 
Amitriptyline 10mg/5ml oral suspension 81084998 Tricyclic antidepressant 
Amitriptyline 10mg/5ml oral solution 81085998 Tricyclic antidepressant 
VENLAFAXINE 37.5mg m/r tablets 81505998 Other 
Venlafaxine 37.5mg modified-release tablets 81506998 Other 
Venlafaxine 150mg modified-release capsules 81749998 Other 
Venlafaxine 75mg modified-release capsules 81750998 Other 
Venlafaxine 150mg modified-release capsules 81929998 Other 
Venlafaxine 75mg modified-release capsules 81930998 Other 
VENLAFAXINE 75mg m/r capsules 82191998 Other 
Imipramine 25mg/5ml oral solution sugar free 82432998 Tricyclic antidepressant 
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Venlafaxine 75mg modified-release capsules 82540998 Other 
ESCITALOPRAM 20mg/mL oral dps 82790998 SSRI 
Escitalopram 20mg/ml oral drops sugar free 82791998 SSRI 
AGOMELATINE 25mg tablets 82861998 Other 
Agomelatine 25mg tablets 82862998 Other 
VENLAFAXINE 150mg m/r capsules 82874998 Other 
VENLAFAXINE 75mg m/r capsules 82875998 Other 
VENLAFAXINE 225mg m/r tablets 82959998 Other 
Venlafaxine 225mg modified-release tablets 82961998 Other 
VENLAFAXINE 150mg m/r tablets 82962998 Other 
VENLAFAXINE 75mg m/r tablets 82963998 Other 
VENLAFAXINE 150mg m/r capsules 83074998 Other 
Venlafaxine 75mg modified-release capsules 83075998 Other 
VENLAFAXINE 150mg m/r capsules 83114998 Other 
VENLAFAXINE 75mg m/r capsules 83115998 Other 
Venlafaxine 150mg modified-release capsules 83145998 Other 
Venlafaxine 75mg modified-release capsules 83146998 Other 
VENLAFAXINE 150mg m/r capsules 83149998 Other 
VENLAFAXINE 75mg m/r capsules 83150998 Other 
VENLAFAXINE 150mg m/r tablets 83157998 Other 
VENLAFAXINE 75mg m/r tablets 83158998 Other 
Venlafaxine 150mg modified-release tablets 83159998 Other 
Venlafaxine 75mg modified-release tablets 83160998 Other 
VENLAFAXINE 75mg m/r tablets 83162998 Other 
VENLAFAXINE 37.5mg tablets 83163998 Other 
VENLAFAXINE 150mg m/r capsules 83204998 Other 
VENLAFAXINE 75mg m/r capsules 83205998 Other 
VENLAFAXINE 150mg m/r capsules 83217998 Other 
VENLAFAXINE 75mg m/r capsules 83218998 Other 
VENLAFAXINE 150mg m/r capsules 83264998 Other 
VENLAFAXINE 75mg m/r capsules 83265998 Other 
Amitrip+perphen 10/2mg tablet 83620998 Tricyclic antidepressant 
Clomipramine 50mg/5ml oral suspension 83878998 Tricyclic antidepressant 
Fluoxetine 20mg/5ml oral solution sugar free 84403998 SSRI 
Fluoxetine 20mg/5ml oral solution sugar free 84436998 SSRI 
PAROXETINE 10mg tablets 84807998 SSRI 
DOXEPIN 50mg capsules 85171998 Tricyclic antidepressant 
DOXEPIN 25mg capsules 85172998 Tricyclic antidepressant 
Paroxetine 10mg tablets 85382998 SSRI 
ESCITALOPRAM 10mg/mL oral dps 85970998 SSRI 
Escitalopram 10mg/ml oral drops sugar free 85971998 SSRI 
Sertraline 50mg/5ml oral suspension 86159998 SSRI 
Venlafaxine 37.5mg/5ml oral suspension 86431998 Other 
Mirtazapine 45mg tablets 86981998 Other 
Mirtazapine 15mg tablets 86982998 Other 
DULOXETINE 60mg g/r capsules 86996998 Other 
DULOXETINE 30mg g/r capsules 86997998 Other 
Duloxetine 60mg gastro-resistant capsules 86998998 Other 
Duloxetine 30mg gastro-resistant capsules 86999998 Other 
CITALOPRAM 10mg tablets 87251998 SSRI 
Mirtazapine 15mg/ml oral solution sugar free 87430998 Other 
ESCITALOPRAM 5mg tablets 87662998 SSRI 
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Escitalopram 5mg tablets 87663998 SSRI 
MIRTAZAPINE 45mg disp tabs 87684998 Other 
MIRTAZAPINE 15mg disp tabs 87685998 Other 
Mirtazapine 45mg orodispersible tablets 87686998 Other 
Mirtazapine 15mg orodispersible tablets 87687998 Other 
MIRTAZAPINE 30mg disp tabs 87945998 Other 
Mirtazapine 30mg orodispersible tablets 87946998 Other 
ESCITALOPRAM 10mg tablets 88285998 SSRI 
MIRTAZAPINE 30mg tablets 88715998 Other 
Mirtazapine 30mg tablets 88717998 Other 
VENLAFAXINE 150mg m/r capsules 88755997 Other 
VENLAFAXINE 75mg m/r capsules 88755998 Other 
Venlafaxine 150mg modified-release capsules 88776997 Other 
Venlafaxine 75mg modified-release capsules 88776998 Other 
REBOXETINE 4mg tablets 88836998 Other 
Reboxetine 4mg tablets 88838998 Other 
DOSULEPIN HCL 75mg tablets 88906997 Tricyclic antidepressant 
DOSULEPIN HCL 25mg capsules 88906998 Tricyclic antidepressant 
LOFEPRAMINE 70mg/5mL s/f susp 89205998 Tricyclic antidepressant 
MIRTAZAPINE 30mg disp tabs 90094979 Other 
Mirtazapine 15mg tablets 90125979 Other 
FLUOXETINE 20mg capsules 90159998 SSRI 
FLUOXETINE 20mg/5mL oral liq 90766998 SSRI 
FLUOXETINE 20mg capsules 90814998 SSRI 
Nefazodone Starter pack 91361996 Other 
Nefazodone 200mg tablets 91361997 Other 
Nefazodone 100mg tablets 91361998 Other 
NEFAZODONE initiation tabs pk 91362996 Other 
NEFAZODONE HCL 200mg tabs 91362997 Other 
NEFAZODONE HCL 100mg tabs 91362998 Other 
Citalopram 40mg tablets 91380996 SSRI 
Citalopram 10mg tablets 91380997 SSRI 
Citalopram 20mg tablets 91380998 SSRI 
CITALOPRAM 40mg tablets 91395996 SSRI 
CITALOPRAM 10mg tablets 91395997 SSRI 
CITALOPRAM 20mg tablets 91395998 SSRI 
Escitalopram 10mg tablets 91671998 SSRI 
CITALOPRAM 40mg/mL oral drops 92172998 SSRI 
Citalopram 40mg/ml oral drops sugar free 92174998 SSRI 
Mirtazapine 15mg orodispersible tablets 92454990 Other 
Sertraline 50mg tablets 92728990 SSRI 
Sertraline 100mg tablets 92729990 SSRI 
Amitriptyline 10mg/5ml sugar free oral solution 92808996 Tricyclic antidepressant 
Amitriptyline 25mg/5ml oral solution sugar free 92808997 Tricyclic antidepressant 
Amitriptyline 50mg/5ml oral solution sugar free 92808998 Tricyclic antidepressant 
Mirtazapine 45mg tablets 92813990 Other 
Mirtazapine 15mg tablets 92814990 Other 
Mirtazapine 45mg orodispersible tablets 92903990 Other 
Mirtazapine 15mg orodispersible tablets 92906990 Other 
Mirtazapine 45mg orodispersible tablets 92979990 Other 
Mirtazapine 30mg orodispersible tablets 92980990 Other 
Mirtazapine 15mg orodispersible tablets 92981990 Other 
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Mirtazapine 45mg orodispersible tablets 92986990 Other 
Mirtazapine 15mg orodispersible tablets 92988990 Other 
Mirtazapine 45mg orodispersible tablets 92992990 Other 
Fluoxetine 20mg capsules 93066990 SSRI 
Sertraline 100mg tablets 93173997 SSRI 
Sertraline 50mg tablets 93173998 SSRI 
SERTRALINE 100mg tablets 93174997 SSRI 
SERTRALINE 50mg tablets 93174998 SSRI 
Mirtazapine 45mg orodispersible tablets 93178990 Other 
Mirtazapine 15mg orodispersible tablets 93180990 Other 
CLOMIPRAMINE HCL 50mg capsules 93358992 Tricyclic antidepressant 
CLOMIPRAMINE HCL 10mg capsules 93360992 Tricyclic antidepressant 
Paroxetine 30mg tablets 93487990 SSRI 
PAROXETINE 10mg/5mL s/f liq 93489996 SSRI 
PAROXETINE 30mg tablets 93489997 SSRI 
PAROXETINE 20mg tablets 93489998 SSRI 
Paroxetine 10mg/5ml oral suspension sugar free 93490996 SSRI 
Paroxetine 30mg tablets 93490997 SSRI 
Paroxetine 20mg tablets 93490998 SSRI 
Sertraline 100mg tablets 93732990 SSRI 
Sertraline 50mg tablets 93749990 SSRI 
Moclobemide 300mg tablets 93749997 Monoamine-oxidase 
inhibitor 
Moclobemide 150mg tablets 93749998 Monoamine-oxidase 
inhibitor 
MOCLOBEMIDE 300mg tablets 93759997 Monoamine-oxidase 
inhibitor 
MOCLOBEMIDE 150mg tablets 93759998 Monoamine-oxidase 
inhibitor 
Trimipramine 50mg capsules 93839990 Tricyclic antidepressant 
Trimipramine 25mg tablets 93840990 Tricyclic antidepressant 
Trimipramine 10mg tablets 93841990 Tricyclic antidepressant 
Sertraline 100mg tablets 93842990 SSRI 
Citalopram 10mg tablets 93948990 SSRI 
Citalopram 10mg tablets 93994990 SSRI 
Citalopram 20mg tablets 93996990 SSRI 
Amoxapine 150mg tablets 94004998 Tricyclic antidepressant 
Amoxapine 100mg tablets 94005996 Tricyclic antidepressant 
Amoxapine 50mg tablets 94005997 Tricyclic antidepressant 
Amoxapine 25mg tablets 94005998 Tricyclic antidepressant 
AMOXAPINE 150mg tablets 94008998 Tricyclic antidepressant 
AMOXAPINE 100mg tablets 94009996 Tricyclic antidepressant 
AMOXAPINE 50mg tablets 94009997 Tricyclic antidepressant 
AMOXAPINE 25mg tablets 94009998 Tricyclic antidepressant 
Mirtazapine 45mg tablets 94035990 Other 
Mirtazapine 15mg tablets 94037990 Other 
AMITRIPTYLINE 75 MG TAB 94067992 Tricyclic antidepressant 
Amitriptyline 25mg tablets 94076990 Tricyclic antidepressant 
Mirtazapine 30mg tablets 94126990 Other 
DOTHIEPIN HCl 75 MG SYR 94145992 Tricyclic antidepressant 
DOTHIEPIN HCl 100 MG SYR 94146992 Tricyclic antidepressant 
MERITAL 50 50 MG CAP 94234992 Tricyclic antidepressant 
NORTRIPTYLINE 10 MG ELI 94249992 Tricyclic antidepressant 
Mirtazapine 15mg tablets 94250990 Other 
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Mirtazapine 45mg tablets 94400990 Other 
Mirtazapine 15mg tablets 94401990 Other 
Fluoxetine 60mg capsules 94447996 SSRI 
Fluoxetine 20mg/5ml oral solution 94447997 SSRI 
Fluoxetine 20mg capsules 94447998 SSRI 
DOTHIEPIN HCl 75 MG MIX 94452992 Tricyclic antidepressant 
FLUOXETINE 60mg capsules 94490996 SSRI 
FLUOXETINE 20mg/5mL oral liq 94490997 SSRI 
FLUOXETINE 20mg capsules 94490998 SSRI 
MERITAL 25 25 MG CAP 94498992 Tricyclic antidepressant 
TRYPTOPHAN 1g/6g powder 94512992 Other 
Trifluoperazine with tranylcypromine 1mg + 10mg Tablet 94626998 Monoamine-oxidase 
inhibitor 
Nortriptyline 30mg / Fluphenazine 1.5mg tablets 94630997 Tricyclic antidepressant 
Nortriptyline 10mg / Fluphenazine 500microgram tablets 94630998 Tricyclic antidepressant 
ASCORBIC ACID/PYRIDOXINE HCL/L-TRYPTOPHA 20 
MG POW 
94663992 Other 
Butriptyline 25mg tablets 94688998 Tricyclic antidepressant 
Amitriptyline 25mg / Perphenazine 2mg tablets 94703997 Tricyclic antidepressant 
Amitriptyline 10mg / Perphenazine 2mg tablets 94703998 Tricyclic antidepressant 
Amitriptyline 25mg / Chlordiazepoxide 10mg capsules 94704997 Tricyclic antidepressant 
Amitriptyline 12.5mg / Chlordiazepoxide 5mg capsules 94704998 Tricyclic antidepressant 
Amitriptyline 25mg tablets 94771990 Tricyclic antidepressant 
Mirtazapine 30mg tablets 94773990 Other 
Mirtazapine 30mg tablets 94797990 Other 
Dosulepin 75mg tablets 94800990 Tricyclic antidepressant 
Dosulepin 25mg capsules 94801990 Tricyclic antidepressant 
Mirtazapine 30mg tablets 94847990 Other 
Citalopram 40mg tablets 94880990 SSRI 
Citalopram 40mg tablets 94893990 SSRI 
Citalopram 20mg tablets 94894990 SSRI 
Citalopram 10mg tablets 94895990 SSRI 
Citalopram 40mg tablets 94936990 SSRI 
Citalopram 20mg tablets 94937990 SSRI 
DOTHIEPIN 100 MG SYR 94940992 Tricyclic antidepressant 
DOTHIEPIN 25 MG SYR 94941992 Tricyclic antidepressant 
DOTHIEPIN HCl 50 MG ELI 94942992 Tricyclic antidepressant 
DOTHIEPIN HCl 25 MG SYR 94943992 Tricyclic antidepressant 
DOTHIEPIN HCl 25 MG MIX 94944992 Tricyclic antidepressant 
Paroxetine 30mg tablets 95007990 SSRI 
Paroxetine 30mg tablets 95028990 SSRI 
Paroxetine 20mg tablets 95051990 SSRI 
Tryptophan with ascorbic acid and pyridoxine powder 95098997 Other 
Tryptophan 500mg tablets 95099998 Other 
Trimipramine 50mg capsules 95107996 Tricyclic antidepressant 
Trimipramine 25mg tablets 95107997 Tricyclic antidepressant 
Trimipramine 10mg tablets 95107998 Tricyclic antidepressant 
Trazodone 150mg modified-release tablets 95141997 Tricyclic antidepressant 
Trazodone 50mg/5ml oral solution sugar free 95141998 Tricyclic antidepressant 
Trazodone 150mg tablets 95142996 Tricyclic antidepressant 
Trazodone 100mg capsules 95142997 Tricyclic antidepressant 
Trazodone 50mg capsules 95142998 Tricyclic antidepressant 
Tranylcypromine with trifluoperazine Tablet 95143998 Monoamine-oxidase 
inhibitor 
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Tranylcypromine 10mg tablets 95144998 Monoamine-oxidase 
inhibitor 
IMIPRAMINE 75 MG TAB 95154992 Tricyclic antidepressant 
IMIPRAMINE 25 MG CAP 95155992 Tricyclic antidepressant 
IMIPRAMINE 50 MG TAB 95156992 Tricyclic antidepressant 
MERITAL AM 100 MG TAB 95262992 Tricyclic antidepressant 
Citalopram 40mg tablets 95269990 SSRI 
Citalopram 20mg tablets 95270990 SSRI 
Citalopram 10mg tablets 95271990 SSRI 
Paroxetine 20mg tablets 95332990 SSRI 
Citalopram 40mg tablets 95333990 SSRI 
Citalopram 20mg tablets 95334990 SSRI 
Citalopram 10mg tablets 95335990 SSRI 
Paroxetine 20mg tablets 95350990 SSRI 
TRYPTOPHAN 500mg tablets 95352992 Other 
Protriptyline 10mg tablet 95372997 Tricyclic antidepressant 
Protriptyline 5mg tablet 95372998 Tricyclic antidepressant 
Fluoxetine 20mg capsules 95388990 SSRI 
Citalopram 40mg tablets 95418990 SSRI 
Citalopram 20mg tablets 95420990 SSRI 
Citalopram 10mg tablets 95421990 SSRI 
Fluoxetine 20mg/5ml oral solution 95426990 SSRI 
Trazodone 150mg tablets 95527990 Tricyclic antidepressant 
Phenelzine 15mg tablets 95560998 Monoamine-oxidase 
inhibitor 
Perphenazine 2mg with Amitriptyline 25mg tablet 95574997 Tricyclic antidepressant 
Perphenazine 2mg with Amitriptyline 10mg tablet 95574998 Tricyclic antidepressant 
Paroxetine 20mg tablets 95578990 SSRI 
Fluoxetine 60mg capsules 95610990 SSRI 
Viloxazine hcl 50mg tablets 95624998 Tricyclic antidepressant 
Citalopram 40mg tablets 95631990 SSRI 
Citalopram 20mg tablets 95632990 SSRI 
Citalopram 10mg tablets 95633990 SSRI 
Tranylcypromine 10mg tablets 95665990 Monoamine-oxidase 
inhibitor 
Citalopram 40mg tablets 95666990 SSRI 
Citalopram 20mg tablets 95667990 SSRI 
Citalopram 10mg tablets 95668990 SSRI 
Nortriptyline 10mg/5ml Liquid 95695996 Tricyclic antidepressant 
Nortriptyline 25mg Capsule 95695997 Tricyclic antidepressant 
Nortriptyline 10mg Capsule 95695998 Tricyclic antidepressant 
Nortriptyline 25mg tablets 95696997 Tricyclic antidepressant 
Nortriptyline 10mg tablets 95696998 Tricyclic antidepressant 
Citalopram 40mg tablets 95703990 SSRI 
Citalopram 20mg tablets 95704990 SSRI 
Citalopram 10mg tablets 95705990 SSRI 
Mianserin 30mg tablets 95809996 Tricyclic antidepressant 
Mianserin 20mg tablets 95809997 Tricyclic antidepressant 
Mianserin 10mg tablets 95809998 Tricyclic antidepressant 
Fluoxetine 20mg/5ml oral solution 95813990 SSRI 
Fluoxetine 20mg/5ml oral solution 95820990 SSRI 
Maprotiline 75mg tablets 95927998 Tricyclic antidepressant 
Maprotiline 50mg tablets 95928996 Tricyclic antidepressant 
Maprotiline 25mg tablets 95928997 Tricyclic antidepressant 
 
 
317 
 
Maprotiline 10mg tablets 95928998 Tricyclic antidepressant 
Lofepramine 70mg/5ml oral suspension sugar free 95999997 Tricyclic antidepressant 
Lofepramine 70mg tablets 95999998 Tricyclic antidepressant 
VENLAFAXINE 150mg m/r capsules 96022979 Other 
VENLAFAXINE 150mg m/r capsules 96029979 Other 
VENLAFAXINE 75mg m/r capsules 96033979 Other 
Venlafaxine 75mg modified-release capsules 96034979 Other 
Moclobemide 150mg tablets 96061990 Monoamine-oxidase 
inhibitor 
Paroxetine 20mg tablets 96087990 SSRI 
Isocarboxazid 10mg tablets 96105998 Monoamine-oxidase 
inhibitor 
Iproniazid 25mg 96107998 Monoamine-oxidase 
inhibitor 
IPRINDOLE 15mg tablets 96108998 Tricyclic antidepressant 
Iprindole hc 30mg 96109997 Tricyclic antidepressant 
Iprindole hc 15mg 96109998 Tricyclic antidepressant 
Imipramine 25mg/5ml oral solution 96130998 Tricyclic antidepressant 
Dosulepin 25mg capsules 96158990 Tricyclic antidepressant 
Fluoxetine 20mg capsules 96272990 SSRI 
Fluoxetine 20mg capsules 96281990 SSRI 
Trazodone 150mg tablets 96295988 Tricyclic antidepressant 
Trazodone 100mg capsules 96295989 Tricyclic antidepressant 
Trazodone 50mg capsules 96295990 Tricyclic antidepressant 
Doxepin 75mg capsules 96307998 Tricyclic antidepressant 
Doxepin 50mg capsules 96308996 Tricyclic antidepressant 
Doxepin 25mg capsules 96308997 Tricyclic antidepressant 
Doxepin 10mg capsules 96308998 Tricyclic antidepressant 
Dosulepin 25mg/5ml oral solution sugar free 96311996 Tricyclic antidepressant 
Dosulepin 75mg tablets 96311997 Tricyclic antidepressant 
Dosulepin 25mg capsules 96311998 Tricyclic antidepressant 
Fluvoxamine 100mg tablets 96345989 SSRI 
NOMIFENSINE HYDROGEN MALEATE 50 MG CAP 96365992 Tricyclic antidepressant 
PROTRIPTYLINE HCl 10 MG TAB 96416992 Tricyclic antidepressant 
Trazodone 150mg tablets 96422988 Tricyclic antidepressant 
Trazodone 100mg capsules 96422989 Tricyclic antidepressant 
Trazodone 50mg capsules 96422990 Tricyclic antidepressant 
Desipramine 25mg tablets 96442998 Tricyclic antidepressant 
Trazodone 150mg tablets 96443988 Tricyclic antidepressant 
Trazodone 100mg capsules 96443989 Tricyclic antidepressant 
Trazodone 50mg capsules 96443990 Tricyclic antidepressant 
Dosulepin 25mg capsules 96467990 Tricyclic antidepressant 
FLUVOXAMINE MALEATE 100mg tabs 96492997 SSRI 
FLUVOXAMINE MALEATE 50mg tabs 96492998 SSRI 
Fluvoxamine 100mg tablets 96493997 SSRI 
Fluvoxamine 50mg tablets 96493998 SSRI 
Fluphen+nortri 500mcg/10mg ta 96499998 Tricyclic antidepressant 
Flupentixol 1mg tablets 96504997 Other 
Flupentixol 500microgram tablets 96504998 Other 
Fluoxetine 20mg capsules 96606990 SSRI 
CLOMIPRAMINE HCL 25mg/2mL inj 96637998 Tricyclic antidepressant 
Clomipramine 75mg modified-release tablets 96638998 Tricyclic antidepressant 
Clomipramine 25mg/5ml oral solution 96639998 Tricyclic antidepressant 
Clomipramine 50mg capsules 96640996 Tricyclic antidepressant 
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Clomipramine 25mg capsules 96640997 Tricyclic antidepressant 
Clomipramine 10mg capsules 96640998 Tricyclic antidepressant 
Fluoxetine 20mg capsules 96644990 SSRI 
Fluoxetine 20mg capsules 96647990 SSRI 
Fluoxetine 20mg capsules 96651990 SSRI 
Fluoxetine 20mg capsules 96654990 SSRI 
Fluoxetine 20mg capsules 96659990 SSRI 
Fluoxetine 20mg capsules 96674990 SSRI 
IMIPRAMINE 100 MG TAB 96687992 Tricyclic antidepressant 
Fluoxetine 20mg capsules 96709990 SSRI 
Trazodone 100mg capsules 96726989 Tricyclic antidepressant 
Trazodone 50mg capsules 96726990 Tricyclic antidepressant 
Fluoxetine 20mg capsules 96729990 SSRI 
Lofepramine 70mg tablets 96793990 Tricyclic antidepressant 
Fluvoxamine 100mg tablets 96810989 SSRI 
Dosulepin 75mg tablets 96868989 Tricyclic antidepressant 
Dosulepin 25mg capsules 96868990 Tricyclic antidepressant 
AMITRIPTYLINE S/F 25 MG/5ML SYR 96891992 Tricyclic antidepressant 
Clomipramine 50mg capsules 96901988 Tricyclic antidepressant 
Clomipramine 25mg capsules 96901989 Tricyclic antidepressant 
Amitriptyline 10mg/ml injection 96924998 Tricyclic antidepressant 
Amitriptyline 75mg modified-release capsules 96925996 Tricyclic antidepressant 
Amitriptyline 50mg modified-release capsules 96925997 Tricyclic antidepressant 
Amitriptyline 25mg modified-release capsules 96925998 Tricyclic antidepressant 
Lofepramine 70mg tablets 96963990 Tricyclic antidepressant 
Dosulepin 25mg capsules 96964990 Tricyclic antidepressant 
BOLVIDON 60 MG TAB 96987992 Tricyclic antidepressant 
IMIPRAMINE HCL 10mg tablets 97091998 Tricyclic antidepressant 
Imipramine 25mg tablets 97112997 Tricyclic antidepressant 
Imipramine 10mg tablets 97112998 Tricyclic antidepressant 
Lofepramine 70mg tablets 97142990 Tricyclic antidepressant 
CLOMIPRAMINE 25 MG TAB 97167992 Tricyclic antidepressant 
Isocarboxazid 10mg tablets 97169990 Monoamine-oxidase 
inhibitor 
Lofepramine 70mg tablets 97192990 Tricyclic antidepressant 
Amitriptyline 50mg tablets 97223996 Tricyclic antidepressant 
Amitriptyline 25mg tablets 97223997 Tricyclic antidepressant 
Amitriptyline 10mg tablets 97223998 Tricyclic antidepressant 
PROTRIPTYLINE HCL 10mg tabs 97505998 Tricyclic antidepressant 
PROTRIPTYLINE HCL 5mg tablets 97507998 Tricyclic antidepressant 
Clomipramine 50mg capsules 97548988 Tricyclic antidepressant 
Clomipramine 25mg capsules 97548989 Tricyclic antidepressant 
Clomipramine 10mg capsules 97548990 Tricyclic antidepressant 
IMIPRAMINE HCl 12.5 MG INJ 97593992 Tricyclic antidepressant 
Fluphen+nortrip 1.5/30mg tab 97632998 Tricyclic antidepressant 
Fluphen+nortri 500mcg/10mg ta 97634998 Tricyclic antidepressant 
MAPROTILINE HCl 75 MG TAB 97704992 Tricyclic antidepressant 
DOSULEPIN HCL 75mg tablets 97722997 Tricyclic antidepressant 
DOSULEPIN HCL 25mg capsules 97722998 Tricyclic antidepressant 
Lofepramine 70mg tablets 97743990 Tricyclic antidepressant 
Dosulepin 75mg tablets 97762989 Tricyclic antidepressant 
Dosulepin 25mg capsules 97762990 Tricyclic antidepressant 
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Clomipramine 25mg capsules 97773989 Tricyclic antidepressant 
NOMIFENSINE HYDROGEN MALEATE 25 MG CAP 97807992 Tricyclic antidepressant 
DOSULEPIN HCL 75mg tablets 97818997 Tricyclic antidepressant 
DOSULEPIN HCL 25mg capsules 97818998 Tricyclic antidepressant 
Lofepramine 70mg tablets 97861990 Tricyclic antidepressant 
SINEQUAN 15 MG TAB 98027992 Tricyclic antidepressant 
Amitriptyline 10mg/5ml sugar free oral solution 98067988 Tricyclic antidepressant 
Amitriptyline 50mg/5ml oral solution sugar free 98067989 Tricyclic antidepressant 
Amitriptyline 25mg/5ml oral solution sugar free 98067990 Tricyclic antidepressant 
Lofepramine 70mg/5ml oral suspension sugar free 98077990 Tricyclic antidepressant 
Dosulepin 75mg/5ml oral solution sugar free 98078989 Tricyclic antidepressant 
Dosulepin 25mg/5ml oral solution sugar free 98078990 Tricyclic antidepressant 
ESCITALOPRAM 20mg tablets 98088998 SSRI 
DOXEPIN 75mg capsules 98123998 Tricyclic antidepressant 
DOXEPIN 50mg capsules 98124996 Tricyclic antidepressant 
DOXEPIN 25mg capsules 98124997 Tricyclic antidepressant 
DOXEPIN 10mg capsules 98124998 Tricyclic antidepressant 
DOSULEPIN HCL 75mg tablets 98126997 Tricyclic antidepressant 
DOSULEPIN HCL 25mg capsules 98126998 Tricyclic antidepressant 
Amitriptyline 10mg/5ml sugar free oral solution 98128998 Tricyclic antidepressant 
AMITRIPTYLINE 75mg m/r caps 98129997 Tricyclic antidepressant 
AMITRIPTYLINE 100mg/10mL inj 98129998 Tricyclic antidepressant 
AMITRIPTYLINE 50mg tablets 98130996 Tricyclic antidepressant 
AMITRIPTYLINE 25mg tablets 98130997 Tricyclic antidepressant 
AMITRIPTYLINE 10mg tablets 98130998 Tricyclic antidepressant 
LOFEPRAMINE 70mg tablets 98132998 Tricyclic antidepressant 
BUTRIPTYLINE 25mg tablets 98134998 Tricyclic antidepressant 
TRIMIPRAMINE 50mg capsules 98136996 Tricyclic antidepressant 
TRIMIPRAMINE 25mg tablets 98136997 Tricyclic antidepressant 
TRIMIPRAMINE 10mg tablets 98136998 Tricyclic antidepressant 
AMITRIPTYLINE 50mg m/r caps 98138997 Tricyclic antidepressant 
AMITRIPTYLINE 25mg m/r caps 98138998 Tricyclic antidepressant 
IMIPRAMINE HCL 25mg/5mL syrup 98140996 Tricyclic antidepressant 
IMIPRAMINE 25mg tablets 98140997 Tricyclic antidepressant 
IMIPRAMINE HCL 10mg tablets 98140998 Tricyclic antidepressant 
CLOMIPRAMINE HCL 75mg m/r tabs 98142998 Tricyclic antidepressant 
CLOMIPRAMINE HCL 25mg/5mL syr 98143998 Tricyclic antidepressant 
CLOMIPRAMINE HCL 50mg capsules 98144996 Tricyclic antidepressant 
CLOMIPRAMINE HCL 25mg capsules 98144997 Tricyclic antidepressant 
CLOMIPRAMINE HCL 10mg capsules 98144998 Tricyclic antidepressant 
DESIPRAMINE HCL 25mg tablets 98146998 Tricyclic antidepressant 
MAPROTILINE HCL 75mg tablets 98147998 Tricyclic antidepressant 
MAPROTILINE HCL 50mg tabs 98148996 Tricyclic antidepressant 
MAPROTILINE HCL 25mg tablets 98148997 Tricyclic antidepressant 
MAPROTILINE HCL 10mg tabs 98148998 Tricyclic antidepressant 
Imipramine 25mg tablets 98149990 Tricyclic antidepressant 
AMITRIPTYLINE 50mg tablets 98150996 Tricyclic antidepressant 
AMITRIPTYLINE 25mg tablets 98150997 Tricyclic antidepressant 
AMITRIPTYLINE 10mg tablets 98150998 Tricyclic antidepressant 
NORTRIPTYLINE 25mg tablets 98152997 Tricyclic antidepressant 
NORTRIPTYLINE 10mg tablets 98152998 Tricyclic antidepressant 
NORTRIPTYLINE 10mg/5mL liquid 98154996 Tricyclic antidepressant 
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NORTRIPTYLINE 25mg capsules 98154997 Tricyclic antidepressant 
NORTRIPTYLINE 10mg capsules 98154998 Tricyclic antidepressant 
TOFRANIL 50 MG TAB 98183992 Tricyclic antidepressant 
TRIMIPRAMINE 50 MG TAB 98212992 Tricyclic antidepressant 
TRYPTOPHAN 500mg tablets 98257998 Other 
TRAZODONE HCL 150mg m/r tabs 98312997 Tricyclic antidepressant 
TRAZODONE HCL 50mg/5mL liquid 98312998 Tricyclic antidepressant 
ZIMELIDINE HCl 100 MG TAB 98327992 Tricyclic antidepressant 
Dosulepin 25mg/5ml mixture 98327997 Tricyclic antidepressant 
Dosulepin 75mg/5ml oral solution sugar free 98327998 Tricyclic antidepressant 
Venlafaxine 50mg tablets 98336996 Other 
Venlafaxine 75mg tablets 98336997 Other 
Venlafaxine 37.5mg tablets 98336998 Other 
Clomipramine 50mg capsules 98340988 Tricyclic antidepressant 
Clomipramine 25mg capsules 98340989 Tricyclic antidepressant 
Clomipramine 10mg capsules 98340990 Tricyclic antidepressant 
Amitriptyline 25mg / Chlordiazepoxide 10mg capsules 98343998 Tricyclic antidepressant 
Dosulepin 25mg capsules 98351989 Tricyclic antidepressant 
Dosulepin 75mg tablets 98351990 Tricyclic antidepressant 
TRAZODONE HCL 150mg tablets 98486996 Tricyclic antidepressant 
TRAZODONE HCL 100mg capsules 98486997 Tricyclic antidepressant 
TRAZODONE HCL 50mg capsules 98486998 Tricyclic antidepressant 
Escitalopram 20mg tablets 98561998 SSRI 
Dosulepin 25mg capsules 98563989 Tricyclic antidepressant 
Dosulepin 75mg tablets 98563990 Tricyclic antidepressant 
Dosulepin 25mg capsules 98783990 Tricyclic antidepressant 
VILOXAZINE 50mg tablets 98959998 Tricyclic antidepressant 
Amitrip+perphen 10/2mg tablet 99017997 Tricyclic antidepressant 
Amitrip+perphen 25/2mg tablet 99017998 Tricyclic antidepressant 
Tranylcyp+trifluop 10/1mg tab 99280998 Monoamine-oxidase 
inhibitor 
TRANYLCYPROMINE 10mg tablets 99281998 Monoamine-oxidase 
inhibitor 
TRYPTOPHAN 500mg tablets 99294998 Other 
Clomipramine 50mg capsules 99297988 Tricyclic antidepressant 
Clomipramine 25mg capsules 99297989 Tricyclic antidepressant 
Clomipramine 10mg capsules 99297990 Tricyclic antidepressant 
TRYPTOPHAN 500mg tablets 99316998 Other 
MIANSERIN 30mg tablets 99338996 Tricyclic antidepressant 
MIANSERIN 20mg tablets 99338997 Tricyclic antidepressant 
MIANSERIN 10mg tablets 99338998 Tricyclic antidepressant 
PHENELZINE 15mg tablets 99377998 Monoamine-oxidase 
inhibitor 
IPRONIAZID 25mg tablets 99448998 Monoamine-oxidase 
inhibitor 
ISOCARBOXAZID 10mg tablets 99450998 Monoamine-oxidase 
inhibitor 
Amitrip+chlordiaz 12.5/5mg ca 99472998 Tricyclic antidepressant 
Mianserin 20mg tablets 99494989 Tricyclic antidepressant 
Imipramine 25mg tablets 99554989 Tricyclic antidepressant 
Imipramine 10mg tablets 99554990 Tricyclic antidepressant 
Imipramine 25mg tablets 99555989 Tricyclic antidepressant 
Imipramine 10mg tablets 99555990 Tricyclic antidepressant 
Imipramine 25mg tablets 99556989 Tricyclic antidepressant 
FLUOXETINE 20mg capsules 99592998 SSRI 
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Dosulepin 75mg tablets 99614989 Tricyclic antidepressant 
Dosulepin 25mg capsules 99614990 Tricyclic antidepressant 
FLUPENTIXOL 1mg tablets 99634997 Other 
FLUPENTIXOL 500mcg tablets 99634998 Other 
AMOXAPINE 25 MG TAB 99791992 Tricyclic antidepressant 
CLOMIPRAMINE HCL 25mg/2mL inj 99794992 Tricyclic antidepressant 
AMITRIPTYLINE 100 MG TAB 99824992 Tricyclic antidepressant 
AMITRIPTYLINE 300 MG TAB 99825992 Tricyclic antidepressant 
AMITRIPTYLINE 200 MG TAB 99826992 Tricyclic antidepressant 
Amitriptyline 25mg tablets 99861989 Tricyclic antidepressant 
Amitriptyline 10mg tablets 99861990 Tricyclic antidepressant 
Amitriptyline 25mg tablets 99862990 Tricyclic antidepressant 
Amitriptyline 50mg tablets 99863988 Tricyclic antidepressant 
Amitriptyline 25mg tablets 99863989 Tricyclic antidepressant 
Amitriptyline 10mg tablets 99863990 Tricyclic antidepressant 
Amitriptyline 50mg tablets 99864988 Tricyclic antidepressant 
Amitriptyline 25mg tablets 99864989 Tricyclic antidepressant 
Amitriptyline 10mg tablets 99864990 Tricyclic antidepressant 
Amitriptyline 25mg tablets 99865990 Tricyclic antidepressant 
Amitriptyline 50mg tablets 99866988 Tricyclic antidepressant 
Amitriptyline 25mg tablets 99866989 Tricyclic antidepressant 
Amitriptyline 10mg tablets 99866990 Tricyclic antidepressant 
Amitriptyline 25mg tablets 99867989 Tricyclic antidepressant 
Amitriptyline 50mg tablets 99868988 Tricyclic antidepressant 
Amitriptyline 25mg tablets 99868989 Tricyclic antidepressant 
Amitriptyline 10mg tablets 99868990 Tricyclic antidepressant 
Amitriptyline 25mg tablets 99869988 Tricyclic antidepressant 
Amitriptyline 50mg tablets 99869989 Tricyclic antidepressant 
Amitriptyline 10mg tablets 99869990 Tricyclic antidepressant 
Amitriptyline 50mg tablets 99870988 Tricyclic antidepressant 
Amitriptyline 25mg tablets 99870989 Tricyclic antidepressant 
Amitriptyline 10mg tablets 99870990 Tricyclic antidepressant 
Amitriptyline 50mg tablets 99871988 Tricyclic antidepressant 
Amitriptyline 25mg tablets 99871989 Tricyclic antidepressant 
Amitriptyline 10mg tablets 99871990 Tricyclic antidepressant 
MIANSERIN 30mg tablets 99882996 Tricyclic antidepressant 
MIANSERIN 20mg tablets 99882997 Tricyclic antidepressant 
MIANSERIN 10mg tablets 99882998 Tricyclic antidepressant 
VENLAFAXINE 50mg tablets 99896996 Other 
VENLAFAXINE 75mg tablets 99896997 Other 
VENLAFAXINE 37.5mg tablets 99896998 Other 
L-TRYPTOPHAN 500 MG CAP 99937992 Other 
20.11 Mood stabilising drugs 
Mood stabilising drug generic name Drug 
Code 
Drug Type 
CARBAMAZEPINE 100mg chew tabs 93531998 carbamazepi
ne 
Carbamazepine 100mg chewable tablets sugar free 93530998 carbamazepi
ne 
Carbamazepine 100mg tablets 99751990 carbamazepi
ne 
Carbamazepine 100mg tablets 98338990 carbamazepi
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Mood stabilising drug generic name Drug 
Code 
Drug Type 
ne 
Carbamazepine 100mg tablets 99752990 carbamazepi
ne 
CARBAMAZEPINE 100mg tablets 92837998 carbamazepi
ne 
Carbamazepine 100mg tablets 96697989 carbamazepi
ne 
Carbamazepine 100mg tablets 97033998 carbamazepi
ne 
CARBAMAZEPINE 100mg tablets 98361998 carbamazepi
ne 
Carbamazepine 100mg tablets 97779990 carbamazepi
ne 
Carbamazepine 100mg/5ml oral suspension sugar free 96885998 carbamazepi
ne 
CARBAMAZEPINE 100mg/5mL sf liq 96479992 carbamazepi
ne 
CARBAMAZEPINE 100mg/5mL sf liq 98360998 carbamazepi
ne 
Carbamazepine 125mg suppositories 92734998 carbamazepi
ne 
CARBAMAZEPINE 125mg supps 92735998 carbamazepi
ne 
CARBAMAZEPINE 200mg chew tabs 93531997 carbamazepi
ne 
Carbamazepine 200mg chewable tablets sugar free 93530997 carbamazepi
ne 
CARBAMAZEPINE 200mg m/r tabs 81480998 carbamazepi
ne 
CARBAMAZEPINE 200mg m/r tabs 93532998 carbamazepi
ne 
CARBAMAZEPINE 200mg m/r tabs 89384998 carbamazepi
ne 
CARBAMAZEPINE 200mg m/r tabs 92131998 carbamazepi
ne 
Carbamazepine 200mg modified-release tablets 96446990 carbamazepi
ne 
Carbamazepine 200mg modified-release tablets 96536990 carbamazepi
ne 
Carbamazepine 200mg modified-release tablets 93579998 carbamazepi
ne 
Carbamazepine 200mg modified-release tablets 97128990 carbamazepi
ne 
Carbamazepine 200mg modified-release tablets 96128990 carbamazepi
ne 
Carbamazepine 200mg tablets 97779989 carbamazepi
ne 
Carbamazepine 200mg tablets 99751989 carbamazepi
ne 
CARBAMAZEPINE 200mg tablets 97086998 carbamazepi
ne 
Carbamazepine 200mg tablets 96916989 carbamazepi
ne 
Carbamazepine 200mg tablets 98338989 carbamazepi
ne 
Carbamazepine 200mg tablets 99752989 carbamazepi
ne 
Carbamazepine 200mg tablets 96697988 carbamazepi
ne 
CARBAMAZEPINE 200mg tablets 92837997 carbamazepi
ne 
CARBAMAZEPINE 200mg tablets 98361997 carbamazepi
ne 
Carbamazepine 200mg tablets 97033997 carbamazepi
ne 
Carbamazepine 250mg suppositories 92734997 carbamazepi
ne 
CARBAMAZEPINE 250mg supps 92735997 carbamazepi
ne 
CARBAMAZEPINE 400mg m/r tabs 95266979 carbamazepi
ne 
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Mood stabilising drug generic name Drug 
Code 
Drug Type 
CARBAMAZEPINE 400mg m/r tabs 88217997 carbamazepi
ne 
CARBAMAZEPINE 400mg m/r tabs 89384997 carbamazepi
ne 
CARBAMAZEPINE 400mg m/r tabs 81479998 carbamazepi
ne 
CARBAMAZEPINE 400mg m/r tabs 93532997 carbamazepi
ne 
Carbamazepine 400mg modified-release tablets 96536989 carbamazepi
ne 
Carbamazepine 400mg modified-release tablets 93579997 carbamazepi
ne 
Carbamazepine 400mg modified-release tablets 96446989 carbamazepi
ne 
Carbamazepine 400mg modified-release tablets 92131997 carbamazepi
ne 
Carbamazepine 400mg modified-release tablets 97128989 carbamazepi
ne 
Carbamazepine 400mg modified-release tablets 96127990 carbamazepi
ne 
CARBAMAZEPINE 400mg tablets 98361996 carbamazepi
ne 
Carbamazepine 400mg tablets 99751988 carbamazepi
ne 
Carbamazepine 400mg tablets 98338988 carbamazepi
ne 
CARBAMAZEPINE 400mg tablets 92837996 carbamazepi
ne 
Carbamazepine 400mg tablets 97033996 carbamazepi
ne 
Carbamazepine 400mg tablets 96916988 carbamazepi
ne 
Carbamazepine 400mg tablets 97779988 carbamazepi
ne 
Carbamazepine 500mg/5ml oral suspension 84311998 carbamazepi
ne 
LAMOTRIGINE 100mg disp tablets 92709996 lamotrigine 
Lamotrigine 100mg dispersible tablets sugar free 92700996 lamotrigine 
LAMOTRIGINE 100mg tablets 95404997 lamotrigine 
Lamotrigine 100mg tablets 94118990 lamotrigine 
Lamotrigine 100mg tablets 95444997 lamotrigine 
Lamotrigine 100mg tablets 94011990 lamotrigine 
Lamotrigine 200mg tablets 94010990 lamotrigine 
Lamotrigine 200mg tablets 91465998 lamotrigine 
LAMOTRIGINE 200mg tablets 91596998 lamotrigine 
LAMOTRIGINE 25mg disp tablets 92709997 lamotrigine 
Lamotrigine 25mg dispersible tablets sugar free 92700997 lamotrigine 
LAMOTRIGINE 25mg tablets 95112979 lamotrigine 
Lamotrigine 25mg tablets 94120990 lamotrigine 
LAMOTRIGINE 25mg tablets 95404996 lamotrigine 
Lamotrigine 25mg tablets 95444996 lamotrigine 
Lamotrigine 25mg tablets 94013990 lamotrigine 
LAMOTRIGINE 2mg disp tablets 91596997 lamotrigine 
Lamotrigine 2mg dispersible tablets sugar free 91465997 lamotrigine 
Lamotrigine 50mg dispersible tablets sugar free 86019998 lamotrigine 
Lamotrigine 50mg Suppository 81677998 lamotrigine 
LAMOTRIGINE 50mg tablets 95404998 lamotrigine 
LAMOTRIGINE 50mg tablets 93460992 lamotrigine 
Lamotrigine 50mg tablets 94012990 lamotrigine 
Lamotrigine 50mg tablets 95444998 lamotrigine 
LAMOTRIGINE 5mg disp tablets 92709998 lamotrigine 
 
 
324 
 
Mood stabilising drug generic name Drug 
Code 
Drug Type 
Lamotrigine 5mg dispersible tablets sugar free 92700998 lamotrigine 
LITH CITRATE 564mg m/r tabs 97534998 lithium 
LITHIUM 10.8 MMOLS/5MLS LIQ 96865992 lithium 
LITHIUM 250 MG CAP 97674992 lithium 
LITHIUM CAR 520mg/5mL s/f liq 93412998 lithium 
LITHIUM CARB 200mg m/r tabs 99217998 lithium 
LITHIUM CARB 300mg m/r tabs 96001998 lithium 
LITHIUM CARB 400mg m/r tabs 92542998 lithium 
LITHIUM CARB 400mg m/r tabs 99217997 lithium 
LITHIUM CARB 400mg m/r tabs 98814998 lithium 
LITHIUM CARB 450mg m/r tabs 99465998 lithium 
Lithium carbonate 200mg modified-release tablets 96004998 lithium 
Lithium carbonate 200mg/5ml oral suspension 84977998 lithium 
Lithium carbonate 250mg tablets 96004997 lithium 
LITHIUM CARBONATE 250mg tabs 99858998 lithium 
Lithium carbonate 300mg Modified-release tablet 96004996 lithium 
Lithium carbonate 400mg modified-release tablets 97979990 lithium 
Lithium carbonate 400mg modified-release tablets 96003998 lithium 
Lithium carbonate 450mg modified-release tablets 96002998 lithium 
LITHIUM CITR 10.8mmol/5mL liq 97705997 lithium 
LITHIUM CITR 5.4mmol/5mL liq 97705998 lithium 
Lithium citrate 1.018g/5ml oral solution 97716998 lithium 
Lithium citrate 509mg/5ml oral solution 96000996 lithium 
Lithium citrate 520mg/5ml oral solution sugar free 96000997 lithium 
Lithium citrate 564mg modified-release tablets 96000998 lithium 
PRIADEL 800 MG TAB 97951992 lithium 
SOD VALPROATE 100mg crush tabs 94409996 valproate 
SOD VALPROATE 100mg m/r grans 83707998 valproate 
SOD VALPROATE 200mg m/r tabs 92918998 valproate 
SOD VALPROATE 200mg m/r tabs 95186979 valproate 
SOD VALPROATE 200mg m/r tabs 95184979 valproate 
SOD VALPROATE 250mg m/r grans 83706998 valproate 
SOD VALPROATE 300mg m/r tabs 92918997 valproate 
SOD VALPROATE 300mg m/r tabs 95177979 valproate 
SOD VALPROATE 300mg m/r tabs 88177998 valproate 
SOD VALPROATE 500mg m/r grans 84665998 valproate 
SOD VALPROATE 500mg m/r tabs 95172979 valproate 
SOD VALPROATE 500mg m/r tabs 92918996 valproate 
SOD VALPROATE 500mg m/r tabs 88178998 valproate 
SOD VALPROATE 50mg m/r grans 83708998 valproate 
SOD VALPROATE 750mg m/r grans 83704998 valproate 
SOD VALPROATE C/R 200 MG TAB 96463992 valproate 
SOD VALPROTE 1g/sach m/r grans 84664998 valproate 
SOD. VALPROATE 200mg e/c tabs 92802998 valproate 
SOD. VALPROATE 200mg e/c tabs 83480998 valproate 
SOD. VALPROATE 200mg e/c tabs 94409998 valproate 
SOD. VALPROATE 200mg/5mL sfliq 94408997 valproate 
SOD. VALPROATE 200mg/5mL sfliq 92802996 valproate 
SOD. VALPROATE 500mg e/c tabs 94409997 valproate 
SOD. VALPROATE 500mg e/c tabs 83479998 valproate 
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Mood stabilising drug generic name Drug 
Code 
Drug Type 
Sodium valproate 100mg modified-release granules sachets sugar 
free 
81956998 valproate 
Sodium valproate 100mg tablets 97910990 valproate 
Sodium valproate 100mg tablets 94568998 valproate 
Sodium valproate 150mg modified-release capsules 84671998 valproate 
Sodium valproate 1g modified-release granules sachets sugar free 82857998 valproate 
Sodium valproate 1g modified-release granules sachets sugar free 84668998 valproate 
Sodium valproate 1g/10ml solution for injection ampoules 84089998 valproate 
Sodium valproate 200mg gastro-resistant tablets 98929990 valproate 
Sodium valproate 200mg gastro-resistant tablets 97721990 valproate 
Sodium valproate 200mg gastro-resistant tablets 96986990 valproate 
Sodium valproate 200mg gastro-resistant tablets 97911989 valproate 
Sodium valproate 200mg gastro-resistant tablets 93444990 valproate 
Sodium valproate 200mg gastro-resistant tablets 96977989 valproate 
Sodium valproate 200mg gastro-resistant tablets 91690990 valproate 
Sodium valproate 200mg gastro-resistant tablets 94606998 valproate 
Sodium valproate 200mg gastro-resistant tablets 97910989 valproate 
Sodium valproate 200mg gastro-resistant tablets 98385990 valproate 
Sodium valproate 200mg modified-release tablets 83321998 valproate 
Sodium valproate 200mg/5ml oral solution 94568996 valproate 
Sodium valproate 200mg/5ml oral solution 95810990 valproate 
Sodium valproate 200mg/5ml oral solution sugar free 94568997 valproate 
Sodium valproate 200mg/5ml oral solution sugar free 96159990 valproate 
Sodium valproate 200mg/5ml oral solution sugar free 97911990 valproate 
Sodium valproate 200mg/5ml oral solution sugar free 98929988 valproate 
SODIUM VALPROATE 200mg/5mL syr 95160979 valproate 
SODIUM VALPROATE 200mg/5mL syr 94408998 valproate 
Sodium valproate 250mg modified-release granules sachets sugar 
free 
81955998 valproate 
Sodium valproate 300mg modified-release capsules 84670998 valproate 
Sodium valproate 300mg modified-release tablets 95180979 valproate 
Sodium valproate 300mg modified-release tablets 92345998 valproate 
Sodium valproate 300mg suppositories 84720998 valproate 
Sodium valproate 300mg/3ml solution for injection ampoules 85030998 valproate 
Sodium valproate 400mg powder and solvent for solution for 
injection vials 
93148998 valproate 
SODIUM VALPROATE 400mg/4mL inj 94408996 valproate 
Sodium valproate 500mg gastro-resistant tablets 98084990 valproate 
Sodium valproate 500mg gastro-resistant tablets 98385989 valproate 
Sodium valproate 500mg gastro-resistant tablets 96977990 valproate 
Sodium valproate 500mg gastro-resistant tablets 92802997 valproate 
Sodium valproate 500mg gastro-resistant tablets 98929989 valproate 
Sodium valproate 500mg gastro-resistant tablets 94606997 valproate 
Sodium valproate 500mg gastro-resistant tablets 93443990 valproate 
Sodium valproate 500mg modified-release granules sachets sugar 
free 
84669998 valproate 
Sodium valproate 500mg modified-release granules sachets sugar 
free 
83705998 valproate 
Sodium valproate 500mg modified-release tablets 90505998 valproate 
Sodium valproate 50mg modified-release granules sachets sugar 
free 
81957998 valproate 
Sodium valproate 600mg/5ml oral solution 65489979 valproate 
Sodium valproate 750mg modified-release granules sachets sugar 
free 
81954998 valproate 
Sodium valproate oral solution 83766998 valproate 
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Mood stabilising drug generic name Drug 
Code 
Drug Type 
Sodium valproate with valproic acid 1000mg modified release 
granules 
83790998 valproate 
Sodium valproate with valproic acid 100mg modified release 
granules 
83794998 valproate 
Sodium valproate with valproic acid 200mg modified release tablets 92917998 valproate 
Sodium valproate with valproic acid 250mg modified release 
granules 
83793998 valproate 
Sodium valproate with valproic acid 300mg modified release tablets 95217990 valproate 
Sodium valproate with valproic acid 300mg modified release tablets 92917997 valproate 
Sodium valproate with valproic acid 500mg modified release 
granules 
83792998 valproate 
Sodium valproate with valproic acid 500mg modified release tablets 95216990 valproate 
Sodium valproate with valproic acid 500mg modified release tablets 92917996 valproate 
Sodium valproate with valproic acid 50mg modified release 
granules 
83709998 valproate 
Sodium valproate with valproic acid 750mg modified release 
granules 
83791998 valproate 
SODUM VALPROATE 150mg m/r caps 84667998 valproate 
SODUM VALPROATE 300mg m/r caps 84666998 valproate 
VALPROIC ACID 150mg e/c caps 93016998 valproate 
Valproic acid 150mg gastro-resistant capsules 93015998 valproate 
VALPROIC ACID 250mg e/c tabs 94068998 valproate 
Valproic acid 250mg gastro-resistant tablets 97628998 valproate 
VALPROIC ACID 300mg e/c caps 93016997 valproate 
Valproic acid 300mg gastro-resistant capsules 93015997 valproate 
VALPROIC ACID 500mg e/c caps 93016996 valproate 
VALPROIC ACID 500mg e/c tabs 94068997 valproate 
Valproic acid 500mg gastro-resistant capsules 93015996 valproate 
Valproic acid 500mg gastro-resistant tablets 97628997 valproate 
20.12 Asthma 
Asthma code description  Med Code 
Acute exacerbation of asthma H333.00 
Allergic asthma H330.11 
Allergic asthma NEC H33zz12 
Allergic bronchitis NEC H33zz13 
Asthma H33..00 
Asthma attack H33z100 
Asthma attack NOS H33z111 
Asthma NOS H33zz00 
Asthma unspecified H33z.00 
Brittle asthma H334.00 
Bronchial asthma H33..11 
Childhood asthma H330.12 
Exercise induced asthma H33zz11 
Extrinsic (atopic) asthma H330.00 
Extrinsic asthma NOS H330z00 
Extrinsic asthma with asthma attack H330111 
Extrinsic asthma with status asthmaticus H330100 
Extrinsic asthma without status asthmaticus H330000 
Hay fever with asthma H330.13 
Hay fever with asthma H330011 
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Asthma code description  Med Code 
Hyperreactive airways disease H33z.11 
Intrinsic asthma H331.00 
Intrinsic asthma NOS H331z00 
Intrinsic asthma with asthma attack H331111 
Intrinsic asthma with status asthmaticus H331100 
Intrinsic asthma without status asthmaticus H331000 
Late onset asthma H331.11 
Late-onset asthma H33z200 
Mixed asthma H332.00 
Pollen asthma H330.14 
Severe asthma attack H33z011 
Status asthmaticus NOS H33z000 
20.13 CKD 
CKD description Med Code 
Chronic kidney disease stage 3 1Z12.00 
Chronic kidney disease stage 4 1Z13.00 
Chronic kidney disease stage 5 1Z14.00 
Chronic kidney disease stage 3A 1Z15.00 
Chronic kidney disease stage 3B 1Z16.00 
Chronic kidney disease stage 3 w ith proteinuria 1Z1B.00 
CKD stage 3 w ith proteinuria 1Z1B.11 
Chronic kidney disease stage 3 w ithout proteinuria 1Z1C.00 
CKD stage 3 w ithout proteinuria 1Z1C.11 
Chronic kidney disease stage 3A with proteinuria 1Z1D.00 
CKD stage 3A with proteinuria 1Z1D.11 
Chronic kidney disease stage 3A without proteinuria 1Z1E.00 
CKD stage 3A without proteinuria 1Z1E.11 
Chronic kidney disease stage 3B with proteinuria 1Z1F.00 
CKD stage 3B with proteinuria 1Z1F.11 
Chronic kidney disease stage 3B without proteinuria 1Z1G.00 
CKD stage 3B without proteinuria 1Z1G.11 
Chronic kidney disease stage 4 w ith proteinuria 1Z1H.00 
CKD stage 4 w ith proteinuria 1Z1H.11 
Chronic kidney disease stage 4 w ithout proteinuria 1Z1J.00 
CKD stage 4 w ithout proteinuria 1Z1J.11 
Chronic kidney disease stage 5 w ith proteinuria 1Z1K.00 
CKD stage 5 w ith proteinuria 1Z1K.11 
Chronic kidney disease stage 5 w ithout proteinuria 1Z1L.00 
CKD stage 5 w ithout proteinuria 1Z1L.11 
20.14 COPD 
COPD description Med Code 
Acute interstitial emphysema H32y111 
Acute vesicular emphysema H32y000 
Atrophic (senile) emphysema H32y100 
Bronchiolitis obliterans H312300 
Bullous emphysema with collapse H320300 
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COPD description Med Code 
Centrilobular emphysema H322.00 
Chron obstruct pulmonary dis wth acute exacerbation, unspec H3y1.00 
Chronic asthmatic bronchitis H312000 
Chronic bronchitis H31..00 
Chronic bronchitis NOS H31z.00 
Chronic bullous emphysema H320.00 
Chronic bullous emphysema NOS H320z00 
Chronic catarrhal bronchitis H310000 
Chronic obstruct pulmonary dis with acute lower resp infectn H3y0.00 
Chronic obstructive airways disease H3...11 
Chronic obstructive airways disease NOS H3z..00 
Chronic obstructive pulmonary disease H3...00 
Chronic obstructive pulmonary disease NOS H3z..11 
Chronic tracheobronchitis H31y100 
Chronic wheezy bronchitis H312011 
Emphysema H32..00 
Emphysema NOS H32z.00 
Emphysematous bronchitis H312100 
Fetid chronic bronchitis H311100 
Giant bullous emphysema H320200 
MacLeod's unilateral emphysema H32y200 
Mild chronic obstructive pulmonary disease H36..00 
Mixed simple and mucopurulent chronic bronchitis H313.00 
Moderate chronic obstructive pulmonary disease H37..00 
Mucopurulent chronic bronchitis H311.00 
Mucopurulent chronic bronchitis NOS H311z00 
Obstructive chronic bronchitis H312.00 
Obstructive chronic bronchitis NOS H312z00 
Other chronic bronchitis H31y.00 
Other chronic bronchitis NOS H31yz00 
Other emphysema H32y.00 
Other emphysema NOS H32yz00 
Other specified chronic obstructive airways disease H3y..00 
Other specified chronic obstructive pulmonary disease H3y..11 
Panlobular emphysema H321.00 
Purulent chronic bronchitis H311000 
Sawyer - Jones syndrome H32yz11 
Segmental bullous emphysema H320000 
Severe chronic obstructive pulmonary disease H38..00 
Simple chronic bronchitis H310.00 
Simple chronic bronchitis NOS H310z00 
Tension pneumatocoele H320311 
Very severe chronic obstructive pulmonary disease H39..00 
Zonal bullous emphysema H320100 
20.15 Familial hypercholesterolaemia 
Familial hypercholesterolaemia description Med Code 
Pure hypercholesterolaemia C320.00 
Familial hypercholesterolaemia C320.11 
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Familial hypercholesterolaemia description Med Code 
Familial hypercholesterolaemia C320000 
Polygenic hypercholesterolaemia C320600 
Other specified pure hypercholesterolaemia C320y00 
Pure hypercholesterolaemia NOS C320z00 
[V]Dietary surveillance in hypercholesterolaemia ZV65317 
20.16 Hypothyroidism 
Hypothyroidism Med Code 
Acquired atrophy of thyroid C045.00 
Acquired hypothyroidism C04..00 
Autoimmune myxoedema C046.00 
Congenital hypothyroidism C03..00 
Congenital hypothyroidism NOS C03z.00 
Congenital hypothyroidism with diffuse goitre C03y000 
Congenital hypothyroidism without goitre C03y100 
Congenital thyroid insufficiency C03z.11 
Cretinism C03..11 
Cretinism C03z.12 
Goitrous cretin C031.00 
Hypothyroid goitre, acquired C04z.13 
Hypothyroidism C04..13 
Hypothyroidism NOS C04z.00 
Hypothyroidism resulting from para-aminosalicylic acid C043000 
Hypothyroidism resulting from phenylbutazone C043100 
Hypothyroidism resulting from resorcinol C043200 
Iatrogenic hypothyroidism NOS C043z00 
Iodine hypothyroidism C042.00 
Irradiation hypothyroidism C041000 
Myxoedema C04..11 
Myxoedema coma C04z100 
Other acquired hypothyroidism C04y.00 
Other iatrogenic hypothyroidism C043.00 
Other postablative hypothyroidism C041.00 
Other specified congenital hypothyroidism C03y.00 
Pendred's syndrome C030.00 
Post ablative hypothyroidism C040.11 
Postablative hypothyroidism NOS C041z00 
Postinfectious hypothyroidism C044.00 
Postsurgical hypothyroidism C040.00 
Premature puberty due to hypothyroidism C04z000 
Pretibial myxoedema - hypothyroid C04z.11 
Subclinical hypothyroidism C047.00 
Thyroid deficiency C04..12 
Thyroid insufficiency C04z.12 
20.17 Cancer 
Cancer description Med 
Code 
Cancer type 
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Cancer description Med 
Code 
Cancer type 
[M]Acute leukaemia NOS BBr0100 HEMA--Leukemia 
[M]Acute lymphoid leukaemia BBr2100 HEMA--Leukemia 
[M]Acute megakaryoblastic leukaemia BBrA500 HEMA--Leukemia 
[M]Acute myelofibrosis BBrA700 HEMA--Leukemia 
[M]Acute myeloid leukaemia BBr6100 HEMA--Leukemia 
[M]Acute myelomonocytic leukaemia BBr6700 HEMA--Leukemia 
[M]Acute promyelocytic leukaemia BBr6600 HEMA--Leukemia 
[M]Adult T-cell leukaemia/lymphoma BBr2700 HEMA--Leukemia 
[M]Blast cell leukaemia BBr0111 HEMA--Leukemia 
[M]Burkitt's cell leukaemia BBr2600 HEMA--Leukemia 
[M]Chronic leukaemia NOS BBr0300 HEMA--Leukemia 
[M]Chronic lymphoid leukaemia BBr2300 HEMA--Leukemia 
[M]Chronic myeloid leukaemia BBr6300 HEMA--Leukemia 
[M]Chronic myelomonocytic leukaemia BBr6800 HEMA--Leukemia 
[M]Eosinophilic leukaemia BBr8000 HEMA--Leukemia 
[M]Eosinophilic leukaemias BBr8.00 HEMA--Leukemia 
[M]Erythroleukaemias BBr4.00 HEMA--Leukemia 
[M]Granulocytic leukaemia NOS BBr6011 HEMA--Leukemia 
[M]Hairy cell leukaemia BBrA400 HEMA--Leukemia 
[M]Leukaemia NOS BBr0000 HEMA--Leukemia 
[M]Leukaemia NOS BBrz.00 HEMA--Leukemia 
[M]Leukaemia unspecified, NOS BBr0z00 HEMA--Leukemia 
[M]Leukaemias BBr..00 HEMA--Leukemia 
[M]Leukaemias unspecified BBr0.00 HEMA--Leukemia 
[M]Lymphatic leukaemia BBr2011 HEMA--Leukemia 
[M]Lymphoid leukaemia NOS BBr2000 HEMA--Leukemia 
[M]Lymphoid leukaemias BBr2.00 HEMA--Leukemia 
[M]Myeloid leukaemia NOS BBr6000 HEMA--Leukemia 
[M]Myeloid leukaemias BBr6.00 HEMA--Leukemia 
[M]Myelosis NOS BBr6012 HEMA--Leukemia 
[M]Other lymphoid leukaemia NOS BBr2z00 HEMA--Leukemia 
[M]Other myeloid leukaemia NOS BBr6z00 HEMA--Leukemia 
[M]Plasma cell leukaemias BBr3.00 HEMA--Leukemia 
[M]Prolymphocytic leukaemia BBr2500 HEMA--Leukemia 
[M]Stem cell leukaemia BBr0113 HEMA--Leukemia 
[M]Thrombocytic leukaemia BBrA111 HEMA--Leukemia 
[X]Other lymphoid leukaemia ByuD500 HEMA--Leukemia 
Acute erythraemia and erythroleukaemia B670.00 HEMA--Leukemia 
Acute leukaemia NOS B680.00 HEMA--Leukemia 
Acute lymphoid leukaemia B640.00 HEMA--Leukemia 
Acute monocytic leukaemia B660.00 HEMA--Leukemia 
Acute myelofibrosis B675.00 HEMA--Leukemia 
Acute myeloid leukaemia B650.00 HEMA--Leukemia 
Acute myelomonocytic leukaemia B690.00 HEMA--Leukemia 
Acute promyelocytic leukaemia B65y100 HEMA--Leukemia 
Adult T-cell leukaemia B64y200 HEMA--Leukemia 
Aleukaemic myeloid leukaemia B65y000 HEMA--Leukemia 
Chloroma B653000 HEMA--Leukemia 
Chronic eosinophilic leukaemia B651000 HEMA--Leukemia 
Chronic erythraemia B671.00 HEMA--Leukemia 
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Cancer description Med 
Code 
Cancer type 
Chronic granulocytic leukaemia B651.11 HEMA--Leukemia 
Chronic leukaemia NOS B681.00 HEMA--Leukemia 
Chronic lymphatic leukaemia B641.11 HEMA--Leukemia 
Chronic lymphoid leukaemia B641.00 HEMA--Leukemia 
Chronic monocytic leukaemia B661.00 HEMA--Leukemia 
Chronic myeloid leukaemia B651.00 HEMA--Leukemia 
Chronic myeloid leukaemia NOS B651z00 HEMA--Leukemia 
Chronic myelomonocytic leukaemia B691.00 HEMA--Leukemia 
Di Guglielmo's disease B670.11 HEMA--Leukemia 
Hairy cell leukaemia B624.12 HEMA--Leukemia 
Heilmeyer - Schoner disease B671.11 HEMA--Leukemia 
Histiocytic leukaemia B66..11 HEMA--Leukemia 
Leukaemia NOS B68z.00 HEMA--Leukemia 
Leukaemia of unspecified cell type B68..00 HEMA--Leukemia 
Leukaemic reticuloend of intra-abdominal lymph nodes B624300 HEMA--Leukemia 
Leukaemic reticuloendotheliosis B624.00 HEMA--Leukemia 
Leukaemic reticuloendotheliosis B624.11 HEMA--Leukemia 
Leukaemic reticuloendotheliosis of unspecified sites B624000 HEMA--Leukemia 
Lymphatic leukaemia B64..11 HEMA--Leukemia 
Lymphoid leukaemia B64..00 HEMA--Leukemia 
Lymphoid leukaemia NOS B64z.00 HEMA--Leukemia 
Malignant neoplasm lymphatic or haematopoietic tissue OS B6y..00 HEMA--Leukemia 
Mast cell leukaemia B673.00 HEMA--Leukemia 
Monoblastic leukaemia B66..12 HEMA--Leukemia 
Monocytic leukaemia B66..00 HEMA--Leukemia 
Monocytic leukaemia NOS B66z.00 HEMA--Leukemia 
Myeloid leukaemia B65..00 HEMA--Leukemia 
Myeloid leukaemia NOS B65z.00 HEMA--Leukemia 
Myeloid sarcoma B653.00 HEMA--Leukemia 
Myelomonocytic leukaemia B69..00 HEMA--Leukemia 
Myeloproliferative disease B6y0.11 HEMA--Leukemia 
Myeloproliferative disorder B6y0.00 HEMA--Leukemia 
Myelosclerosis with myeloid metaplasia B6y1.00 HEMA--Leukemia 
Other and unspecified leukaemia B67y.00 HEMA--Leukemia 
Other leukaemia of unspecified cell type B68y.00 HEMA--Leukemia 
Other lymphoid leukaemia B64y.00 HEMA--Leukemia 
Other lymphoid leukaemia NOS B64yz00 HEMA--Leukemia 
Other myeloid leukaemia NOS B65yz00 HEMA--Leukemia 
Other specified leukaemia B67..00 HEMA--Leukemia 
Other specified leukaemia NOS B67z.00 HEMA--Leukemia 
Prolymphocytic leukaemia B64y100 HEMA--Leukemia 
Subacute lymphoid leukaemia B642.00 HEMA--Leukemia 
Subacute myeloid leukaemia B652.00 HEMA--Leukemia 
Thrombocytic leukaemia B672.11 HEMA--Leukemia 
[X]Additional neoplasm classification terms Byu..00 HEMA--Myeloma 
Immunoproliferative neoplasm or myeloma NOS B63z.00 HEMA--Myeloma 
Kahler's disease B630.11 HEMA--Myeloma 
Lambda light chain myeloma B630300 HEMA--Myeloma 
Malignant plasma cell neoplasm, extramedullary 
plasmacytoma 
B630000 HEMA--Myeloma 
Multiple myeloma B630.00 HEMA--Myeloma 
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Multiple myeloma and immunoproliferative neoplasms B63..00 HEMA--Myeloma 
Myelomatosis B630.12 HEMA--Myeloma 
Other immunoproliferative neoplasms B63y.00 HEMA--Myeloma 
Plasma cell leukaemia B631.00 HEMA--Myeloma 
Plasmacytoma NOS B630200 HEMA--Myeloma 
Solitary myeloma B630100 HEMA--Myeloma 
[M]Adenoma of the nipple BB9A.11 Breast  
[M]Comedocarcinoma NOS BB93.00 Breast  
[M]Cystosarcoma phyllodes NOS BBM8.00 Breast  
[M]Cystosarcoma phyllodes, malignant BBM9.00 Breast  
[M]Duct adenoma NOS BB95.11 Breast  
[M]Duct carcinoma NOS BB91.11 Breast  
[M]Ductal papilloma BB95.12 Breast  
[M]Ductal, lobular and medullary neoplasms BB9..00 Breast  
[M]Ductal, lobular or medullary neoplasm NOS BB9z.00 Breast  
[M]Erosive nipple adenomatosis BB9A.12 Breast  
[M]Infiltrating duct and lobular carcinoma BB91100 Breast  
[M]Infiltrating duct carcinoma BB91.00 Breast  
[M]Intracystic carcinoma NOS BB9M.00 Breast  
[M]Intracystic papillary adenoma BB97.00 Breast  
[M]Intraductal carcinoma, noninfiltrating NOS BB90.00 Breast  
[M]Intraductal papillary adenocarcinoma with invasion BB91000 Breast  
[M]Intraductal papilloma BB95.00 Breast  
[M]Intraductal papillomatosis NOS BB99.00 Breast  
[M]Juvenile breast carcinoma BB94.00 Breast  
[M]Secretory breast carcinoma BB94.11 Breast  
[M]Subareolar duct papillomatosis BB9A.00 Breast  
[X]Malignant neoplasm of breast Byu6.00 Breast  
Ca female breast B34..11 Breast  
Cystosarcoma phyllodes B933.11 Breast  
Malignant neoplasm of areola of female breast B340100 Breast  
Malignant neoplasm of areola of male breast B350100 Breast  
Malignant neoplasm of axillary tail of female breast B346.00 Breast  
Malignant neoplasm of central part of female breast B341.00 Breast  
Malignant neoplasm of female breast B34..00 Breast  
Malignant neoplasm of female breast NOS B34z.00 Breast  
Malignant neoplasm of lower-inner quadrant of female breast B343.00 Breast  
Malignant neoplasm of lower-outer quadrant of female breast B345.00 Breast  
Malignant neoplasm of male breast B35..00 Breast  
Malignant neoplasm of male breast NOS B35zz00 Breast  
Malignant neoplasm of nipple and areola of female breast B340.00 Breast  
Malignant neoplasm of nipple and areola of male breast B350.00 Breast  
Malignant neoplasm of nipple of female breast B340000 Breast  
Malignant neoplasm of nipple of male breast B350000 Breast  
Malignant neoplasm of nipple or areola of female breast NOS B340z00 Breast  
Malignant neoplasm of other site of female breast B34y.00 Breast  
Malignant neoplasm of other site of female breast NOS B34yz00 Breast  
Malignant neoplasm of upper-inner quadrant of female breast B342.00 Breast  
Malignant neoplasm of upper-outer quadrant of female breast B344.00 Breast  
Malignant neoplasm, overlapping lesion of breast B347.00 Breast  
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Neoplasm of uncertain behaviour of breast B933.00 Breast  
Neoplasm of unspecified nature of breast BA03.00 Breast  
[X]Malignant melanoma of other+unspecified parts of face Byu4000 DERM--Melanoma 
[X]Malignant melanoma of skin, unspecified Byu4100 DERM--Melanoma 
H/O Malignant melanoma 1425000 DERM--Melanoma 
Malignant melanoma of ankle B327500 DERM--Melanoma 
Malignant melanoma of auricle (ear) B322000 DERM--Melanoma 
Malignant melanoma of axilla B325000 DERM--Melanoma 
Malignant melanoma of back B325700 DERM--Melanoma 
Malignant melanoma of breast B325100 DERM--Melanoma 
Malignant melanoma of buttock B325200 DERM--Melanoma 
Malignant melanoma of chest wall B325800 DERM--Melanoma 
Malignant melanoma of chin B323100 DERM--Melanoma 
Malignant melanoma of ear and external auricular canal B322.00 DERM--Melanoma 
Malignant melanoma of external surface of cheek B323000 DERM--Melanoma 
Malignant melanoma of external surface of nose B323400 DERM--Melanoma 
Malignant melanoma of eyebrow B323200 DERM--Melanoma 
Malignant melanoma of eyelid including canthus B321.00 DERM--Melanoma 
Malignant melanoma of face NOS B323z00 DERM--Melanoma 
Malignant melanoma of finger B326400 DERM--Melanoma 
Malignant melanoma of foot B327700 DERM--Melanoma 
Malignant melanoma of fore-arm B326200 DERM--Melanoma 
Malignant melanoma of forehead B323300 DERM--Melanoma 
Malignant melanoma of great toe B327900 DERM--Melanoma 
Malignant melanoma of groin B325300 DERM--Melanoma 
Malignant melanoma of hand B326300 DERM--Melanoma 
Malignant melanoma of heel B327600 DERM--Melanoma 
Malignant melanoma of knee B327200 DERM--Melanoma 
Malignant melanoma of lip B320.00 DERM--Melanoma 
Malignant melanoma of lower leg B327400 DERM--Melanoma 
Malignant melanoma of lower limb and hip B327.00 DERM--Melanoma 
Malignant melanoma of lower limb or hip NOS B327z00 DERM--Melanoma 
Malignant melanoma of neck B324100 DERM--Melanoma 
Malignant melanoma of other and unspecified parts of face  B323.00 DERM--Melanoma 
Malignant melanoma of other specified skin site B32y.00 DERM--Melanoma 
Malignant melanoma of perianal skin B325400 DERM--Melanoma 
Malignant melanoma of perineum B325500 DERM--Melanoma 
Malignant melanoma of popliteal fossa area B327300 DERM--Melanoma 
Malignant melanoma of scalp B324000 DERM--Melanoma 
Malignant melanoma of scalp and neck B324.00 DERM--Melanoma 
Malignant melanoma of shoulder B326000 DERM--Melanoma 
Malignant melanoma of skin B32..00 DERM--Melanoma 
Malignant melanoma of skin NOS B32z.00 DERM--Melanoma 
Malignant melanoma of temple B323500 DERM--Melanoma 
Malignant melanoma of thigh B327100 DERM--Melanoma 
Malignant melanoma of thumb B326500 DERM--Melanoma 
Malignant melanoma of toe B327800 DERM--Melanoma 
Malignant melanoma of trunk (excluding scrotum) B325.00 DERM--Melanoma 
Malignant melanoma of trunk, excluding scrotum, NOS B325z00 DERM--Melanoma 
Malignant melanoma of umbilicus B325600 DERM--Melanoma 
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Malignant melanoma of upper arm B326100 DERM--Melanoma 
Malignant melanoma of upper limb and shoulder B326.00 DERM--Melanoma 
Malignant melanoma of upper limb or shoulder NOS B326z00 DERM--Melanoma 
[M]Adnexal and skin appendage neoplasms BB6..00 DERM--Basal 
[M]Basal cell adenoma BB5A.00 DERM--Basal 
[M]Basal cell carcinoma NOS BB31.00 DERM--Basal 
[M]Basal cell carcinoma, fibroepithelial type BB34.00 DERM--Basal 
[M]Basal cell carcinoma, morphoea type BB33.00 DERM--Basal 
[M]Basal cell neoplasm NOS BB3z.00 DERM--Basal 
[M]Basal cell neoplasms BB3..00 DERM--Basal 
[M]Basal cell tumour BB30.00 DERM--Basal 
[M]Basosquamous carcinoma BB35.00 DERM--Basal 
[M]Granular cell carcinoma BB5b.00 DERM--Basal 
[M]Metatypical carcinoma BB36.00 DERM--Basal 
[M]Multicentric basal cell carcinoma BB32.00 DERM--Basal 
[M]Skin appendage carcinoma BB60100 DERM--Basal 
Basal cell carcinoma B33..11 DERM--Basal 
Epithelioma basal cell B33..16 DERM--Basal 
Cervical carcinoma (uterus) B41..11 GU--Cervix 
Malignant neoplasm of cervical stump B41y000 GU--Cervix 
Malignant neoplasm of cervix uteri B41..00 GU--Cervix 
Malignant neoplasm of cervix uteri NOS B41z.00 GU--Cervix 
Malignant neoplasm of endocervical canal B410000 GU--Cervix 
Malignant neoplasm of endocervical gland B410100 GU--Cervix 
Malignant neoplasm of endocervix B410.00 GU--Cervix 
Malignant neoplasm of endocervix NOS B410z00 GU--Cervix 
Malignant neoplasm of exocervix B411.00 GU--Cervix 
Malignant neoplasm of other site of cervix B41y.00 GU--Cervix 
Malignant neoplasm of other site of cervix NOS B41yz00 GU--Cervix 
Malignant neoplasm of squamocolumnar junction of cervix B41y100 GU--Cervix 
Malignant neoplasm, overlapping lesion of cervix uteri B412.00 GU--Cervix 
[M]Dysgerminoma BBQ0.00 GU--Testis 
[M]Leydig cell tumour BBCC.00 GU--Testis 
[M]Pick's tubular adenoma BBC9.11 GU--Testis 
[M]Seminoma NOS BBQ1z00 GU--Testis 
[M]Seminoma, anaplastic type BBQ1000 GU--Testis 
[M]Seminomas BBQ1.00 GU--Testis 
[M]Sertoli cell carcinoma BBCA.00 GU--Testis 
[M]Sertoli cell tumour BBC9.13 GU--Testis 
[M]Spermatocytic seminoma BBQ1100 GU--Testis 
[M]Testicular adenoma BBC9.14 GU--Testis 
[M]Testicular stromal tumour BBC0.13 GU--Testis 
Malignant neoplasm of descended testis B471.00 GU--Testis 
Malignant neoplasm of descended testis NOS B471z00 GU--Testis 
Malignant neoplasm of testis B47..00 GU--Testis 
Malignant neoplasm of testis NOS B47z.00 GU--Testis 
Malignant neoplasm of undescended testis B470.00 GU--Testis 
Neoplasm of uncertain behaviour of testis B914.00 GU--Testis 
Seminoma of descended testis B471000 GU--Testis 
Seminoma of testis B47z.11 GU--Testis 
 
 
335 
 
Cancer description Med 
Code 
Cancer type 
Seminoma of undescended testis B470200 GU--Testis 
Teratoma of descended testis B471100 GU--Testis 
Teratoma of testis B47z.12 GU--Testis 
Teratoma of undescended testis B470300 GU--Testis 
[M]Borderline mucinous cystadenoma of the ovary BB80200 GU--Ovary 
[M]Brenner tumour NOS BBM0z00 GU--Ovary 
[M]Brenner tumour, borderline malignancy BBM0000 GU--Ovary 
[M]Brenner tumour, malignant BBM0100 GU--Ovary 
[M]Brenner tumours BBM0.00 GU--Ovary 
[M]Hilar cell tumour BBCD.00 GU--Ovary 
[M]Lipid cell tumour of ovary BBCE.00 GU--Ovary 
[M]Ovarian cystadenoma or carcinoma BB81.11 GU--Ovary 
[M]Ovarian cystic, mucinous and serous neoplasms BB81.00 GU--Ovary 
[M]Ovarian cystic, mucinous or serous neoplasm NOS BB81z00 GU--Ovary 
[M]Ovarian mucinous tumour BB81.12 GU--Ovary 
[M]Ovarian papillary tumour BB81.13 GU--Ovary 
[M]Ovarian serous tumour BB81.14 GU--Ovary 
[M]Ovarian stromal tumour BBC0.12 GU--Ovary 
[M]Papillary cystadenocarcinoma, NOS BB81500 GU--Ovary 
[M]Papillary cystadenoma NOS BB81300 GU--Ovary 
[M]Papillary cystadenoma, borderline malignancy BB81400 GU--Ovary 
[M]Papillary serous cystadenocarcinoma BB81800 GU--Ovary 
[M]Papillary serous cystadenoma NOS BB81600 GU--Ovary 
[M]Papillary serous cystadenoma, borderline malignancy BB81700 GU--Ovary 
[M]Serous cystadenocarcinoma, NOS BB81200 GU--Ovary 
[M]Serous cystadenoma NOS BB81000 GU--Ovary 
[M]Serous cystadenoma, borderline malignancy BB81100 GU--Ovary 
[M]Struma ovarii NOS BBQA000 GU--Ovary 
[M]Struma ovarii, malignant BBQA100 GU--Ovary 
[M]Strumal carcinoid BBQA200 GU--Ovary 
Cancer of ovary B440.11 GU--Ovary 
Malignant neoplasm of ovary B440.00 GU--Ovary 
Malignant neoplasm of ovary and other uterine adnexa B44..00 GU--Ovary 
Neoplasm of uncertain behaviour of ovary B912.00 GU--Ovary 
Malignant neoplasm of prostate B46..00 GU--Prostate 
Neoplasm of uncertain behaviour of prostate B915.00 GU--Prostate 
[M]Adenofibroma NOS BBM4.00 GU--Uterus 
[M]Cellular intracanalicular fibroadenoma BBM7.00 GU--Uterus 
[M]Cystadenofibroma NOS BBM4.11 GU--Uterus 
[M]Endometrial stromal sarcoma BBL0.00 GU--Uterus 
[M]Endometrioid adenoma NOS BB5j000 GU--Uterus 
[M]Endometrioid adenoma or carcinoma NOS BB5jz00 GU--Uterus 
[M]Endometrioid adenoma, borderline malignancy BB5j100 GU--Uterus 
[M]Endometrioid adenomas and carcinomas BB5j.00 GU--Uterus 
[M]Endometrioid carcinoma BB5j200 GU--Uterus 
[M]Endometrioid cystadenoma NOS BB5j011 GU--Uterus 
[M]Fibroadenoma phyllodes BBM7.12 GU--Uterus 
[M]Giant fibroadenoma NOS BBM7.13 GU--Uterus 
[M]Intracanalicular fibroadenoma NOS BBM2.00 GU--Uterus 
[M]Mucinous adenofibroma BBM6.00 GU--Uterus 
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[M]Serous adenofibroma BBM5.00 GU--Uterus 
[M]Tubular adenocarcinoma BB5M100 GU--Uterus 
[M]Tubular adenoma NOS BB5M000 GU--Uterus 
[M]Tubular adenoma or adenocarcinoma NOS BB5Mz00 GU--Uterus 
[M]Tubular adenomas and adenocarcinomas BB5M.00 GU--Uterus 
Malignant neoplasm of body of uterus B43..00 GU--Uterus 
Malignant neoplasm of body of uterus NOS B43z.00 GU--Uterus 
Malignant neoplasm of cornu of corpus uteri B430000 GU--Uterus 
Malignant neoplasm of corpus uteri NOS B430z00 GU--Uterus 
Malignant neoplasm of corpus uteri, excluding isthmus B430.00 GU--Uterus 
Malignant neoplasm of endometrium B430211 GU--Uterus 
Malignant neoplasm of endometrium of corpus uteri B430200 GU--Uterus 
Malignant neoplasm of fundus of corpus uteri B430100 GU--Uterus 
Malignant neoplasm of isthmus of uterine body B431.00 GU--Uterus 
Malignant neoplasm of isthmus of uterine body NOS B431z00 GU--Uterus 
Malignant neoplasm of lower uterine segment B431000 GU--Uterus 
Malignant neoplasm of myometrium of corpus uteri B430300 GU--Uterus 
Malignant neoplasm of other site of uterine body B43y.00 GU--Uterus 
Malignant neoplasm of overlapping lesion of corpus uteri B432.00 GU--Uterus 
Malignant neoplasm of uterine adnexa NOS B44z.00 GU--Uterus 
Malignant neoplasm of uterus, part unspecified B40..00 GU--Uterus 
Neoplasm of uncertain behaviour of uterus B910.00 GU--Uterus 
[M]Glucagonoma NOS BB5B400 GI--Pancreas 
[M]Glucagonoma, malignant BB5B500 GI--Pancreas 
[M]Insulinoma NOS BB5B200 GI--Pancreas 
[M]Islet cell adenoma BB5B000 GI--Pancreas 
[M]Islet cell carcinoma BB5B100 GI--Pancreas 
[M]Nesidioblastoma BB5B011 GI--Pancreas 
[M]Pancreatic adenoma or carcinoma NOS BB5Bz00 GI--Pancreas 
[M]Pancreatic adenomas and carcinomas BB5B.00 GI--Pancreas 
Malignant neoplasm of body of pancreas B171.00 GI--Pancreas 
Malignant neoplasm of ectopic pancreatic tissue B17y000 GI--Pancreas 
Malignant neoplasm of head of pancreas B170.00 GI--Pancreas 
Malignant neoplasm of Islets of Langerhans B174.00 GI--Pancreas 
Malignant neoplasm of other specified sites of pancreas B17y.00 GI--Pancreas 
Malignant neoplasm of pancreas B17..00 GI--Pancreas 
Malignant neoplasm of pancreas NOS B17z.00 GI--Pancreas 
Malignant neoplasm of pancreatic duct B173.00 GI--Pancreas 
Malignant neoplasm of tail of pancreas B172.00 GI--Pancreas 
Malignant neoplasm, overlapping lesion of pancreas B175.00 GI--Pancreas 
Neoplasm of uncertain behaviour of pancreas B905100 GI--Pancreas 
Gastric neoplasm B11..11 GI--Upper  
Malignant neoplasm of abdominal oesophagus B102.00 GI--Upper  
Malignant neoplasm of body of stomach B114.00 GI--Upper  
Malignant neoplasm of cardia of stomach B110.00 GI--Upper  
Malignant neoplasm of cardia of stomach NOS B110z00 GI--Upper  
Malignant neoplasm of cardiac orifice of stomach B110000 GI--Upper  
Malignant neoplasm of cardio-oesophageal junction of 
stomach 
B110100 GI--Upper  
Malignant neoplasm of cervical oesophagus B100.00 GI--Upper  
Malignant neoplasm of fundus of stomach B113.00 GI--Upper  
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Malignant neoplasm of greater curve of stomach unspecified B116.00 GI--Upper  
Malignant neoplasm of lesser curve of stomach unspecified B115.00 GI--Upper  
Malignant neoplasm of lower third of oesophagus B105.00 GI--Upper  
Malignant neoplasm of middle third of oesophagus B104.00 GI--Upper  
Malignant neoplasm of oesophagus B10..00 GI--Upper  
Malignant neoplasm of oesophagus NOS B10z.00 GI--Upper  
Malignant neoplasm of other specified part of oesophagus B10y.00 GI--Upper  
Malignant neoplasm of other specified site of stomach B11y.00 GI--Upper  
Malignant neoplasm of other specified site of stomach NOS B11yz00 GI--Upper  
Malignant neoplasm of prepylorus of stomach B111000 GI--Upper  
Malignant neoplasm of pyloric antrum of stomach B112.00 GI--Upper  
Malignant neoplasm of pyloric canal of stomach B111100 GI--Upper  
Malignant neoplasm of pylorus of stomach B111.00 GI--Upper  
Malignant neoplasm of pylorus of stomach NOS B111z00 GI--Upper  
Malignant neoplasm of stomach B11..00 GI--Upper  
Malignant neoplasm of stomach NOS B11z.00 GI--Upper  
Malignant neoplasm of thoracic oesophagus B101.00 GI--Upper  
Malignant neoplasm of upper third of oesophagus B103.00 GI--Upper  
Malignant neoplasm, overlapping lesion of oesophagus B106.00 GI--Upper  
Malignant neoplasm, overlapping lesion of stomach B117.00 GI--Upper  
Neoplasm of uncertain behaviour of duodenum B902100 GI--Upper  
Neoplasm of uncertain behaviour of oesophagus B905000 GI--Upper  
Neoplasm of uncertain behaviour of stomach B902000 GI--Upper  
Oesophageal cancer B10z.11 GI--Upper  
[M]Adenocarcinoma in adenomatous polyp BB5L100 GI--Low er  
[M]Adenocarcinoma in multiple adenomatous polyps BB5L300 GI--Low er  
[M]Adenoma or or adenocarcinoma in polyposis coli BB5N.11 GI--Low er  
[M]Adenomatosis NOS BB5N011 GI--Low er  
[M]Adenomatous and adenocarcinomatous polyps BB5L.00 GI--Low er  
[M]Adenomatous and adenocarcinomatous polyps of colon BB5N.00 GI--Low er  
[M]Adenomatous or adenocarcinomatous polyp NOS BB5Lz00 GI--Low er  
[M]Adenomatous or adenocarcinomatous polyps of the colon 
NOS 
BB5Nz00 GI--Low er  
[M]Adenomatous polyp NOS BB5L000 GI--Low er  
[M]Adenomatous polyposis coli BB5N000 GI--Low er  
[M]Familial polyposis coli BB5N012 GI--Low er  
[M]Multiple adenomatous polyps BB5N200 GI--Low er  
[M]Multiple polyposis BB5N211 GI--Low er  
[M]Polypoid adenoma BB5L011 GI--Low er  
Anal carcinoma B142.11 GI--Low er  
Cancer of bowel B1z0.11 GI--Low er  
Carcinoma of caecum B134.11 GI--Low er  
Carcinoma of rectum B141.11 GI--Low er  
Colonic cancer B13z.11 GI--Low er  
Malig neop other site rectum, rectosigmoid junction and anus B14y.00 GI--Low er  
Malignant neoplasm of anal canal B142.00 GI--Low er  
Malignant neoplasm of anus unspecified B143.00 GI--Low er  
Malignant neoplasm of appendix B135.00 GI--Low er  
Malignant neoplasm of ascending colon B136.00 GI--Low er  
Malignant neoplasm of caecum B134.00 GI--Low er  
Malignant neoplasm of cloacogenic zone B142000 GI--Low er  
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Malignant neoplasm of colon B13..00 GI--Low er  
Malignant neoplasm of colon NOS B13z.00 GI--Low er  
Malignant neoplasm of descending colon B132.00 GI--Low er  
Malignant neoplasm of duodenum B120.00 GI--Low er  
Malignant neoplasm of hepatic flexure of colon B130.00 GI--Low er  
Malignant neoplasm of ileum B122.00 GI--Low er  
Malignant neoplasm of jejunum B121.00 GI--Low er  
Malignant neoplasm of Meckel's diverticulum B123.00 GI--Low er  
Malignant neoplasm of other specified site small intestine B12y.00 GI--Low er  
Malignant neoplasm of other specified sites of colon B13y.00 GI--Low er  
Malignant neoplasm of rectosigmoid junction B140.00 GI--Low er  
Malignant neoplasm of rectum B141.00 GI--Low er  
Malignant neoplasm of rectum, rectosigmoid junction and anus B14..00 GI--Low er  
Malignant neoplasm of sigmoid colon B133.00 GI--Low er  
Malignant neoplasm of small intestine and duodenum B12..00 GI--Low er  
Malignant neoplasm of small intestine NOS B12z.00 GI--Low er  
Malignant neoplasm of splenic flexure of colon B137.00 GI--Low er  
Malignant neoplasm of transverse colon B131.00 GI--Low er  
Malignant neoplasm rectum,rectosigmoid junction and anus 
NOS 
B14z.00 GI--Low er  
Malignant neoplasm, overlapping lesion of colon B138.00 GI--Low er  
Malignant neoplasm, overlapping lesion of small intestine B124.00 GI--Low er  
Neoplasm of uncertain behaviour of anal canal and sphincter  B905200 GI--Low er  
Neoplasm of uncertain behaviour of colon B902400 GI--Low er  
Neoplasm of uncertain behaviour of rectum B902500 GI--Low er  
Neoplasm of uncertain or unknown behaviour of appendix B902600 GI--Low er  
Rectal carcinoma B141.12 GI--Low er  
[M]Basaloid carcinoma BB48.00 GU--Bladder 
[M]Cloacogenic carcinoma BB49.00 GU--Bladder 
[M]Papillary transitional cell carcinoma BB4A.00 GU--Bladder 
[M]Schneiderian papilloma BB44.00 GU--Bladder 
[M]Transitional cell carcinoma NOS BB43.00 GU--Bladder 
[M]Transitional cell carcinoma, spindle cell type BB47.00 GU--Bladder 
[M]Transitional cell papilloma or carcinoma NOS BB4z.00 GU--Bladder 
[M]Transitional cell papilloma, inverted type BB45.00 GU--Bladder 
[M]Urinary bladder papilloma BB41.11 GU--Bladder 
[M]Urothelial carcinoma BB43.11 GU--Bladder 
[M]Urothelial papilloma BB41.00 GU--Bladder 
Malignant neoplasm of anterior wall of urinary bladder B493.00 GU--Bladder 
Malignant neoplasm of bladder neck B495.00 GU--Bladder 
Malignant neoplasm of dome of urinary bladder B491.00 GU--Bladder 
Malignant neoplasm of lateral wall of urinary bladder B492.00 GU--Bladder 
Malignant neoplasm of other site of urinary bladder B49y.00 GU--Bladder 
Malignant neoplasm of posterior wall of urinary bladder B494.00 GU--Bladder 
Malignant neoplasm of trigone of urinary bladder B490.00 GU--Bladder 
Malignant neoplasm of urachus B497.00 GU--Bladder 
Malignant neoplasm of ureteric orifice B496.00 GU--Bladder 
Malignant neoplasm of urinary bladder B49..00 GU--Bladder 
Malignant neoplasm of urinary bladder NOS B49z.00 GU--Bladder 
Malignant neoplasm, overlapping lesion of bladder B49y000 GU--Bladder 
Neoplasm of uncertain behaviour of bladder  B917.00 GU--Bladder 
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Neoplasm of unspecified nature of bladder BA04.00 GU--Bladder 
Transitional cell papilloma of bladder B917.12 GU--Bladder 
[M]Adenosarcoma BBL7111 GU--Kidney 
[M]Adrenal cortical adenoma NOS BB5h000 GU--Kidney 
[M]Adrenal cortical carcinoma BB5h100 GU--Kidney 
[M]Adrenal cortical tumours BB5h.00 GU--Kidney 
[M]Adrenal cortical tumours NOS BB5hz00 GU--Kidney 
[M]Grawitz tumour BB5a011 GU--Kidney 
[M]Hypernephroma BB5a012 GU--Kidney 
[M]Mesoblastic nephroma BBL7000 GU--Kidney 
[M]Mesonephroma, malignant BBS2.00 GU--Kidney 
[M]Mesonephromas BBS..00 GU--Kidney 
[M]Mixed and stromal renal neoplasms BBL7.00 GU--Kidney 
[M]Nephroblastoma NOS BBL7100 GU--Kidney 
[M]Nephromas and nephroblastomas BBL7.11 GU--Kidney 
[M]Renal adenoma and carcinoma BB5a.00 GU--Kidney 
[M]Renal adenoma or carcinoma NOS BB5az00 GU--Kidney 
[M]Renal cell carcinoma BB5a000 GU--Kidney 
[M]Wilms' tumour BBL7112 GU--Kidney 
Hypernephroma B4A0000 GU--Kidney 
Malig neop of kidney and other unspecified urinary organs B4A..00 GU--Kidney 
Malignant neoplasm of kidney or urinary organs NOS B4Az.00 GU--Kidney 
Malignant neoplasm of kidney parenchyma B4A0.00 GU--Kidney 
Malignant neoplasm of other urinary organs B4Ay.00 GU--Kidney 
Malignant neoplasm of renal calyces B4A1000 GU--Kidney 
Malignant neoplasm of renal pelvis B4A1.00 GU--Kidney 
Malignant neoplasm of renal pelvis NOS B4A1z00 GU--Kidney 
Malignant neoplasm of ureter B4A2.00 GU--Kidney 
Malignant neoplasm of urethra B4A3.00 GU--Kidney 
Neoplasm of uncertain behaviour of kidney B91z100 GU--Kidney 
Neoplasm of uncertain or unknown behaviour of renal pelvis B91z300 GU--Kidney 
Renal malignant neoplasm B4A..11 GU--Kidney 
Renal neoplasm of uncertain behaviour B91z111 GU--Kidney 
Uncertain neoplasm ureter B91z200 GU--Kidney 
[M]Cribriform carcinoma BB5K.00 Head and Neck 
[X]Malignant neoplasm of lip, oral cavity and pharynx Byu0.00 Head and Neck 
Malig neop auditory tube, middle ear and mastoid air cells B201.00 Head and Neck 
Malig neop nasal cavities, middle ear and accessory sinuses B20..00 Head and Neck 
Malig neop other site nasal cavity, middle ear and sinuses B20y.00 Head and Neck 
Malig neop other/ill-defined sites lip, oral cavity, pharynx B0z..00 Head and Neck 
Malignant neoplasm aryepiglottic fold, hypopharyngeal aspect B082.00 Head and Neck 
Malignant neoplasm of accessory sinus NOS B20z.00 Head and Neck 
Malignant neoplasm of adenoid B071000 Head and Neck 
Malignant neoplasm of anterior 2/3 of tongue unspecified B014.00 Head and Neck 
Malignant neoplasm of anterior epiglottis B064.00 Head and Neck 
Malignant neoplasm of anterior epiglottis NOS B064z00 Head and Neck 
Malignant neoplasm of anterior portion of floor of mouth B040.00 Head and Neck 
Malignant neoplasm of anterior wall of nasopharynx B073.00 Head and Neck 
Malignant neoplasm of arytenoid cartilage B213000 Head and Neck 
Malignant neoplasm of base of tongue B010.00 Head and Neck 
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Malignant neoplasm of base of tongue dorsal surface B010000 Head and Neck 
Malignant neoplasm of buccal mucosa B050.11 Head and Neck 
Malignant neoplasm of cheek mucosa B050.00 Head and Neck 
Malignant neoplasm of cheek NOS B550100 Head and Neck 
Malignant neoplasm of cricoid cartilage B213100 Head and Neck 
Malignant neoplasm of dorsal surface of tongue B011.00 Head and Neck 
Malignant neoplasm of dorsum of tongue NOS B011z00 Head and Neck 
Malignant neoplasm of epiglottis NOS B215.00 Head and Neck 
Malignant neoplasm of epiglottis, free border B064000 Head and Neck 
Malignant neoplasm of ethmoid sinus B203.00 Head and Neck 
Malignant neoplasm of faucial pillar  B062000 Head and Neck 
Malignant neoplasm of faucial tonsil B060000 Head and Neck 
Malignant neoplasm of floor of mouth B04..00 Head and Neck 
Malignant neoplasm of floor of mouth NOS B04z.00 Head and Neck 
Malignant neoplasm of frenulum linguae B013100 Head and Neck 
Malignant neoplasm of frontal sinus B204.00 Head and Neck 
Malignant neoplasm of glossoepiglottic fold B064100 Head and Neck 
Malignant neoplasm of glottis B210.00 Head and Neck 
Malignant neoplasm of gum B03..00 Head and Neck 
Malignant neoplasm of gum NOS B03z.00 Head and Neck 
Malignant neoplasm of hard palate B052.00 Head and Neck 
Malignant neoplasm of head NOS B550000 Head and Neck 
Malignant neoplasm of head, neck and face B550.00 Head and Neck 
Malignant neoplasm of head, neck and face NOS B550z00 Head and Neck 
Malignant neoplasm of hypopharynx B08..00 Head and Neck 
Malignant neoplasm of hypopharynx NOS B08z.00 Head and Neck 
Malignant neoplasm of jaw NOS B550300 Head and Neck 
Malignant neoplasm of junctional region of epiglottis B065.00 Head and Neck 
Malignant neoplasm of laryngeal cartilage B213.00 Head and Neck 
Malignant neoplasm of laryngopharynx B0z2.00 Head and Neck 
Malignant neoplasm of larynx B21..00 Head and Neck 
Malignant neoplasm of larynx NOS B21z.00 Head and Neck 
Malignant neoplasm of larynx, other specified site B21y.00 Head and Neck 
Malignant neoplasm of lateral portion of floor of mouth B041.00 Head and Neck 
Malignant neoplasm of lateral wall of nasopharynx NOS B072z00 Head and Neck 
Malignant neoplasm of lateral wall of oropharynx B066.00 Head and Neck 
Malignant neoplasm of lingual tonsil B016.00 Head and Neck 
Malignant neoplasm of lip, oral cavity and pharynx NOS B0zz.00 Head and Neck 
Malignant neoplasm of lower buccal sulcus B051100 Head and Neck 
Malignant neoplasm of lower gum B031.00 Head and Neck 
Malignant neoplasm of major salivary gland NOS B02z.00 Head and Neck 
Malignant neoplasm of major salivary glands B02..00 Head and Neck 
Malignant neoplasm of mastoid air cells B201300 Head and Neck 
Malignant neoplasm of maxillary sinus B202.00 Head and Neck 
Malignant neoplasm of mouth NOS B05z.00 Head and Neck 
Malignant neoplasm of nasal cavities B200.00 Head and Neck 
Malignant neoplasm of nasal cavities NOS B200z00 Head and Neck 
Malignant neoplasm of nasopharynx B07..00 Head and Neck 
Malignant neoplasm of nasopharynx NOS B07z.00 Head and Neck 
Malignant neoplasm of neck NOS B550400 Head and Neck 
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Malignant neoplasm of nose NOS B550200 Head and Neck 
Malignant neoplasm of oropharynx B06..00 Head and Neck 
Malignant neoplasm of oropharynx NOS B06z.00 Head and Neck 
Malignant neoplasm of oropharynx, other specified sites B06y.00 Head and Neck 
Malignant neoplasm of other and unspecified parts of mouth B05..00 Head and Neck 
Malignant neoplasm of other major salivary glands B02y.00 Head and Neck 
Malignant neoplasm of other sites lip, oral cavity, pharynx B0zy.00 Head and Neck 
Malignant neoplasm of other sites of floor of mouth B04y.00 Head and Neck 
Malignant neoplasm of other specified hypopharyngeal site B08y.00 Head and Neck 
Malignant neoplasm of other specified mouth parts B05y.00 Head and Neck 
Malignant neoplasm of other specified site of oropharynx NOS B06yz00 Head and Neck 
Malignant neoplasm of overlapping lesion of tonsil B060200 Head and Neck 
Malignant neoplasm of palate NOS B055z00 Head and Neck 
Malignant neoplasm of palate unspecified B055.00 Head and Neck 
Malignant neoplasm of palatine tonsil B060100 Head and Neck 
Malignant neoplasm of palatoglossal arch B062200 Head and Neck 
Malignant neoplasm of parotid gland B020.00 Head and Neck 
Malignant neoplasm of pharyngeal recess B072000 Head and Neck 
Malignant neoplasm of pharyngeal tonsil B071100 Head and Neck 
Malignant neoplasm of pharynx unspecified B0z0.00 Head and Neck 
Malignant neoplasm of postcricoid region B080.00 Head and Neck 
Malignant neoplasm of posterior pharynx B083.00 Head and Neck 
Malignant neoplasm of posterior wall of nasopharynx B071.00 Head and Neck 
Malignant neoplasm of posterior wall of nasopharynx NOS B071z00 Head and Neck 
Malignant neoplasm of pyriform sinus B081.00 Head and Neck 
Malignant neoplasm of retromolar area B056.00 Head and Neck 
Malignant neoplasm of roof of mouth B055100 Head and Neck 
Malignant neoplasm of roof of nasopharynx B070.00 Head and Neck 
Malignant neoplasm of septum of nose B200200 Head and Neck 
Malignant neoplasm of soft palate B053.00 Head and Neck 
Malignant neoplasm of sphenoidal sinus B205.00 Head and Neck 
Malignant neoplasm of subglottis B212.00 Head and Neck 
Malignant neoplasm of sublingual gland B022.00 Head and Neck 
Malignant neoplasm of submandibular gland B021.00 Head and Neck 
Malignant neoplasm of supraclavicular fossa NOS B550500 Head and Neck 
Malignant neoplasm of supraglottis B211.00 Head and Neck 
Malignant neoplasm of thyroid cartilage B213300 Head and Neck 
Malignant neoplasm of tongue B01..00 Head and Neck 
Malignant neoplasm of tongue NOS B01z.00 Head and Neck 
Malignant neoplasm of tongue, junctional zone B015.00 Head and Neck 
Malignant neoplasm of tongue, tip and lateral border B012.00 Head and Neck 
Malignant neoplasm of tonsil B060.00 Head and Neck 
Malignant neoplasm of tonsillar fossa B061.00 Head and Neck 
Malignant neoplasm of tonsillar fossa NOS B062z00 Head and Neck 
Malignant neoplasm of tonsillar pillar B062.00 Head and Neck 
Malignant neoplasm of tympanic cavity B201100 Head and Neck 
Malignant neoplasm of upper gum B030.00 Head and Neck 
Malignant neoplasm of uvula B054.00 Head and Neck 
Malignant neoplasm of vallecula B063.00 Head and Neck 
Malignant neoplasm of ventral surface of tongue B013.00 Head and Neck 
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Malignant neoplasm of ventral tongue surface NOS B013z00 Head and Neck 
Malignant neoplasm of vestibule of nose B200300 Head and Neck 
Malignant neoplasm tonsil NOS B060z00 Head and Neck 
Malignant neoplasm, overlapping lesion of accessory sinuses B206.00 Head and Neck 
Malignant neoplasm, overlapping lesion of floor of mouth B042.00 Head and Neck 
Malignant neoplasm, overlapping lesion of larynx B214.00 Head and Neck 
Malignant neoplasm, overlapping lesion of nasopharynx B074.00 Head and Neck 
Malignant overlapping lesion of tongue B017.00 Head and Neck 
Mixed parotid tumour B900011 Head and Neck 
Neoplasm of uncertain behaviour of aryepiglottic fold B906600 Head and Neck 
Neoplasm of uncertain behaviour of cheek B901500 Head and Neck 
Neoplasm of uncertain behaviour of epiglottis B906200 Head and Neck 
Neoplasm of uncertain behaviour of ethmoidal sinus B90z600 Head and Neck 
Neoplasm of uncertain behaviour of floor of mouth B901400 Head and Neck 
Neoplasm of uncertain behaviour of gums B901300 Head and Neck 
Neoplasm of uncertain behaviour of hypopharynx B901900 Head and Neck 
Neoplasm of uncertain behaviour of larynx B906.00 Head and Neck 
Neoplasm of uncertain behaviour of major salivary glands B900.00 Head and Neck 
Neoplasm of uncertain behaviour of mastoid air cells B90z400 Head and Neck 
Neoplasm of uncertain behaviour of maxillary sinus B90z500 Head and Neck 
Neoplasm of uncertain behaviour of nasopharynx B901700 Head and Neck 
Neoplasm of uncertain behaviour of oral cavity B901.11 Head and Neck 
Neoplasm of uncertain behaviour of oropharynx B901800 Head and Neck 
Neoplasm of uncertain behaviour of palate B901600 Head and Neck 
Neoplasm of uncertain behaviour of parotid gland B900000 Head and Neck 
Neoplasm of uncertain behaviour of pharynx B901.12 Head and Neck 
Neoplasm of uncertain behaviour of submandibular gland B900200 Head and Neck 
Neoplasm of uncertain behaviour of thyroid cartilage B906000 Head and Neck 
Neoplasm of uncertain behaviour of tongue B901100 Head and Neck 
Neoplasm of uncertain behaviour of trachea B907000 Head and Neck 
Neoplasm of uncertain behaviour of tympanic cavity B90z100 Head and Neck 
Neoplasm of uncertain behaviour of vocal cord B906800 Head and Neck 
Overlapping lesion of other and unspecified parts of mouth B057.00 Head and Neck 
[M] Epithelioid cell naevus BBEb.00 DERM--NOS 
[M] Spitz naevus BBEN.13 DERM--NOS 
[M]Abdominal desmoid BBGB.11 DERM--NOS 
[M]Abdominal fibromatosis BBGB.00 DERM--NOS 
[M]Achromic naevus BBE9.11 DERM--NOS 
[M]Acral lentiginous melanoma, malignant BBEG000 DERM--NOS 
[M]Adenoid squamous cell carcinoma BB2G.00 DERM--NOS 
[M]Aggressive fibromatosis BBGA.00 DERM--NOS 
[M]Amelanotic melanoma BBEA.00 DERM--NOS 
[M]Angioblastoma BBTF.11 DERM--NOS 
[M]Angioendothelioma BBT7z11 DERM--NOS 
[M]Angiofibroma NOS BBTE.00 DERM--NOS 
[M]Angiokeratoma BBTB.00 DERM--NOS 
[M]Angioma NOS BBT0.11 DERM--NOS 
[M]Angiosarcoma BBT1.11 DERM--NOS 
[M]Arteriovenous haemangioma BBT4.11 DERM--NOS 
[M]Atypical fibrous histiocytoma BBGE.00 DERM--NOS 
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[M]Atypical fibroxanthoma BBGH.00 DERM--NOS 
[M]Basal cell adenocarcinoma BB5y000 DERM--NOS 
[M]Blood vessel tumours BBT..00 DERM--NOS 
[M]Blue naevus NOS BBEU.00 DERM--NOS 
[M]Blue naevus, malignant BBEV.00 DERM--NOS 
[M]Capillary haemangioma BBT8.00 DERM--NOS 
[M]Cavernous haemangioma BBT2.00 DERM--NOS 
[M]Cellular blue naevus BBEW.00 DERM--NOS 
[M]Chorioangioma BBT0.12 DERM--NOS 
[M]Compound naevus BBEK.00 DERM--NOS 
[M]Dermal naevus BBEJ.11 DERM--NOS 
[M]Dermatofibroma lenticulare BBGK.11 DERM--NOS 
[M]Dermatofibroma NOS BBGK.00 DERM--NOS 
[M]Dermatofibroma protuberans BBGL.00 DERM--NOS 
[M]Dermatofibrosarcoma NOS BBGM.00 DERM--NOS 
[M]Desmoid NOS BBGA.11 DERM--NOS 
[M]Desmoplastic fibroma BBGC.00 DERM--NOS 
[M]Desmoplastic melanoma, malignant BBE1100 DERM--NOS 
[M]Dyskeratotic papilloma BB25.11 DERM--NOS 
[M]Dysplastic naevus BBEY.00 DERM--NOS 
[M]Eccrine dermal cylindroma BB5H.00 DERM--NOS 
[M]Elastofibroma BBG9.00 DERM--NOS 
[M]Epidermoid carcinoma NOS BB2A.11 DERM--NOS 
[M]Epidermoid carcinoma, keratinising type BB2C.11 DERM--NOS 
[M]Epithelial neoplasms NOS BB1..00 DERM--NOS 
[M]Epithelioid and spindle cell naevus BBEN.00 DERM--NOS 
[M]Epithelioid haemangioendothelioma NOS BBTJ.00 DERM--NOS 
[M]Epithelioid haemangioendothelioma, malignant BBTK.00 DERM--NOS 
[M]Epithelioid haemangioma BBTG.00 DERM--NOS 
[M]Epithelioma adenoides cyst BB38.12 DERM--NOS 
[M]Extra-abdominal desmoid BBGA.12 DERM--NOS 
[M]Fascial fibroma BBG6.00 DERM--NOS 
[M]Fibroma durum BBG0.11 DERM--NOS 
[M]Fibroma NOS BBG0.00 DERM--NOS 
[M]Fibromatous neoplasm NOS BBGz.00 DERM--NOS 
[M]Fibromatous neoplasms BBG..00 DERM--NOS 
[M]Fibromyxoma BBG2.00 DERM--NOS 
[M]Fibromyxosarcoma BBG3.00 DERM--NOS 
[M]Fibrosarcoma NOS BBG1.00 DERM--NOS 
[M]Fibrous histiocytoma NOS BBGD.00 DERM--NOS 
[M]Fibrous histiocytoma, malignant BBGF.00 DERM--NOS 
[M]Fibrous papule of nose BBE6.00 DERM--NOS 
[M]Fibroxanthoma NOS BBGG.00 DERM--NOS 
[M]Fibroxanthoma, malignant BBGJ.00 DERM--NOS 
[M]Fibroxanthosarcoma BBGJ.11 DERM--NOS 
[M]Giant pigmented naevus BBEL.00 DERM--NOS 
[M]Haemangioblastoma BBTF.00 DERM--NOS 
[M]Haemangioendothelioma, malignant BBT7100 DERM--NOS 
[M]Haemangioma NOS BBT0.00 DERM--NOS 
[M]Haemangiomatous tumours BBT..11 DERM--NOS 
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[M]Haemangiopericytoma NOS BBTD100 DERM--NOS 
[M]Haemangiosarcoma BBT1.00 DERM--NOS 
[M]Hairy naevus NOS BBE0.11 DERM--NOS 
[M]Halo naevus BBE5.00 DERM--NOS 
[M]Histiocytoid haemangioma BBTH.00 DERM--NOS 
[M]Histiocytoma NOS BBGK.12 DERM--NOS 
[M]Hutchinson's melanotic freckle BBEF.00 DERM--NOS 
[M]Hyperkeratotic papilloma BB25.12 DERM--NOS 
[M]Infantile fibrosarcoma BBG8.00 DERM--NOS 
[M]Infantile haemangioma BBT8.12 DERM--NOS 
[M]Intradermal naevus BBEJ.00 DERM--NOS 
[M]Intraepidermal carcinoma NOS BB29.12 DERM--NOS 
[M]Intraepidermal epithelioma of Jadassohn BB37.00 DERM--NOS 
[M]Intraepidermal naevus BBEB.11 DERM--NOS 
[M]Intraepithelial squamous cell carcinoma BB29.13 DERM--NOS 
[M]Intramuscular haemangioma BBT9.00 DERM--NOS 
[M]Intravascular bronchial alveolar tumour BBTL.00 DERM--NOS 
[M]Invasive fibroma BBGA.13 DERM--NOS 
[M]Inverted papilloma BB27.00 DERM--NOS 
[M]Involuting naevus BBE6.11 DERM--NOS 
[M]Jadassohn's blue naevus BBEU.11 DERM--NOS 
[M]Junctional naevus BBEB.00 DERM--NOS 
[M]Juvenila melanoma BBEN.11 DERM--NOS 
[M]Juvenila naevus BBEN.12 DERM--NOS 
[M]Juvenile angiofibroma BBTE.11 DERM--NOS 
[M]Juvenile haemangioma BBT8.13 DERM--NOS 
[M]Kaposi's sarcoma BBTA.00 DERM--NOS 
[M]Keratotic papilloma BB25.13 DERM--NOS 
[M]Lentigo maligna BBEF.11 DERM--NOS 
[M]Lentigo maligna melanoma BBEG.11 DERM--NOS 
[M]Lymphoepithelial carcinoma BB2M.00 DERM--NOS 
[M]Magnocellular naevus BBE8.00 DERM--NOS 
[M]Malherbe's calcified epithelioma BB3B.11 DERM--NOS 
[M]Malignant melanoma in Hutchinson's melanotic freckle BBEG.00 DERM--NOS 
[M]Malignant melanoma in junctional naevus BBEC.00 DERM--NOS 
[M]Malignant melanoma NOS BBE1.00 DERM--NOS 
[M]Malignant melanoma, regressing BBE1000 DERM--NOS 
[M]Melanocarcinoma BBE1.11 DERM--NOS 
[M]Melanocytoma of eyeball BBE8.11 DERM--NOS 
[M]Melanoma in situ BBEX.00 DERM--NOS 
[M]Melanoma NOS BBE1.12 DERM--NOS 
[M]Melanosarcoma NOS BBE1.13 DERM--NOS 
[M]Mixed epithelioid and spindle melanoma BBET.00 DERM--NOS 
[M]Myofibromatosis BBGN.00 DERM--NOS 
[M]Myxofibroma NOS BBG2.11 DERM--NOS 
[M]Naevi and melanomas BBE..00 DERM--NOS 
[M]Naevi or melanoma NOS BBEz.00 DERM--NOS 
[M]Naevocarcinoma BBE1.14 DERM--NOS 
[M]Naevus NOS BBE0.12 DERM--NOS 
[M]Neuronaevus BBE7.00 DERM--NOS 
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[M]Nodular melanoma BBE2.00 DERM--NOS 
[M]Nonpigmented naevus BBE9.00 DERM--NOS 
[M]Papillary and squamous cell neoplasms BB2..00 DERM--NOS 
[M]Papillary carcinoma NOS BB22.00 DERM--NOS 
[M]Papillary epidermoid carcinoma BB26.11 DERM--NOS 
[M]Papillary neoplasms BB2..11 DERM--NOS 
[M]Papillary or squamous cell neoplasm NOS BB2z.00 DERM--NOS 
[M]Papillary squamous cell carcinoma BB26.00 DERM--NOS 
[M]Papilloma NOS (excluding papilloma of urinary bladder) BB20.00 DERM--NOS 
[M]Papillomatosis NOS BB28.00 DERM--NOS 
[M]Parakeratotic papilloma BB25.14 DERM--NOS 
[M]Periosteal fibroma BBG4.00 DERM--NOS 
[M]Pigmented dermatofibrosarcoma protuberans BBGP.00 DERM--NOS 
[M]Pigmented naevus NOS BBE0.00 DERM--NOS 
[M]Pilomatrixoma BB3B.00 DERM--NOS 
[M]Plexiform haemangioma BBT8.14 DERM--NOS 
[M]Precancerous melanosis NOS BBED.00 DERM--NOS 
[M]Racemose haemangioma BBT4.00 DERM--NOS 
[M]Sclerosing haemangioma BBGK.13 DERM--NOS 
[M]Spindle cell melanoma NOS BBEQ.00 DERM--NOS 
[M]Spindle cell naevus BBEa.00 DERM--NOS 
[M]Squamous cell carcinoma NOS BB2A.00 DERM--NOS 
[M]Squamous cell carcinoma of skin NOS BB2A.13 DERM--NOS 
[M]Squamous cell carcinoma, keratinising type NOS BB2C.00 DERM--NOS 
[M]Squamous cell carcinoma, microinvasive BB2J.00 DERM--NOS 
[M]Squamous cell carcinoma, spindle cell type BB2F.00 DERM--NOS 
[M]Squamous cell neoplasms BB2..12 DERM--NOS 
[M]Squamous cell papilloma BB25.00 DERM--NOS 
[M]Subepidermal nodular fibrosis BBGK.14 DERM--NOS 
[M]Superficial spreading melanoma BBEH.00 DERM--NOS 
[M]Transitional cell papilloma NOS BB40.00 DERM--NOS 
[M]Transitional cell papillomas and carcinomas BB4..00 DERM--NOS 
[M]Trichoepithelioma BB38.00 DERM--NOS 
[M]Trichofolliculoma BB39.00 DERM--NOS 
[M]Tricholemmoma BB3A.00 DERM--NOS 
[M]Turban tumour BB5H.11 DERM--NOS 
[M]Venous haemangioma BBT3.00 DERM--NOS 
[M]Verrucous keratotic haemangioma BBTC.00 DERM--NOS 
[M]Verrucous papilloma BB23.00 DERM--NOS 
[M]Xanthofibroma BBGG.11 DERM--NOS 
[X]Malignant neoplasm of skin, unspecified Byu4300 DERM--NOS 
[X]Malignant neoplasm overlapping lesion of skin Byu5A00 DERM--NOS 
[X]Melanoma and other malignant neoplasms of skin Byu4.00 DERM--NOS 
[X]Oth malignant neoplasm/skin of oth+unspecfd parts of face  Byu4200 DERM--NOS 
Basal cell naevus syndrome B33z111 DERM--NOS 
Carcinoma of lip B00..11 DERM--NOS 
Carcinoma of lip, oral cavity and pharynx B0...11 DERM--NOS 
Dermatofibrosarcoma protuberans B339.00 DERM--NOS 
Epithelioma B33..12 DERM--NOS 
Kaposi's sarcoma of skin B33z000 DERM--NOS 
 
 
346 
 
Cancer description Med 
Code 
Cancer type 
Kaposi's sarcoma, unspecified B59zX00 DERM--NOS 
Malig neop skin of ear and external auricular canal NOS B332z00 DERM--NOS 
Malignant neoplasm of canthus B331000 DERM--NOS 
Malignant neoplasm of commissure of lip B005.00 DERM--NOS 
Malignant neoplasm of eyelid including canthus B331.00 DERM--NOS 
Malignant neoplasm of lip B00..00 DERM--NOS 
Malignant neoplasm of lip, oral cavity and pharynx B0...00 DERM--NOS 
Malignant neoplasm of lip, unspecified B007.00 DERM--NOS 
Malignant neoplasm of lip, vermilion border NOS B00zz00 DERM--NOS 
Malignant neoplasm of lower eyelid B331200 DERM--NOS 
Malignant neoplasm of lower lip, buccal aspect B003000 DERM--NOS 
Malignant neoplasm of lower lip, external B001000 DERM--NOS 
Malignant neoplasm of lower lip, inner aspect B003.00 DERM--NOS 
Malignant neoplasm of lower lip, mucosa B003200 DERM--NOS 
Malignant neoplasm of lower lip, vermilion border B001.00 DERM--NOS 
Malignant neoplasm of lower lip, vermilion border NOS B001z00 DERM--NOS 
Malignant neoplasm of other specified skin sites B33y.00 DERM--NOS 
Malignant neoplasm of overlapping lesion of lip B006.00 DERM--NOS 
Malignant neoplasm of perianal skin B335900 DERM--NOS 
Malignant neoplasm of pinna NEC B332200 DERM--NOS 
Malignant neoplasm of scalp B334000 DERM--NOS 
Malignant neoplasm of scalp and skin of neck B334.00 DERM--NOS 
Malignant neoplasm of scalp or skin of neck NOS B334z00 DERM--NOS 
Malignant neoplasm of sebaceous gland B33..14 DERM--NOS 
Malignant neoplasm of skin NOS B33z.00 DERM--NOS 
Malignant neoplasm of skin of abdominal wall B335300 DERM--NOS 
Malignant neoplasm of skin of ankle B337500 DERM--NOS 
Malignant neoplasm of skin of auricle (ear) B332000 DERM--NOS 
Malignant neoplasm of skin of axillary fold B335000 DERM--NOS 
Malignant neoplasm of skin of back B335700 DERM--NOS 
Malignant neoplasm of skin of breast B335200 DERM--NOS 
Malignant neoplasm of skin of buttock B335800 DERM--NOS 
Malignant neoplasm of skin of cheek, external B333000 DERM--NOS 
Malignant neoplasm of skin of chest, excluding breast B335100 DERM--NOS 
Malignant neoplasm of skin of chin B333100 DERM--NOS 
Malignant neoplasm of skin of external auditory meatus B332100 DERM--NOS 
Malignant neoplasm of skin of eyebrow B333200 DERM--NOS 
Malignant neoplasm of skin of finger B336400 DERM--NOS 
Malignant neoplasm of skin of foot B337700 DERM--NOS 
Malignant neoplasm of skin of fore-arm B336200 DERM--NOS 
Malignant neoplasm of skin of forehead B333300 DERM--NOS 
Malignant neoplasm of skin of great toe B337900 DERM--NOS 
Malignant neoplasm of skin of groin B335500 DERM--NOS 
Malignant neoplasm of skin of hand B336300 DERM--NOS 
Malignant neoplasm of skin of hip B337000 DERM--NOS 
Malignant neoplasm of skin of knee B337200 DERM--NOS 
Malignant neoplasm of skin of lip B330.00 DERM--NOS 
Malignant neoplasm of skin of lower leg B337400 DERM--NOS 
Malignant neoplasm of skin of lower limb and hip B337.00 DERM--NOS 
Malignant neoplasm of skin of lower limb or hip NOS B337z00 DERM--NOS 
 
 
347 
 
Cancer description Med 
Code 
Cancer type 
Malignant neoplasm of skin of neck B334100 DERM--NOS 
Malignant neoplasm of skin of nose (external) B333400 DERM--NOS 
Malignant neoplasm of skin of perineum B335600 DERM--NOS 
Malignant neoplasm of skin of popliteal fossa area B337300 DERM--NOS 
Malignant neoplasm of skin of scapular region B335A00 DERM--NOS 
Malignant neoplasm of skin of shoulder B336000 DERM--NOS 
Malignant neoplasm of skin of temple B333500 DERM--NOS 
Malignant neoplasm of skin of thigh B337100 DERM--NOS 
Malignant neoplasm of skin of thumb B336500 DERM--NOS 
Malignant neoplasm of skin of toe B337800 DERM--NOS 
Malignant neoplasm of skin of trunk, excluding scrotum B335.00 DERM--NOS 
Malignant neoplasm of skin of trunk, excluding scrotum, NOS B335z00 DERM--NOS 
Malignant neoplasm of skin of upper arm B336100 DERM--NOS 
Malignant neoplasm of skin of upper limb and shoulder B336.00 DERM--NOS 
Malignant neoplasm of skin of upper limb or shoulder NOS B336z00 DERM--NOS 
Malignant neoplasm of sweat gland B33..15 DERM--NOS 
Malignant neoplasm of upper eyelid B331100 DERM--NOS 
Malignant neoplasm of upper lip, buccal aspect B002000 DERM--NOS 
Malignant neoplasm of upper lip, external B000000 DERM--NOS 
Malignant neoplasm of upper lip, lipstick area B000100 DERM--NOS 
Malignant neoplasm of upper lip, mucosa B002200 DERM--NOS 
Malignant neoplasm of upper lip, oral aspect B002300 DERM--NOS 
Malignant neoplasm of upper lip, vermilion border B000.00 DERM--NOS 
Malignant neoplasm overlapping lesion of skin B33X.00 DERM--NOS 
Malignant neoplasm skin of ear and external auricular canal B332.00 DERM--NOS 
Malignant neoplasm skin of other and unspecified parts face B333.00 DERM--NOS 
Malignant neoplasm skin other and unspec part of face NOS B333z00 DERM--NOS 
Naevoid basal cell carcinoma syndrome B33z100 DERM--NOS 
Neoplasm of uncertain behaviour of lip B901000 DERM--NOS 
Neoplasm of uncertain behaviour of skin B932.00 DERM--NOS 
Neoplasm of unspecified nature of skin BA02200 DERM--NOS 
Other malignant neoplasm of skin B33..00 DERM--NOS 
Rodent ulcer B33..13 DERM--NOS 
Squamous cell carcinoma of skin B338.00 DERM--NOS 
Squamous cell carcinoma of skin NOS B33z.11 DERM--NOS 
[M] Alpha heavy chain disease BBm6.00 HEMA--NOS 
[M] Monoclonal gammopathy BBm7.00 HEMA--NOS 
[M]Acute panmyelosis BBs1.00 HEMA--NOS 
[M]Acute progressive histiocytosis X BBm3.12 HEMA--NOS 
[M]Chronic lymphoproliferative disease BBs5.00 HEMA--NOS 
[M]Chronic myeloproliferative disease BBs2.00 HEMA--NOS 
[M]Idiopathic thrombocythaemia BBs4.00 HEMA--NOS 
[M]Letterer - Siwe disease BBm3.00 HEMA--NOS 
[M]Malignant histiocytosis BBm1.00 HEMA--NOS 
[M]Malignant reticulosis BBm1.11 HEMA--NOS 
[M]Misc myeloproliferative and lymphoproliferative disorders BBs..00 HEMA--NOS 
[M]Misc myeloproliferative or lymphoproliferative dis NOS BBsz.00 HEMA--NOS 
[M]Monostotic myeloma BBn2.11 HEMA--NOS 
[M]Multiple myeloma BBn0.11 HEMA--NOS 
[M]Mycosis fungoides BBl..00 HEMA--NOS 
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[M]Mycosis fungoides BBl0.00 HEMA--NOS 
[M]Mycosis fungoides NOS BBlz.00 HEMA--NOS 
[M]Myeloma NOS BBn0.12 HEMA--NOS 
[M]Myelomatosis BBn0.13 HEMA--NOS 
[M]Myelosclerosis with myeloid metaplasia BBs3.00 HEMA--NOS 
[M]Plasma cell myeloma BBn0.00 HEMA--NOS 
[M]Plasma cell tumour NOS BBnz.00 HEMA--NOS 
[M]Plasma cell tumours BBn..00 HEMA--NOS 
[M]Plasmacytic myeloma BBn0.14 HEMA--NOS 
[M]Plasmacytoma NOS BBn2.00 HEMA--NOS 
[M]Polycythaemia rubra vera BBs0.11 HEMA--NOS 
[M]Polycythaemia vera BBs0.00 HEMA--NOS 
[M]Waldenstrom's macroglobulinaemia BBmK.00 HEMA--NOS 
Histiocytic tumour NOS B935.11 HEMA--NOS 
Idiopathic thrombocythaemia B937.12 HEMA--NOS 
Malignant histiocytosis B623.00 HEMA--NOS 
Malignant histiocytosis NOS B623z00 HEMA--NOS 
Malignant histiocytosis of intra-abdominal lymph nodes B623300 HEMA--NOS 
Malignant histiocytosis of unspecified site B623000 HEMA--NOS 
Malignant neoplasm of histiocytic tissue B6...11 HEMA--NOS 
Malignant neoplasm of spleen NEC B1z1.00 HEMA--NOS 
Malignant neoplasm of spleen NOS B1z1z00 HEMA--NOS 
Mastocytoma NOS B935.12 HEMA--NOS 
Myelodysplasia B937.14 HEMA--NOS 
Myeloma - solitary B936.11 HEMA--NOS 
Neo/uncertn+unknwn behav/lymph,h'matopetc+rel tiss,unspcf B93X.00 HEMA--NOS 
Neop uncertain behaviour other lymphatic/haematopoietic tiss B937.00 HEMA--NOS 
Neoplasm of uncertain behaviour of histiocytic and mast cell B935.00 HEMA--NOS 
Neoplasm of uncertain behaviour of plasma cells B936.00 HEMA--NOS 
Neoplasm of uncertain behaviour of spleen B905300 HEMA--NOS 
Plasmacytoma NOS B936.12 HEMA--NOS 
Polycythaemia rubra vera B934.11 HEMA--NOS 
Polycythaemia vera B934.00 HEMA--NOS 
Primary polycythaemia B934.12 HEMA--NOS 
[M]Adenocarcinoid tumour BB5R800 GI--NOS  
[M]Chief cell adenoma BB5c000 GI--NOS  
[M]G cell tumour NOS BB5C011 GI--NOS  
[M]Gastrinoma and carcinomas BB5C.00 GI--NOS  
[M]Gastrinoma NOS BB5C000 GI--NOS  
[M]Gastrinoma or carcinoma NOS BB5Cz00 GI--NOS  
[M]Gastrinoma, malignant BB5C100 GI--NOS  
[M]Goblet cell tumour BB5R611 GI--NOS  
[M]Merkel cell carcinoma BB5RA00 GI--NOS  
[X]Malignant neoplasm of digestive organs Byu1.00 GI--NOS  
[X]Malignant neoplasm of intestinal tract, part unspecified Byu1200 GI--NOS  
[X]Malignant neoplsm/ill-defin sites within digestive system Byu1300 GI--NOS  
Carcinoma of digestive organs and peritoneum B1...11 GI--NOS  
Malig neop oth/ill-defined sites digestive tract/peritoneum B1z..00 GI--NOS  
Malignant neoplasm of digestive organs and peritoneum B1...00 GI--NOS  
Malignant neoplasm of digestive tract and peritoneum NOS B1zz.00 GI--NOS  
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Malignant neoplasm of intestinal tract, part unspecified B1z0.00 GI--NOS  
Malignant neoplasm of mesentery B18y700 GI--NOS  
Malignant neoplasm of omentum B18y300 GI--NOS  
Malignant neoplasm of parietal peritoneum B18y400 GI--NOS  
Malignant neoplasm of pelvic peritoneum B18y500 GI--NOS  
Malignant neoplasm of perinephric tissue B180100 GI--NOS  
Malignant neoplasm of retrocaecal tissue B180200 GI--NOS  
Malignant neoplasm of retroperitoneum B180.00 GI--NOS  
Malignant neoplasm of retroperitoneum and peritoneum B18..00 GI--NOS  
Malignant neoplasm of retroperitoneum and peritoneum NOS B18z.00 GI--NOS  
Malignant neoplasm of retroperitoneum NOS B180z00 GI--NOS  
Malignant neoplasm of specified parts of peritoneum B18y.00 GI--NOS  
Malignant neoplasm of specified parts of peritoneum NOS B18yz00 GI--NOS  
Malignant neoplasm of the pouch of Douglas B18y600 GI--NOS  
Malignant neoplasm other spec digestive tract and peritoneum B1zy.00 GI--NOS  
Malignant neoplasm, overlapping lesion of digestive system B1z2.00 GI--NOS  
Mesothelioma of peritoneum B181.00 GI--NOS  
Neoplasm of uncertain behaviour of peritoneum B904100 GI--NOS  
Neoplasm of uncertain behaviour of retroperitoneum B904000 GI--NOS  
Neoplasm of unspecified nature of digestive system BA00.00 GI--NOS  
Overlapping malign lesion of retroperitoneum and peritoneum B182.00 GI--NOS  
[M]Acidophil adenoma BB5V200 Endocrinologic 
[M]Adrenal rest tumour BBCF.00 Endocrinologic 
[M]Basophil adenoma BB5V600 Endocrinologic 
[M]C cell carcinoma BB9B.11 Endocrinologic 
[M]Carcinoid tumours NOS BB5Rz00 Endocrinologic 
[M]Chromophobe adenoma BB5V000 Endocrinologic 
[M]Chromophobe carcinoma BB5V100 Endocrinologic 
[M]Colloid adenoma BB5f511 Endocrinologic 
[M]Cylindroid adenocarcinoma BB5J.11 Endocrinologic 
[M]Extra-adrenal paraganglioma, NOS BBD7.00 Endocrinologic 
[M]Follicular adenocarcinoma NOS BB5f100 Endocrinologic 
[M]Follicular adenocarcinoma, well differentiated type BB5f200 Endocrinologic 
[M]Follicular adenoma BB5f000 Endocrinologic 
[M]Follicular carcinoma BB5f111 Endocrinologic 
[M]Hurthle cell adenocarcinoma BB5W11
1 
Endocrinologic 
[M]Hurthle cell adenoma BB5W01
1 
Endocrinologic 
[M]Macrofollicular adenoma BB5f500 Endocrinologic 
[M]Medullary carcinoma NOS BB9B.00 Endocrinologic 
[M]Medullary carcinoma with amyloid stroma BB9C.00 Endocrinologic 
[M]Microfollicular adenoma BB5f400 Endocrinologic 
[M]Mucoid cell adenoma BB5V611 Endocrinologic 
[M]Mucoid cell carcinoma BB5V711 Endocrinologic 
[M]Multiple endocrine adenomas BB5g.00 Endocrinologic 
[M]Neuroendocrine carcinoma BB5R900 Endocrinologic 
[M]Oxyphilic adenoma BB5W00
0 
Endocrinologic 
[M]Oxyphilic adenomas and adenocarcinomas BB5W.00 Endocrinologic 
[M]Papillary and follicular adenocarcinoma BB5f600 Endocrinologic 
[M]Parathyroid adenoma or adenocarcinoma NOS BB5cz00 Endocrinologic 
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[M]Parathyroid adenomas and adenocarcinomas BB5c.00 Endocrinologic 
[M]Phaeochromocytoma NOS BBD9.00 Endocrinologic 
[M]Phaeochromocytoma, malignant BBDA.00 Endocrinologic 
[M]Pituitary adenoma or carcinoma NOS BB5Vz00 Endocrinologic 
[M]Pituitary adenomas and carcinomas BB5V.00 Endocrinologic 
[M]Prolactinoma BB5y400 Endocrinologic 
[M]Thyroid adenoma and adenocarcinoma BB5f.00 Endocrinologic 
[M]Thyroid adenoma or adenocarcinoma NOS BB5fz00 Endocrinologic 
[X]Malignant neoplasm of thyroid and other endocrine glands ByuB.00 Endocrinologic 
Malig neop of endocrine gland or related structure NOS B54z.00 Endocrinologic 
Malig neop of other endocrine glands and related structures B54..00 Endocrinologic 
Malig neop pituitary gland or craniopharyngeal duct NOS B542z00 Endocrinologic 
Malignant neoplasm of adrenal cortex B540000 Endocrinologic 
Malignant neoplasm of adrenal gland B540.00 Endocrinologic 
Malignant neoplasm of adrenal gland NOS B540z00 Endocrinologic 
Malignant neoplasm of aortic body B545100 Endocrinologic 
Malignant neoplasm of aortic body and other paraganglia B545.00 Endocrinologic 
Malignant neoplasm of carotid body B544.00 Endocrinologic 
Malignant neoplasm of coccygeal body B545200 Endocrinologic 
Malignant neoplasm of craniopharyngeal duct B542100 Endocrinologic 
Malignant neoplasm of glomus jugulare B545000 Endocrinologic 
Malignant neoplasm of other specified endocrine gland B54y.00 Endocrinologic 
Malignant neoplasm of parathyroid gland B541.00 Endocrinologic 
Malignant neoplasm of pineal gland B543.00 Endocrinologic 
Malignant neoplasm of pituitary gland B542000 Endocrinologic 
Malignant neoplasm of thyroid gland B53..00 Endocrinologic 
Malignant neoplasm pituitary gland and craniopharyngeal duct B542.00 Endocrinologic 
Neop of uncertain behaviour of endocrine and nervous system B92..00 Endocrinologic 
Neop uncertain behaviour pituitary and craniopharyngeal duct B920.00 Endocrinologic 
Neop uncertain behaviour pituitary and craniopharyngeal NOS B920z00 Endocrinologic 
Neoplasm of uncertain behaviour of craniopharyngeal duct B920100 Endocrinologic 
Neoplasm of uncertain behaviour of endocrine gland NOS B924z00 Endocrinologic 
Neoplasm of uncertain behaviour of parathyroid gland B924100 Endocrinologic 
Neoplasm of uncertain behaviour of pituitary gland B920000 Endocrinologic 
Neoplasm of uncertain behaviour of thyroid gland B924000 Endocrinologic 
Phaeochromocytoma B540.11 Endocrinologic 
[M]Angiomyxoma BBHZ.00 Chest--(not lung) 
[M]Aortic body tumour BBD5.00 Chest--(not lung) 
[M]Carotid body tumour BBD6.00 Chest--(not lung) 
[M]Myxoma NOS BBH0.00 Chest--(not lung) 
[M]Myxomatous neoplasm NOS BBHz.00 Chest--(not lung) 
[M]Myxomatous neoplasms BBH..00 Chest--(not lung) 
[M]Myxosarcoma BBH1.00 Chest--(not lung) 
[M]Thymoma BBB6.00 Chest--(not lung) 
[M]Thymoma NOS BBB6z00 Chest--(not lung) 
[X]Malignant neoplasm/overlap lesion/heart,mediastinm+pleura Byu2100 Chest--(not lung) 
Carcinoma of respiratory tract and intrathoracic organs B2...11 Chest--(not lung) 
Malig neo, overlapping lesion of heart, mediastinum & pleura B25..00 Chest--(not lung) 
Malig neop of respiratory tract and intrathoracic organs B2...00 Chest--(not lung) 
Malig neop of upper respiratory tract, part unspecified B2z0.00 Chest--(not lung) 
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Malig neop other/ill-defined sites resp/intrathoracic organs B2z..00 Chest--(not lung) 
Malignant neoplasm of anterior mediastinum B242.00 Chest--(not lung) 
Malignant neoplasm of axilla NOS B551000 Chest--(not lung) 
Malignant neoplasm of chest wall NOS B551100 Chest--(not lung) 
Malignant neoplasm of endocardium B241000 Chest--(not lung) 
Malignant neoplasm of heart, thymus and mediastinum NOS B24z.00 Chest--(not lung) 
Malignant neoplasm of mediastinum, part unspecified B24X.00 Chest--(not lung) 
Malignant neoplasm of myocardium B241200 Chest--(not lung) 
Malignant neoplasm of posterior mediastinum B243.00 Chest--(not lung) 
Malignant neoplasm of respiratory tract NOS B2zz.00 Chest--(not lung) 
Malignant neoplasm of thorax B551.00 Chest--(not lung) 
Malignant neoplasm of thorax NOS B551z00 Chest--(not lung) 
Malignant neoplasm of thymus B240.00 Chest--(not lung) 
Malignant neoplasm of thymus, heart and mediastinum B24..00 Chest--(not lung) 
Malignant neoplasm, overlap lesion of resp & intrathor orgs B26..00 Chest--(not lung) 
Mesothelioma of pericardium B241400 Chest--(not lung) 
Neoplasm of uncertain behaviour of heart B93y100 Chest--(not lung) 
Neoplasm of uncertain behaviour of mediastinum B908200 Chest--(not lung) 
Neoplasm of uncertain behaviour of thymus B908100 Chest--(not lung) 
Malignant neoplasm of clitoris B453.00 GU--External 
Malignant neoplasm of female genital organ NOS B45z.00 GU--External 
Malignant neoplasm of greater vestibular (Bartholin's) gland B451000 GU--External 
Malignant neoplasm of labia majora B451.00 GU--External 
Malignant neoplasm of labia majora NOS B451z00 GU--External 
Malignant neoplasm of labia minora B452.00 GU--External 
Malignant neoplasm of overlapping lesion of vulva B45y000 GU--External 
Malignant neoplasm of vagina B450.00 GU--External 
Malignant neoplasm of vagina NOS B450z00 GU--External 
Malignant neoplasm of vaginal vault B450100 GU--External 
Malignant neoplasm of vulva unspecified B454.00 GU--External 
Malignant neoplasm/overlapping lesion/feml genital organs B45X.00 GU--External 
Neoplasm of uncertain behaviour of penis B916000 GU--External 
Neoplasm of uncertain behaviour of vagina B913000 GU--External 
Neoplasm of uncertain behaviour of vulva B913100 GU--External 
Primary vulval cancer B454.11 GU--External 
[M] Angioimmunoblastic lymphadenopathy BBm8.00 HEMA--Lymph 
[M] Cutaneous lymphoma BBmD.00 HEMA--Lymph 
[M] Large cell lymphoma BBmH.00 HEMA--Lymph 
[M] Monocytoid B-cell lymphoma BBm9.00 HEMA--Lymph 
[M] Peripheral T-cell lymphoma NOS BBm5.00 HEMA--Lymph 
[M] T-gamma lymphoproliferative disease BBmC.00 HEMA--Lymph 
[M]AngiocentricT-cell lymphoma BBv2.00 HEMA--Lymph 
[M]Brill - Symmers' disease BBk0.11 HEMA--Lymph 
[M]Capillary lymphangioma BBU2.00 HEMA--Lymph 
[M]Cavernous lymphangioma BBU3.00 HEMA--Lymph 
[M]Cystic hygroma BBU4.11 HEMA--Lymph 
[M]Cystic lymphangioma BBU4.00 HEMA--Lymph 
[M]Follicular lymphosarcoma NOS BBk0.12 HEMA--Lymph 
[M]Giant follicular lymphoma BBk0.13 HEMA--Lymph 
[M]Haemolymphangioma BBU7.00 HEMA--Lymph 
 
 
352 
 
Cancer description Med 
Code 
Cancer type 
[M]Hodgkin,s disease, lymphocytic predominance, diffuse BBj1000 HEMA--Lymph 
[M]Hodgkin,s disease, lymphocytic predominance, nodular BBj1100 HEMA--Lymph 
[M]Hodgkin,s disease, nodular sclerosis, lymphocytic deplet BBj6200 HEMA--Lymph 
[M]Hodgkin,s disease, nodular sclerosis, lymphocytic predom BBj6000 HEMA--Lymph 
[M]Hodgkin,s disease, nodular sclerosis, mixed cellularity BBj6100 HEMA--Lymph 
[M]Hodgkin's disease BBj..00 HEMA--Lymph 
[M]Hodgkin's disease NOS BBj0.00 HEMA--Lymph 
[M]Hodgkin's disease NOS BBjz.00 HEMA--Lymph 
[M]Hodgkin's disease, lymphocytic predominance BBj1.00 HEMA--Lymph 
[M]Hodgkin's disease, mixed cellularity BBj2.00 HEMA--Lymph 
[M]Hodgkin's disease, nodular sclerosis NOS BBj6.00 HEMA--Lymph 
[M]Hodgkin's disease, nodular sclerosis, cellular phase BBj7.00 HEMA--Lymph 
[M]Hodgkin's sarcoma BBjA.00 HEMA--Lymph 
[M]Hygroma BBU4.12 HEMA--Lymph 
[M]Lymphangioma NOS BBU0.00 HEMA--Lymph 
[M]Lymphangiomatous tumours BBU..11 HEMA--Lymph 
[M]Lymphangiomyoma BBU5.00 HEMA--Lymph 
[M]Lymphangiomyomatosis BBU6.00 HEMA--Lymph 
[M]Lymphangiosarcoma BBU1.00 HEMA--Lymph 
[M]Lymphatic vessel tumours BBU..00 HEMA--Lymph 
[M]Lymphoblastic lymphoma NOS BBgG.12 HEMA--Lymph 
[M]Lymphoblastic lymphosarcoma NOS BBgG.11 HEMA--Lymph 
[M]Lymphoblastoma NOS BBgG.13 HEMA--Lymph 
[M]Lymphocytic lymphoma NOS BBgC.11 HEMA--Lymph 
[M]Lymphocytic lymphosarcoma NOS BBgC.12 HEMA--Lymph 
[M]Lymphoma NOS BBg1.11 HEMA--Lymph 
[M]Lymphoma, diffuse or NOS BBgz.00 HEMA--Lymph 
[M]Lymphoma, nodular or follicular NOS BBkz.00 HEMA--Lymph 
[M]Lymphomas, nodular or follicular BBk..00 HEMA--Lymph 
[M]Lymphomas, NOS or diffuse BBg..00 HEMA--Lymph 
[M]Malig lymp, follicular centre cell, cleaved, follicular BBk5.00 HEMA--Lymph 
[M]Malig lymphoma, follicular centre cell, non-cleaved NOS BBgK.00 HEMA--Lymph 
[M]Malig lymphoma, lymphocytic, intermediate different NOS BBgD.00 HEMA--Lymph 
[M]Malign lymphoma,lymphocytic,intermediate differn, diffuse BBgN.00 HEMA--Lymph 
[M]Malignant lymphoma NOS BBg1.00 HEMA--Lymph 
[M]Malignant lymphoma, centroblastic type NOS BBgJ.00 HEMA--Lymph 
[M]Malignant lymphoma, centroblastic type, follicular BBk7.00 HEMA--Lymph 
[M]Malignant lymphoma, centroblastic-centrocytic, diffuse BBgA.00 HEMA--Lymph 
[M]Malignant lymphoma, centrocytic BBgE.00 HEMA--Lymph 
[M]Malignant lymphoma, convoluted cell type NOS BBg5.00 HEMA--Lymph 
[M]Malignant lymphoma, diffuse NOS BBg1000 HEMA--Lymph 
[M]Malignant lymphoma, follicular centre cell NOS BBgB.00 HEMA--Lymph 
[M]Malignant lymphoma, immunoblastic type BBg8.00 HEMA--Lymph 
[M]Malignant lymphoma, large cell, cleaved, diffuse BBgS.00 HEMA--Lymph 
[M]Malignant lymphoma, large cell, diffuse NOS BBgR.00 HEMA--Lymph 
[M]Malignant lymphoma, large cell, noncleaved, diffuse BBgT.00 HEMA--Lymph 
[M]Malignant lymphoma, lymphocytic, poorly different NOS BBgG.00 HEMA--Lymph 
[M]Malignant lymphoma, lymphocytic, well differentiated NOS BBgC.00 HEMA--Lymph 
[M]Malignant lymphoma, lymphoplasmacytoid type BBg7.00 HEMA--Lymph 
[M]Malignant lymphoma, mixed small and large cell, diffuse BBgP.00 HEMA--Lymph 
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[M]Malignant lymphoma, nodular NOS BBk0.00 HEMA--Lymph 
[M]Malignant lymphoma, non Hodgkin's type BBg2.00 HEMA--Lymph 
[M]Malignant lymphoma, small cell, noncleaved, diffuse BBgV.00 HEMA--Lymph 
[M]Malignant lymphoma, small cleaved cell, diffuse BBgM.00 HEMA--Lymph 
[M]Malignant lymphoma, small lymphocytic NOS BBgL.00 HEMA--Lymph 
[M]Malignant lymphoma, stem cell type BBg4.00 HEMA--Lymph 
[M]Malignant lymphoma, undifferentiated cell type NOS BBg3.00 HEMA--Lymph 
[M]Malignant lymphomatous polyposis BBgQ.00 HEMA--Lymph 
[M]Monocytoid B-cell lymphoma BBv0.00 HEMA--Lymph 
[M]Myelodysplastic syndrome BBv..00 HEMA--Lymph 
[M]Non Hodgkins lymphoma BBg2.11 HEMA--Lymph 
[M]True histiocytic lymphoma BBm4.00 HEMA--Lymph 
[X]2ndry+unspcf malignant neoplasm lymph nodes/multi 
regions 
ByuC200 HEMA--Lymph 
[X]Diffuse non-Hodgkin's lymphoma, unspecified ByuDC00 HEMA--Lymph 
[X]Malignant neoplasms of lymphoid, haematopoietic and rela ByuD.00 HEMA--Lymph 
[X]Non-Hodgkin's lymphoma NOS ByuDF11 HEMA--Lymph 
[X]Non-Hodgkin's lymphoma, unspecified type ByuDF00 HEMA--Lymph 
[X]Oth and unspecif peripheral & cutaneous T-cell lymphomas ByuDD00 HEMA--Lymph 
[X]Other Hodgkin's disease ByuD000 HEMA--Lymph 
[X]Other specified types of non-Hodgkin's lymphoma ByuD300 HEMA--Lymph 
[X]Other types of diffuse non-Hodgkin's lymphoma ByuD200 HEMA--Lymph 
[X]Other types of follicular non-Hodgkin's lymphoma ByuD100 HEMA--Lymph 
[X]Unspecified B-cell non-Hodgkin's lymphoma ByuDE00 HEMA--Lymph 
Burkitt's lymphoma B602.00 HEMA--Lymph 
Burkitt's lymphoma NOS B602z00 HEMA--Lymph 
Burkitt's lymphoma of lymph nodes of head, face and neck B602100 HEMA--Lymph 
Diffuse non-Hodgkin mixed sml & lge cell (diffuse) lymphoma B627500 HEMA--Lymph 
Diffuse non-Hodgkin's centroblastic lymphoma B627D00 HEMA--Lymph 
Diffuse non-Hodgkin's immunoblastic (diffuse) lymphoma B627600 HEMA--Lymph 
Diffuse non-Hodgkin's lymphoblastic (diffuse) lymphoma B627700 HEMA--Lymph 
Diffuse non-Hodgkin's lymphoma undifferentiated (diffuse) B627800 HEMA--Lymph 
Diffuse non-Hodgkin's lymphoma, unspecified B627X00 HEMA--Lymph 
Diffuse non-Hodgkin's small cell (diffuse) lymphoma B627300 HEMA--Lymph 
Follicular lymphoma NOS B627C11 HEMA--Lymph 
Follicular non-Hodg mixed sml cleavd & lge cell lymphoma B627100 HEMA--Lymph 
Follicular non-Hodgkin's large cell lymphoma B627200 HEMA--Lymph 
Follicular non-Hodgkin's lymphoma B627C00 HEMA--Lymph 
Follicular non-Hodgkin's small cleaved cell lymphoma B627000 HEMA--Lymph 
Histiocytosis X (acute, progressive) B625.11 HEMA--Lymph 
Hodgkin's disease B61..00 HEMA--Lymph 
Hodgkin's disease NOS B61z.00 HEMA--Lymph 
Hodgkin's disease NOS B61zz00 HEMA--Lymph 
Hodgkin's disease NOS of intrathoracic lymph nodes B61z200 HEMA--Lymph 
Hodgkin's disease NOS of lymph nodes of axilla and arm B61z400 HEMA--Lymph 
Hodgkin's disease NOS of lymph nodes of head, face and neck B61z100 HEMA--Lymph 
Hodgkin's disease NOS of lymph nodes of multiple sites B61z800 HEMA--Lymph 
Hodgkin's disease NOS, unspecified site B61z000 HEMA--Lymph 
Hodgkin's disease, lymphocytic depletion B616.00 HEMA--Lymph 
Hodgkin's disease, lymphocytic depletion NOS B616z00 HEMA--Lymph 
Hodgkin's disease, lymphocytic-histiocytic predominance B613.00 HEMA--Lymph 
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Hodgkin's disease, mixed cellularity B615.00 HEMA--Lymph 
Hodgkin's disease, mixed cellularity NOS B615z00 HEMA--Lymph 
Hodgkin's disease, nodular sclerosis B614.00 HEMA--Lymph 
Hodgkin's disease, nodular sclerosis NOS B614z00 HEMA--Lymph 
Hodgkin's disease, nodular sclerosis of unspecified site B614000 HEMA--Lymph 
Hodgkin's granuloma B611.00 HEMA--Lymph 
Hodgkin's lymphocytic depletion lymph nodes axilla and arm B616400 HEMA--Lymph 
Hodgkin's nodular sclerosis of head, face and neck B614100 HEMA--Lymph 
Hodgkin's nodular sclerosis of intra-abdominal lymph nodes B614300 HEMA--Lymph 
Hodgkin's nodular sclerosis of intrathoracic lymph nodes B614200 HEMA--Lymph 
Hodgkin's nodular sclerosis of lymph nodes of multiple sites B614800 HEMA--Lymph 
Hodgkin's paragranuloma B610.00 HEMA--Lymph 
Hodgkin's sarcoma B612.00 HEMA--Lymph 
Hodgkin's, lymphocytic-histiocytic pred intrathoracic nodes B613200 HEMA--Lymph 
Hodgkin's, lymphocytic-histiocytic pred of head, face, neck B613100 HEMA--Lymph 
Hodgkin's, lymphocytic-histiocytic predominance unspec site B613000 HEMA--Lymph 
Immunoproliferative neoplasm B62zz11 HEMA--Lymph 
Kaposi's sarcoma of lymph nodes B6z0.00 HEMA--Lymph 
Letterer-Siwe disease B625.00 HEMA--Lymph 
Letterer-Siwe disease NOS B625z00 HEMA--Lymph 
Letterer-Siwe disease of intrathoracic lymph nodes B625200 HEMA--Lymph 
Letterer-Siwe disease of lymph nodes of multiple sites B625800 HEMA--Lymph 
Lymphoepithelioid lymphoma B62x100 HEMA--Lymph 
Lymphosarcoma B601.00 HEMA--Lymph 
Lymphosarcoma and reticulosarcoma B60..00 HEMA--Lymph 
Lymphosarcoma NOS B601z00 HEMA--Lymph 
Lymphosarcoma of intra-abdominal lymph nodes B601300 HEMA--Lymph 
Lymphosarcoma of intrathoracic lymph nodes B601200 HEMA--Lymph 
Lymphosarcoma of lymph nodes of head, face and neck B601100 HEMA--Lymph 
Lymphosarcoma of lymph nodes of inguinal region and leg B601500 HEMA--Lymph 
Lymphosarcoma of unspecified site B601000 HEMA--Lymph 
Malignant immunoproliferative small intestinal disease B62x500 HEMA--Lymph 
Malignant lymphoma NOS B62y.00 HEMA--Lymph 
Malignant lymphoma NOS B62yz00 HEMA--Lymph 
Malignant lymphoma NOS of intra-abdominal lymph nodes B62y300 HEMA--Lymph 
Malignant lymphoma NOS of intrapelvic lymph nodes B62y600 HEMA--Lymph 
Malignant lymphoma NOS of intrathoracic lymph nodes B62y200 HEMA--Lymph 
Malignant lymphoma NOS of lymph node inguinal region and 
leg 
B62y500 HEMA--Lymph 
Malignant lymphoma NOS of lymph nodes of axilla and arm B62y400 HEMA--Lymph 
Malignant lymphoma NOS of lymph nodes of head, face and 
neck 
B62y100 HEMA--Lymph 
Malignant lymphoma NOS of lymph nodes of multiple sites B62y800 HEMA--Lymph 
Malignant lymphoma NOS of spleen B62y700 HEMA--Lymph 
Malignant lymphoma NOS of unspecified site B62y000 HEMA--Lymph 
Malignant lymphoma otherwise specified B62x.00 HEMA--Lymph 
Malignant mast cell tumour NOS B626z00 HEMA--Lymph 
Malignant mast cell tumours B626.00 HEMA--Lymph 
Malignant neoplasm lymphatic or haematopoietic tissue NOS B6z..00 HEMA--Lymph 
Malignant neoplasm of lymphatic and haemopoietic tissue B6...00 HEMA--Lymph 
Malignant neoplasms of lymphoid and histiocytic tissue NOS B62z.00 HEMA--Lymph 
Malignant reticulosis B62x400 HEMA--Lymph 
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Mast cell malignancy of lymph nodes of multiple sites B626800 HEMA--Lymph 
Mycosis fungoides B621.00 HEMA--Lymph 
Mycosis fungoides NOS B621z00 HEMA--Lymph 
Mycosis fungoides of intra-abdominal lymph nodes B621300 HEMA--Lymph 
Mycosis fungoides of lymph nodes of inguinal region and leg B621500 HEMA--Lymph 
Mycosis fungoides of unspecified site B621000 HEMA--Lymph 
Nodular lymphoma (Brill - Symmers disease) B620.00 HEMA--Lymph 
Nodular lymphoma NOS B620z00 HEMA--Lymph 
Nodular lymphoma of intra-abdominal lymph nodes B620300 HEMA--Lymph 
Nodular lymphoma of lymph nodes of head, face and neck B620100 HEMA--Lymph 
Nodular lymphoma of lymph nodes of inguinal region and leg B620500 HEMA--Lymph 
Nodular lymphoma of lymph nodes of multiple sites B620800 HEMA--Lymph 
Nodular lymphoma of unspecified site B620000 HEMA--Lymph 
Non - Hodgkin's lymphoma B627.00 HEMA--Lymph 
Oth and unspecif peripheral & cutaneous T-cell lymphomas B62xX00 HEMA--Lymph 
Other malignant neoplasm of lymphoid and histiocytic tissue B62..00 HEMA--Lymph 
Other types of follicular non-Hodgkin's lymphoma B627B00 HEMA--Lymph 
Peripheral T-cell lymphoma B62x200 HEMA--Lymph 
Reticulosarcoma B600.00 HEMA--Lymph 
Reticulosarcoma of intra-abdominal lymph nodes B600300 HEMA--Lymph 
Reticulosarcoma of lymph nodes of head, face and neck B600100 HEMA--Lymph 
Reticulosarcoma of unspecified site B600000 HEMA--Lymph 
Sezary's disease B622.00 HEMA--Lymph 
Unspec malig neop lymphoid/histiocytic lymph node 
head/neck 
B62z100 HEMA--Lymph 
Unspec malig neop lymphoid/histiocytic nodes inguinal/leg B62z500 HEMA--Lymph 
Unspec malig neop lymphoid/histiocytic of intrathoracic node B62z200 HEMA--Lymph 
Unspecified B-cell non-Hodgkin's lymphoma B627W00 HEMA--Lymph 
[M]Bile duct carcinoma BB5D111 GI--Liver 
Gallbladder 
[M]Bile duct cystadenocarcinoma BB5D300 GI--Liver 
Gallbladder 
[M]Bile duct cystadenoma BB5D200 GI--Liver 
Gallbladder 
[M]Biliary tract adenomas and adenocarcinomas BB5D.11 GI--Liver 
Gallbladder 
[M]Cholangiocarcinoma BB5D100 GI--Liver 
Gallbladder 
[M]Cholangioma BB5D011 GI--Liver 
Gallbladder 
[M]Hepatobiliary adenoma or carcinoma NOS BB5Dz00 GI--Liver 
Gallbladder 
[M]Hepatobiliary tract adenomas and carcinomas BB5D.00 GI--Liver 
Gallbladder 
[M]Hepatoblastoma BBL8.00 GI--Liver 
Gallbladder 
[M]Hepatocellular adenoma BB5D411 GI--Liver 
Gallbladder 
[M]Hepatocellular carcinoma NOS BB5D500 GI--Liver 
Gallbladder 
[M]Hepatocellular carcinoma, fibrolamellar BB5D800 GI--Liver 
Gallbladder 
[M]Hepatoma NOS BB5D511 GI--Liver 
Gallbladder 
[M]Hepatoma, malignant BB5D512 GI--Liver 
Gallbladder 
[M]Infiltrating ductular carcinoma BB9G.00 GI--Liver 
Gallbladder 
[M]Liver cell adenoma BB5D400 GI--Liver 
Gallbladder 
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[M]Liver cell carcinoma BB5D513 GI--Liver 
Gallbladder 
[X]Malignant neoplasm of respiratory and intrathoracic orga Byu2.00 GI--Liver 
Gallbladder 
[X]Other specified carcinomas of liver Byu1100 GI--Liver 
Gallbladder 
Carcinoma common bile duct B161211 GI--Liver 
Gallbladder 
Carcinoma gallbladder B160.11 GI--Liver 
Gallbladder 
Hepatoblastoma of liver B150100 GI--Liver 
Gallbladder 
Hepatocellular carcinoma B150300 GI--Liver 
Gallbladder 
Malignant neoplasm gallbladder and extrahepatic bile ducts B16..00 GI--Liver 
Gallbladder 
Malignant neoplasm gallbladder/extrahepatic bile ducts NOS B16z.00 GI--Liver 
Gallbladder 
Malignant neoplasm of ampulla of Vater B162.00 GI--Liver 
Gallbladder 
Malignant neoplasm of common bile duct B161200 GI--Liver 
Gallbladder 
Malignant neoplasm of extrahepatic bile ducts B161.00 GI--Liver 
Gallbladder 
Malignant neoplasm of extrahepatic bile ducts NOS B161z00 GI--Liver 
Gallbladder 
Malignant neoplasm of gallbladder B160.00 GI--Liver 
Gallbladder 
Malignant neoplasm of hepatic duct B161100 GI--Liver 
Gallbladder 
Malignant neoplasm of interlobular bile ducts B151000 GI--Liver 
Gallbladder 
Malignant neoplasm of intrahepatic bile ducts B151.00 GI--Liver 
Gallbladder 
Malignant neoplasm of intrahepatic biliary passages B151200 GI--Liver 
Gallbladder 
Malignant neoplasm of intrahepatic gall duct B151400 GI--Liver 
Gallbladder 
Malignant neoplasm of liver and intrahepatic bile ducts B15..00 GI--Liver 
Gallbladder 
Malignant neoplasm of liver and intrahepatic bile ducts NOS B15z.00 GI--Liver 
Gallbladder 
Malignant neoplasm of liver unspecified B152.00 GI--Liver 
Gallbladder 
Malignant neoplasm other gallbladder/extrahepatic bile duct B16y.00 GI--Liver 
Gallbladder 
Malignant neoplasm, overlapping lesion of biliary tract B163.00 GI--Liver 
Gallbladder 
Neoplasm of uncertain behaviour of biliary system B903.11 GI--Liver 
Gallbladder 
Neoplasm of uncertain behaviour of gall bladder B903300 GI--Liver 
Gallbladder 
Neoplasm of uncertain behaviour of liver B903000 GI--Liver 
Gallbladder 
Neoplasm of uncertain behaviour of liver and biliary passage B903.00 GI--Liver 
Gallbladder 
Neoplasm of uncertain behaviour of sphincter of Oddi B903700 GI--Liver 
Gallbladder 
Primary angiosarcoma of liver B150200 GI--Liver 
Gallbladder 
Primary carcinoma of liver B150000 GI--Liver 
Gallbladder 
Primary malignant neoplasm of liver B150.00 GI--Liver 
Gallbladder 
Primary malignant neoplasm of liver NOS B150z00 GI--Liver 
Gallbladder 
[M]Androblastoma BBC6.00 GU--NOS  
[M]Arrhenoblastoma NOS BBC6z11 GU--NOS  
[M]Chorioadenoma BBR1.11 GU--NOS  
[M]Choriocarcinoma BBR2.00 GU--NOS  
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[M]Choriocarcinoma combined with teratoma BBR3.00 GU--NOS  
[M]Classical hydatidiform mole BBR7.00 GU--NOS  
[M]Complete hydatidiform mole BBR8.00 GU--NOS  
[M]Cystadenocarcinoma NOS BB80100 GU--NOS  
[M]Cystadenoma and carcinoma BB80.00 GU--NOS  
[M]Cystadenoma NOS BB80000 GU--NOS  
[M]Cystoma NOS BB80011 GU--NOS  
[M]Embryonal carcinoma NOS BBQ3.00 GU--NOS  
[M]Endodermal sinus tumour BBQ4.00 GU--NOS  
[M]Germinoma BBQ2.00 GU--NOS  
[M]Gonadal stromal tumour BBC0.11 GU--NOS  
[M]Gonadoblastoma BBQ6.00 GU--NOS  
[M]Granulosa cell tumour NOS BBC3.00 GU--NOS  
[M]Granulosa cell tumour, malignant BBC4.00 GU--NOS  
[M]Granulosa cell-theca cell tumour BBC5.00 GU--NOS  
[M]Hydatid mole BBR0.11 GU--NOS  
[M]Hydatidiform mole NOS BBR0.00 GU--NOS  
[M]Invasive hydatidiform mole BBR1.00 GU--NOS  
[M]Invasive mole NOS BBR1.13 GU--NOS  
[M]Juvenile granulosa cell tumour BBC3000 GU--NOS  
[M]Krukenberg tumour BB85111 GU--NOS  
[M]Malignant teratoma, trophoblastic BBR4.00 GU--NOS  
[M]Mucinous adenocarcinoma BB82100 GU--NOS  
[M]Mucinous adenoma BB82000 GU--NOS  
[M]Mucinous adenoma and adenocarcinoma BB82.00 GU--NOS  
[M]Mucinous adenoma or adenocarcinoma NOS BB82z00 GU--NOS  
[M]Mucinous cystadenocarcinoma NOS BB81E00 GU--NOS  
[M]Mucinous cystadenoma NOS BB81C00 GU--NOS  
[M]Mucinous cystadenoma, borderline malignancy BB81D00 GU--NOS  
[M]Mucin-producing adenocarcinoma BB84.00 GU--NOS  
[M]Mucoid adenocarcionoma BB82113 GU--NOS  
[M]Mucous adenocarcinoma BB82114 GU--NOS  
[M]Orchioblastoma BBQ4.12 GU--NOS  
[M]Papillary cystadenoma, borderline malignancy BB81K00 GU--NOS  
[M]Papillary cystic tumour BB81L00 GU--NOS  
[M]Papillary mucinous cystadenocarcinoma BB81H00 GU--NOS  
[M]Papillary mucinous cystadenoma NOS BB81F00 GU--NOS  
[M]Papillary serous cystadenoma, borderline malignancy BB81M00 GU--NOS  
[M]Partial hydatidiform mole BBR5.00 GU--NOS  
[M]Placental site trophoblastic tumour BBR6.00 GU--NOS  
[M]Pseudomucinous adenocarcinoma BB81E11 GU--NOS  
[M]Pseudomucinous cystadenoma NOS BB81C11 GU--NOS  
[M]Pseudomyxoma peritonei BB83.00 GU--NOS  
[M]Serous cystadenoma, borderline malignancy BB81J00 GU--NOS  
[M]Serous surface papillary carcinoma BB81B00 GU--NOS  
[M]Serous surface papilloma NOS BB81900 GU--NOS  
[M]Sertoli-Leydig cell tumour BBC7.00 GU--NOS  
[M]Sex cord tumour with annular tubules BBC0000 GU--NOS  
[M]Sex cord-stromal tumour BBC0.00 GU--NOS  
[M]Signet ring carcinoma BB85.00 GU--NOS  
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[M]Signet ring cell carcinoma BB85000 GU--NOS  
[M]Specialised gonadal neoplasms BBC..00 GU--NOS  
[M]Thecal cell neoplasm NOS BBC1z00 GU--NOS  
[M]Thecal cell neoplasms BBC1.00 GU--NOS  
[M]Thecoma NOS BBC1000 GU--NOS  
[M]Thecoma, luteinized BBC1200 GU--NOS  
[M]Trophoblastic neoplasm NOS BBRz.00 GU--NOS  
[M]Trophoblastic neoplasms BBR..00 GU--NOS  
[M]Yolk sac tumour BBQ4.14 GU--NOS  
[X]Malignant neoplasm of female genital organ, unspecified Byu7300 GU--NOS  
[X]Malignant neoplasm of female genital organs Byu7.00 GU--NOS  
[X]Malignant neoplasm of male genital organ, unspecified Byu8200 GU--NOS  
[X]Malignant neoplasm of male genital organs Byu8.00 GU--NOS  
[X]Malignant neoplasm of urinary tract Byu9.00 GU--NOS  
[X]Malignant neoplasm of uterine adnexa, unspecified Byu7000 GU--NOS  
[X]Malignant neoplasm/other specified female genital organs Byu7100 GU--NOS  
[X]Malignant neoplasm/other specified male genital organs Byu8000 GU--NOS  
Carcinoma of genitourinary organ B4...11 GU--NOS  
Choriocarcinoma B420.00 GU--NOS  
Choriocarcinoma B911013 GU--NOS  
Malig neop of other and unspecified female genital organs B45..00 GU--NOS  
Malignant hydatidiform mole B911000 GU--NOS  
Malignant neoplasm of body of penis B482.00 GU--NOS  
Malignant neoplasm of epididymis B484.00 GU--NOS  
Malignant neoplasm of fallopian tube B441.00 GU--NOS  
Malignant neoplasm of genitourinary organ B4...00 GU--NOS  
Malignant neoplasm of genitourinary organ NOS B4z..00 GU--NOS  
Malignant neoplasm of genitourinary organ OS B4y..00 GU--NOS  
Malignant neoplasm of glans penis B481.00 GU--NOS  
Malignant neoplasm of other male genital organ B48y.00 GU--NOS  
Malignant neoplasm of other male genital organ NOS B48yz00 GU--NOS  
Malignant neoplasm of other site of uterine adnexa B44y.00 GU--NOS  
Malignant neoplasm of parametrium B443.00 GU--NOS  
Malignant neoplasm of penis and other male genital organ NOS B48z.00 GU--NOS  
Malignant neoplasm of penis and other male genital organs B48..00 GU--NOS  
Malignant neoplasm of penis, part unspecified B483.00 GU--NOS  
Malignant neoplasm of placenta B42..00 GU--NOS  
Malignant neoplasm of prepuce (foreskin) B480.00 GU--NOS  
Malignant neoplasm of round ligament B444.00 GU--NOS  
Malignant neoplasm of scrotum B486.00 GU--NOS  
Malignant neoplasm of seminal vesicle B48y000 GU--NOS  
Malignant neoplasm of spermatic cord B485.00 GU--NOS  
Malignant neoplasm of tunica vaginalis B48y100 GU--NOS  
Malignant neoplasm, overlapping lesion male genital orgs B48y200 GU--NOS  
Malignant neoplasm, overlapping lesion of penis B487.00 GU--NOS  
Neoplasm of uncertain behaviour of epididymis B916100 GU--NOS  
Neoplasm of uncertain behaviour of genitourinary organs B91..00 GU--NOS  
Neoplasm of uncertain behaviour of scrotum B916200 GU--NOS  
Neoplasm of uncertain behaviour of urinary organ NOS B91z.11 GU--NOS  
Neoplasm of uncertain behaviour other female genital organs B913.00 GU--NOS  
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Neoplasm of unspecified nature of other genitourinary organs BA05.00 GU--NOS  
[M]Adenocarcinoma in villous adenoma BB5U100 RESP--Lung 
Cancer 
[M]Alveolar adenocarcinoma BB5S400 RESP--Lung 
Cancer 
[M]Alveolar cell carcinoma BB5S211 RESP--Lung 
Cancer 
[M]Bronchial adenoma NOS BB5S100 RESP--Lung 
Cancer 
[M]Bronchiolar carcinoma BB5S212 RESP--Lung 
Cancer 
[M]Bronchiolo-alveolar adenocarcinoma BB5S200 RESP--Lung 
Cancer 
[M]Cylindroid bronchial adenoma BB5J.12 RESP--Lung 
Cancer 
[M]Cystic mesothelioma BBP9.00 RESP--Lung 
Cancer 
[M]Epithelioid mesothelioma, malignant BBP5.00 RESP--Lung 
Cancer 
[M]Lobular carcinoma NOS BB9F.00 RESP--Lung 
Cancer 
[M]Mesothelial neoplasm NOS BBPz.00 RESP--Lung 
Cancer 
[M]Mesothelial neoplasms BBP..00 RESP--Lung 
Cancer 
[M]Mesothelioma, malignant BBP1.00 RESP--Lung 
Cancer 
[M]Mesothelioma, unspecified BBPX.00 RESP--Lung 
Cancer 
[M]Oat cell carcinoma BB1K.00 RESP--Lung 
Cancer 
[M]Papillary adenocarcinoma NOS BB5T100 RESP--Lung 
Cancer 
[M]Papillary adenoma NOS BB5T000 RESP--Lung 
Cancer 
[M]Papillary adenoma or adenocarcinoma NOS BB5Tz00 RESP--Lung 
Cancer 
[M]Papillary adenomas and adenocarcinomas BB5T.00 RESP--Lung 
Cancer 
[M]Papillotubular adenoma BB5U311 RESP--Lung 
Cancer 
[M]Pulmonary adenomatosis BB5S000 RESP--Lung 
Cancer 
[M]Respiratory tract adenoma or adenocarcinoma NOS BB5Sz00 RESP--Lung 
Cancer 
[M]Respiratory tract adenomas and adenocarcinomas BB5S.00 RESP--Lung 
Cancer 
[M]Round cell carcinoma BB1J.12 RESP--Lung 
Cancer 
[M]Small cell carcinoma NOS BB1J.00 RESP--Lung 
Cancer 
[M]Small cell carcinoma, fusiform cell type BB1L.00 RESP--Lung 
Cancer 
[M]Small cell carcinoma, intermediate cell BB1M.00 RESP--Lung 
Cancer 
[M]Small cell-large cell carcinoma BB1N.00 RESP--Lung 
Cancer 
[M]Tubulovillous adenoma BB5U300 RESP--Lung 
Cancer 
[M]Villoglandular adenoma BB5U312 RESP--Lung 
Cancer 
[M]Villous adenocarcinoma BB5U200 RESP--Lung 
Cancer 
[M]Villous adenoma NOS BB5U000 RESP--Lung 
Cancer 
[M]Villous adenoma or adenocarcinoma NOS BB5Uz00 RESP--Lung 
Cancer 
[M]Villous adenomas and adenocarcinomas BB5U.00 RESP--Lung 
Cancer 
[M]Villous papilloma BB5U011 RESP--Lung 
Cancer 
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[X]Malignant neoplasm of bronchus or lung, unspecified Byu2000 RESP--Lung 
Cancer 
[X]Malignant neoplasm/ill-defined sites w ithin resp system Byu2400 RESP--Lung 
Cancer 
[X]Mesothelioma of lung Byu5011 RESP--Lung 
Cancer 
[X]Mesothelioma of other sites Byu5000 RESP--Lung 
Cancer 
Lung cancer B22z.11 RESP--Lung 
Cancer 
Malignant neoplasm of bronchus or lung NOS B22z.00 RESP--Lung 
Cancer 
Malignant neoplasm of carina of bronchus B221000 RESP--Lung 
Cancer 
Malignant neoplasm of hilus of lung B221100 RESP--Lung 
Cancer 
Malignant neoplasm of lower lobe bronchus B224000 RESP--Lung 
Cancer 
Malignant neoplasm of lower lobe of lung B224100 RESP--Lung 
Cancer 
Malignant neoplasm of lower lobe, bronchus or lung B224.00 RESP--Lung 
Cancer 
Malignant neoplasm of lower lobe, bronchus or lung NOS B224z00 RESP--Lung 
Cancer 
Malignant neoplasm of main bronchus B221.00 RESP--Lung 
Cancer 
Malignant neoplasm of main bronchus NOS B221z00 RESP--Lung 
Cancer 
Malignant neoplasm of middle lobe bronchus B223000 RESP--Lung 
Cancer 
Malignant neoplasm of middle lobe of lung B223100 RESP--Lung 
Cancer 
Malignant neoplasm of middle lobe, bronchus or lung B223.00 RESP--Lung 
Cancer 
Malignant neoplasm of middle lobe, bronchus or lung NOS B223z00 RESP--Lung 
Cancer 
Malignant neoplasm of other sites of bronchus or lung B22y.00 RESP--Lung 
Cancer 
Malignant neoplasm of overlapping lesion of bronchus & lung B225.00 RESP--Lung 
Cancer 
Malignant neoplasm of parietal pleura B230.00 RESP--Lung 
Cancer 
Malignant neoplasm of pleura B23..00 RESP--Lung 
Cancer 
Malignant neoplasm of pleura NOS B23z.00 RESP--Lung 
Cancer 
Malignant neoplasm of trachea B220.00 RESP--Lung 
Cancer 
Malignant neoplasm of trachea NOS B220z00 RESP--Lung 
Cancer 
Malignant neoplasm of trachea, bronchus and lung B22..00 RESP--Lung 
Cancer 
Malignant neoplasm of upper lobe bronchus B222000 RESP--Lung 
Cancer 
Malignant neoplasm of upper lobe of lung B222100 RESP--Lung 
Cancer 
Malignant neoplasm of upper lobe, bronchus or lung B222.00 RESP--Lung 
Cancer 
Malignant neoplasm of upper lobe, bronchus or lung NOS B222z00 RESP--Lung 
Cancer 
Malignant neoplasm of visceral pleura B231.00 RESP--Lung 
Cancer 
Mesothelioma B226.00 RESP--Lung 
Cancer 
Mesothelioma of pleura B232.00 RESP--Lung 
Cancer 
Neoplasm of uncertain behaviour of bronchus B907100 RESP--Lung 
Cancer 
Neoplasm of uncertain behaviour of lung B907200 RESP--Lung 
Cancer 
Neoplasm of uncertain behaviour of pleura B908000 RESP--Lung 
Cancer 
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Neoplasm of uncertain behaviour trachea, bronchus and lung B907.00 RESP--Lung 
Cancer 
Neoplasm of unspecified nature of respiratory system BA01.00 RESP--Lung 
Cancer 
Pancoast's syndrome B222.11 RESP--Lung 
Cancer 
[M]Adenoacanthoma BBB2.11 CNS--Brain 
[M]Adenocarcinoma with cartilaginous and osseous 
metaplasia 
BBB3.00 CNS--Brain 
[M]Adenocarcinoma with squamous metaplasia BBB2.00 CNS--Brain 
[M]Adenolymphoma BBB1.00 CNS--Brain 
[M]Adenosquamous carcinoma BBB0.00 CNS--Brain 
[M]Aesthesioneuroblastoma BBcC.00 CNS--Brain 
[M]Astroblastoma BBbK.00 CNS--Brain 
[M]Astrocytic glioma BBbB.11 CNS--Brain 
[M]Astrocytoma NOS BBbB.00 CNS--Brain 
[M]Astrocytoma, anaplastic type BBbC.00 CNS--Brain 
[M]Cerebellar sarcoma NOS BBbW.00 CNS--Brain 
[M]Chordoma BBa5.00 CNS--Brain 
[M]Choroid plexus papilloma NOS BBb5.00 CNS--Brain 
[M]Complex epithelial neoplasm NOS BBBz.00 CNS--Brain 
[M]Complex epithelial neoplasms BBB..00 CNS--Brain 
[M]Craniopharyngioma BBa0.00 CNS--Brain 
[M]Desmoplastic medulloblastoma BBbU.00 CNS--Brain 
[M]Ependymoblastoma BBb8.11 CNS--Brain 
[M]Ependymoma NOS BBb7.00 CNS--Brain 
[M]Ependymoma, anaplastic type BBb8.00 CNS--Brain 
[M]Fibrillary astrocytoma BBbF.00 CNS--Brain 
[M]Gangliocytoma BBc0011 CNS--Brain 
[M]Ganglioglioma BBc6.00 CNS--Brain 
[M]Ganglioneuroblastoma BBc0100 CNS--Brain 
[M]Ganglioneuroma BBc0000 CNS--Brain 
[M]Ganglioneuromatosis BBc0200 CNS--Brain 
[M]Ganglioneuromatous neoplasms BBc0.00 CNS--Brain 
[M]Gemistocytic astrocytoma BBbE.00 CNS--Brain 
[M]Giant cell glioblastoma BBbM.00 CNS--Brain 
[M]Glioblastoma multiforme BBbL.11 CNS--Brain 
[M]Glioblastoma NOS BBbL.00 CNS--Brain 
[M]Glioma NOS BBb0.11 CNS--Brain 
[M]Glioma NOS BBbz.00 CNS--Brain 
[M]Glioma, malignant BBb0.00 CNS--Brain 
[M]Gliomas BBb..00 CNS--Brain 
[M]Gliomatosis cerebri BBb1.00 CNS--Brain 
[M]Gliosarcoma BBb0.12 CNS--Brain 
[M]Juvenile astrocytoma BBbG.11 CNS--Brain 
[M]Medulloblastoma NOS BBbT.00 CNS--Brain 
[M]Medulloepithelioma NOS BBc2.00 CNS--Brain 
[M]Medullomyoblastoma BBbV.00 CNS--Brain 
[M]Melanoameloblastoma BBa4.11 CNS--Brain 
[M]Melanotic neuroectodermal tumour BBa4.00 CNS--Brain 
[M]Melanotic progonoma BBa4.12 CNS--Brain 
[M]Mixed glioma BBb2.00 CNS--Brain 
[M]Mixed glioma BBb2.11 CNS--Brain 
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[M]Myxopapillary ependymoma BBbA.00 CNS--Brain 
[M]Neuroastrocytoma BBc7.11 CNS--Brain 
[M]Neuroblastoma NOS BBc1.00 CNS--Brain 
[M]Neurocytoma BBc7.00 CNS--Brain 
[M]Neuroepithelioma NOS BBc4.00 CNS--Brain 
[M]Neuroepitheliomatous neoplasms BBc..00 CNS--Brain 
[M]Olfactory neuroblastoma BBcC.11 CNS--Brain 
[M]Olfactory neurogenic tumour BBcA.00 CNS--Brain 
[M]Oligodendroblastoma BBbS.00 CNS--Brain 
[M]Oligodendroglioma NOS BBbQ.00 CNS--Brain 
[M]Oligodendroglioma, anaplastic type BBbR.00 CNS--Brain 
[M]Papillary ependymoma BBb9.00 CNS--Brain 
[M]Pilocytic astrocytoma BBbG.00 CNS--Brain 
[M]Piloid astrocytoma BBbG.12 CNS--Brain 
[M]Pinealoma BBa1.00 CNS--Brain 
[M]Pineoblastoma BBa3.00 CNS--Brain 
[M]Pineocytoma BBa2.00 CNS--Brain 
[M]Pleomorphic xanthoastrocytoma BBbZ.00 CNS--Brain 
[M]Primitive neuroectodermal tumour BBba.00 CNS--Brain 
[M]Retinoblastoma NOS BBc9z00 CNS--Brain 
[M]Retinoblastomas BBc9.00 CNS--Brain 
[M]Spongioblastoma polare BBbJ.00 CNS--Brain 
[M]Subependymal astrocytoma NOS BBb3.11 CNS--Brain 
[M]Subependymal astrocytoma NOS BBb3.12 CNS--Brain 
[M]Subependymal giant cell astrocytoma BBb4.00 CNS--Brain 
[M]Subependymal glioma BBb3.00 CNS--Brain 
[M]Subependymoma BBb3.13 CNS--Brain 
[M]Warthin's tumour BBB1.11 CNS--Brain 
Cerebral tumour - malignant B51..11 CNS--Brain 
Malignant neoplasm cerebrum (excluding lobes and ventricles) B510.00 CNS--Brain 
Malignant neoplasm of basal ganglia B510000 CNS--Brain 
Malignant neoplasm of brain B51..00 CNS--Brain 
Malignant neoplasm of brain NOS B51z.00 CNS--Brain 
Malignant neoplasm of brain stem B517.00 CNS--Brain 
Malignant neoplasm of brain stem NOS B517z00 CNS--Brain 
Malignant neoplasm of cerebellum B516.00 CNS--Brain 
Malignant neoplasm of cerebral cortex B510100 CNS--Brain 
Malignant neoplasm of cerebral peduncle B517000 CNS--Brain 
Malignant neoplasm of cerebral ventricles B515.00 CNS--Brain 
Malignant neoplasm of cerebrum NOS B510z00 CNS--Brain 
Malignant neoplasm of choroid plexus B515000 CNS--Brain 
Malignant neoplasm of corpus callosum B51y000 CNS--Brain 
Malignant neoplasm of frontal lobe B511.00 CNS--Brain 
Malignant neoplasm of hippocampus B512000 CNS--Brain 
Malignant neoplasm of hypothalamus B510400 CNS--Brain 
Malignant neoplasm of medulla oblongata B517100 CNS--Brain 
Malignant neoplasm of occipital lobe B514.00 CNS--Brain 
Malignant neoplasm of other parts of brain B51y.00 CNS--Brain 
Malignant neoplasm of parietal lobe B513.00 CNS--Brain 
Malignant neoplasm of pons B517300 CNS--Brain 
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Malignant neoplasm of temporal lobe B512.00 CNS--Brain 
Malignant neoplasm of temporal lobe NOS B512z00 CNS--Brain 
Malignant neoplasm of thalamus B510500 CNS--Brain 
Neoplasm of uncertain behaviour of adrenal gland B922.00 CNS--Brain 
Neoplasm of uncertain behaviour of brain B925000 CNS--Brain 
Neoplasm of uncertain behaviour of carotid body B923000 CNS--Brain 
Neoplasm of uncertain behaviour of meninges B926.00 CNS--Brain 
Neoplasm of uncertain behaviour of pineal gland B921.00 CNS--Brain 
Neoplasm of uncertain or unknown behav brain, supratentorial B925200 CNS--Brain 
Neoplasm of unspecified nature of brain BA06.00 CNS--Brain 
[M]Acoustic neuroma BBe5.11 CNS--NOS 
[M]Angioblastic meningioma BBd7.11 CNS--NOS 
[M]Angiomatous meningioma BBd6.00 CNS--NOS 
[M]Chemodectoma BBD7.11 CNS--NOS 
[M]Fibrous meningioma BBd4.00 CNS--NOS 
[M]Glomus jugulare tumour BBD4.00 CNS--NOS 
[M]Gynandroblastoma BBC8.00 CNS--NOS 
[M]Haemangioblastic meningioma BBd7.00 CNS--NOS 
[M]Haemangiopericytic meningioma BBd8.00 CNS--NOS 
[M]Jugular paraganglioma BBD4.11 CNS--NOS 
[M]Leptomeningeal sarcoma BBd2.11 CNS--NOS 
[M]Melanotic neurofibroma BBe3.00 CNS--NOS 
[M]Meningioma NOS BBd0.00 CNS--NOS 
[M]Meningioma NOS BBdz.00 CNS--NOS 
[M]Meningioma, malignant BBd2.00 CNS--NOS 
[M]Meningiomas BBd..00 CNS--NOS 
[M]Meningotheliomatous meningioma BBd3.00 CNS--NOS 
[M]Multiple meningiomatosis BBd1.12 CNS--NOS 
[M]Multiple neurofibromatosis BBe1.11 CNS--NOS 
[M]Nerve sheath tumour BBe..00 CNS--NOS 
[M]Nerve sheath tumour NOS BBez.00 CNS--NOS 
[M]Neurilemmoma NOS BBe5.00 CNS--NOS 
[M]Neurilemmoma, malignant BBe7.00 CNS--NOS 
[M]Neurinoma BBe5.12 CNS--NOS 
[M]Neurinomatosis BBe6.00 CNS--NOS 
[M]Neuroepitheliomatous neoplasm NOS BBcz.00 CNS--NOS 
[M]Neurofibroma NOS BBe0.00 CNS--NOS 
[M]Neurofibromas BBe..11 CNS--NOS 
[M]Neurofibromatosis NOS BBe1.00 CNS--NOS 
[M]Neurofibrosarcoma BBe2.00 CNS--NOS 
[M]Neuroma NOS BBe8.00 CNS--NOS 
[M]Neurothekeoma BBeA.00 CNS--NOS 
[M]Paraganglioma NOS BBD0.00 CNS--NOS 
[M]Paragangliomas and glomus tumours BBD..00 CNS--NOS 
[M]Plexiform neurofibroma BBe4.00 CNS--NOS 
[M]Psammomatous meningioma BBd5.00 CNS--NOS 
[M]Schwannoma NOS BBe5.13 CNS--NOS 
[M]Schwannoma, malignant BBe7.11 CNS--NOS 
[M]Transitional meningioma BBd9.00 CNS--NOS 
[M]Triton tumour, malignant BBe9.00 CNS--NOS 
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[M]Von Recklinghausen's disease BBe1.12 CNS--NOS 
[X]Malig neopl, overlap lesion brain & other part of CNS ByuA300 CNS--NOS 
[X]Malignant neoplasm of eye, brain and other parts of cent ByuA.00 CNS--NOS 
[X]Malignant neoplasm of meninges, unspecified ByuA200 CNS--NOS 
[X]Malignant neoplasm/central nervous system, unspecified ByuA100 CNS--NOS 
[X]Malignant neoplasm/other and unspecified cranial nerves ByuA000 CNS--NOS 
[X]Malignant neoplasm/peripheral nerves of trunk,unspecified Byu5400 CNS--NOS 
Malig neop of other and unspecified parts of nervous system B52..00 CNS--NOS 
Malig neopl peripheral nerves and autonomic nervous system B524.00 CNS--NOS 
Malig neopl, overlap lesion brain & other part of CNS B52W.00 CNS--NOS 
Malignant neoplasm of acoustic nerve B520200 CNS--NOS 
Malignant neoplasm of cauda equina B525.00 CNS--NOS 
Malignant neoplasm of cerebral meninges B521.00 CNS--NOS 
Malignant neoplasm of choroid B506.00 CNS--NOS 
Malignant neoplasm of ciliary body B500000 CNS--NOS 
Malignant neoplasm of conjunctiva B503.00 CNS--NOS 
Malignant neoplasm of cornea B504.00 CNS--NOS 
Malignant neoplasm of cranial nerves B520.00 CNS--NOS 
Malignant neoplasm of cranial nerves NOS B520z00 CNS--NOS 
Malignant neoplasm of eye B50..00 CNS--NOS 
Malignant neoplasm of eye NOS B50z.00 CNS--NOS 
Malignant neoplasm of eyeball NOS B500z00 CNS--NOS 
Malignant neoplasm of iris B500100 CNS--NOS 
Malignant neoplasm of lacrimal duct B507.00 CNS--NOS 
Malignant neoplasm of lacrimal gland B502.00 CNS--NOS 
Malignant neoplasm of meninges, unspecified B52X.00 CNS--NOS 
Malignant neoplasm of nasolacrimal duct B507100 CNS--NOS 
Malignant neoplasm of nervous system NOS B52z.00 CNS--NOS 
Malignant neoplasm of optic nerve B520100 CNS--NOS 
Malignant neoplasm of orbit B501.00 CNS--NOS 
Malignant neoplasm of orbit NOS B501z00 CNS--NOS 
Malignant neoplasm of other specified part of nervous system B52y.00 CNS--NOS 
Malignant neoplasm of other specified site of eye B50y.00 CNS--NOS 
Malignant neoplasm of peripheral nerve of low limb, incl hip B524200 CNS--NOS 
Malignant neoplasm of peripheral nerve of pelvis B524500 CNS--NOS 
Malignant neoplasm of peripheral nerve,upp limb,incl should B524100 CNS--NOS 
Malignant neoplasm of peripheral nerves of head, face & neck B524000 CNS--NOS 
Malignant neoplasm of retina B505.00 CNS--NOS 
Malignant neoplasm of spinal cord B522.00 CNS--NOS 
Malignant neoplasm of spinal meninges B523.00 CNS--NOS 
Malignant neoplasm of spinal meninges NOS B523z00 CNS--NOS 
Malignant neoplasm, overlapping lesion of eye and adnexa B508.00 CNS--NOS 
Neop unspec nature of endocrine glands, other nervous 
system 
BA07.00 CNS--NOS 
Neopl uncert/unkn behav of periph nerves & autonom nerv sys B928.00 CNS--NOS 
Neoplasm of uncertain behaviour of eye B93y000 CNS--NOS 
Neoplasm of uncertain behaviour of nervous system OS/NOS B92z.00 CNS--NOS 
Neoplasm of uncertain behaviour of spinal cord B925100 CNS--NOS 
Neurofibromatosis - Von Recklinghausen's disease B927.00 CNS--NOS 
Von Recklinghausen's disease B927.11 CNS--NOS 
[M]Adult rhabdomyoma BBK3500 CONN--NOS 
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[M]Alveolar rhabdomyosarcoma BBK3700 CONN--NOS 
[M]Angioleiomyoma BBK1011 CONN--NOS 
[M]Angiomyoma BBK1000 CONN--NOS 
[M]Angiomyomatous neoplasm NOS BBK1z00 CONN--NOS 
[M]Angiomyomatous neoplasms BBK1.00 CONN--NOS 
[M]Angiomyosarcoma BBK1100 CONN--NOS 
[M]Cellular leiomyoma BBK0500 CONN--NOS 
[M]Clear cell sarcoma of tendons and aponeuroses BBN5.00 CONN--NOS 
[M]Embryonal rhabdomyosarcoma BBK3600 CONN--NOS 
[M]Epithelioid cell sarcoma BBF6.00 CONN--NOS 
[M]Epithelioid leiomyoma BBK0300 CONN--NOS 
[M]Epithelioid leiomyosarcoma BBK0400 CONN--NOS 
[M]Fibroepithelial neoplasm NOS BBMz.00 CONN--NOS 
[M]Fibroepithelial neoplasms BBM..00 CONN--NOS 
[M]Fibroid uterus BBK0011 CONN--NOS 
[M]Fibromyoma BBK0012 CONN--NOS 
[M]Giant fibroadenoma BBMB.00 CONN--NOS 
[M]Granular cell tumour NOS BBf0.00 CONN--NOS 
[M]Granular cell tumours and alveolar soft part sarcoma BBf..00 CONN--NOS 
[M]Intravascular leiomyomatosis BBK0100 CONN--NOS 
[M]Juvenile fibroadenoma BBMA.00 CONN--NOS 
[M]Leiomyoblastoma BBK0311 CONN--NOS 
[M]Leiomyofibroma BBK0013 CONN--NOS 
[M]Leiomyoma NOS BBK0000 CONN--NOS 
[M]Leiomyomatous neoplasm NOS BBK0z00 CONN--NOS 
[M]Leiomyomatous neoplasms BBK0.00 CONN--NOS 
[M]Leiomyosarcoma NOS BBK0200 CONN--NOS 
[M]Miscellaneous reticuloendothelial neoplasm NOS BBmz.00 CONN--NOS 
[M]Miscellaneous reticuloendothelial neoplasms BBm..00 CONN--NOS 
[M]Myofibroma BBK0014 CONN--NOS 
[M]Myoma BBK2000 CONN--NOS 
[M]Myoma and myosarcoma BBK2.00 CONN--NOS 
[M]Myoma or myosarcoma NOS BBK2z00 CONN--NOS 
[M]Myomatous neoplasm NOS BBKz.00 CONN--NOS 
[M]Myomatous neoplasms BBK..00 CONN--NOS 
[M]Myosarcoma BBK2100 CONN--NOS 
[M]Myxoid leiomyosarcoma BBK0700 CONN--NOS 
[M]Pleomorphic cell sarcoma BBF4.11 CONN--NOS 
[M]Pleomorphic rhabdomyosarcoma BBK3200 CONN--NOS 
[M]Reticulum cell sarcoma NOS BBh0.11 CONN--NOS 
[M]Rhabdomyoma NOS BBK3000 CONN--NOS 
[M]Rhabdomyomatous neoplasms BBK3.00 CONN--NOS 
[M]Rhabdomyosarcoma NOS BBK3100 CONN--NOS 
[M]Round cell sarcoma BBF5.11 CONN--NOS 
[M]Sarcoma botryoides BBK3611 CONN--NOS 
[M]Sarcoma NOS BBF1.00 CONN--NOS 
[M]Sarcomatosis NOS BBF2.00 CONN--NOS 
[M]Small cell sarcoma BBF5.00 CONN--NOS 
[M]Smooth muscle tumour NOS BBK3800 CONN--NOS 
[M]Soft tissue tumour or sarcoma NOS BBFz.00 CONN--NOS 
 
 
366 
 
Cancer description Med 
Code 
Cancer type 
[M]Soft tissue tumours and sarcomas NOS BBF..00 CONN--NOS 
[M]Spindle cell sarcoma BBF3.00 CONN--NOS 
[M]Synovial neoplasm NOS BBNz.00 CONN--NOS 
[M]Synovial neoplasms BBN..00 CONN--NOS 
[M]Synovial sarcoma NOS BBN1.00 CONN--NOS 
[M]Synovial sarcoma, biphasic type BBN4.00 CONN--NOS 
[M]Synovioma NOS BBN1.11 CONN--NOS 
[M]Vascular leiomyoma BBK1012 CONN--NOS 
[X]Malignant neoplasm/bone+articular cartilage, unspecified Byu3300 CONN--NOS 
Carcinoma of bone, connective tissue, skin and breast B3...11 CONN--NOS 
Malig neop connective and soft tissue head, face, neck NOS B310z00 CONN--NOS 
Malig neop connective and soft tissue hip and leg NOS B312z00 CONN--NOS 
Malig neop connective and soft tissue of popliteal space B312200 CONN--NOS 
Malig neop connective and soft tissue upper limb/shoulder B311.00 CONN--NOS 
Malig neop of bone, connective tissue, skin and breast B3...00 CONN--NOS 
Malig neop of bone, connective tissue, skin and breast NOS B3z..00 CONN--NOS 
Malig neop of bone, connective tissue, skin and breast OS B3y..00 CONN--NOS 
Malig neop of connective and soft tissue head, face and neck B310.00 CONN--NOS 
Malig neop of connective and soft tissue of abdomen NOS B314z00 CONN--NOS 
Malig neop of connective and soft tissue of abdominal wall B314000 CONN--NOS 
Malig neop of connective and soft tissue of hip and leg B312.00 CONN--NOS 
Malig neop of connective and soft tissue of inguinal region B315100 CONN--NOS 
Malig neop of connective and soft tissue of lower leg B312300 CONN--NOS 
Malig neop of connective and soft tissue of pelvis NOS B315z00 CONN--NOS 
Malig neop of connective and soft tissue of thorax NOS B313z00 CONN--NOS 
Malig neop of connective and soft tissue thigh and upper leg B312100 CONN--NOS 
Malig neop of connective and soft tissue trunk unspecified B316.00 CONN--NOS 
Malignant neoplasm of cartilage of ear B310300 CONN--NOS 
Malignant neoplasm of connective and other soft tissue B31..00 CONN--NOS 
Malignant neoplasm of connective and soft tissue of abdomen B314.00 CONN--NOS 
Malignant neoplasm of connective and soft tissue of axilla B313000 CONN--NOS 
Malignant neoplasm of connective and soft tissue of buttock B315000 CONN--NOS 
Malignant neoplasm of connective and soft tissue of finger B311400 CONN--NOS 
Malignant neoplasm of connective and soft tissue of foot B312400 CONN--NOS 
Malignant neoplasm of connective and soft tissue of fore-arm B311200 CONN--NOS 
Malignant neoplasm of connective and soft tissue of hand B311300 CONN--NOS 
Malignant neoplasm of connective and soft tissue of pelvis B315.00 CONN--NOS 
Malignant neoplasm of connective and soft tissue of perineum B315200 CONN--NOS 
Malignant neoplasm of connective and soft tissue of shoulder B311000 CONN--NOS 
Malignant neoplasm of connective and soft tissue of thorax B313.00 CONN--NOS 
Malignant neoplasm of connective and soft tissue of thumb B311500 CONN--NOS 
Malignant neoplasm of connective and soft tissue, site NOS B31z.00 CONN--NOS 
Malignant neoplasm of connective and soft tissue, upper arm B311100 CONN--NOS 
Malignant neoplasm of great vessels B313200 CONN--NOS 
Malignant neoplasm of soft tissue of face B310100 CONN--NOS 
Malignant neoplasm of soft tissue of head B310000 CONN--NOS 
Malignant neoplasm of soft tissue of neck B310200 CONN--NOS 
Malignant neoplasm of tarsus of eyelid B310400 CONN--NOS 
Neoplasm of unspec nature of bone, skin or soft tissue NOS BA02z00 CONN--NOS 
Neoplasm of unspecified nature of bone, skin and soft tissue BA02.00 CONN--NOS 
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Sarcoma of bone and connective tissue B3...12 CONN--NOS 
[M] Small cell osteosarcoma BBVA.00 CONN--Bone 
[M]Adamantinoma NOS BBZF.11 CONN--Bone 
[M]Adamantinoma of long bones BBY1.00 CONN--Bone 
[M]Adenomatoid odontogenic tumour BBZD.00 CONN--Bone 
[M]Ameloblastic fibroma BBZM.00 CONN--Bone 
[M]Ameloblastic fibro-odontoma BBZB.00 CONN--Bone 
[M]Ameloblastic fibrosarcoma BBZN.00 CONN--Bone 
[M]Ameloblastic odontosarcoma BBZC.00 CONN--Bone 
[M]Ameloblastoma NOS BBZF.00 CONN--Bone 
[M]Ameloblastoma, malignant BBZG.00 CONN--Bone 
[M]Calcifying epithelial odontogenic tumour BBZP.00 CONN--Bone 
[M]Calcifying odontogenic cyst BBZE.00 CONN--Bone 
[M]Cartilaginous exostosis BBW0.11 CONN--Bone 
[M]Cementifying fibroma BBZ6.00 CONN--Bone 
[M]Cementoma NOS BBZ4.00 CONN--Bone 
[M]Chondroblastic osteosarcoma BBV2.00 CONN--Bone 
[M]Chondroblastoma NOS BBW7.00 CONN--Bone 
[M]Chondroma NOS BBW2.00 CONN--Bone 
[M]Chondromatosis NOS BBW3.00 CONN--Bone 
[M]Chondromatous giant cell tumour BBW7.11 CONN--Bone 
[M]Chondromatous neoplasm NOS BBWz.00 CONN--Bone 
[M]Chondromatous neoplasms BBW..00 CONN--Bone 
[M]Chondromyxoid fibroma BBWA.00 CONN--Bone 
[M]Chondrosarcoma NOS BBW4.00 CONN--Bone 
[M]Dentinoma BBZ3.00 CONN--Bone 
[M]Ecchondroma BBW0.12 CONN--Bone 
[M]Ecchondrosis BBW1.11 CONN--Bone 
[M]Enchondroma BBW2.11 CONN--Bone 
[M]Endothelial bone sarcoma BBY0.11 CONN--Bone 
[M]Ewing's sarcoma BBY0.00 CONN--Bone 
[M]Fibroblastic osteosarcoma BBV3.00 CONN--Bone 
[M]Fibrochondrosarcoma BBW4.11 CONN--Bone 
[M]Giant cell bone sarcoma BBX1.11 CONN--Bone 
[M]Giant cell tumour of bone NOS BBX0.00 CONN--Bone 
[M]Giant osteoid osteoma BBV8.11 CONN--Bone 
[M]Gigantiform cementoma BBZ7.00 CONN--Bone 
[M]Juxtacortical chondrosarcoma BBW6.00 CONN--Bone 
[M]Mesenchymal chondrosarcoma BBW9.00 CONN--Bone 
[M]Miscellaneous bone tumour NOS BBYz.00 CONN--Bone 
[M]Miscellaneous bone tumours BBY..00 CONN--Bone 
[M]Myxoid chondrosarcoma BBV9.00 CONN--Bone 
[M]Odontogenic fibroma NOS BBZL.00 CONN--Bone 
[M]Odontogenic myxoma BBZK.00 CONN--Bone 
[M]Odontogenic tumour NOS BBZ1.00 CONN--Bone 
[M]Odontogenic tumours BBZ..00 CONN--Bone 
[M]Odontoma NOS BBZ8.00 CONN--Bone 
[M]Ossifying fibroma BBY2.00 CONN--Bone 
[M]Ossifying fibroma BBY2.11 CONN--Bone 
[M]Osteoblastic sarcoma BBV1.11 CONN--Bone 
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[M]Osteoblastoma BBV8.00 CONN--Bone 
[M]Osteocartilaginous exostosis BBW0.13 CONN--Bone 
[M]Osteochondroma BBW0.00 CONN--Bone 
[M]Osteochondromatosis NOS BBW1.00 CONN--Bone 
[M]Osteochondrosarcoma BBV1.12 CONN--Bone 
[M]Osteoclastoma BBX0.11 CONN--Bone 
[M]Osteoclastoma, malignant BBX1.12 CONN--Bone 
[M]Osteofibroma BBY2.12 CONN--Bone 
[M]Osteogenic sarcoma NOS BBV1.13 CONN--Bone 
[M]Osteoid osteoma NOS BBV7.00 CONN--Bone 
[M]Osteoma NOS BBV0.00 CONN--Bone 
[M]Osteoma or osteosarcoma NOS BBVz.00 CONN--Bone 
[M]Osteomas and osteosarcomas BBV..00 CONN--Bone 
[M]Osteosarcoma in Paget's disease of bone BBV5.00 CONN--Bone 
[M]Osteosarcoma NOS BBV1.00 CONN--Bone 
[M]Paget's disease and infiltrating breast duct carcinoma BB9K.00 CONN--Bone 
[M]Paget's disease and intraductal carcinoma of breast BB9K000 CONN--Bone 
[M]Paget's disease, breast BB9J.11 CONN--Bone 
[M]Paget's disease, extramammary, exc Paget's disease bone BB9L.00 CONN--Bone 
[M]Paget's disease, mammary BB9J.00 CONN--Bone 
[M]Parosteal osteosarcoma BBV..12 CONN--Bone 
[M]Periosteal chondroma BBW5.11 CONN--Bone 
[M]Squamous odontogenic tumour BBZJ.00 CONN--Bone 
[M]Telangiectatic osteosarcoma BBV4.00 CONN--Bone 
[M]Tibial adamantinoma BBY1.11 CONN--Bone 
[X]Malignant neoplasm of bone and articular cartilage Byu3.00 CONN--Bone 
[X]Malignant neoplasm/overlap lesion/bone+articulr cartilage Byu3200 CONN--Bone 
Chondroma B30..11 CONN--Bone 
Malignant neoplasm of bone and articular cartilage B30..00 CONN--Bone 
Malignant neoplasm of bone and articular cartilage NOS B30z.00 CONN--Bone 
Malignant neoplasm of bones of skull and face  B300.00 CONN--Bone 
Malignant neoplasm of bones of skull and face NOS B300z00 CONN--Bone 
Malignant neoplasm of carpal bone - lunate B305100 CONN--Bone 
Malignant neoplasm of carpal bone - scaphoid B305000 CONN--Bone 
Malignant neoplasm of cervical vertebra B302000 CONN--Bone 
Malignant neoplasm of clavicle B303200 CONN--Bone 
Malignant neoplasm of coccygeal vertebra B306400 CONN--Bone 
Malignant neoplasm of costal cartilage B303300 CONN--Bone 
Malignant neoplasm of costo-vertebral joint B303400 CONN--Bone 
Malignant neoplasm of femur B307000 CONN--Bone 
Malignant neoplasm of fibula B307100 CONN--Bone 
Malignant neoplasm of humerus B304200 CONN--Bone 
Malignant neoplasm of ilium B306000 CONN--Bone 
Malignant neoplasm of ischium B306100 CONN--Bone 
Malignant neoplasm of long bones of leg B307.00 CONN--Bone 
Malignant neoplasm of long bones of leg NOS B307z00 CONN--Bone 
Malignant neoplasm of lumbar vertebra B302200 CONN--Bone 
Malignant neoplasm of malar bone B300200 CONN--Bone 
Malignant neoplasm of mandible B301.00 CONN--Bone 
Malignant neoplasm of maxilla B300A00 CONN--Bone 
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Malignant neoplasm of metacarpal bones B305.12 CONN--Bone 
Malignant neoplasm of occipital bone B300400 CONN--Bone 
Malignant neoplasm of orbital bone B300500 CONN--Bone 
Malignant neoplasm of parietal bone B300600 CONN--Bone 
Malignant neoplasm of pelvic bones, sacrum and coccyx B306.00 CONN--Bone 
Malignant neoplasm of pelvis, sacrum or coccyx NOS B306z00 CONN--Bone 
Malignant neoplasm of phalanges of foot B308D00 CONN--Bone 
Malignant neoplasm of phalanges of hand B305D00 CONN--Bone 
Malignant neoplasm of rib B303000 CONN--Bone 
Malignant neoplasm of rib, sternum and clavicle NOS B303z00 CONN--Bone 
Malignant neoplasm of ribs, sternum and clavicle  B303.00 CONN--Bone 
Malignant neoplasm of sacral vertebra B306300 CONN--Bone 
Malignant neoplasm of scapula B304000 CONN--Bone 
Malignant neoplasm of scapula and long bones of upper arm B304.00 CONN--Bone 
Malignant neoplasm of sphenoid bone B300700 CONN--Bone 
Malignant neoplasm of sternum B303100 CONN--Bone 
Malignant neoplasm of temporal bone B300800 CONN--Bone 
Malignant neoplasm of thoracic vertebra B302100 CONN--Bone 
Malignant neoplasm of tibia B307200 CONN--Bone 
Malignant neoplasm of vertebral column B302.00 CONN--Bone 
Malignant neoplasm of vertebral column NOS B302z00 CONN--Bone 
Malignant neoplasm of vomer B300C00 CONN--Bone 
Malignant neoplasm of xiphoid process B303500 CONN--Bone 
Malignant neoplasm of zygomatic bone B300900 CONN--Bone 
Malignant neoplasm/bones+articular cartilage/limb,unspfd B30X.00 CONN--Bone 
Malignant neoplasm/overlap lesion/bone+articulr cartilage B30W.00 CONN--Bone 
Malignant sacral teratoma B306500 CONN--Bone 
Neoplasm of unspecified nature of bone BA02000 CONN--Bone 
Osteoma B30..12 CONN--Bone 
Osteosarcoma B30z000 CONN--Bone 
[M]Acinar cell carcinoma BBA2.00 Neoplasm--NOS 
[M]Acinar cell neoplasms BBA..00 Neoplasm--NOS 
[M]Acinar cell tumour BBA1.00 Neoplasm--NOS 
[M]Adenocarcinoma in tubulovillous adenoma BB52000 Neoplasm--NOS 
[M]Adenocarcinoma NOS BB52.00 Neoplasm--NOS 
[M]Adenocarcinoma, intestinal type BB57.00 Neoplasm--NOS 
[M]Adenocarcinomas BB5..11 Neoplasm--NOS 
[M]Adenoid cystic carcinoma BB5J.00 Neoplasm--NOS 
[M]Adenoma and adenocarcinoms OS BB5y.00 Neoplasm--NOS 
[M]Adenoma NOS BB50.00 Neoplasm--NOS 
[M]Adenoma or adenocarcinoma NOS BB5z.00 Neoplasm--NOS 
[M]Adenomas BB5..12 Neoplasm--NOS 
[M]Adenomas and adenocarcinomas BB5..00 Neoplasm--NOS 
[M]Adenomatoid tumour NOS BBP8.00 Neoplasm--NOS 
[M]Adenosarcoma BBLE.00 Neoplasm--NOS 
[M]Adnexal and skin appendage neoplasm NOS BB6z.00 Neoplasm--NOS 
[M]Adult cystic teratoma BBQ7011 Neoplasm--NOS 
[M]Angiolipoma NOS BBJB200 Neoplasm--NOS 
[M]Angiolipomatous neoplasms BBJB.00 Neoplasm--NOS 
[M]Angiomyolipoma BBJB000 Neoplasm--NOS 
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[M]Apocrine adenoma BB62000 Neoplasm--NOS 
[M]Apocrine adenoma and adenocarcinomas BB62.00 Neoplasm--NOS 
[M]Apudoma BB5y300 Neoplasm--NOS 
[M]Argentaffinoma NOS BB5R211 Neoplasm--NOS 
[M]Brown fat tumour BBJD.11 Neoplasm--NOS 
[M]Carcinoid bronchial adenoma BB5R111 Neoplasm--NOS 
[M]Carcinoid tumour NOS BB5R000 Neoplasm--NOS 
[M]Carcinoid tumour, argentaffin, NOS BB5R200 Neoplasm--NOS 
[M]Carcinoid tumour, malignant BB5R100 Neoplasm--NOS 
[M]Carcinoid tumours BB5R.00 Neoplasm--NOS 
[M]Carcinoma in pleomorphic adenoma BBLG.00 Neoplasm--NOS 
[M]Carcinoma NOS BB12.00 Neoplasm--NOS 
[M]Carcinoma, anaplastic type, NOS BB19.00 Neoplasm--NOS 
[M]Carcinoma, diffuse type BB58.00 Neoplasm--NOS 
[M]Carcinoma, undifferentiated type, NOS BB18.00 Neoplasm--NOS 
[M]Carcinomatosis BB14.00 Neoplasm--NOS 
[M]Carcinosarcoma NOS BBL9.00 Neoplasm--NOS 
[M]Carcinosarcoma, embryonal type BBLA.00 Neoplasm--NOS 
[M]Ceruminous adenoma BB6A000 Neoplasm--NOS 
[M]Ceruminous adenoma and adenocarcinoma BB6A.00 Neoplasm--NOS 
[M]Chondroid syringoma BBL3.11 Neoplasm--NOS 
[M]Clear cell adenocarcinoma NOS BB5X100 Neoplasm--NOS 
[M]Clear cell adenofibroma BB5Z.00 Neoplasm--NOS 
[M]Clear cell adenoma BB5X000 Neoplasm--NOS 
[M]Clear cell adenoma or adenocarcinoma NOS BB5Xz00 Neoplasm--NOS 
[M]Clear cell adenomas and adenocarcinomas BB5X.00 Neoplasm--NOS 
[M]Clear cell hidradenoma BB63.11 Neoplasm--NOS 
[M]Clear cell sarcoma of kidney BBLJ.00 Neoplasm--NOS 
[M]Complex mixed and stromal neoplasms BBL..00 Neoplasm--NOS 
[M]Complex mixed or stromal neoplasm NOS BBLz.00 Neoplasm--NOS 
[M]Cylindroma NOS BB5J.13 Neoplasm--NOS 
[M]Cystic, mucinous and serous neoplasms BB8..00 Neoplasm--NOS 
[M]Cystic, mucinous or serous neoplasm NOS BB8z.00 Neoplasm--NOS 
[M]Dedifferentiated liposarcoma BBJH.00 Neoplasm--NOS 
[M]Dermoid cyst BBQ8.00 Neoplasm--NOS 
[M]Dermoid cyst with malignant transformation BBQ9.00 Neoplasm--NOS 
[M]Dermoid NOS BBQ8.11 Neoplasm--NOS 
[M]Eccrine acrospiroma BB63.00 Neoplasm--NOS 
[M]Eccrine papillary adenoma BB6B.00 Neoplasm--NOS 
[M]Eccrine poroma BB63.12 Neoplasm--NOS 
[M]Eccrine spiradenoma BB64.00 Neoplasm--NOS 
[M]Embryonal sarcoma BBLD.00 Neoplasm--NOS 
[M]Embryonal teratoma BBQ7211 Neoplasm--NOS 
[M]Endometrial stromal nodule BBLF.00 Neoplasm--NOS 
[M]Endosalpingioma BBS3.00 Neoplasm--NOS 
[M]Fibroadenoma NOS BBM1.00 Neoplasm--NOS 
[M]Fibrolipoma BBJ2.00 Neoplasm--NOS 
[M]Fibroma molle BBJ2.11 Neoplasm--NOS 
[M]Fibromyxolipoma BBJ4.00 Neoplasm--NOS 
[M]Gangliocytic paraganglioma BBDE.00 Neoplasm--NOS 
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[M]Germ cell neoplasm NOS BBQz.00 Neoplasm--NOS 
[M]Germ cell neoplasms BBQ..00 Neoplasm--NOS 
[M]Giant cell and spindle cell carcinoma BB1B.00 Neoplasm--NOS 
[M]Giant cell carcinoma BB1C.00 Neoplasm--NOS 
[M]Giant cell tumour NOS BBXz.00 Neoplasm--NOS 
[M]Giant cell tumour of soft parts NOS BBX2.00 Neoplasm--NOS 
[M]Giant cell tumours BBX..00 Neoplasm--NOS 
[M]Glomangioma BBDD.00 Neoplasm--NOS 
[M]Glomangiomyoma BBDF.00 Neoplasm--NOS 
[M]Glomangiosarcoma BBDB.00 Neoplasm--NOS 
[M]Glomus tumour BBDC.00 Neoplasm--NOS 
[M]Hibernoma BBJD.00 Neoplasm--NOS 
[M]Hidradenoma NOS BB61011 Neoplasm--NOS 
[M]Hidrocystoma BB65.00 Neoplasm--NOS 
[M]Hypernephroid tumour BB5Y.00 Neoplasm--NOS 
[M]Immature teratoma BBQ7212 Neoplasm--NOS 
[M]Infiltrating lipoma BBJ9.11 Neoplasm--NOS 
[M]Inflammatory carcinoma BB9H.00 Neoplasm--NOS 
[M]Intraepithelial carcinoma NOS BB11.11 Neoplasm--NOS 
[M]Intramuscular lipoma BBJ9.00 Neoplasm--NOS 
[M]Klatskin's tumour BB5y200 Neoplasm--NOS 
[M]Linitis plastica BB55.00 Neoplasm--NOS 
[M]Lipoadenoma BB5e.00 Neoplasm--NOS 
[M]Lipoma NOS BBJ0.00 Neoplasm--NOS 
[M]Lipomatous neoplasms BBJ..00 Neoplasm--NOS 
[M]Lipomatous neoplasms NOS BBJz.00 Neoplasm--NOS 
[M]Liposarcoma NOS BBJ1.00 Neoplasm--NOS 
[M]Liposarcoma, well differentiated type BBJ3.00 Neoplasm--NOS 
[M]Malignant mastocytosis BBp2.00 Neoplasm--NOS 
[M]Malignant teratoma, intermediate type BBQ7500 Neoplasm--NOS 
[M]Malignant teratoma, undifferentiated type BBQ7400 Neoplasm--NOS 
[M]Malignant tumour, fusiform cell type BB0A.00 Neoplasm--NOS 
[M]Malignant tumour, giant cell type BB09.00 Neoplasm--NOS 
[M]Malignant tumour, small cell type BB08.00 Neoplasm--NOS 
[M]Mast cell tumours BBp..00 Neoplasm--NOS 
[M]Mastocytoma NOS BBp0.00 Neoplasm--NOS 
[M]Mature teratoma BBQ7012 Neoplasm--NOS 
[M]Mesenchymoma NOS BBLCz00 Neoplasm--NOS 
[M]Mesenchymomas BBLC.00 Neoplasm--NOS 
[M]Mesodermal mixed tumour BBL6.00 Neoplasm--NOS 
[M]Microcystic adenoma BB50000 Neoplasm--NOS 
[M]Miscellaneous tumour NOS BBaz.00 Neoplasm--NOS 
[M]Miscellaneous tumours BBa..00 Neoplasm--NOS 
[M]Mixed germ cell tumour BBQB.00 Neoplasm--NOS 
[M]Mixed tumour NOS BBL3.12 Neoplasm--NOS 
[M]Mixed tumour, malignant, NOS BBL4.00 Neoplasm--NOS 
[M]Mixed type liposarcoma BBJ8.00 Neoplasm--NOS 
[M]Monomorphic adenoma BB59.00 Neoplasm--NOS 
[M]Morphology of neoplasms BB...00 Neoplasm--NOS 
[M]Mucocarcinoid tumour, malignant BB5R600 Neoplasm--NOS 
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[M]Mucoepidermoid carcinoma BB71.00 Neoplasm--NOS 
[M]Mucoepidermoid neoplasms BB7..00 Neoplasm--NOS 
[M]Mucoepidermoid tumour BB70.00 Neoplasm--NOS 
[M]Mullerian mixed tumour BBL5.00 Neoplasm--NOS 
[M]Myelolipoma BBJC.00 Neoplasm--NOS 
[M]Myoepithelioma BBLB.00 Neoplasm--NOS 
[M]Myxoid liposarcoma BBJ5.00 Neoplasm--NOS 
[M]Myxolipoma BBJ4.11 Neoplasm--NOS 
[M]Myxoliposarcoma BBJ5.12 Neoplasm--NOS 
[M]Neoplasm morphology NOS BBz..00 Neoplasm--NOS 
[M]Neoplasm, malignant BB02.00 Neoplasm--NOS 
[M]Neoplasms NOS BB0..00 Neoplasm--NOS 
[M]No microscopic confirmation of tumour BBy..00 Neoplasm--NOS 
[M]Nodular hidradenoma BB61012 Neoplasm--NOS 
[M]Oncocytic adenoma BB5W01
2 
Neoplasm--NOS 
[M]Oncocytoma BB5W01
3 
Neoplasm--NOS 
[M]Oxyphilic adenocarcinoma BB5W10
0 
Neoplasm--NOS 
[M]Papillary hydradenoma BB66.00 Neoplasm--NOS 
[M]Papillary syringadenoma BB67.00 Neoplasm--NOS 
[M]Paraganglioma or glomus tumour NOS BBDz.00 Neoplasm--NOS 
[M]Pericanalicular fibroadenoma BBM3.00 Neoplasm--NOS 
[M]Pleomorphic adenoma BBL3.00 Neoplasm--NOS 
[M]Pleomorphic carcinoma BB1A.00 Neoplasm--NOS 
[M]Pleomorphic lipoma BBJF.00 Neoplasm--NOS 
[M]Pleomorphic liposarcoma BBJ7.00 Neoplasm--NOS 
[M]Pneumoblastoma BBLA.11 Neoplasm--NOS 
[M]Polygonal cell carcinoma BB1F.00 Neoplasm--NOS 
[M]Pseudosarcomatous carcinoma BB1E.00 Neoplasm--NOS 
[M]Pulmonary blastoma BBLM.00 Neoplasm--NOS 
[M]Rhabdoid sarcoma BBLH.00 Neoplasm--NOS 
[M]Scirrhous adenocarcinoma BB54.00 Neoplasm--NOS 
[M]Sclerosing stromal tumour BBCG.00 Neoplasm--NOS 
[M]Sebaceous adenocarcinoma BB69100 Neoplasm--NOS 
[M]Sebaceous adenoma BB69000 Neoplasm--NOS 
[M]Sebaceous adenoma and adenocarcinoma BB69.00 Neoplasm--NOS 
[M]Soft fibroma BBJ2.12 Neoplasm--NOS 
[M]Solid carcinoma NOS BB5P.00 Neoplasm--NOS 
[M]Spheroidal cell carcinoma BB1G.00 Neoplasm--NOS 
[M]Spindle cell carcinoma BB1D.00 Neoplasm--NOS 
[M]Spindle cell lipoma BBJA.00 Neoplasm--NOS 
[M]Spiradenoma NOS BB64.11 Neoplasm--NOS 
[M]Superficial spreading adenocarcinoma BB56.00 Neoplasm--NOS 
[M]Sweat gland adenocarcinoma BB61200 Neoplasm--NOS 
[M]Sweat gland adenoma BB61000 Neoplasm--NOS 
[M]Sweat gland adenoma and adenocarcinomas BB61.00 Neoplasm--NOS 
[M]Sweat gland tumour NOS BB61100 Neoplasm--NOS 
[M]Syringadenoma NOS BB61013 Neoplasm--NOS 
[M]Syringoma NOS BB68.00 Neoplasm--NOS 
[M]Teratoblastoma, malignant BBQ7213 Neoplasm--NOS 
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[M]Teratoma NOS BBQ7100 Neoplasm--NOS 
[M]Teratoma NOS BBQ7z00 Neoplasm--NOS 
[M]Teratoma, malignant, NOS BBQ7200 Neoplasm--NOS 
[M]Teratomas BBQ7.00 Neoplasm--NOS 
[M]Trabecular adenoma BB5E.00 Neoplasm--NOS 
[M]Tubular androblastoma NOS BBC9.00 Neoplasm--NOS 
[M]Tumour cells, malignant BB07.00 Neoplasm--NOS 
[M]Tumour morphology BB...11 Neoplasm--NOS 
[M]Tumourlet BB1H.00 Neoplasm--NOS 
[M]Unspecified epithelial neoplasm BB1z.00 Neoplasm--NOS 
[M]Unspecified tumour cell NOS BB0z.00 Neoplasm--NOS 
[M]Vipoma BB5y100 Neoplasm--NOS 
[X]Malignant neoplasm of mesothelial and soft tissue Byu5.00 Neoplasm--NOS 
[X]Malignant neoplasm of other specified sites ByuC000 Neoplasm--NOS 
[X]Malignant neoplasm without specification of site ByuC800 Neoplasm--NOS 
[X]Malignant neoplasms/independent (primary) multiple sites ByuE.00 Neoplasm--NOS 
[X]Malignant neoplasms/independent(primary)multiple sites ByuE000 Neoplasm--NOS 
[X]Mesothelioma, unspecified Byu5100 Neoplasm--NOS 
[X]Myelodysplastic syndrome, unspecified ByuHD00 Neoplasm--NOS 
[X]Neoplasms of uncertain and unknown behaviour ByuH.00 Neoplasm--NOS 
Cancers B....11 Neoplasm--NOS 
H/O: cancer 142..11 Neoplasm--NOS 
H/O: malignancy 142..13 Neoplasm--NOS 
H/O: malignant neoplasm (*) 142..00 Neoplasm--NOS 
H/O: neoplasm 142..15 Neoplasm--NOS 
Malignant neoplasm of abdomen B552.00 Neoplasm--NOS 
Malignant neoplasm of back NOS B55y000 Neoplasm--NOS 
Malignant neoplasm of inguinal region NOS B553000 Neoplasm--NOS 
Malignant neoplasm of lower limb NOS B555.00 Neoplasm--NOS 
Malignant neoplasm of other and ill defined site NOS B55z.00 Neoplasm--NOS 
Malignant neoplasm of other and ill-defined sites B55..00 Neoplasm--NOS 
Malignant neoplasm of other specified sites B55y.00 Neoplasm--NOS 
Malignant neoplasm of pelvis B553.00 Neoplasm--NOS 
Malignant neoplasm of pelvis NOS B553z00 Neoplasm--NOS 
Malignant neoplasm of presacral region B553100 Neoplasm--NOS 
Malignant neoplasm of specified site NOS B55yz00 Neoplasm--NOS 
Malignant neoplasm of trunk NOS B55y100 Neoplasm--NOS 
Malignant neoplasm of unspecified site NOS B59z.00 Neoplasm--NOS 
Malignant neoplasm of upper limb NOS B554.00 Neoplasm--NOS 
Neop of uncertain behaviour of other specified sites NOS B93yz00 Neoplasm--NOS 
Neop uncertain behaviour of digestive and respiratory system B90..00 Neoplasm--NOS 
Neop uncertain behaviour other and unspec sites and tissues B93..00 Neoplasm--NOS 
Neop uncertain behaviour other unspec site and tissue NOS B93z.00 Neoplasm--NOS 
Neoplasm of uncertain behaviour NOS B9z..00 Neoplasm--NOS 
Neoplasm of uncertain behaviour of coccygeal body B923300 Neoplasm--NOS 
Neoplasm of uncertain behaviour of glomus jugulare B923100 Neoplasm--NOS 
Neoplasm of uncertain behaviour of paraganglia NOS B923z00 Neoplasm--NOS 
Neoplasm of uncertain behaviour otherwise specified B9y..00 Neoplasm--NOS 
Neoplasm of unspecified nature BA0..00 Neoplasm--NOS 
Neoplasm of unspecified nature NOS BA0z.00 Neoplasm--NOS 
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Neoplasm of unspecified nature NOS BAz..00 Neoplasm--NOS 
Neoplasm of unspecified nature of other specified sites BA0y.00 Neoplasm--NOS 
Neoplasms B....00 Neoplasm--NOS 
Neoplasms NOS Bz...00 Neoplasm--NOS 
Neoplasms of uncertain behaviour B9...00 Neoplasm--NOS 
Neoplasms otherwise specified By...00 Neoplasm--NOS 
Primary malignant neoplasm of unknown site B593.00 Neoplasm--NOS 
Unspecified nature neoplasm BA...00 Neoplasm--NOS 
[M]Adenocarcinoma, metastatic, NOS BB53.00 Metastasis 
[M]Carcinoma, metastatic, NOS BB13.00 Metastasis 
[M]Epithelioma, malignant BB16.00 Metastasis 
[M]Large cell carcinoma NOS BB17.00 Metastasis 
[M]Metastatic signet ring cell carcinoma BB85100 Metastasis 
[M]Neoplasm, malig, uncertain whether primary or metastatic BB04.00 Metastasis 
[M]Neoplasm, metastatic BB03.00 Metastasis 
[M]Secondary carcinoma BB13.11 Metastasis 
[M]Secondary neoplasm BB03.11 Metastasis 
[M]Squamous cell carcinoma, metastatic NOS BB2B.00 Metastasis 
[M]Squamous cell carcinoma, small cell, non-keratinising BB2E.00 Metastasis 
[M]Tumour embolism BB03.13 Metastasis 
[X]2ndry malignant neoplasm/oth+unspec parts/nervous 
system 
ByuC600 Metastasis 
[X]Malignant neoplasm of ill-defined, secondary and unspeci ByuC.00 Metastasis 
[X]Secondary malignant neoplasm of other specified sites ByuC700 Metastasis 
[X]Secondary malignant neoplasm/oth+unspc respiratory 
organs 
ByuC300 Metastasis 
[X]Secondary malignant neoplasm/oth+unspcfd digestive 
organs 
ByuC400 Metastasis 
Carcinoma of other and unspecified sites B5...11 Metastasis 
Carcinomatosis B590.11 Metastasis 
Cerebral metastasis B583200 Metastasis 
Disseminated malignancy NOS B590.00 Metastasis 
Kaposi's sarcoma of multiple organs B592X00 Metastasis 
Liver metastases B577.11 Metastasis 
Lymph node metastases B56..11 Metastasis 
Malignant ascites B576200 Metastasis 
Malignant neoplasm of other and unspecified site NOS B5z..00 Metastasis 
Malignant neoplasm of other and unspecified site OS B5y..00 Metastasis 
Malignant neoplasm of other and unspecified sites B5...00 Metastasis 
Malignant neoplasm of unspecified site B59..00 Metastasis 
Malignant neoplasms of independent (primary) multiple sites B592.00 Metastasis 
Metastases of respiratory and/or digestive systems B57..11 Metastasis 
Other malignant neoplasm NOS B591.00 Metastasis 
Pathological fracture due to metastatic bone disease B585000 Metastasis 
Secondary and unspec malig neop ant mediastinal lymph 
nodes 
B561300 Metastasis 
Secondary and unspec malig neop anterior cervical LN B560800 Metastasis 
Secondary and unspec malig neop axilla and upper limb LN B563.00 Metastasis 
Secondary and unspec malig neop axilla and upper limb LN 
NOS 
B563z00 Metastasis 
Secondary and unspec malig neop axillary lymph nodes B563000 Metastasis 
Secondary and unspec malig neop bronchopulmonary lymph 
nodes 
B561800 Metastasis 
Secondary and unspec malig neop circumflex iliac LN B565200 Metastasis 
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Secondary and unspec malig neop common iliac lymph nodes B562300 Metastasis 
Secondary and unspec malig neop deep cervical LN B560900 Metastasis 
Secondary and unspec malig neop deep parotid lymph nodes B560400 Metastasis 
Secondary and unspec malig neop external iliac lymph nodes B562400 Metastasis 
Secondary and unspec malig neop inferior mesenteric LN B562200 Metastasis 
Secondary and unspec malig neop infraclavicular lymph nodes B563200 Metastasis 
Secondary and unspec malig neop inguinal and lower limb LN B564.00 Metastasis 
Secondary and unspec malig neop internal mammary lymph 
nodes 
B561000 Metastasis 
Secondary and unspec malig neop intra-abdominal LN NOS B562z00 Metastasis 
Secondary and unspec malig neop intra-abdominal lymph 
nodes 
B562.00 Metastasis 
Secondary and unspec malig neop intrapelvic LN NOS B565z00 Metastasis 
Secondary and unspec malig neop intrapelvic lymph nodes B565.00 Metastasis 
Secondary and unspec malig neop intrathoracic LN NOS B561z00 Metastasis 
Secondary and unspec malig neop intrathoracic lymph nodes B561.00 Metastasis 
Secondary and unspec malig neop lymph nodes 
head/face/neck 
B560.00 Metastasis 
Secondary and unspec malig neop lymph nodes multiple sites B56y.00 Metastasis 
Secondary and unspec malig neop lymph nodes NOS B56z.00 Metastasis 
Secondary and unspec malig neop of inguinal and leg LN NOS B564z00 Metastasis 
Secondary and unspec malig neop of superficial parotid LN B560000 Metastasis 
Secondary and unspec malig neop paratracheal lymph nodes B561500 Metastasis 
Secondary and unspec malig neop pectoral lymph nodes B563300 Metastasis 
Secondary and unspec malig neop post mediastinal lymph 
nodes 
B561400 Metastasis 
Secondary and unspec malig neop pulmonary lymph nodes B561900 Metastasis 
Secondary and unspec malig neop submandibular lymph 
nodes 
B560500 Metastasis 
Secondary and unspec malig neop submental lymph nodes B560700 Metastasis 
Secondary and unspec malig neop superfic tracheobronchial 
LN 
B561600 Metastasis 
Secondary and unspec malig neop superficial cervical LN B560200 Metastasis 
Secondary and unspec malig neop superficial mesenteric LN B562100 Metastasis 
Secondary and unspec malignant neoplasm mastoid lymph 
nodes 
B560100 Metastasis 
Secondary and unspec malignant neoplasm occipital lymph 
node 
B560300 Metastasis 
Secondary and unspecified malignant neoplasm of lymph 
nodes 
B56..00 Metastasis 
Secondary cancer of the cervix B58y211 Metastasis 
Secondary carcinoma of other specified sites B58..11 Metastasis 
Secondary carcinoma of respiratory and/or digestive systems B57..12 Metastasis 
Secondary malig neop of large intestine or rectum NOS B575z00 Metastasis 
Secondary malig neop of respiratory and digestive systems B57..00 Metastasis 
Secondary malig neop of respiratory or digestive system NOS B57z.00 Metastasis 
Secondary malig neop of retroperitoneum and peritoneum B576.00 Metastasis 
Secondary malig neop of small intestine or duodenum NOS B574z00 Metastasis 
Secondary malignant neoplasm of adrenal gland B587.00 Metastasis 
Secondary malignant neoplasm of bladder B581100 Metastasis 
Secondary malignant neoplasm of bone and bone marrow B585.00 Metastasis 
Secondary malignant neoplasm of brain B583000 Metastasis 
Secondary malignant neoplasm of brain and spinal cord B583.00 Metastasis 
Secondary malignant neoplasm of brain or spinal cord NOS B583z00 Metastasis 
Secondary malignant neoplasm of breast B58y000 Metastasis 
Secondary malignant neoplasm of cervix uteri B58y200 Metastasis 
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Secondary malignant neoplasm of colon B575000 Metastasis 
Secondary malignant neoplasm of duodenum B574000 Metastasis 
Secondary malignant neoplasm of kidney B580.00 Metastasis 
Secondary malignant neoplasm of large intestine and rectum B575.00 Metastasis 
Secondary malignant neoplasm of liver B153.00 Metastasis 
Secondary malignant neoplasm of liver B577.00 Metastasis 
Secondary malignant neoplasm of lung B570.00 Metastasis 
Secondary malignant neoplasm of mediastinum B571.00 Metastasis 
Secondary malignant neoplasm of other digestive organ B57y.00 Metastasis 
Secondary malignant neoplasm of other part of nervous 
system 
B584.00 Metastasis 
Secondary malignant neoplasm of other respiratory organs B573.00 Metastasis 
Secondary malignant neoplasm of other specified site NOS B58yz00 Metastasis 
Secondary malignant neoplasm of other specified site NOS B58z.00 Metastasis 
Secondary malignant neoplasm of other specified sites B58..00 Metastasis 
Secondary malignant neoplasm of other specified sites B58y.00 Metastasis 
Secondary malignant neoplasm of other urinary organ NOS B581z00 Metastasis 
Secondary malignant neoplasm of other urinary organs B581.00 Metastasis 
Secondary malignant neoplasm of ovary B586.00 Metastasis 
Secondary malignant neoplasm of penis B58y700 Metastasis 
Secondary malignant neoplasm of peritoneum B576100 Metastasis 
Secondary malignant neoplasm of pleura B572.00 Metastasis 
Secondary malignant neoplasm of prostate B58y500 Metastasis 
Secondary malignant neoplasm of retroperitoneum B576000 Metastasis 
Secondary malignant neoplasm of skin B582.00 Metastasis 
Secondary malignant neoplasm of skin NOS B582z00 Metastasis 
Secondary malignant neoplasm of skin of breast B582600 Metastasis 
Secondary malignant neoplasm of skin of face B582100 Metastasis 
Secondary malignant neoplasm of skin of head B582000 Metastasis 
Secondary malignant neoplasm of skin of hip and leg B582500 Metastasis 
Secondary malignant neoplasm of skin of neck B582200 Metastasis 
Secondary malignant neoplasm of skin of shoulder and arm B582400 Metastasis 
Secondary malignant neoplasm of skin of trunk B582300 Metastasis 
Secondary malignant neoplasm of small intestine and 
duodenum 
B574.00 Metastasis 
Secondary malignant neoplasm of spinal cord B583100 Metastasis 
Secondary malignant neoplasm of testis B58y600 Metastasis 
Secondary malignant neoplasm of tongue B58y900 Metastasis 
Secondary malignant neoplasm of unknown site B594.00 Metastasis 
Secondary malignant neoplasm of ureter B581000 Metastasis 
Secondary malignant neoplasm of urethra B581200 Metastasis 
Secondary malignant neoplasm of uterus B58y100 Metastasis 
Secondary malignant neoplasm of vagina B58y300 Metastasis 
Secondary malignant neoplasm of vulva B58y400 Metastasis 
Secondary unspec malig neop lymph nodes head/face/neck 
NOS 
B560z00 Metastasis 
[M]Adenocarcinoma in situ BB51.00 In Situ  
[M]Adenocarcinoma in situ in adenomatous polyp BB5L200 In Situ  
[M]Adenocarcinoma in situ in tubulovillous adenoma BB51100 In Situ  
[M]Adenocarcinoma in situ in villous adenoma BB51000 In Situ  
[M]Bowen's disease BB2L.00 In Situ  
[M]Carcinoma in situ NOS BB11.00 In Situ  
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[M]Epidermoid carcinoma in situ BB29.11 In Situ  
[M]Intraductal carcinoma and lobular carcinoma in situ BB9E000 In Situ  
[M]Intraepit neop,grade III,of cervix, vulva and vagina BB2N.00 In Situ  
[M]Lobular carcinoma in situ BB9E.00 In Situ  
[M]Papillary carcinoma in situ BB21.00 In Situ  
[M]Queyrat's erythroplasia BB2K.00 In Situ  
[M]Squamous cell ca-in-situ, questionable stromal invasion BB2H.00 In Situ  
[M]Squamous cell carcinoma in situ NOS BB29.00 In Situ  
[M]Transitional cell carcinoma in situ BB42.00 In Situ  
[M]Verrucous carcinoma NOS BB24.00 In Situ  
[M]Verrucous epidermoid carcinoma BB24.11 In Situ  
[M]Verrucous squamous cell carcinoma BB24.12 In Situ  
[X]Carcinoma in situ of oth+unspecified male genital organs ByuFC00 In Situ  
[X]Carcinoma in situ of other specified digestive organs ByuF100 In Situ  
[X]Carcinoma in situ of skin, unspecified ByuF900 In Situ  
[X]Carcinoma in situ/other+unspecified parts of intestine ByuF000 In Situ  
[X]Melanoma in situ, unspecified ByuFF00 In Situ  
[X]Other carcinoma in situ of breast ByuFG00 In Situ  
Anal intraepithelial neoplasia grade III B805000 In Situ  
Bowen's disease B8...11 In Situ  
Ca-in-situ of G.I. tract B80..11 In Situ  
Carcinoma in situ B8...00 In Situ  
Carcinoma in situ NOS B8z..00 In Situ  
Carcinoma in situ of adrenal gland B8yy100 In Situ  
Carcinoma in situ of ampulla of Vater B808600 In Situ  
Carcinoma in situ of anal canal B805.00 In Situ  
Carcinoma in situ of anus NOS B806.00 In Situ  
Carcinoma in situ of appendix B803500 In Situ  
Carcinoma in situ of aryepiglottic fold B810600 In Situ  
Carcinoma in situ of ascending colon B803600 In Situ  
Carcinoma in situ of biliary system B808.11 In Situ  
Carcinoma in situ of bladder B837.00 In Situ  
Carcinoma in situ of body of stomach B802200 In Situ  
Carcinoma in situ of body of uterus B832.11 In Situ  
Carcinoma in situ of breast B830.00 In Situ  
Carcinoma in situ of breast and genitourinary system B83..00 In Situ  
Carcinoma in situ of bronchus and lung B812.00 In Situ  
Carcinoma in situ of bronchus or lung NOS B812z00 In Situ  
Carcinoma in situ of caecum B803400 In Situ  
Carcinoma in situ of cardia of stomach B802000 In Situ  
Carcinoma in situ of carina of bronchus B812000 In Situ  
Carcinoma in situ of cervix uteri B831.00 In Situ  
Carcinoma in situ of cheek B800500 In Situ  
Carcinoma in situ of colon B803.00 In Situ  
Carcinoma in situ of colon NOS B803z00 In Situ  
Carcinoma in situ of common bile duct B808500 In Situ  
Carcinoma in situ of cricoid cartilage B810100 In Situ  
Carcinoma in situ of cystic duct B808400 In Situ  
Carcinoma in situ of descending colon B803200 In Situ  
Carcinoma in situ of digestive organs B80..00 In Situ  
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Carcinoma in situ of duodenum B807000 In Situ  
Carcinoma in situ of ear B822.11 In Situ  
Carcinoma in situ of endocervix B831000 In Situ  
Carcinoma in situ of endometrium B832000 In Situ  
Carcinoma in situ of epiglottis B810200 In Situ  
Carcinoma in situ of ethmoidal sinus B81y700 In Situ  
Carcinoma in situ of Eustachian tube B81y400 In Situ  
Carcinoma in situ of exocervix B831100 In Situ  
Carcinoma in situ of eye B8y0.00 In Situ  
Carcinoma in situ of fallopian tube B833100 In Situ  
Carcinoma in situ of female genital organs NOS B833z00 In Situ  
Carcinoma in situ of floor of mouth B800400 In Situ  
Carcinoma in situ of gall bladder B808300 In Situ  
Carcinoma in situ of glottis B810811 In Situ  
Carcinoma in situ of gums B800300 In Situ  
Carcinoma in situ of hepatic duct B808200 In Situ  
Carcinoma in situ of hepatic flexure of colon B803000 In Situ  
Carcinoma in situ of hypopharynx B800900 In Situ  
Carcinoma in situ of ileum B807200 In Situ  
Carcinoma in situ of intrahepatic bile ducts B808100 In Situ  
Carcinoma in situ of jejunum B807100 In Situ  
Carcinoma in situ of larynx B810.00 In Situ  
Carcinoma in situ of larynx NOS B810z00 In Situ  
Carcinoma in situ of lip B800000 In Situ  
Carcinoma in situ of lip, oral cavity and pharynx NOS B800z00 In Situ  
Carcinoma in situ of liver B808000 In Situ  
Carcinoma in situ of liver or biliary system NOS B808z00 In Situ  
Carcinoma in situ of lower 1/3 oesophagus B801200 In Situ  
Carcinoma in situ of lower lobe bronchus and lung B812400 In Situ  
Carcinoma in situ of main bronchus B812100 In Situ  
Carcinoma in situ of maxillary sinus B81y600 In Situ  
Carcinoma in situ of middle 1/3 oesophagus B801100 In Situ  
Carcinoma in situ of middle lobe bronchus and lung B812300 In Situ  
Carcinoma in situ of nasal cavity B81y100 In Situ  
Carcinoma in situ of nasal sinuses B81y.11 In Situ  
Carcinoma in situ of nasopharynx B800700 In Situ  
Carcinoma in situ of oesophagus B801.00 In Situ  
Carcinoma in situ of oesophagus NOS B801z00 In Situ  
Carcinoma in situ of oral cavity B800.11 In Situ  
Carcinoma in situ of oropharynx B800800 In Situ  
Carcinoma in situ of other and unspecified parts of uterus B832.00 In Situ  
Carcinoma in situ of other and unspecified sites B8y..00 In Situ  
Carcinoma in situ of other and unspecified small intestine B807.00 In Situ  
Carcinoma in situ of other specified part respiratory system B81y.00 In Situ  
Carcinoma in situ of other specified site B8yy.00 In Situ  
Carcinoma in situ of other specified site NOS B8yyz00 In Situ  
Carcinoma in situ of other specified sites of skin B82y.00 In Situ  
Carcinoma in situ of ovary B833000 In Situ  
Carcinoma in situ of palate B800600 In Situ  
Carcinoma in situ of pancreas B80z000 In Situ  
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Cancer description Med 
Code 
Cancer type 
Carcinoma in situ of parathyroid gland B8yy200 In Situ  
Carcinoma in situ of penis B835.00 In Situ  
Carcinoma in situ of perianal skin B825800 In Situ  
Carcinoma in situ of pharynx B800.12 In Situ  
Carcinoma in situ of pituitary gland B8yy300 In Situ  
Carcinoma in situ of pleura B81y000 In Situ  
Carcinoma in situ of prostate B834.00 In Situ  
Carcinoma in situ of pyloric antrum B802300 In Situ  
Carcinoma in situ of pyloric canal B802400 In Situ  
Carcinoma in situ of rectosigmoid junction B804000 In Situ  
Carcinoma in situ of rectum B804100 In Situ  
Carcinoma in situ of rectum and rectosigmoid junction B804.00 In Situ  
Carcinoma in situ of rectum or rectosigmoid junction NOS B804z00 In Situ  
Carcinoma in situ of respiratory organ NOS B81z.00 In Situ  
Carcinoma in situ of respiratory system B81..00 In Situ  
Carcinoma in situ of salivary glands B800200 In Situ  
Carcinoma in situ of scalp B824000 In Situ  
Carcinoma in situ of scalp and skin of neck B824.00 In Situ  
Carcinoma in situ of scrotum B836300 In Situ  
Carcinoma in situ of sigmoid colon B803300 In Situ  
Carcinoma in situ of skin B82..00 In Situ  
Carcinoma in situ of skin NOS B82z.00 In Situ  
Carcinoma in situ of skin of abdominal wall B825400 In Situ  
Carcinoma in situ of skin of auricle B822000 In Situ  
Carcinoma in situ of skin of axilla B825200 In Situ  
Carcinoma in situ of skin of back B825300 In Situ  
Carcinoma in situ of skin of breast B825000 In Situ  
Carcinoma in situ of skin of cheek B823300 In Situ  
Carcinoma in situ of skin of chest wall NOS B825100 In Situ  
Carcinoma in situ of skin of eyebrow B823100 In Situ  
Carcinoma in situ of skin of eyelid including canthus B821.00 In Situ  
Carcinoma in situ of skin of foot B827400 In Situ  
Carcinoma in situ of skin of forehead skin B823000 In Situ  
Carcinoma in situ of skin of groin B825500 In Situ  
Carcinoma in situ of skin of hand B826300 In Situ  
Carcinoma in situ of skin of hip B827000 In Situ  
Carcinoma in situ of skin of jaw B823600 In Situ  
Carcinoma in situ of skin of knee B827200 In Situ  
Carcinoma in situ of skin of leg B827.11 In Situ  
Carcinoma in situ of skin of lip B820.00 In Situ  
Carcinoma in situ of skin of lower arm B826200 In Situ  
Carcinoma in situ of skin of lower leg B827300 In Situ  
Carcinoma in situ of skin of lower limb and hip B827.00 In Situ  
Carcinoma in situ of skin of lower limb or hip NOS B827z00 In Situ  
Carcinoma in situ of skin of neck B824100 In Situ  
Carcinoma in situ of skin of nose B823400 In Situ  
Carcinoma in situ of skin of other parts of face B823.00 In Situ  
Carcinoma in situ of skin of other parts of face NOS B823z00 In Situ  
Carcinoma in situ of skin of perineum B825600 In Situ  
Carcinoma in situ of skin of shoulder B826000 In Situ  
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Cancer description Med 
Code 
Cancer type 
Carcinoma in situ of skin of temple B823500 In Situ  
Carcinoma in situ of skin of thigh B827100 In Situ  
Carcinoma in situ of skin of trunk NOS B825z00 In Situ  
Carcinoma in situ of skin of trunk, excluding scrotum B825.00 In Situ  
Carcinoma in situ of skin of upper arm B826100 In Situ  
Carcinoma in situ of skin of upper limb and shoulder B826.00 In Situ  
Carcinoma in situ of skin of upper limb or shoulder NOS B826z00 In Situ  
Carcinoma in situ of sphenoidal sinus B81y900 In Situ  
Carcinoma in situ of sphincter of Oddi B808700 In Situ  
Carcinoma in situ of spleen B80z100 In Situ  
Carcinoma in situ of splenic flexure of colon B803700 In Situ  
Carcinoma in situ of stomach B802.00 In Situ  
Carcinoma in situ of stomach NOS B802z00 In Situ  
Carcinoma in situ of testis B836000 In Situ  
Carcinoma in situ of thyroid cartilage B810000 In Situ  
Carcinoma in situ of thyroid gland B8yy000 In Situ  
Carcinoma in situ of tongue B800100 In Situ  
Carcinoma in situ of trachea B811.00 In Situ  
Carcinoma in situ of transverse colon B803100 In Situ  
Carcinoma in situ of upper lobe bronchus and lung B812200 In Situ  
Carcinoma in situ of urinary organs NOS B83z.00 In Situ  
Carcinoma in situ of vagina B833200 In Situ  
Carcinoma in situ of vestibular fold B810700 In Situ  
Carcinoma in situ of vocal fold - glottis B810800 In Situ  
Carcinoma in situ of vulva B833300 In Situ  
Carcinoma in situ other and unspecified female genital organ B833.00 In Situ  
Carcinoma in situ other and unspecified small intestine NOS B807z00 In Situ  
Carcinoma in situ skin of ear and external auricular canal B822.00 In Situ  
Carcinoma in situ skin of ear/external auricular canal NOS B822z00 In Situ  
Cervical intraepithelial neoplasia B831.12 In Situ  
Cervical intraepithelial neoplasia grade III B831.13 In Situ  
CIN III - carcinoma in situ of cervix B831.11 In Situ  
Erythroplasia B8...12 In Situ  
High grade prostatic intraepithelial neoplasia B834000 In Situ  
Intraductal carcinoma in situ of breast B830100 In Situ  
Lobular carcinoma in situ of breast B830000 In Situ  
Melanoma in situ of back B828900 In Situ  
Melanoma in situ of back of hand B828800 In Situ  
Melanoma in situ of eyelid, including canthus B828100 In Situ  
Melanoma in situ of lip B828000 In Situ  
Melanoma in situ of lower limb, including hip B828600 In Situ  
Melanoma in situ of other and unspecified parts of face B828X00 In Situ  
Melanoma in situ of scalp B828700 In Situ  
Melanoma in situ of scalp and neck B828300 In Situ  
Melanoma in situ of skin B828.00 In Situ  
Melanoma in situ of trunk B828400 In Situ  
Melanoma in situ of upper limb, including shoulder B828500 In Situ  
Melanoma in situ, unspecified B828W00 In Situ  
Queyrats's erythroplasia B8...13 In Situ  
Vulval intraepithelial neoplasia B833311 In Situ  
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20.18 Atrial fibrillation 
Atrial fibrillation description Med Code 
Atrial fibrillation G573000 
Atrial fibrillation and flutter G573.00 
Atrial fibrillation and flutter NOS G573z00 
Non-rheumatic atrial fibrillation G573300 
Paroxysmal atrial fibrillation G573200 
Permanent atrial fibrillation G573400 
Persistent atrial fibrillation G573500 
20.19 Dementia 
Dementia description Med Code 
[X] Presenile dementia NOS Eu02z11 
[X] Presenile psychosis NOS Eu02z12 
[X] Primary degenerative dementia NOS Eu02z13 
[X] Senile dementia NOS Eu02z14 
[X] Senile dementia, depressed or paranoid type Eu02z16 
[X] Senile psychosis NOS Eu02z15 
[X] Unspecified dementia Eu02z00 
[X]Alzheimer's dementia unspec Eu00z11 
[X]Alzheimer's disease type 1 Eu00111 
[X]Alzheimer's disease type 2 Eu00013 
[X]Arteriosclerotic dementia Eu01.11 
[X]Delirium superimposed on dementia Eu04100 
[X]Dementia in Alzheimer's dis, atypical or mixed type Eu00200 
[X]Dementia in Alzheimer's disease Eu00.00 
[X]Dementia in Alzheimer's disease with early onset Eu00000 
[X]Dementia in Alzheimer's disease with late onset Eu00100 
[X]Dementia in Alzheimer's disease, unspecified Eu00z00 
[X]Mixed cortical and subcortical vascular dementia Eu01300 
[X]Multi-infarct dementia Eu01100 
[X]Other Alzheimer's disease Fyu3000 
[X]Other vascular dementia Eu01y00 
[X]Predominantly cortical dementia Eu01111 
[X]Presenile dementia,Alzheimer's type Eu00011 
[X]Primary degen dementia of Alzheimer's type, senile onset Eu00113 
[X]Primary degen dementia, Alzheimer's type, presenile onset Eu00012 
[X]Senile dementia,Alzheimer's type Eu00112 
[X]Subcortical vascular dementia Eu01200 
[X]Vascular dementia Eu01.00 
[X]Vascular dementia of acute onset Eu01000 
[X]Vascular dementia, unspecified Eu01z00 
Alzheimer's disease F110.00 
Alzheimer's disease with early onset F110000 
Alzheimer's disease with late onset F110100 
Arteriosclerotic dementia E004.00 
Arteriosclerotic dementia NOS E004z00 
Arteriosclerotic dementia with delirium E004100 
Arteriosclerotic dementia with depression E004300 
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Dementia description Med Code 
Arteriosclerotic dementia with paranoia E004200 
Dementia annual review 6AB..00 
Dementia monitoring 66h..00 
Dementia monitoring administration 9Ou..00 
Dementia monitoring first letter 9Ou1.00 
Dementia monitoring second letter 9Ou2.00 
Dementia monitoring telephone invite 9Ou5.00 
Dementia monitoring third letter 9Ou3.00 
Dementia monitoring verbal invite 9Ou4.00 
Excepted from dementia quality indicators: Informed dissent 9hD1.00 
Excepted from dementia quality indicators: Patient unsuitabl 9hD0.00 
Exception reporting: dementia quality indicators 9hD..00 
H/O: dementia 1461.00 
Language disorder of dementia ZS7C500 
Multi infarct dementia E004.11 
Other senile and presenile organic psychoses E00y.00 
Presbyophrenic psychosis E00y.11 
Presenile dementia E001.00 
Presenile dementia NOS E001z00 
Presenile dementia w ith delirium E001100 
Presenile dementia w ith depression E001300 
Presenile dementia w ith paranoia E001200 
Senile and presenile organic psychotic conditions E00..00 
Senile dementia E00..11 
Senile dementia w ith delirium E003.00 
Senile dementia w ith depression E002100 
Senile dementia w ith depressive or paranoid features E002.00 
Senile dementia w ith depressive or paranoid features NOS E002z00 
Senile dementia w ith paranoia E002000 
Senile or presenile psychoses NOS E00z.00 
Senile/presenile dementia E00..12 
Uncomplicated arteriosclerotic dementia E004000 
Uncomplicated presenile dementia E001000 
Uncomplicated senile dementia E000.00 
20.20 Palliative care 
Terminal illness / Palliative care description Med Code  
[V]Palliative care ZV57C00  
Anticipatory palliative care 8BAe.00  
DS 1500 Disability living allowance completed 9EB5.00  
GSF supportive care stage 1 - advancing disease 8CM1000  
GSF supportive care stage 2 - increasing decline 8CM1100  
GSF supportv care stge 3 - last days: cat C - wks prognosis 8CM1200  
GSF supportv care stge 3 - last days: cat D - days prognosis 8CM1300  
Has end of life advanced care plan 8CME.00  
Last days of life 2JE..00  
Liverpool care pathway for the dying 8CM4.00  
On end of life care register 9Ng7.00  
On gold standards palliative care framework 8CM1.00  
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Terminal illness / Palliative care description Med Code  
Palliative treatment 8BJ1.00  
Refer for terminal care 8H7L.00  
Refer to terminal care consult 8H6A.00  
Referral to community palliative care team declined 8IEE.00  
Referral to palliative care service 8H7g.00  
Referred to community specialist palliative care team 8HH7.00  
Specialist palliative care 8BAP.00  
Specialist palliative care treatment - daycare 8BAS.00  
Specialist palliative care treatment - outpatient 8BAT.00  
Terminal care 8BA2.00  
Terminal illness - late stage 1Z01.00  
 
21 Investigation of the age at which SMI is diagnosed: 
The selected age limits (30 and 99 years) are supported by exploratory work 
evaluating the ages at which rates of new diagnoses of SMI are made in people 
who were registered at or before their 18
th
, 20
th
, 25
th
 or 30
th
 birthday. This work 
showed that the majority of people who were registered with a THIN practice from 
an early age (and had a recording of SMI) had a first diagnosis of bipolar disorder 
or schizophrenia recorded before the age of thirty. This is also supported by other 
studies in UK primary care, which found that over 70% of people with 
schizophrenia were first diagnosed by the age of 30 years (Roberts et al., 2007). 
Furthermore, rates of recording of new cases of SMI in UK primary care are 
highest in people aged 16-34 years of age(Hardoon et al., 2013). Obtaining a firm 
diagnosis of SMI may take a substantial length of time: therefore the recorded age 
of onset is likely to be older than the actual age that the illness first began. When 
combined with a preference for using an age limit that is compatible with most CVD 
risk scores, setting the minimum age at entry into the cohort at 30 years is justified.  
22 Association between estimated CVD risk and statin 
prescribing within the subset of people who had all 
components of physical health check recorded 
There was some evidence of interaction between the spline functions and the 
presence or absence of SMI for people with schizophrenia (p=0.001) but not 
bipolar disorder (p=0.12). Visualisation of the predicted values from the regression 
model for the schizophrenia cohort (Figure 22-1) suggested that prescribing rates 
were might be different in people with schizophrenia compared to people without 
SMI only at risk scores above 30%. However, it should be noted that almost 90% 
of the people included in the analysis had a risk score that was below 30%, 
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meaning that the fit of the spline at values above 30% is based on a relatively small 
subset of data. 
Figure 22-1: Predicted rate of statin prescribing and estimated CVD risk 
score for people with schizophrenia and comparison people without SMI  
 
The dashed vertical lines indicate the placement of the knots w ithin the regression spline at the 10th, 50th 
and 90th percentiles of data: the spline function is cubic betw een knots and linear before the f irst knot 
and after the last knot 
23 Statin prescribing for primary prevention of CVD in people 
with and without SMI  
23.1 Abstract submitted to Primary Care Mental Health Annual 
Conference 
Introduction: Cardiovascular disease (CVD) screening rates in people with severe 
mental illness (SMI) have increased since the introduction of the Quality and 
Outcomes Framework. However, the impact on statin prescribing is unknown.  
Aim: to describe differences in new statin prescriptions in UK GP patients with and 
without SMI who do not have a pre-existing CVD condition. 
Method: A cohort was constructed using primary care data from The Health 
Improvement Network for the period January 2007-December 2012.  Individuals 
aged 30-99 years with a schizophrenia or bipolar disorder diagnosis were selected 
and age and gender frequency-matched to ten control patients in the same 
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practice who did not have an SMI diagnosis. Individuals were excluded if they had 
pre-existing CVD or a previous statin prescription. Prescribing differences between 
individuals with SMI and controls were investigated in Poisson regression models 
with new statin prescription as the outcome.  Models were adjusted for calendar 
time (with year as a categorical variable) or estimated CVD risk, which was 
incorporated as a restricted cubic spline. 
Results: A total of 8,530 individuals with schizophrenia and 7,561 with bipolar 
disorder and ten-times as many controls were included in the study. Time-adjusted 
IRRs for statin prescribing amongst 30-59 year olds were; 1.92 (95% CI: 1.74-2.11) 
for schizophrenia and 1.98 (95% CI: 1.78-2.2) for bipolar disorder compared to 
controls without SMI.  However, individuals aged 60-99 years with schizophrenia 
(but not bipolar disorder) had lower rates of statin prescribing than controls; IRR 
0.75 (95% CI: 0.67-0.84). After adjusting for estimated CVD risk, individuals with 
schizophrenia (but not bipolar disorder) were less frequently prescribed stat ins 
than controls; IRR 0.93 (95% CI: 0.87-0.98).   
Conclusion: There is evidence of disparity in prescribing for older Individuals with 
schizophrenia, and after accounting for estimated CVD risk, relative to controls 
without SMI. 
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23.2 Abstract submitted to SAPC 
Title: Patterns of statin prescribing for the primary prevention of cardiovascular 
disease in people with severe mental illness 
The Problem: Severe mental illness (SMI) such as bipolar disorder and 
schizophrenia is associated with excess cardiovascular disease (CVD) morbidity 
and mortality, which has significant financial and social cost implications.  This 
healthcare need is recognised within UK primary care and, since the introduction of 
GP incentives in 2004, rates of CVD screening have increased amongst individuals 
with SMI.  However, the impact on statin prescribing is unknown.  
The Approach: We used data from The Health Improvement Network (THIN) 
primary care database from 2007 to 2012 to describe differences in new statin 
prescriptions in UK patients with and without SMI with no pre-existing CVD 
conditions.  Individuals aged 30-99 years with a diagnosis of schizophrenia or 
bipolar disorder were selected and age and gender frequency-matched to ten 
control patients in the same practice who did not have an SMI diagnosis. 
Individuals were excluded if they had pre-existing CVD or a previous statin 
prescription. Prescribing differences between individuals with SMI and controls 
were investigated in Poisson regression models with new statin prescription as the 
outcome.  Models were adjusted for calendar time or estimated CVD risk.  
Findings: A total of 8,530 individuals with schizophrenia and 7,561 with bipolar 
disorder were included in the study: 85,088 and 74,446 frequency-matched 
controls without SMI were also selected for comparison with individuals with 
schizophrenia or bipolar disorder (respectively). Time-adjusted incidence rate 
ratios (IRR) for statin prescribing amongst 30-59 year olds were; 1.92 (95% CI: 
1.74-2.11) for schizophrenia and 1.98 (95% CI: 1.78-2.20) for bipolar disorder 
compared to controls without SMI.  Individuals aged 60-99 years with 
schizophrenia  had lower rates of statin prescribing than controls; IRR 0.75 (95% 
CI: 0.67-0.84), but there were no such difference for bipolar disorder; IRR 0.99 
(95% CI: 0.88-1.11).  After adjusting for estimated CVD risk, individuals with 
schizophrenia (but not bipolar disorder) were less frequently prescribed statins 
than controls; IRR 0.93 (95% CI: 0.87-0.98).   
Consequences: The introduction of GP incentives for CVD screening has 
successfully increased statin prescribing amongst younger individuals with SMI.  
However, evidence of disparity in statin prescribing is apparent for older individuals 
with schizophrenia (relative to controls without SMI) may suggest an unmet need 
for statin prescribing in this group.  Further work is required to ascertain the impact 
of CVD interventions in people with SMI, and how the uptake of effective measures 
can be improved. 
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23.3 Abstract submitted to the International Society for Pharmaco-
Epidemiology Annual Conference 
Title: Patterns of statin prescribing for the primary prevention of cardiovascular 
disease in people with severe mental illness 
Background: Severe mental illness (SMI) such as bipolar disorder and 
schizophrenia is associated with excess cardiovascular disease (CVD) morbidity 
and mortality, which may indicate an unmet need for interventions to prevent CVD.  
Statins are the most commonly prescribed CVD drug, but uptake is unknown for 
individuals with SMI. 
Objectives: To quantify differences in new statin prescribing for primary CVD 
prevention between individuals with and without SMI 
Methods: We used data from The Health Improvement Network (THIN) primary 
care database from 2007 to 2012 to describe differences in new statin 
prescriptions in UK patients with and without SMI with no pre-existing CVD 
conditions. Individuals aged 30-99 years with a schizophrenia or bipolar disorder 
diagnosis were selected and age and gender frequency-matched to ten control 
patients in the same practice who did not have an SMI diagnosis. Prescribing 
differences between individuals with SMI and controls were investigated in Poisson 
regression models with new statin prescription as the outcome.  Models were 
adjusted for calendar time or estimated CVD risk.  
Results:  A total of 8,530 individuals with schizophrenia and 7,561 with bipolar 
disorder and ten-times as many controls were included in the study. Time-adjusted 
Incidence Rate Ratios (IRR) for statin prescribing amongst 30-59 year olds were; 
1.92 (95% CI: 1.74-2.11) for schizophrenia and 1.98 (95% CI: 1.78-2.2) for bipolar 
disorder compared to controls without SMI.  Individuals aged 60-99 years with 
schizophrenia  had lower rates of statin prescribing than controls; IRR 0.75 (95% 
CI: 0.67-0.84), but there were no such difference for bipolar disorder; IRR 0.99 
(95% CI: 0.88-1.11).  After adjusting for estimated CVD risk, individuals with 
schizophrenia (but not bipolar disorder) were less frequently prescribed statins 
than controls; IRR 0.93 (95% CI: 0.87-0.98).   
Conclusions: Evidence of disparity in statin prescribing is apparent for older 
individuals with schizophrenia (relative to controls without SMI), suggesting an 
unmet need for statin prescribing in this group. 
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24 The effectiveness of statins for primary prevention of CVD in 
people with SMI: a staggered cohort study in THIN 
24.1 Abstract submitted to Public Health England’s Applied 
Epidemiology Scientific Conference 2016 
Reducing inequalities in cardiovascular health in people with severe mental 
illness: evaluating the real-life impact of statin prescribing 
Cardiovascular disease (CVD) is the leading cause of death amongst people with 
severe mental illness (SMI) and drives substantial portion of the 15-20 year deficit 
in life expectancy experienced by this group relative to the general population.  
Statins form a core part of CVD prevention in the general population, but the 
evidence-base for people with SMI is unclear. We aimed to estimate the 
effectiveness of statins for primary prevention of CVD amongst people with SMI 
using data from The Health Improvement Network, which captures primary care 
data on 6% of the UK population.  
The average treatment effect of statin prescribing was estimated using a staggered 
cohort design that compared people with SMI who did (statin users), or did not 
(statin non-users), receive a statin prescription within a two year period between 
January 2002 and December 2010. Combined first myocardial infarction (MI) and 
stroke events were the primary outcome. All-cause mortality and change in total 
cholesterol concentration were evaluated as secondary outcomes.  The 
association between statin prescribing and the outcomes were estimated using a 
Poisson regression model (or linear regression for cholesterol), that incorporated 
an extensive array of covariates identified from the literature.  Unobserved 
covariate data on total cholesterol, blood pressure, weight, height and smoking 
status were estimated using multiple imputation. 
A total of 2,944 statin users and 42,886 statin non-users were identified across the 
series of cohorts. Statin prescribing was associated with statistically significant 
reductions in total cholesterol (of 1.2mmol/L for up to 2 years, p<0.001) and non-
significant reductions in the rate of MI and stroke (IRR 0.89; 95% CI; 0.68-1.15) 
and all-cause mortality 0.89 (95% CI; 0.78, 1.02).  
Our results are broadly similar to those for the general population and provide new 
assurance that statin prescribing may help reduce cardiovascular health 
inequalities amongst people with SMI. 
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25 Example MI impute dryrun output (for imputation of 
cholesterol data for the baseline year 2002) 
Conditional models: 
log_chol2002: regress log_chol2002 log_height i.eversmoke log_sys2004 
log_sys2003 log_sys2002 log_sys2001 log_sys2000 log_weight2004 
log_weight2003 log_weight2002 log_chol2004 log_weight2001 log_chol2003 
log_weight2000 log_chol2001 log_chol2000 Jan2002 cvd NA i.ageband sex 
TYPEGROUP BL_diabetes BL_heavydrink BL_antihyp BL_nonstatin BL_antipsy 
BL_antidep BL_moods BL_copd BL_hypothy BL_cancer BL_ckd BL_FH , noisily 
 
26 Example MI impute output 
Multivariate imputation                     Imputations =       10 
Chained equations                                 added =       10 
Imputed: m=1 through m=10                       updated =        0 
 
Initialization: monotone                     Iterations =      100 
burn-in =       10 
 
 log_chol2004: linear regression 
 log_chol2003: linear regression 
 log_chol2000: linear regression 
 log_chol2001: linear regression 
 log_chol2002: linear regression 
 log_height: linear regression 
 log_weight2000: linear regression 
 log_weight2004: linear regression 
 log_weight2001: linear regression 
 log_weight2003: linear regression 
 log_weight2002: linear regression 
 log_sys2000: linear regression 
 log_sys2004: linear regression 
 log_sys2001: linear regression 
 log_sys2003: linear regression 
 log_sys2002: linear regression 
 eversmoke: logistic regression 
 
 
Observations per m              
---------------------------------------------- 
  Variable    Complete   Incomplete   Imputed      Total 
 
 log_chol2004        1630         6414      6414       8044 
 log_chol2003        1312         6732      6732       8044 
 log_chol2000         400         7644      7644       8044 
 log_chol2001         688         7356      7356       8044 
 log_chol2002         964         7080      7080       8044 
 log_height          7402          642       642       8044 
 log_weight2000      1289         6755      6755       8044 
 log_weight2004      2361         5683      5683       8044 
 log_weight2001      1592         6452      6452       8044 
 log_weight2003      2033         6011      6011       8044 
 log_weight2002      1635         6409      6409       8044 
 log_sys2000         2501         5543      5543       8044 
 log_sys2004         4245         3799      3799       8044 
 log_sys2001         3068         4976      4976       8044 
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 log_sys2003         3926         4118      4118       8044 
 log_sys2002         3409         4635      4635       8044 
 eversmoke           6772         1272      1272       8044 
 
(complete + incomplete = total; imputed is the minimum across m of the 
number of filled-in observations.) 
(saving in Stata 13 format) 
(FYI, saveold has options version(12) and version(11) that write files in 
older Stata formats) 
 
file N:\Ruth\Stata\THIN\Multi trial study\FINAL COMBINED DATASETS AND LOG 
FILES/Jan2002_FULLIMPUTED_test.dta saved 
 
Table 8: Output from multivariable logistic regression model for associations 
between covariates and either statin prescribing or CVD events in complete 
cases 
COMPLETE CASES Statin Prescribing 
 
CVD events 
    OR 95% CI 
 
OR 95% CI 
Age band 
40-44 1.00 -- -- 
 
1.00 -- -- 
45-49 0.97 0.75 1.24 
 
3.64 1.66 7.95 
50-54 1.54 1.22 1.96 
 
3.81 1.76 8.28 
55-59 1.98 1.56 2.53 
 
4.82 2.24 10.36 
60-64 1.93 1.50 2.48 
 
5.87 2.73 12.64 
65-69 2.19 1.66 2.87 
 
8.43 3.92 18.13 
70-74 1.85 1.35 2.52 
 
10.80 4.94 23.64 
75-79 2.04 1.42 2.93 
 
9.74 4.21 22.57 
80-84 0.96 0.59 1.57 
 
11.45 4.61 28.40 
Sex 
Male 1.00 -- -- 
 
1.00 -- -- 
Female 0.55 0.48 0.63 
 
0.73 0.57 0.93 
 
Diabetes 5.11 4.42 5.90 
 
1.29 1.00 1.66 
 
Cholesterol 2.59 2.43 2.77 
 
1.08 0.98 1.20 
 
Systolic BP 1.01 1.01 1.02 
 
1.02 1.01 1.03 
 
BMI 1.03 1.02 1.04 
 
1.01 0.99 1.03 
Smoking status 
Never 1.00 -- -- 
 
1.00 -- -- 
Ex 1.20 0.97 1.49 
 
1.36 0.96 1.94 
Current 1.75 1.50 2.04 
 
1.33 1.00 1.77 
SMI type 
Bipolar 1.00 -- -- 
 
1.00 -- -- 
Schizophrenia 1.00 0.86 1.16 
 
0.96 0.73 1.26 
Cohort 
2002/3 1.00 -- -- 
 
1.00 -- -- 
2004/5 2.18 1.64 2.89 
 
0.68 0.47 0.98 
2006/7 2.29 1.74 3.00 
 
0.52 0.36 0.75 
2008/9 1.75 1.33 2.30 
 
0.33 0.22 0.50 
2009/10 1.16 0.89 1.53 
 
0.16 0.10 0.25 
Consultation rate 
<4 1.00 -- -- 
 
1.00 -- -- 
4-6 1.14 0.89 1.47 
 
1.23 0.73 2.08 
7-12 1.26 0.99 1.60 
 
1.26 0.77 2.07 
>13 1.38 1.08 1.76 
 
1.40 0.85 2.30 
Antipsychotic 
None 1.00 -- -- 
 
1.00 -- -- 
1 0.95 0.80 1.13 
 
0.95 0.70 1.28 
2 0.97 0.83 1.12 
 
0.97 0.73 1.28 
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COMPLETE CASES Statin Prescribing 
 
CVD events 
    OR 95% CI 
 
OR 95% CI 
Townsend  
Deprivation score 
1 1.00 -- -- 
 
1.00 -- -- 
2 0.99 0.79 1.24 
 
1.09 0.73 1.63 
3 1.01 0.82 1.26 
 
1.56 1.07 2.27 
4 0.93 0.75 1.15 
 
1.05 0.71 1.55 
5 1.16 0.93 1.44 
 
1.00 0.66 1.50 
 
Antihypertensive 1.52 1.31 1.75 
 
0.86 0.66 1.10 
 
Antidepressant 1.23 1.07 1.40 
 
1.63 1.29 2.08 
 
Mood stabiliser 0.86 0.73 1.00 
 
1.07 0.81 1.42 
 
Asthma 1.09 0.89 1.34 
 
1.37 0.96 1.94 
 
COPD 1.09 0.78 1.51 
 
2.35 1.55 3.56 
 
FH 10.27 7.09 14.87 
 
1.16 0.66 2.03 
 
AF 0.98 0.52 1.84 
 
0.58 0.17 1.94 
 
Cancer 0.61 0.36 1.04 
 
0.65 0.26 1.65 
 
Hypothyroidism 0.99 0.55 1.80 
 
0.48 0.11 2.05 
 
CKD 0.87 0.67 1.13 
 
1.22 0.79 1.87 
 
Heavy drinking 0.77 0.64 0.92 
 
0.59 0.40 0.86 
 
Non statin use 1.11 0.68 1.82 
 
0.97 0.38 2.49 
 
 
Table 9: Output from multivariable logistic regression model for 
associations between covariates and either statin prescribing or CVD 
events in the full dataset (with imputed values) 
IMPUTED DATA Statin Prescribing 
 
CVD events 
    OR 95% CI 
 
OR 95% CI 
Age band 
40-44 1.00 -- -- 
 
1.00 -- -- 
45-49 1.18 0.98 1.42 
 
2.00 1.57 2.56 
50-54 1.66 1.40 1.98 
 
2.47 1.94 3.15 
55-59 2.11 1.77 2.51 
 
3.21 2.53 4.07 
60-64 2.41 2.01 2.88 
 
4.43 3.49 5.61 
65-69 2.71 2.24 3.28 
 
6.18 4.87 7.85 
70-74 2.30 1.85 2.85 
 
7.64 5.97 9.77 
75-79 1.78 1.39 2.28 
 
7.05 5.42 9.16 
80-84 0.98 0.70 1.37 
 
7.82 5.89 10.38 
Sex 
Male 1.00 -- -- 
 
1.00 -- -- 
Female 0.56 0.50 0.61 
 
0.71 0.64 0.79 
 
Diabetes 7.20 6.49 7.99 
 
1.31 1.13 1.51 
 
Cholesterol 2.25 2.15 2.36 
 
1.06 1.00 1.13 
 
Systolic BP 1.01 1.01 1.02 
 
1.01 1.01 1.01 
 
BMI 1.04 1.04 1.05 
 
1.01 1.00 1.02 
Smoking status 
Never 1.00 -- -- 
 
1.00 -- -- 
Ex 1.27 1.10 1.47 
 
1.12 0.96 1.30 
Current 1.58 1.41 1.76 
 
1.38 1.23 1.54 
SMI type 
Bipolar 1.00 -- -- 
 
1.00 -- -- 
Schizophrenia 1.01 0.91 1.13 
 
0.83 0.74 0.93 
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IMPUTED DATA Statin Prescribing 
 
CVD events 
    OR 95% CI 
 
OR 95% CI 
Cohort 
2002/3 1.00 -- -- 
 
1.00 -- -- 
2004/5 2.12 1.78 2.53 
 
0.71 0.63 0.81 
2006/7 2.84 2.39 3.37 
 
0.48 0.42 0.56 
2008/9 2.49 2.09 2.97 
 
0.33 0.28 0.38 
2009/10 2.15 1.80 2.57 
 
0.15 0.13 0.19 
Consultation rate 
<4 1.00 -- -- 
 
1.00 -- -- 
4-6 1.79 1.53 2.11 
 
1.01 0.87 1.17 
7-12 2.34 2.00 2.73 
 
1.10 0.96 1.27 
>13 2.87 2.46 3.35 
 
1.10 0.95 1.27 
Antipsychotic 
None 1.00 -- -- 
 
1.00 -- -- 
1 0.94 0.84 1.06 
 
1.01 0.89 1.14 
2 1.11 1.00 1.23 
 
1.05 0.94 1.18 
Townsend  
Deprivation score 
1 1.00 -- -- 
 
1.00 -- -- 
2 0.96 0.82 1.12 
 
1.21 1.03 1.42 
3 1.01 0.87 1.18 
 
1.41 1.21 1.65 
4 0.91 0.78 1.06 
 
1.22 1.04 1.43 
5 1.13 0.97 1.32 
 
1.27 1.07 1.50 
 
Antihypertensive 2.35 2.12 2.60 
 
1.31 1.17 1.47 
 
Antidepressant 0.96 0.83 1.11 
 
1.18 1.00 1.38 
 
Mood stabiliser 1.04 0.83 1.31 
 
1.15 0.93 1.43 
 
Asthma 1.03 0.94 1.13 
 
1.12 1.01 1.23 
 
COPD 0.85 0.76 0.94 
 
1.00 0.89 1.12 
 
FH 38.39 28.99 50.83 
 
1.42 0.95 2.12 
 
AF 1.22 0.83 1.79 
 
1.04 0.71 1.53 
 
Cancer 0.64 0.43 0.94 
 
0.69 0.46 1.02 
 
Hypothyroidism 1.14 0.74 1.76 
 
1.21 0.76 1.94 
 
CKD 1.29 1.06 1.57 
 
1.17 0.90 1.51 
 
Heavy drinking 0.95 0.83 1.07 
 
0.98 0.85 1.14 
 
Non statin use 1.81 1.24 2.66 
 
0.99 0.51 1.89 
 
Table 6: Output from multivariable linear regression model for 
associations between statin prescribing and total cholesterol at 1 year 
after the index date (complete cases) 
Factor 
 
Coefficient Std. Err. P>t 95% CI 
Statin prescription -1.29 0.03 0.00 -1.35 -1.23 
Cholesterol at baseline -0.36 0.01 0.00 -0.39 -0.34 
Age band 
40-44 baseline -- -- -- 
45-49 -0.05 0.04 0.26 -0.13 0.04 
50-54 -0.05 0.04 0.25 -0.13 0.03 
55-59 -0.02 0.05 0.70 -0.11 0.07 
60-64 -0.06 0.05 0.17 -0.15 0.03 
65-69 -0.13 0.05 0.01 -0.23 -0.03 
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Factor 
 
Coefficient Std. Err. P>t 95% CI 
70-74 -0.11 0.06 0.05 -0.22 0.00 
75-79 -0.20 0.07 0.00 -0.33 -0.07 
80-84 -0.13 0.08 0.10 -0.27 0.02 
Sex 
Male baseline -- -- -- 
Female 0.09 0.02 0.00 0.05 0.14 
 
Diabetes -0.11 0.03 0.00 -0.16 -0.06 
 
Systolic BP 0.00 0.00 0.17 0.00 0.00 
 
BMI 0.00 0.00 0.05 -0.01 0.00 
Smoking status 
Never baseline -- -- -- 
Ex -0.02 0.04 0.53 -0.10 0.05 
Current 0.02 0.03 0.51 -0.04 0.07 
SMI type 
Bipolar baseline -- -- -- 
Schizophrenia -0.04 0.03 0.19 -0.09 0.02 
Cohort 
2002/3 baseline -- -- -- 
2004/5 -0.11 0.06 0.07 -0.22 0.01 
2006/7 -0.11 0.06 0.05 -0.23 0.00 
2008/9 -0.06 0.06 0.33 -0.17 0.06 
2009/10 -0.05 0.06 0.34 -0.16 0.06 
Consultation rate 
<4 baseline -- -- -- 
04-Jun 0.00 0.05 0.95 -0.09 0.10 
07-Dec -0.03 0.04 0.53 -0.12 0.06 
>13 -0.01 0.04 0.80 -0.10 0.08 
Antipsychotic 
None baseline -- -- -- 
1 -0.05 0.03 0.16 -0.11 0.02 
2 -0.06 0.03 0.03 -0.12 -0.01 
Townsend score  
for deprivation 
1 baseline -- -- -- 
2 -0.02 0.04 0.67 -0.10 0.06 
3 -0.07 0.04 0.07 -0.15 0.00 
4 -0.08 0.04 0.04 -0.15 0.00 
5 -0.03 0.04 0.42 -0.11 0.04 
 
Antihypertensive -0.05 0.03 0.06 -0.10 0.00 
 
Antidepressant 0.03 0.02 0.20 -0.02 0.08 
 
Mood stabiliser 0.03 0.03 0.33 -0.03 0.08 
 
Asthma 0.08 0.04 0.03 0.01 0.15 
 
COPD -0.03 0.05 0.53 -0.14 0.07 
 
FH -0.06 0.07 0.42 -0.21 0.09 
 
AF 0.00 0.12 1.00 -0.24 0.24 
 
Cancer -0.05 0.11 0.67 -0.26 0.17 
 
Hypothyroidism -0.24 0.10 0.02 -0.44 -0.04 
 
CKD -0.02 0.04 0.64 -0.10 0.06 
 
Heavy drinking 0.04 0.03 0.22 -0.02 0.10 
 
Non statin use 0.20 0.10 0.05 0.00 0.39 
 
_cons 1.96 0.16 0.00 1.64 2.27 
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Table 7: Output from multivariable linear regression model for 
associations between statin prescribing and total cholesterol at 2 
years after the index date (complete cases) 
Factor 
 
Coefficient Std. Err. P>t 95% CI 
Statin prescription -1.19 0.04 0.00 -1.26 -1.12 
Cholesterol at baseline -0.41 0.01 0.00 -0.44 -0.38 
Age band 
40-44 baseline -- -- -- 
45-49 -0.01 0.05 0.86 -0.10 0.08 
50-54 -0.04 0.05 0.36 -0.13 0.05 
55-59 -0.01 0.05 0.79 -0.10 0.08 
60-64 -0.02 0.05 0.73 -0.11 0.08 
65-69 -0.15 0.05 0.01 -0.26 -0.04 
70-74 -0.19 0.06 0.00 -0.31 -0.08 
75-79 -0.19 0.08 0.02 -0.35 -0.03 
80-84 -0.28 0.08 0.00 -0.44 -0.12 
Sex 
Male baseline -- -- -- 
Female 0.14 0.03 0.00 0.09 0.19 
 
Diabetes -0.14 0.03 0.00 -0.20 -0.08 
 
Systolic BP 0.00 0.00 0.03 0.00 0.00 
 
BMI -0.01 0.00 0.00 -0.01 0.00 
Smoking status 
Never baseline -- -- -- 
Ex -0.05 0.04 0.18 -0.13 0.02 
Current -0.06 0.03 0.05 -0.12 0.00 
SMI type 
Bipolar baseline -- -- -- 
Schizophrenia -0.03 0.03 0.27 -0.09 0.03 
Cohort 
2002/3 baseline -- -- -- 
2004/5 -0.08 0.07 0.26 -0.23 0.06 
2006/7 0.03 0.07 0.69 -0.11 0.17 
2008/9 0.04 0.07 0.57 -0.10 0.18 
2009/10 0.13 0.07 0.07 -0.01 0.26 
Consultation rate 
<4 baseline -- -- -- 
04-Jun 0.03 0.05 0.55 -0.06 0.12 
07-Dec 0.05 0.04 0.28 -0.04 0.13 
>13 0.04 0.04 0.31 -0.04 0.13 
Antipsychotic 
None baseline -- -- -- 
1 -0.06 0.04 0.07 -0.13 0.01 
2 -0.07 0.03 0.02 -0.13 -0.01 
Townsend score  
for deprivation 
1 baseline -- -- -- 
2 -0.01 0.04 0.78 -0.10 0.07 
3 -0.12 0.04 0.01 -0.20 -0.04 
4 -0.06 0.04 0.12 -0.14 0.02 
5 -0.07 0.04 0.09 -0.15 0.01 
 
Antihypertensive -0.03 0.03 0.35 -0.09 0.03 
 
Antidepressant 0.02 0.03 0.51 -0.03 0.07 
 
Mood stabiliser -0.03 0.03 0.35 -0.09 0.03 
 
Asthma 0.10 0.04 0.02 0.02 0.19 
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Factor 
 
Coefficient Std. Err. P>t 95% CI 
 
COPD -0.09 0.06 0.13 -0.22 0.03 
 
FH 0.04 0.09 0.63 -0.13 0.21 
 
AF -0.08 0.10 0.43 -0.27 0.11 
 
Cancer 0.00 0.13 0.99 -0.25 0.25 
 
Hypothyroidism -0.03 0.14 0.84 -0.31 0.25 
 
CKD -0.03 0.04 0.54 -0.11 0.06 
 
Heavy drinking 0.04 0.04 0.30 -0.03 0.11 
 
Non statin use 0.08 0.09 0.37 -0.09 0.25 
 
_cons 2.05 0.17 0.00 1.71 2.39 
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Table 25: Summary of the number and unadjusted rate of CVD outcomes and all-cause mortality in the main analysis 
Type of outcome 
Complete cases Full population 
Statin - Statin + Statin - Statin + 
N rate* 95% CI N rate* 95% CI N rate* 95% CI N rate* 95% CI 
MI and Stroke 106 4.91 (4.06, 5.94) 45 5.43 (4.05, 7.27) 927 4.17 (3.91, 4.45) 83 5.74 (4.62, 7.11) 
MI 37 1.71 (1.24, 2.37) 19 2.29 (1.46, 3.59) 316 1.42 (1.27, 1.59) 31 2.14 (1.51, 3.05) 
stroke 69 3.20 (2.52, 4.05) 26 3.14 (2.13, 4.61) 611 2.75 (2.54, 2.98) 52 3.60 (2.74, 4.72) 
All-cause mortality 363 16.75 (15.1, 18.6) 146 17.54 (14.9, 20.6) 4287 19.26 (18.7, 19.8) 284 19.57 (17.4, 22.0) 
*Crude rate per 1000 person years 
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Table 9: Analysis of complete case data in the main analysis.  
Estimates presented alongside imputed data results 
Section of Main Analysis 
N=6915 N=45824 
Complete case 
analysis 
Imputed data 
analysis 
VARIABLES IN THE ADJUSTED MODEL IRR 95% CI IRR 95% CI 
Impact of adding additional 
variables into the model 
Crude 1.11 0.78 1.58 1.39 1.11 1.74 
Age + Sex 1.06 0.75 1.51 1.16 0.93 1.46 
Diabetes 1.01 0.70 1.44 1.04 0.82 1.31 
Cholesterol 1.06 0.72 1.56 0.98 0.77 1.25 
BMI 1.03 0.70 1.53 0.96 0.75 1.22 
Sys BP 0.99 0.67 1.46 0.92 0.72 1.18 
Smoker 0.96 0.65 1.42 0.89 0.70 1.14 
SMI type 0.96 0.65 1.43 0.89 0.70 1.14 
Year 0.92 0.62 1.37 0.92 0.72 1.18 
Fully adjusted* 0.88 0.58 1.36 0.89 0.68 1.15 
                
        
COHORT-SPECIFIC ESTIMATES   IRR 95% CI IRR 95% CI 
Cohort (fully adjusted*) 
2002/3 0.41 0.02 7.08 0.68 0.35 1.32 
2004/5 0.91 0.40 2.06 1.19 0.75 1.88 
2006/7 0.98 0.43 2.24 0.99 0.58 1.69 
2008/9 0.71 0.24 2.07 0.70 0.35 1.41 
2010/11 2.70 0.64 8.35 0.77 0.26 2.31 
                
                
PRIMARY OUTCOME   IRR 95% CI IRR 95% CI 
(fully adjusted*) MI and Stroke 0.88 0.58 1.36 0.89 0.68 1.15 
                
                
SECONDARY OUTCOMES   IRR 95% CI IRR 95% CI 
(fully adjusted*) 
All cause 
mortality 1.02 0.82 1.27 0.89 0.78 1.02 
Stroke 0.85 0.49 1.48 0.96 0.68 1.34 
MI 0.93 0.47 1.83 0.75 0.48 1.15 
                
                
SUB-GROUP ANALYSES (fully adjusted*) IRR 95% CI IRR 95% CI 
SMI type 
Bipolar disorder 0.78 0.38 1.61 0.89 0.60 1.32 
Schizophrenia 0.90 0.53 1.52 0.85 0.60 1.20 
                
Gender 
Men 0.95 0.53 1.72 0.96 0.65 1.42 
Women 0.86 0.46 1.61 0.84 0.58 1.20 
                
CVD risk strata 
≥10% 0.96 0.60 1.53 0.93 0.69 1.26 
≥15% 1.03 0.65 1.62 0.90 0.67 1.21 
≥20% 1.00 0.63 1.60 0.82 0.59 1.13 
≥25% 0.91 0.55 1.50 0.73 0.52 1.05 
                
* Final model covariates (baseline): age and sex, diabetes, total cholesterol concentration, 
BMI, systolic blood pressure (Sys BP), smoking status, SMI type, cohort time period, 
antihypertensive use, antidepressant use, quartile of consultation rate, antipsychotic use and 
type, mood-stabiliser use, Townsend score, asthma, COPD, hypothyroidism, CKD, AF, 
familial hypercholesterolaemia, heavy drinking, non-statin lipid modification, cancer 
 
 
